Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

Both POS N
treatments POS N
resulted POS N
in POS N
significant POS N
reductions POS N
in POS N
mean POS N
intervisit POS N
IOP POS N
range POS N
during POS N
26 POS N
weeks. POS N

After POS N
treatment, POS N
6% POS N
(19/313) POS N
and POS N
11% POS N
(35/318) POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
and POS N
timolol POS N
groups, POS N
respectively, POS N
had POS N
high POS N
intervisit POS N
IOP POS N
ranges POS N
(P POS N
= POS N
.026). POS N

Both POS N
treatments POS N
resulted POS N
in POS N
significant POS N
reductions POS N
in POS N
mean POS N
intervisit POS N
IOP POS N
range POS N
during POS N
26 POS N
weeks. POS N

Significant POS N
risk POS N
factors POS N
for POS N
high POS N
posttreatment POS N
intervisit POS N
range POS N
(multivariate POS N
logistic POS N
regression) POS N
were POS N
high POS N
pretreatment POS N
intervisit POS N
IOP POS N
range, POS N
treatment POS N
with POS N
timolol, POS N
Black POS N
race, POS N
longer POS N
time POS N
since POS N
diagnosis, POS N
and POS N
higher POS N
mean POS N
pretreatment POS N
IOP. POS N

Both POS N
treatments POS N
resulted POS N
in POS N
significant POS N
reductions POS N
in POS N
mean POS N
intervisit POS N
IOP POS N
range POS N
during POS N
26 POS N
weeks. POS N

Compared POS N
with POS N
timolol, POS N
treatment POS N
with POS N
latanoprost POS N
results POS N
in POS N
significantly POS N
fewer POS N
patients POS N
with POS N
a POS N
high POS N
IOP POS N
fluctuation. POS N

After POS N
treatment, POS N
6% POS N
(19/313) POS N
and POS N
11% POS N
(35/318) POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
and POS N
timolol POS N
groups, POS N
respectively, POS N
had POS N
high POS N
intervisit POS N
IOP POS N
ranges POS N
(P POS N
= POS N
.026). POS N

Both POS N
treatments POS N
resulted POS N
in POS N
significant POS N
reductions POS N
in POS N
mean POS N
intervisit POS N
IOP POS N
range POS N
during POS N
26 POS N
weeks. POS N

After POS N
treatment, POS N
6% POS N
(19/313) POS N
and POS N
11% POS N
(35/318) POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
and POS N
timolol POS N
groups, POS N
respectively, POS N
had POS N
high POS N
intervisit POS N
IOP POS N
ranges POS N
(P POS N
= POS N
.026). POS N

Significant POS N
risk POS N
factors POS N
for POS N
high POS N
posttreatment POS N
intervisit POS N
range POS N
(multivariate POS N
logistic POS N
regression) POS N
were POS N
high POS N
pretreatment POS N
intervisit POS N
IOP POS N
range, POS N
treatment POS N
with POS N
timolol, POS N
Black POS N
race, POS N
longer POS N
time POS N
since POS N
diagnosis, POS N
and POS N
higher POS N
mean POS N
pretreatment POS N
IOP. POS N

After POS N
treatment, POS N
6% POS N
(19/313) POS N
and POS N
11% POS N
(35/318) POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
and POS N
timolol POS N
groups, POS N
respectively, POS N
had POS N
high POS N
intervisit POS N
IOP POS N
ranges POS N
(P POS N
= POS N
.026). POS N

Compared POS N
with POS N
timolol, POS N
treatment POS N
with POS N
latanoprost POS N
results POS N
in POS N
significantly POS N
fewer POS N
patients POS N
with POS N
a POS N
high POS N
IOP POS N
fluctuation. POS N

Significant POS N
risk POS N
factors POS N
for POS N
high POS N
posttreatment POS N
intervisit POS N
range POS N
(multivariate POS N
logistic POS N
regression) POS N
were POS N
high POS N
pretreatment POS N
intervisit POS N
IOP POS N
range, POS N
treatment POS N
with POS N
timolol, POS N
Black POS N
race, POS N
longer POS N
time POS N
since POS N
diagnosis, POS N
and POS N
higher POS N
mean POS N
pretreatment POS N
IOP. POS N

Both POS N
treatments POS N
resulted POS N
in POS N
significant POS N
reductions POS N
in POS N
mean POS N
intervisit POS N
IOP POS N
range POS N
during POS N
26 POS N
weeks. POS N

Significant POS N
risk POS N
factors POS N
for POS N
high POS N
posttreatment POS N
intervisit POS N
range POS N
(multivariate POS N
logistic POS N
regression) POS N
were POS N
high POS N
pretreatment POS N
intervisit POS N
IOP POS N
range, POS N
treatment POS N
with POS N
timolol, POS N
Black POS N
race, POS N
longer POS N
time POS N
since POS N
diagnosis, POS N
and POS N
higher POS N
mean POS N
pretreatment POS N
IOP. POS N

After POS N
treatment, POS N
6% POS N
(19/313) POS N
and POS N
11% POS N
(35/318) POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
and POS N
timolol POS N
groups, POS N
respectively, POS N
had POS N
high POS N
intervisit POS N
IOP POS N
ranges POS N
(P POS N
= POS N
.026). POS N

Significant POS N
risk POS N
factors POS N
for POS N
high POS N
posttreatment POS N
intervisit POS N
range POS N
(multivariate POS N
logistic POS N
regression) POS N
were POS N
high POS N
pretreatment POS N
intervisit POS N
IOP POS N
range, POS N
treatment POS N
with POS N
timolol, POS N
Black POS N
race, POS N
longer POS N
time POS N
since POS N
diagnosis, POS N
and POS N
higher POS N
mean POS N
pretreatment POS N
IOP. POS N

Compared POS N
with POS N
timolol, POS N
treatment POS N
with POS N
latanoprost POS N
results POS N
in POS N
significantly POS N
fewer POS N
patients POS N
with POS N
a POS N
high POS N
IOP POS N
fluctuation. POS N

Compared POS N
with POS N
timolol, POS N
treatment POS N
with POS N
latanoprost POS N
results POS N
in POS N
significantly POS N
fewer POS N
patients POS N
with POS N
a POS N
high POS N
IOP POS N
fluctuation. POS N

Both POS N
treatments POS N
resulted POS N
in POS N
significant POS N
reductions POS N
in POS N
mean POS N
intervisit POS N
IOP POS N
range POS N
during POS N
26 POS N
weeks. POS N

Compared POS N
with POS N
timolol, POS N
treatment POS N
with POS N
latanoprost POS N
results POS N
in POS N
significantly POS N
fewer POS N
patients POS N
with POS N
a POS N
high POS N
IOP POS N
fluctuation. POS N

After POS N
treatment, POS N
6% POS N
(19/313) POS N
and POS N
11% POS N
(35/318) POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
and POS N
timolol POS N
groups, POS N
respectively, POS N
had POS N
high POS N
intervisit POS N
IOP POS N
ranges POS N
(P POS N
= POS N
.026). POS N

Compared POS N
with POS N
timolol, POS N
treatment POS N
with POS N
latanoprost POS N
results POS N
in POS N
significantly POS N
fewer POS N
patients POS N
with POS N
a POS N
high POS N
IOP POS N
fluctuation. POS N

Significant POS N
risk POS N
factors POS N
for POS N
high POS N
posttreatment POS N
intervisit POS N
range POS N
(multivariate POS N
logistic POS N
regression) POS N
were POS N
high POS N
pretreatment POS N
intervisit POS N
IOP POS N
range, POS N
treatment POS N
with POS N
timolol, POS N
Black POS N
race, POS N
longer POS N
time POS N
since POS N
diagnosis, POS N
and POS N
higher POS N
mean POS N
pretreatment POS N
IOP. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

the POS N
overall POS N
probability POS N
of POS N
success POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
was POS N
0.613 POS N
and POS N
0.733 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

The POS N
success POS N
probability POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
in POS N
reducing POS N
IOP POS N
below POS N
18 POS N
mm POS N
Hg POS N
was POS N
0.748 POS N
and POS N
0.825 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

the POS N
overall POS N
probability POS N
of POS N
success POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
was POS N
0.613 POS N
and POS N
0.733 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

In POS N
POAG POS N
and POS N
CPACG POS N
patients, POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
were POS N
effective POS N
in POS N
reducing POS N
IOP POS N
for POS N
up POS N
to POS N
15 POS N
years POS N
after POS N
surgery. POS N

The POS N
success POS N
probability POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
in POS N
reducing POS N
IOP POS N
below POS N
18 POS N
mm POS N
Hg POS N
was POS N
0.748 POS N
and POS N
0.825 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

the POS N
overall POS N
probability POS N
of POS N
success POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
was POS N
0.613 POS N
and POS N
0.733 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

The POS N
success POS N
probability POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
in POS N
reducing POS N
IOP POS N
below POS N
18 POS N
mm POS N
Hg POS N
was POS N
0.748 POS N
and POS N
0.825 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

In POS N
POAG POS N
and POS N
CPACG POS N
patients, POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
were POS N
effective POS N
in POS N
reducing POS N
IOP POS N
for POS N
up POS N
to POS N
15 POS N
years POS N
after POS N
surgery. POS N

In POS N
POAG POS N
and POS N
CPACG POS N
patients, POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
were POS N
effective POS N
in POS N
reducing POS N
IOP POS N
for POS N
up POS N
to POS N
15 POS N
years POS N
after POS N
surgery. POS N

the POS N
overall POS N
probability POS N
of POS N
success POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
was POS N
0.613 POS N
and POS N
0.733 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

In POS N
POAG POS N
and POS N
CPACG POS N
patients, POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
were POS N
effective POS N
in POS N
reducing POS N
IOP POS N
for POS N
up POS N
to POS N
15 POS N
years POS N
after POS N
surgery. POS N

The POS N
success POS N
probability POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
in POS N
reducing POS N
IOP POS N
below POS N
18 POS N
mm POS N
Hg POS N
was POS N
0.748 POS N
and POS N
0.825 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Six POS N
months POS N
after POS N
surgery, POS N
intraocular POS N
pressures POS N
averaged POS N
10.9 POS N
+/- POS N
5.3 POS N
mmHg POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
in POS N
the POS N
MMC-treated POS N
eyes POS N
versus POS N
14.2 POS N
+/- POS N
5.5 POS N
mmHg POS N
in POS N
the POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.08) POS N
and POS N
were POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
12 POS N
mmHg POS N
in POS N
60.0% POS N
of POS N
MMC-treated POS N
eyes POS N
and POS N
21.1% POS N
of POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.03). POS N

Drug-induced POS N
corneal POS N
epithelial POS N
defects POS N
were POS N
seen POS N
in POS N
nine POS N
5-FU-treated POS N
eyes POS N
and POS N
in POS N
no POS N
MMC-treated POS N
eyes POS N
(P POS N
= POS N
0.0004). POS N

Six POS N
months POS N
after POS N
surgery, POS N
intraocular POS N
pressures POS N
averaged POS N
10.9 POS N
+/- POS N
5.3 POS N
mmHg POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
in POS N
the POS N
MMC-treated POS N
eyes POS N
versus POS N
14.2 POS N
+/- POS N
5.5 POS N
mmHg POS N
in POS N
the POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.08) POS N
and POS N
were POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
12 POS N
mmHg POS N
in POS N
60.0% POS N
of POS N
MMC-treated POS N
eyes POS N
and POS N
21.1% POS N
of POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.03). POS N

These POS N
results POS N
suggest POS N
that POS N
intraoperative POS N
MMC POS N
may POS N
be POS N
a POS N
viable POS N
alternative POS N
to POS N
postoperative POS N
5-FU, POS N
with POS N
lower POS N
overall POS N
intraocular POS N
pressures, POS N
decreased POS N
dependence POS N
on POS N
postoperative POS N
ocular POS N
antihypertensive POS N
medications, POS N
and POS N
decreased POS N
corneal POS N
toxicity. POS N

Drug-induced POS N
corneal POS N
epithelial POS N
defects POS N
were POS N
seen POS N
in POS N
nine POS N
5-FU-treated POS N
eyes POS N
and POS N
in POS N
no POS N
MMC-treated POS N
eyes POS N
(P POS N
= POS N
0.0004). POS N

Six POS N
months POS N
after POS N
surgery, POS N
intraocular POS N
pressures POS N
averaged POS N
10.9 POS N
+/- POS N
5.3 POS N
mmHg POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
in POS N
the POS N
MMC-treated POS N
eyes POS N
versus POS N
14.2 POS N
+/- POS N
5.5 POS N
mmHg POS N
in POS N
the POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.08) POS N
and POS N
were POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
12 POS N
mmHg POS N
in POS N
60.0% POS N
of POS N
MMC-treated POS N
eyes POS N
and POS N
21.1% POS N
of POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.03). POS N

Drug-induced POS N
corneal POS N
epithelial POS N
defects POS N
were POS N
seen POS N
in POS N
nine POS N
5-FU-treated POS N
eyes POS N
and POS N
in POS N
no POS N
MMC-treated POS N
eyes POS N
(P POS N
= POS N
0.0004). POS N

These POS N
results POS N
suggest POS N
that POS N
intraoperative POS N
MMC POS N
may POS N
be POS N
a POS N
viable POS N
alternative POS N
to POS N
postoperative POS N
5-FU, POS N
with POS N
lower POS N
overall POS N
intraocular POS N
pressures, POS N
decreased POS N
dependence POS N
on POS N
postoperative POS N
ocular POS N
antihypertensive POS N
medications, POS N
and POS N
decreased POS N
corneal POS N
toxicity. POS N

These POS N
results POS N
suggest POS N
that POS N
intraoperative POS N
MMC POS N
may POS N
be POS N
a POS N
viable POS N
alternative POS N
to POS N
postoperative POS N
5-FU, POS N
with POS N
lower POS N
overall POS N
intraocular POS N
pressures, POS N
decreased POS N
dependence POS N
on POS N
postoperative POS N
ocular POS N
antihypertensive POS N
medications, POS N
and POS N
decreased POS N
corneal POS N
toxicity. POS N

Six POS N
months POS N
after POS N
surgery, POS N
intraocular POS N
pressures POS N
averaged POS N
10.9 POS N
+/- POS N
5.3 POS N
mmHg POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
in POS N
the POS N
MMC-treated POS N
eyes POS N
versus POS N
14.2 POS N
+/- POS N
5.5 POS N
mmHg POS N
in POS N
the POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.08) POS N
and POS N
were POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
12 POS N
mmHg POS N
in POS N
60.0% POS N
of POS N
MMC-treated POS N
eyes POS N
and POS N
21.1% POS N
of POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.03). POS N

These POS N
results POS N
suggest POS N
that POS N
intraoperative POS N
MMC POS N
may POS N
be POS N
a POS N
viable POS N
alternative POS N
to POS N
postoperative POS N
5-FU, POS N
with POS N
lower POS N
overall POS N
intraocular POS N
pressures, POS N
decreased POS N
dependence POS N
on POS N
postoperative POS N
ocular POS N
antihypertensive POS N
medications, POS N
and POS N
decreased POS N
corneal POS N
toxicity. POS N

Drug-induced POS N
corneal POS N
epithelial POS N
defects POS N
were POS N
seen POS N
in POS N
nine POS N
5-FU-treated POS N
eyes POS N
and POS N
in POS N
no POS N
MMC-treated POS N
eyes POS N
(P POS N
= POS N
0.0004). POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

Fifteen POS N
eyes POS N
(88%) POS N
in POS N
the POS N
mitomycin POS N
group POS N
and POS N
seven POS N
(47%) POS N
in POS N
the POS N
fluorouracil POS N
group POS N
achieved POS N
an POS N
intraocular POS N
pressure POS N
of POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
20 POS N
mm POS N
Hg POS N
without POS N
antiglaucoma POS N
medication. POS N

Corneal POS N
complications POS N
were POS N
less POS N
common POS N
in POS N
the POS N
group POS N
given POS N
mitomycin POS N
than POS N
in POS N
that POS N
given POS N
fluorouracil POS N
(12% POS N
vs POS N
53%). POS N

Fifteen POS N
eyes POS N
(88%) POS N
in POS N
the POS N
mitomycin POS N
group POS N
and POS N
seven POS N
(47%) POS N
in POS N
the POS N
fluorouracil POS N
group POS N
achieved POS N
an POS N
intraocular POS N
pressure POS N
of POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
20 POS N
mm POS N
Hg POS N
without POS N
antiglaucoma POS N
medication. POS N

The POS N
incidence POS N
of POS N
other POS N
complications POS N
was POS N
similar POS N
between POS N
the POS N
two POS N
groups. POS N

Corneal POS N
complications POS N
were POS N
less POS N
common POS N
in POS N
the POS N
group POS N
given POS N
mitomycin POS N
than POS N
in POS N
that POS N
given POS N
fluorouracil POS N
(12% POS N
vs POS N
53%). POS N

Fifteen POS N
eyes POS N
(88%) POS N
in POS N
the POS N
mitomycin POS N
group POS N
and POS N
seven POS N
(47%) POS N
in POS N
the POS N
fluorouracil POS N
group POS N
achieved POS N
an POS N
intraocular POS N
pressure POS N
of POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
20 POS N
mm POS N
Hg POS N
without POS N
antiglaucoma POS N
medication. POS N

Corneal POS N
complications POS N
were POS N
less POS N
common POS N
in POS N
the POS N
group POS N
given POS N
mitomycin POS N
than POS N
in POS N
that POS N
given POS N
fluorouracil POS N
(12% POS N
vs POS N
53%). POS N

The POS N
incidence POS N
of POS N
other POS N
complications POS N
was POS N
similar POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
incidence POS N
of POS N
other POS N
complications POS N
was POS N
similar POS N
between POS N
the POS N
two POS N
groups. POS N

Fifteen POS N
eyes POS N
(88%) POS N
in POS N
the POS N
mitomycin POS N
group POS N
and POS N
seven POS N
(47%) POS N
in POS N
the POS N
fluorouracil POS N
group POS N
achieved POS N
an POS N
intraocular POS N
pressure POS N
of POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
20 POS N
mm POS N
Hg POS N
without POS N
antiglaucoma POS N
medication. POS N

The POS N
incidence POS N
of POS N
other POS N
complications POS N
was POS N
similar POS N
between POS N
the POS N
two POS N
groups. POS N

Corneal POS N
complications POS N
were POS N
less POS N
common POS N
in POS N
the POS N
group POS N
given POS N
mitomycin POS N
than POS N
in POS N
that POS N
given POS N
fluorouracil POS N
(12% POS N
vs POS N
53%). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

At POS N
15 POS N
months, POS N
the POS N
mean POS N
number POS N
of POS N
medications POS N
was POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(0.4 POS N
+/- POS N
0.7 POS N
and POS N
1.3 POS N
+/- POS N
1.0, POS N
respectively; POS N
P POS N
= POS N
.007), POS N
as POS N
was POS N
the POS N
proportion POS N
of POS N
patients POS N
on POS N
ocular POS N
hypotensive POS N
medication POS N
(33% POS N
and POS N
76%, POS N
respectively). POS N

Phacoemulsification POS N
with POS N
stent POS N
implantation POS N
was POS N
more POS N
effective POS N
in POS N
controlling POS N
IOP POS N
than POS N
phacoemulsification POS N
alone; POS N

At POS N
15 POS N
months, POS N
the POS N
mean POS N
number POS N
of POS N
medications POS N
was POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(0.4 POS N
+/- POS N
0.7 POS N
and POS N
1.3 POS N
+/- POS N
1.0, POS N
respectively; POS N
P POS N
= POS N
.007), POS N
as POS N
was POS N
the POS N
proportion POS N
of POS N
patients POS N
on POS N
ocular POS N
hypotensive POS N
medication POS N
(33% POS N
and POS N
76%, POS N
respectively). POS N

the POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
at POS N
both POS N
time POS N
points POS N
(P POS N
= POS N
.031 POS N
and POS N
P POS N
= POS N
.042, POS N
respectively). POS N

At POS N
15 POS N
months, POS N
the POS N
mean POS N
number POS N
of POS N
medications POS N
was POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(0.4 POS N
+/- POS N
0.7 POS N
and POS N
1.3 POS N
+/- POS N
1.0, POS N
respectively; POS N
P POS N
= POS N
.007), POS N
as POS N
was POS N
the POS N
proportion POS N
of POS N
patients POS N
on POS N
ocular POS N
hypotensive POS N
medication POS N
(33% POS N
and POS N
76%, POS N
respectively). POS N

The POS N
mean POS N
IOP POS N
was POS N
14.8 POS N
+/- POS N
1.2 POS N
mm POS N
Hg POS N
in POS N
the POS N
combined POS N
group POS N
and POS N
15.7 POS N
+/- POS N
1.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
control POS N
group POS N
at POS N
15 POS N
months POS N
and POS N
16.6 POS N
+/- POS N
3.1 POS N
mm POS N
Hg POS N
and POS N
19.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg, POS N
respectively, POS N
after POS N
washout; POS N

Phacoemulsification POS N
with POS N
stent POS N
implantation POS N
was POS N
more POS N
effective POS N
in POS N
controlling POS N
IOP POS N
than POS N
phacoemulsification POS N
alone; POS N

At POS N
15 POS N
months, POS N
the POS N
mean POS N
number POS N
of POS N
medications POS N
was POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(0.4 POS N
+/- POS N
0.7 POS N
and POS N
1.3 POS N
+/- POS N
1.0, POS N
respectively; POS N
P POS N
= POS N
.007), POS N
as POS N
was POS N
the POS N
proportion POS N
of POS N
patients POS N
on POS N
ocular POS N
hypotensive POS N
medication POS N
(33% POS N
and POS N
76%, POS N
respectively). POS N

Phacoemulsification POS N
with POS N
stent POS N
implantation POS N
was POS N
more POS N
effective POS N
in POS N
controlling POS N
IOP POS N
than POS N
phacoemulsification POS N
alone; POS N

the POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
at POS N
both POS N
time POS N
points POS N
(P POS N
= POS N
.031 POS N
and POS N
P POS N
= POS N
.042, POS N
respectively). POS N

Phacoemulsification POS N
with POS N
stent POS N
implantation POS N
was POS N
more POS N
effective POS N
in POS N
controlling POS N
IOP POS N
than POS N
phacoemulsification POS N
alone; POS N

The POS N
mean POS N
IOP POS N
was POS N
14.8 POS N
+/- POS N
1.2 POS N
mm POS N
Hg POS N
in POS N
the POS N
combined POS N
group POS N
and POS N
15.7 POS N
+/- POS N
1.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
control POS N
group POS N
at POS N
15 POS N
months POS N
and POS N
16.6 POS N
+/- POS N
3.1 POS N
mm POS N
Hg POS N
and POS N
19.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg, POS N
respectively, POS N
after POS N
washout; POS N

the POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
at POS N
both POS N
time POS N
points POS N
(P POS N
= POS N
.031 POS N
and POS N
P POS N
= POS N
.042, POS N
respectively). POS N

At POS N
15 POS N
months, POS N
the POS N
mean POS N
number POS N
of POS N
medications POS N
was POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(0.4 POS N
+/- POS N
0.7 POS N
and POS N
1.3 POS N
+/- POS N
1.0, POS N
respectively; POS N
P POS N
= POS N
.007), POS N
as POS N
was POS N
the POS N
proportion POS N
of POS N
patients POS N
on POS N
ocular POS N
hypotensive POS N
medication POS N
(33% POS N
and POS N
76%, POS N
respectively). POS N

the POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
at POS N
both POS N
time POS N
points POS N
(P POS N
= POS N
.031 POS N
and POS N
P POS N
= POS N
.042, POS N
respectively). POS N

Phacoemulsification POS N
with POS N
stent POS N
implantation POS N
was POS N
more POS N
effective POS N
in POS N
controlling POS N
IOP POS N
than POS N
phacoemulsification POS N
alone; POS N

the POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
at POS N
both POS N
time POS N
points POS N
(P POS N
= POS N
.031 POS N
and POS N
P POS N
= POS N
.042, POS N
respectively). POS N

The POS N
mean POS N
IOP POS N
was POS N
14.8 POS N
+/- POS N
1.2 POS N
mm POS N
Hg POS N
in POS N
the POS N
combined POS N
group POS N
and POS N
15.7 POS N
+/- POS N
1.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
control POS N
group POS N
at POS N
15 POS N
months POS N
and POS N
16.6 POS N
+/- POS N
3.1 POS N
mm POS N
Hg POS N
and POS N
19.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg, POS N
respectively, POS N
after POS N
washout; POS N

The POS N
mean POS N
IOP POS N
was POS N
14.8 POS N
+/- POS N
1.2 POS N
mm POS N
Hg POS N
in POS N
the POS N
combined POS N
group POS N
and POS N
15.7 POS N
+/- POS N
1.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
control POS N
group POS N
at POS N
15 POS N
months POS N
and POS N
16.6 POS N
+/- POS N
3.1 POS N
mm POS N
Hg POS N
and POS N
19.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg, POS N
respectively, POS N
after POS N
washout; POS N

At POS N
15 POS N
months, POS N
the POS N
mean POS N
number POS N
of POS N
medications POS N
was POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(0.4 POS N
+/- POS N
0.7 POS N
and POS N
1.3 POS N
+/- POS N
1.0, POS N
respectively; POS N
P POS N
= POS N
.007), POS N
as POS N
was POS N
the POS N
proportion POS N
of POS N
patients POS N
on POS N
ocular POS N
hypotensive POS N
medication POS N
(33% POS N
and POS N
76%, POS N
respectively). POS N

The POS N
mean POS N
IOP POS N
was POS N
14.8 POS N
+/- POS N
1.2 POS N
mm POS N
Hg POS N
in POS N
the POS N
combined POS N
group POS N
and POS N
15.7 POS N
+/- POS N
1.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
control POS N
group POS N
at POS N
15 POS N
months POS N
and POS N
16.6 POS N
+/- POS N
3.1 POS N
mm POS N
Hg POS N
and POS N
19.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg, POS N
respectively, POS N
after POS N
washout; POS N

Phacoemulsification POS N
with POS N
stent POS N
implantation POS N
was POS N
more POS N
effective POS N
in POS N
controlling POS N
IOP POS N
than POS N
phacoemulsification POS N
alone; POS N

The POS N
mean POS N
IOP POS N
was POS N
14.8 POS N
+/- POS N
1.2 POS N
mm POS N
Hg POS N
in POS N
the POS N
combined POS N
group POS N
and POS N
15.7 POS N
+/- POS N
1.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
control POS N
group POS N
at POS N
15 POS N
months POS N
and POS N
16.6 POS N
+/- POS N
3.1 POS N
mm POS N
Hg POS N
and POS N
19.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg, POS N
respectively, POS N
after POS N
washout; POS N

the POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
at POS N
both POS N
time POS N
points POS N
(P POS N
= POS N
.031 POS N
and POS N
P POS N
= POS N
.042, POS N
respectively). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

At POS N
1-year POS N
follow-up, POS N
complete POS N
success POS N
rates POS N
were POS N
81.8% POS N
for POS N
Ex-PRESS POS N
and POS N
47.5% POS N
for POS N
trabeculectomy POS N
(P=0.0020), POS N
and POS N
71.7% POS N
and POS N
37.5% POS N
(P=0.0070), POS N
respectively, POS N
for POS N
the POS N
more POS N
stringent POS N
target. POS N

There POS N
was POS N
a POS N
similar POS N
level POS N
of POS N
postoperative POS N
interventions POS N
and POS N
complications POS N
for POS N
each POS N
group. POS N

At POS N
1-year POS N
follow-up, POS N
complete POS N
success POS N
rates POS N
were POS N
81.8% POS N
for POS N
Ex-PRESS POS N
and POS N
47.5% POS N
for POS N
trabeculectomy POS N
(P=0.0020), POS N
and POS N
71.7% POS N
and POS N
37.5% POS N
(P=0.0070), POS N
respectively, POS N
for POS N
the POS N
more POS N
stringent POS N
target. POS N

In POS N
open-angle POS N
glaucoma, POS N
the POS N
Ex-PRESS POS N
mini POS N
glaucoma POS N
shunt POS N
implanted POS N
under POS N
a POS N
superficial POS N
scleral POS N
flap POS N
produces POS N
significantly POS N
higher POS N
success POS N
rates, POS N
and POS N
a POS N
similar POS N
complication POS N
rate, POS N
compared POS N
with POS N
trabeculectomy. POS N

At POS N
1-year POS N
follow-up, POS N
complete POS N
success POS N
rates POS N
were POS N
81.8% POS N
for POS N
Ex-PRESS POS N
and POS N
47.5% POS N
for POS N
trabeculectomy POS N
(P=0.0020), POS N
and POS N
71.7% POS N
and POS N
37.5% POS N
(P=0.0070), POS N
respectively, POS N
for POS N
the POS N
more POS N
stringent POS N
target. POS N

The POS N
Ex-PRESS POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
device POS N
for POS N
treating POS N
open-angle POS N
glaucoma. POS N

There POS N
was POS N
a POS N
similar POS N
level POS N
of POS N
postoperative POS N
interventions POS N
and POS N
complications POS N
for POS N
each POS N
group. POS N

At POS N
1-year POS N
follow-up, POS N
complete POS N
success POS N
rates POS N
were POS N
81.8% POS N
for POS N
Ex-PRESS POS N
and POS N
47.5% POS N
for POS N
trabeculectomy POS N
(P=0.0020), POS N
and POS N
71.7% POS N
and POS N
37.5% POS N
(P=0.0070), POS N
respectively, POS N
for POS N
the POS N
more POS N
stringent POS N
target. POS N

There POS N
was POS N
a POS N
similar POS N
level POS N
of POS N
postoperative POS N
interventions POS N
and POS N
complications POS N
for POS N
each POS N
group. POS N

In POS N
open-angle POS N
glaucoma, POS N
the POS N
Ex-PRESS POS N
mini POS N
glaucoma POS N
shunt POS N
implanted POS N
under POS N
a POS N
superficial POS N
scleral POS N
flap POS N
produces POS N
significantly POS N
higher POS N
success POS N
rates, POS N
and POS N
a POS N
similar POS N
complication POS N
rate, POS N
compared POS N
with POS N
trabeculectomy. POS N

There POS N
was POS N
a POS N
similar POS N
level POS N
of POS N
postoperative POS N
interventions POS N
and POS N
complications POS N
for POS N
each POS N
group. POS N

The POS N
Ex-PRESS POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
device POS N
for POS N
treating POS N
open-angle POS N
glaucoma. POS N

In POS N
open-angle POS N
glaucoma, POS N
the POS N
Ex-PRESS POS N
mini POS N
glaucoma POS N
shunt POS N
implanted POS N
under POS N
a POS N
superficial POS N
scleral POS N
flap POS N
produces POS N
significantly POS N
higher POS N
success POS N
rates, POS N
and POS N
a POS N
similar POS N
complication POS N
rate, POS N
compared POS N
with POS N
trabeculectomy. POS N

At POS N
1-year POS N
follow-up, POS N
complete POS N
success POS N
rates POS N
were POS N
81.8% POS N
for POS N
Ex-PRESS POS N
and POS N
47.5% POS N
for POS N
trabeculectomy POS N
(P=0.0020), POS N
and POS N
71.7% POS N
and POS N
37.5% POS N
(P=0.0070), POS N
respectively, POS N
for POS N
the POS N
more POS N
stringent POS N
target. POS N

In POS N
open-angle POS N
glaucoma, POS N
the POS N
Ex-PRESS POS N
mini POS N
glaucoma POS N
shunt POS N
implanted POS N
under POS N
a POS N
superficial POS N
scleral POS N
flap POS N
produces POS N
significantly POS N
higher POS N
success POS N
rates, POS N
and POS N
a POS N
similar POS N
complication POS N
rate, POS N
compared POS N
with POS N
trabeculectomy. POS N

There POS N
was POS N
a POS N
similar POS N
level POS N
of POS N
postoperative POS N
interventions POS N
and POS N
complications POS N
for POS N
each POS N
group. POS N

In POS N
open-angle POS N
glaucoma, POS N
the POS N
Ex-PRESS POS N
mini POS N
glaucoma POS N
shunt POS N
implanted POS N
under POS N
a POS N
superficial POS N
scleral POS N
flap POS N
produces POS N
significantly POS N
higher POS N
success POS N
rates, POS N
and POS N
a POS N
similar POS N
complication POS N
rate, POS N
compared POS N
with POS N
trabeculectomy. POS N

The POS N
Ex-PRESS POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
device POS N
for POS N
treating POS N
open-angle POS N
glaucoma. POS N

The POS N
Ex-PRESS POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
device POS N
for POS N
treating POS N
open-angle POS N
glaucoma. POS N

At POS N
1-year POS N
follow-up, POS N
complete POS N
success POS N
rates POS N
were POS N
81.8% POS N
for POS N
Ex-PRESS POS N
and POS N
47.5% POS N
for POS N
trabeculectomy POS N
(P=0.0020), POS N
and POS N
71.7% POS N
and POS N
37.5% POS N
(P=0.0070), POS N
respectively, POS N
for POS N
the POS N
more POS N
stringent POS N
target. POS N

The POS N
Ex-PRESS POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
device POS N
for POS N
treating POS N
open-angle POS N
glaucoma. POS N

There POS N
was POS N
a POS N
similar POS N
level POS N
of POS N
postoperative POS N
interventions POS N
and POS N
complications POS N
for POS N
each POS N
group. POS N

The POS N
Ex-PRESS POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
device POS N
for POS N
treating POS N
open-angle POS N
glaucoma. POS N

In POS N
open-angle POS N
glaucoma, POS N
the POS N
Ex-PRESS POS N
mini POS N
glaucoma POS N
shunt POS N
implanted POS N
under POS N
a POS N
superficial POS N
scleral POS N
flap POS N
produces POS N
significantly POS N
higher POS N
success POS N
rates, POS N
and POS N
a POS N
similar POS N
complication POS N
rate, POS N
compared POS N
with POS N
trabeculectomy. POS N

TMMC POS N
and POS N
T5-FU POS N
appeared POS N
to POS N
have POS N
similar POS N
efficacy POS N
in POS N
lowering POS N
IOP. POS N

Mean POS N
preoperative POS N
IOPs POS N
in POS N
the POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
were POS N
31.2 POS N
± POS N
9.8 POS N
and POS N
30.6 POS N
± POS N
9.9 POS N
mmHg, POS N
respectively. POS N
Postoperatively, POS N
mean POS N
IOPs POS N
were POS N
11.4 POS N
± POS N
4.9 POS N
and POS N
13.6 POS N
± POS N
3.9 POS N
mmHg, POS N
respectively POS N
for POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
after POS N
6 POS N
months. POS N

TMMC POS N
and POS N
T5-FU POS N
appeared POS N
to POS N
have POS N
similar POS N
efficacy POS N
in POS N
lowering POS N
IOP. POS N

statistical POS N
tests POS N
showed POS N
no POS N
difference POS N
in POS N
mean POS N
and POS N
median POS N
IOP. POS N

TMMC POS N
and POS N
T5-FU POS N
appeared POS N
to POS N
have POS N
similar POS N
efficacy POS N
in POS N
lowering POS N
IOP. POS N

Three POS N
cases POS N
of POS N
hypotonia POS N
(IOP POS N
< POS N
6 POS N
mmHg) POS N
and POS N
1 POS N
case POS N
of POS N
epithelial POS N
keratitis POS N
were POS N
detected. POS N

Mean POS N
preoperative POS N
IOPs POS N
in POS N
the POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
were POS N
31.2 POS N
± POS N
9.8 POS N
and POS N
30.6 POS N
± POS N
9.9 POS N
mmHg, POS N
respectively. POS N
Postoperatively, POS N
mean POS N
IOPs POS N
were POS N
11.4 POS N
± POS N
4.9 POS N
and POS N
13.6 POS N
± POS N
3.9 POS N
mmHg, POS N
respectively POS N
for POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
after POS N
6 POS N
months. POS N

TMMC POS N
and POS N
T5-FU POS N
appeared POS N
to POS N
have POS N
similar POS N
efficacy POS N
in POS N
lowering POS N
IOP. POS N

Mean POS N
preoperative POS N
IOPs POS N
in POS N
the POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
were POS N
31.2 POS N
± POS N
9.8 POS N
and POS N
30.6 POS N
± POS N
9.9 POS N
mmHg, POS N
respectively. POS N
Postoperatively, POS N
mean POS N
IOPs POS N
were POS N
11.4 POS N
± POS N
4.9 POS N
and POS N
13.6 POS N
± POS N
3.9 POS N
mmHg, POS N
respectively POS N
for POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
after POS N
6 POS N
months. POS N

statistical POS N
tests POS N
showed POS N
no POS N
difference POS N
in POS N
mean POS N
and POS N
median POS N
IOP. POS N

Mean POS N
preoperative POS N
IOPs POS N
in POS N
the POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
were POS N
31.2 POS N
± POS N
9.8 POS N
and POS N
30.6 POS N
± POS N
9.9 POS N
mmHg, POS N
respectively. POS N
Postoperatively, POS N
mean POS N
IOPs POS N
were POS N
11.4 POS N
± POS N
4.9 POS N
and POS N
13.6 POS N
± POS N
3.9 POS N
mmHg, POS N
respectively POS N
for POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
after POS N
6 POS N
months. POS N

Three POS N
cases POS N
of POS N
hypotonia POS N
(IOP POS N
< POS N
6 POS N
mmHg) POS N
and POS N
1 POS N
case POS N
of POS N
epithelial POS N
keratitis POS N
were POS N
detected. POS N

statistical POS N
tests POS N
showed POS N
no POS N
difference POS N
in POS N
mean POS N
and POS N
median POS N
IOP. POS N

TMMC POS N
and POS N
T5-FU POS N
appeared POS N
to POS N
have POS N
similar POS N
efficacy POS N
in POS N
lowering POS N
IOP. POS N

statistical POS N
tests POS N
showed POS N
no POS N
difference POS N
in POS N
mean POS N
and POS N
median POS N
IOP. POS N

Mean POS N
preoperative POS N
IOPs POS N
in POS N
the POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
were POS N
31.2 POS N
± POS N
9.8 POS N
and POS N
30.6 POS N
± POS N
9.9 POS N
mmHg, POS N
respectively. POS N
Postoperatively, POS N
mean POS N
IOPs POS N
were POS N
11.4 POS N
± POS N
4.9 POS N
and POS N
13.6 POS N
± POS N
3.9 POS N
mmHg, POS N
respectively POS N
for POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
after POS N
6 POS N
months. POS N

statistical POS N
tests POS N
showed POS N
no POS N
difference POS N
in POS N
mean POS N
and POS N
median POS N
IOP. POS N

Three POS N
cases POS N
of POS N
hypotonia POS N
(IOP POS N
< POS N
6 POS N
mmHg) POS N
and POS N
1 POS N
case POS N
of POS N
epithelial POS N
keratitis POS N
were POS N
detected. POS N

Three POS N
cases POS N
of POS N
hypotonia POS N
(IOP POS N
< POS N
6 POS N
mmHg) POS N
and POS N
1 POS N
case POS N
of POS N
epithelial POS N
keratitis POS N
were POS N
detected. POS N

TMMC POS N
and POS N
T5-FU POS N
appeared POS N
to POS N
have POS N
similar POS N
efficacy POS N
in POS N
lowering POS N
IOP. POS N

Three POS N
cases POS N
of POS N
hypotonia POS N
(IOP POS N
< POS N
6 POS N
mmHg) POS N
and POS N
1 POS N
case POS N
of POS N
epithelial POS N
keratitis POS N
were POS N
detected. POS N

Mean POS N
preoperative POS N
IOPs POS N
in POS N
the POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
were POS N
31.2 POS N
± POS N
9.8 POS N
and POS N
30.6 POS N
± POS N
9.9 POS N
mmHg, POS N
respectively. POS N
Postoperatively, POS N
mean POS N
IOPs POS N
were POS N
11.4 POS N
± POS N
4.9 POS N
and POS N
13.6 POS N
± POS N
3.9 POS N
mmHg, POS N
respectively POS N
for POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
after POS N
6 POS N
months. POS N

Three POS N
cases POS N
of POS N
hypotonia POS N
(IOP POS N
< POS N
6 POS N
mmHg) POS N
and POS N
1 POS N
case POS N
of POS N
epithelial POS N
keratitis POS N
were POS N
detected. POS N

statistical POS N
tests POS N
showed POS N
no POS N
difference POS N
in POS N
mean POS N
and POS N
median POS N
IOP. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

At POS N
24 POS N
months, POS N
complete POS N
success POS N
rates POS N
were POS N
53.3% POS N
for POS N
the POS N
ELT POS N
group POS N
and POS N
40% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.35, POS N
Fisher's POS N
exact POS N
test); POS N

Both POS N
ELT POS N
and POS N
SLT POS N
proved POS N
to POS N
be POS N
effective POS N
techniques POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
refractory POS N
to POS N
medical POS N
therapy. POS N

At POS N
24 POS N
months, POS N
complete POS N
success POS N
rates POS N
were POS N
53.3% POS N
for POS N
the POS N
ELT POS N
group POS N
and POS N
40% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.35, POS N
Fisher's POS N
exact POS N
test); POS N

qualified POS N
success POS N
rates POS N
were POS N
33.3% POS N
for POS N
the POS N
ELT POS N
and POS N
26.6% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.5, POS N
Fisher's POS N
exact POS N
test). POS N

At POS N
24 POS N
months, POS N
complete POS N
success POS N
rates POS N
were POS N
53.3% POS N
for POS N
the POS N
ELT POS N
group POS N
and POS N
40% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.35, POS N
Fisher's POS N
exact POS N
test); POS N

Mean POS N
IOP POS N
decreased POS N
from POS N
25.0+/-1.9 POS N
to POS N
17.6+/-2.2 POS N
mmHg POS N
(-29.6%; POS N
P<0.0001) POS N
in POS N
the POS N
ELT POS N
group POS N
and POS N
from POS N
23.9+/-0.9 POS N
to POS N
19.1+/-1.8 POS N
mmHg POS N
(-21%; POS N
P<0.0001) POS N
in POS N
the POS N
SLT POS N
group. POS N

Both POS N
ELT POS N
and POS N
SLT POS N
proved POS N
to POS N
be POS N
effective POS N
techniques POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
refractory POS N
to POS N
medical POS N
therapy. POS N

At POS N
24 POS N
months, POS N
complete POS N
success POS N
rates POS N
were POS N
53.3% POS N
for POS N
the POS N
ELT POS N
group POS N
and POS N
40% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.35, POS N
Fisher's POS N
exact POS N
test); POS N

Both POS N
ELT POS N
and POS N
SLT POS N
proved POS N
to POS N
be POS N
effective POS N
techniques POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
refractory POS N
to POS N
medical POS N
therapy. POS N

qualified POS N
success POS N
rates POS N
were POS N
33.3% POS N
for POS N
the POS N
ELT POS N
and POS N
26.6% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.5, POS N
Fisher's POS N
exact POS N
test). POS N

Both POS N
ELT POS N
and POS N
SLT POS N
proved POS N
to POS N
be POS N
effective POS N
techniques POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
refractory POS N
to POS N
medical POS N
therapy. POS N

Mean POS N
IOP POS N
decreased POS N
from POS N
25.0+/-1.9 POS N
to POS N
17.6+/-2.2 POS N
mmHg POS N
(-29.6%; POS N
P<0.0001) POS N
in POS N
the POS N
ELT POS N
group POS N
and POS N
from POS N
23.9+/-0.9 POS N
to POS N
19.1+/-1.8 POS N
mmHg POS N
(-21%; POS N
P<0.0001) POS N
in POS N
the POS N
SLT POS N
group. POS N

qualified POS N
success POS N
rates POS N
were POS N
33.3% POS N
for POS N
the POS N
ELT POS N
and POS N
26.6% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.5, POS N
Fisher's POS N
exact POS N
test). POS N

At POS N
24 POS N
months, POS N
complete POS N
success POS N
rates POS N
were POS N
53.3% POS N
for POS N
the POS N
ELT POS N
group POS N
and POS N
40% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.35, POS N
Fisher's POS N
exact POS N
test); POS N

qualified POS N
success POS N
rates POS N
were POS N
33.3% POS N
for POS N
the POS N
ELT POS N
and POS N
26.6% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.5, POS N
Fisher's POS N
exact POS N
test). POS N

Both POS N
ELT POS N
and POS N
SLT POS N
proved POS N
to POS N
be POS N
effective POS N
techniques POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
refractory POS N
to POS N
medical POS N
therapy. POS N

qualified POS N
success POS N
rates POS N
were POS N
33.3% POS N
for POS N
the POS N
ELT POS N
and POS N
26.6% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.5, POS N
Fisher's POS N
exact POS N
test). POS N

Mean POS N
IOP POS N
decreased POS N
from POS N
25.0+/-1.9 POS N
to POS N
17.6+/-2.2 POS N
mmHg POS N
(-29.6%; POS N
P<0.0001) POS N
in POS N
the POS N
ELT POS N
group POS N
and POS N
from POS N
23.9+/-0.9 POS N
to POS N
19.1+/-1.8 POS N
mmHg POS N
(-21%; POS N
P<0.0001) POS N
in POS N
the POS N
SLT POS N
group. POS N

Mean POS N
IOP POS N
decreased POS N
from POS N
25.0+/-1.9 POS N
to POS N
17.6+/-2.2 POS N
mmHg POS N
(-29.6%; POS N
P<0.0001) POS N
in POS N
the POS N
ELT POS N
group POS N
and POS N
from POS N
23.9+/-0.9 POS N
to POS N
19.1+/-1.8 POS N
mmHg POS N
(-21%; POS N
P<0.0001) POS N
in POS N
the POS N
SLT POS N
group. POS N

At POS N
24 POS N
months, POS N
complete POS N
success POS N
rates POS N
were POS N
53.3% POS N
for POS N
the POS N
ELT POS N
group POS N
and POS N
40% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.35, POS N
Fisher's POS N
exact POS N
test); POS N

Mean POS N
IOP POS N
decreased POS N
from POS N
25.0+/-1.9 POS N
to POS N
17.6+/-2.2 POS N
mmHg POS N
(-29.6%; POS N
P<0.0001) POS N
in POS N
the POS N
ELT POS N
group POS N
and POS N
from POS N
23.9+/-0.9 POS N
to POS N
19.1+/-1.8 POS N
mmHg POS N
(-21%; POS N
P<0.0001) POS N
in POS N
the POS N
SLT POS N
group. POS N

Both POS N
ELT POS N
and POS N
SLT POS N
proved POS N
to POS N
be POS N
effective POS N
techniques POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
refractory POS N
to POS N
medical POS N
therapy. POS N

Mean POS N
IOP POS N
decreased POS N
from POS N
25.0+/-1.9 POS N
to POS N
17.6+/-2.2 POS N
mmHg POS N
(-29.6%; POS N
P<0.0001) POS N
in POS N
the POS N
ELT POS N
group POS N
and POS N
from POS N
23.9+/-0.9 POS N
to POS N
19.1+/-1.8 POS N
mmHg POS N
(-21%; POS N
P<0.0001) POS N
in POS N
the POS N
SLT POS N
group. POS N

qualified POS N
success POS N
rates POS N
were POS N
33.3% POS N
for POS N
the POS N
ELT POS N
and POS N
26.6% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.5, POS N
Fisher's POS N
exact POS N
test). POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

The POS N
mean POS N
(standard POS N
error POS N
of POS N
mean POS N
[SE]) POS N
IOP POS N
reductions POS N
at POS N
months POS N
one POS N
was POS N
7.2 POS N
(0.4), POS N
at POS N
month POS N
3 POS N
was POS N
7.3 POS N
(0.4), POS N
and POS N
at POS N
month POS N
6 POS N
was POS N
7.1 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
7.5 POS N
(0.3), POS N
7.8 POS N
(0.3), POS N
and POS N
7.4 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

The POS N
latanoprost POS N
and POS N
dorzolamide/timolol POS N
combination POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP POS N
compared POS N
to POS N
untreated POS N
baseline. POS N

The POS N
mean POS N
(standard POS N
error POS N
of POS N
mean POS N
[SE]) POS N
IOP POS N
reductions POS N
at POS N
months POS N
one POS N
was POS N
7.2 POS N
(0.4), POS N
at POS N
month POS N
3 POS N
was POS N
7.3 POS N
(0.4), POS N
and POS N
at POS N
month POS N
6 POS N
was POS N
7.1 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
7.5 POS N
(0.3), POS N
7.8 POS N
(0.3), POS N
and POS N
7.4 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

The POS N
2 POS N
therapies POS N
were POS N
similarly POS N
effective. POS N

The POS N
latanoprost POS N
and POS N
dorzolamide/timolol POS N
combination POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP POS N
compared POS N
to POS N
untreated POS N
baseline. POS N

The POS N
mean POS N
(standard POS N
error POS N
of POS N
mean POS N
[SE]) POS N
IOP POS N
reductions POS N
at POS N
months POS N
one POS N
was POS N
7.2 POS N
(0.4), POS N
at POS N
month POS N
3 POS N
was POS N
7.3 POS N
(0.4), POS N
and POS N
at POS N
month POS N
6 POS N
was POS N
7.1 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
7.5 POS N
(0.3), POS N
7.8 POS N
(0.3), POS N
and POS N
7.4 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

The POS N
latanoprost POS N
and POS N
dorzolamide/timolol POS N
combination POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP POS N
compared POS N
to POS N
untreated POS N
baseline. POS N

The POS N
2 POS N
therapies POS N
were POS N
similarly POS N
effective. POS N

The POS N
2 POS N
therapies POS N
were POS N
similarly POS N
effective. POS N

The POS N
mean POS N
(standard POS N
error POS N
of POS N
mean POS N
[SE]) POS N
IOP POS N
reductions POS N
at POS N
months POS N
one POS N
was POS N
7.2 POS N
(0.4), POS N
at POS N
month POS N
3 POS N
was POS N
7.3 POS N
(0.4), POS N
and POS N
at POS N
month POS N
6 POS N
was POS N
7.1 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
7.5 POS N
(0.3), POS N
7.8 POS N
(0.3), POS N
and POS N
7.4 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

The POS N
2 POS N
therapies POS N
were POS N
similarly POS N
effective. POS N

The POS N
latanoprost POS N
and POS N
dorzolamide/timolol POS N
combination POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP POS N
compared POS N
to POS N
untreated POS N
baseline. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

A POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
at POS N
6 POS N
months POS N
was POS N
achieved POS N
in POS N
53 POS N
of POS N
56 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
and POS N
54 POS N
of POS N
57 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
(P POS N
= POS N
1.00). POS N

At POS N
12 POS N
months, POS N
45 POS N
of POS N
48 POS N
(94%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
met POS N
a POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
while POS N
48 POS N
of POS N
54 POS N
(89%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
did POS N
(P POS N
=.49). POS N

A POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
at POS N
6 POS N
months POS N
was POS N
achieved POS N
in POS N
53 POS N
of POS N
56 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
and POS N
54 POS N
of POS N
57 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
(P POS N
= POS N
1.00). POS N

The POS N
most POS N
common POS N
complications POS N
in POS N
each POS N
group POS N
were POS N
persistent POS N
choroidal POS N
effusions POS N
and POS N
bleb POS N
leak. POS N

A POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
at POS N
6 POS N
months POS N
was POS N
achieved POS N
in POS N
53 POS N
of POS N
56 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
and POS N
54 POS N
of POS N
57 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
(P POS N
= POS N
1.00). POS N

Our POS N
study POS N
suggests POS N
that POS N
intraoperative POS N
topical POS N
5-FU POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
intraoperative POS N
topical POS N
MMC POS N
in POS N
reducing POS N
IOP POS N
of POS N
eyes POS N
undergoing POS N
primary POS N
trabeculectomy. POS N

At POS N
12 POS N
months, POS N
45 POS N
of POS N
48 POS N
(94%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
met POS N
a POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
while POS N
48 POS N
of POS N
54 POS N
(89%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
did POS N
(P POS N
=.49). POS N

A POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
at POS N
6 POS N
months POS N
was POS N
achieved POS N
in POS N
53 POS N
of POS N
56 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
and POS N
54 POS N
of POS N
57 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
(P POS N
= POS N
1.00). POS N

At POS N
12 POS N
months, POS N
45 POS N
of POS N
48 POS N
(94%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
met POS N
a POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
while POS N
48 POS N
of POS N
54 POS N
(89%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
did POS N
(P POS N
=.49). POS N

The POS N
most POS N
common POS N
complications POS N
in POS N
each POS N
group POS N
were POS N
persistent POS N
choroidal POS N
effusions POS N
and POS N
bleb POS N
leak. POS N

At POS N
12 POS N
months, POS N
45 POS N
of POS N
48 POS N
(94%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
met POS N
a POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
while POS N
48 POS N
of POS N
54 POS N
(89%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
did POS N
(P POS N
=.49). POS N

Our POS N
study POS N
suggests POS N
that POS N
intraoperative POS N
topical POS N
5-FU POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
intraoperative POS N
topical POS N
MMC POS N
in POS N
reducing POS N
IOP POS N
of POS N
eyes POS N
undergoing POS N
primary POS N
trabeculectomy. POS N

The POS N
most POS N
common POS N
complications POS N
in POS N
each POS N
group POS N
were POS N
persistent POS N
choroidal POS N
effusions POS N
and POS N
bleb POS N
leak. POS N

A POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
at POS N
6 POS N
months POS N
was POS N
achieved POS N
in POS N
53 POS N
of POS N
56 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
and POS N
54 POS N
of POS N
57 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
(P POS N
= POS N
1.00). POS N

The POS N
most POS N
common POS N
complications POS N
in POS N
each POS N
group POS N
were POS N
persistent POS N
choroidal POS N
effusions POS N
and POS N
bleb POS N
leak. POS N

At POS N
12 POS N
months, POS N
45 POS N
of POS N
48 POS N
(94%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
met POS N
a POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
while POS N
48 POS N
of POS N
54 POS N
(89%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
did POS N
(P POS N
=.49). POS N

The POS N
most POS N
common POS N
complications POS N
in POS N
each POS N
group POS N
were POS N
persistent POS N
choroidal POS N
effusions POS N
and POS N
bleb POS N
leak. POS N

Our POS N
study POS N
suggests POS N
that POS N
intraoperative POS N
topical POS N
5-FU POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
intraoperative POS N
topical POS N
MMC POS N
in POS N
reducing POS N
IOP POS N
of POS N
eyes POS N
undergoing POS N
primary POS N
trabeculectomy. POS N

Our POS N
study POS N
suggests POS N
that POS N
intraoperative POS N
topical POS N
5-FU POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
intraoperative POS N
topical POS N
MMC POS N
in POS N
reducing POS N
IOP POS N
of POS N
eyes POS N
undergoing POS N
primary POS N
trabeculectomy. POS N

A POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
at POS N
6 POS N
months POS N
was POS N
achieved POS N
in POS N
53 POS N
of POS N
56 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
and POS N
54 POS N
of POS N
57 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
(P POS N
= POS N
1.00). POS N

Our POS N
study POS N
suggests POS N
that POS N
intraoperative POS N
topical POS N
5-FU POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
intraoperative POS N
topical POS N
MMC POS N
in POS N
reducing POS N
IOP POS N
of POS N
eyes POS N
undergoing POS N
primary POS N
trabeculectomy. POS N

At POS N
12 POS N
months, POS N
45 POS N
of POS N
48 POS N
(94%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
met POS N
a POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
while POS N
48 POS N
of POS N
54 POS N
(89%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
did POS N
(P POS N
=.49). POS N

Our POS N
study POS N
suggests POS N
that POS N
intraoperative POS N
topical POS N
5-FU POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
intraoperative POS N
topical POS N
MMC POS N
in POS N
reducing POS N
IOP POS N
of POS N
eyes POS N
undergoing POS N
primary POS N
trabeculectomy. POS N

The POS N
most POS N
common POS N
complications POS N
in POS N
each POS N
group POS N
were POS N
persistent POS N
choroidal POS N
effusions POS N
and POS N
bleb POS N
leak. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

Cumulative POS N
successes POS N
in POS N
the POS N
Ahmed POS N
group POS N
were POS N
0.73 POS N
at POS N
1 POS N
year POS N
and POS N
0.62 POS N
at POS N
2 POS N
years, POS N
whereas POS N
cumulative POS N
successes POS N
in POS N
the POS N
Baerveldt POS N
group POS N
were POS N
0.92 POS N
at POS N
1 POS N
year POS N
and POS N
0.85 POS N
at POS N
2 POS N
years POS N
(Kaplan-Meier POS N
survival POS N
functions: POS N
P POS N
= POS N
0.03, POS N
log POS N
rank POS N
test). POS N

Male POS N
gender, POS N
African POS N
descent, POS N
neovascular POS N
glaucoma, POS N
and POS N
Ahmed POS N
implantation POS N
were POS N
found POS N
to POS N
be POS N
significant POS N
predictors POS N
of POS N
failure. POS N

Cumulative POS N
successes POS N
in POS N
the POS N
Ahmed POS N
group POS N
were POS N
0.73 POS N
at POS N
1 POS N
year POS N
and POS N
0.62 POS N
at POS N
2 POS N
years, POS N
whereas POS N
cumulative POS N
successes POS N
in POS N
the POS N
Baerveldt POS N
group POS N
were POS N
0.92 POS N
at POS N
1 POS N
year POS N
and POS N
0.85 POS N
at POS N
2 POS N
years POS N
(Kaplan-Meier POS N
survival POS N
functions: POS N
P POS N
= POS N
0.03, POS N
log POS N
rank POS N
test). POS N

At POS N
last POS N
follow-up POS N
visit, POS N
eyes POS N
in POS N
the POS N
Ahmed POS N
group POS N
had POS N
a POS N
significantly POS N
higher POS N
mean POS N
IOP POS N
(19.8+/-9.5 POS N
vs. POS N
15.8+/-7.9 POS N
mmHg, POS N
P POS N
= POS N
0.003, POS N
t POS N
test) POS N
and POS N
more POS N
antiglaucoma POS N
medications POS N
(1.4+/-1.2 POS N
vs. POS N
0.9+/-1.1 POS N
medications, POS N
P POS N
= POS N
0.008, POS N
Mann-Whitney POS N
test) POS N
than POS N
eyes POS N
in POS N
the POS N
Baerveldt POS N
group. POS N

Cumulative POS N
successes POS N
in POS N
the POS N
Ahmed POS N
group POS N
were POS N
0.73 POS N
at POS N
1 POS N
year POS N
and POS N
0.62 POS N
at POS N
2 POS N
years, POS N
whereas POS N
cumulative POS N
successes POS N
in POS N
the POS N
Baerveldt POS N
group POS N
were POS N
0.92 POS N
at POS N
1 POS N
year POS N
and POS N
0.85 POS N
at POS N
2 POS N
years POS N
(Kaplan-Meier POS N
survival POS N
functions: POS N
P POS N
= POS N
0.03, POS N
log POS N
rank POS N
test). POS N

Our POS N
study POS N
suggests POS N
that POS N
the POS N
Ahmed POS N
S2 POS N
Glaucoma POS N
Valve POS N
may POS N
be POS N
less POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
the POS N
Baerveldt POS N
250-mm(2) POS N
Glaucoma POS N
Implant. POS N

Male POS N
gender, POS N
African POS N
descent, POS N
neovascular POS N
glaucoma, POS N
and POS N
Ahmed POS N
implantation POS N
were POS N
found POS N
to POS N
be POS N
significant POS N
predictors POS N
of POS N
failure. POS N

Cumulative POS N
successes POS N
in POS N
the POS N
Ahmed POS N
group POS N
were POS N
0.73 POS N
at POS N
1 POS N
year POS N
and POS N
0.62 POS N
at POS N
2 POS N
years, POS N
whereas POS N
cumulative POS N
successes POS N
in POS N
the POS N
Baerveldt POS N
group POS N
were POS N
0.92 POS N
at POS N
1 POS N
year POS N
and POS N
0.85 POS N
at POS N
2 POS N
years POS N
(Kaplan-Meier POS N
survival POS N
functions: POS N
P POS N
= POS N
0.03, POS N
log POS N
rank POS N
test). POS N

Male POS N
gender, POS N
African POS N
descent, POS N
neovascular POS N
glaucoma, POS N
and POS N
Ahmed POS N
implantation POS N
were POS N
found POS N
to POS N
be POS N
significant POS N
predictors POS N
of POS N
failure. POS N

At POS N
last POS N
follow-up POS N
visit, POS N
eyes POS N
in POS N
the POS N
Ahmed POS N
group POS N
had POS N
a POS N
significantly POS N
higher POS N
mean POS N
IOP POS N
(19.8+/-9.5 POS N
vs. POS N
15.8+/-7.9 POS N
mmHg, POS N
P POS N
= POS N
0.003, POS N
t POS N
test) POS N
and POS N
more POS N
antiglaucoma POS N
medications POS N
(1.4+/-1.2 POS N
vs. POS N
0.9+/-1.1 POS N
medications, POS N
P POS N
= POS N
0.008, POS N
Mann-Whitney POS N
test) POS N
than POS N
eyes POS N
in POS N
the POS N
Baerveldt POS N
group. POS N

Male POS N
gender, POS N
African POS N
descent, POS N
neovascular POS N
glaucoma, POS N
and POS N
Ahmed POS N
implantation POS N
were POS N
found POS N
to POS N
be POS N
significant POS N
predictors POS N
of POS N
failure. POS N

Our POS N
study POS N
suggests POS N
that POS N
the POS N
Ahmed POS N
S2 POS N
Glaucoma POS N
Valve POS N
may POS N
be POS N
less POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
the POS N
Baerveldt POS N
250-mm(2) POS N
Glaucoma POS N
Implant. POS N

At POS N
last POS N
follow-up POS N
visit, POS N
eyes POS N
in POS N
the POS N
Ahmed POS N
group POS N
had POS N
a POS N
significantly POS N
higher POS N
mean POS N
IOP POS N
(19.8+/-9.5 POS N
vs. POS N
15.8+/-7.9 POS N
mmHg, POS N
P POS N
= POS N
0.003, POS N
t POS N
test) POS N
and POS N
more POS N
antiglaucoma POS N
medications POS N
(1.4+/-1.2 POS N
vs. POS N
0.9+/-1.1 POS N
medications, POS N
P POS N
= POS N
0.008, POS N
Mann-Whitney POS N
test) POS N
than POS N
eyes POS N
in POS N
the POS N
Baerveldt POS N
group. POS N

Cumulative POS N
successes POS N
in POS N
the POS N
Ahmed POS N
group POS N
were POS N
0.73 POS N
at POS N
1 POS N
year POS N
and POS N
0.62 POS N
at POS N
2 POS N
years, POS N
whereas POS N
cumulative POS N
successes POS N
in POS N
the POS N
Baerveldt POS N
group POS N
were POS N
0.92 POS N
at POS N
1 POS N
year POS N
and POS N
0.85 POS N
at POS N
2 POS N
years POS N
(Kaplan-Meier POS N
survival POS N
functions: POS N
P POS N
= POS N
0.03, POS N
log POS N
rank POS N
test). POS N

At POS N
last POS N
follow-up POS N
visit, POS N
eyes POS N
in POS N
the POS N
Ahmed POS N
group POS N
had POS N
a POS N
significantly POS N
higher POS N
mean POS N
IOP POS N
(19.8+/-9.5 POS N
vs. POS N
15.8+/-7.9 POS N
mmHg, POS N
P POS N
= POS N
0.003, POS N
t POS N
test) POS N
and POS N
more POS N
antiglaucoma POS N
medications POS N
(1.4+/-1.2 POS N
vs. POS N
0.9+/-1.1 POS N
medications, POS N
P POS N
= POS N
0.008, POS N
Mann-Whitney POS N
test) POS N
than POS N
eyes POS N
in POS N
the POS N
Baerveldt POS N
group. POS N

Male POS N
gender, POS N
African POS N
descent, POS N
neovascular POS N
glaucoma, POS N
and POS N
Ahmed POS N
implantation POS N
were POS N
found POS N
to POS N
be POS N
significant POS N
predictors POS N
of POS N
failure. POS N

At POS N
last POS N
follow-up POS N
visit, POS N
eyes POS N
in POS N
the POS N
Ahmed POS N
group POS N
had POS N
a POS N
significantly POS N
higher POS N
mean POS N
IOP POS N
(19.8+/-9.5 POS N
vs. POS N
15.8+/-7.9 POS N
mmHg, POS N
P POS N
= POS N
0.003, POS N
t POS N
test) POS N
and POS N
more POS N
antiglaucoma POS N
medications POS N
(1.4+/-1.2 POS N
vs. POS N
0.9+/-1.1 POS N
medications, POS N
P POS N
= POS N
0.008, POS N
Mann-Whitney POS N
test) POS N
than POS N
eyes POS N
in POS N
the POS N
Baerveldt POS N
group. POS N

Our POS N
study POS N
suggests POS N
that POS N
the POS N
Ahmed POS N
S2 POS N
Glaucoma POS N
Valve POS N
may POS N
be POS N
less POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
the POS N
Baerveldt POS N
250-mm(2) POS N
Glaucoma POS N
Implant. POS N

Our POS N
study POS N
suggests POS N
that POS N
the POS N
Ahmed POS N
S2 POS N
Glaucoma POS N
Valve POS N
may POS N
be POS N
less POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
the POS N
Baerveldt POS N
250-mm(2) POS N
Glaucoma POS N
Implant. POS N

Cumulative POS N
successes POS N
in POS N
the POS N
Ahmed POS N
group POS N
were POS N
0.73 POS N
at POS N
1 POS N
year POS N
and POS N
0.62 POS N
at POS N
2 POS N
years, POS N
whereas POS N
cumulative POS N
successes POS N
in POS N
the POS N
Baerveldt POS N
group POS N
were POS N
0.92 POS N
at POS N
1 POS N
year POS N
and POS N
0.85 POS N
at POS N
2 POS N
years POS N
(Kaplan-Meier POS N
survival POS N
functions: POS N
P POS N
= POS N
0.03, POS N
log POS N
rank POS N
test). POS N

Our POS N
study POS N
suggests POS N
that POS N
the POS N
Ahmed POS N
S2 POS N
Glaucoma POS N
Valve POS N
may POS N
be POS N
less POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
the POS N
Baerveldt POS N
250-mm(2) POS N
Glaucoma POS N
Implant. POS N

Male POS N
gender, POS N
African POS N
descent, POS N
neovascular POS N
glaucoma, POS N
and POS N
Ahmed POS N
implantation POS N
were POS N
found POS N
to POS N
be POS N
significant POS N
predictors POS N
of POS N
failure. POS N

Our POS N
study POS N
suggests POS N
that POS N
the POS N
Ahmed POS N
S2 POS N
Glaucoma POS N
Valve POS N
may POS N
be POS N
less POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
the POS N
Baerveldt POS N
250-mm(2) POS N
Glaucoma POS N
Implant. POS N

At POS N
last POS N
follow-up POS N
visit, POS N
eyes POS N
in POS N
the POS N
Ahmed POS N
group POS N
had POS N
a POS N
significantly POS N
higher POS N
mean POS N
IOP POS N
(19.8+/-9.5 POS N
vs. POS N
15.8+/-7.9 POS N
mmHg, POS N
P POS N
= POS N
0.003, POS N
t POS N
test) POS N
and POS N
more POS N
antiglaucoma POS N
medications POS N
(1.4+/-1.2 POS N
vs. POS N
0.9+/-1.1 POS N
medications, POS N
P POS N
= POS N
0.008, POS N
Mann-Whitney POS N
test) POS N
than POS N
eyes POS N
in POS N
the POS N
Baerveldt POS N
group. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

No POS N
patient POS N
required POS N
reoperation. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

No POS N
patient POS N
required POS N
reoperation. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

No POS N
patient POS N
required POS N
reoperation. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Forty-two POS N
percent POS N
(n=10) POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
a POS N
successful POS N
outcome POS N
(IOP<18 POS N
mm POS N
Hg POS N
with POS N
no POS N
treatment) POS N
at POS N
last POS N
follow-up POS N
visit, POS N
compared POS N
to POS N
21% POS N
(n=5) POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

IOP POS N
was POS N
lower POS N
in POS N
the POS N
trab POS N
group POS N
with POS N
differences POS N
in POS N
IOP POS N
being POS N
statistically POS N
significant POS N
at POS N
month POS N
12 POS N
(P=<0.001), POS N
24 POS N
(P=<0.001), POS N
30 POS N
(P=0.030), POS N
36 POS N
(P=<0.001), POS N
and POS N
48 POS N
(P=0.018). POS N

Forty-two POS N
percent POS N
(n=10) POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
a POS N
successful POS N
outcome POS N
(IOP<18 POS N
mm POS N
Hg POS N
with POS N
no POS N
treatment) POS N
at POS N
last POS N
follow-up POS N
visit, POS N
compared POS N
to POS N
21% POS N
(n=5) POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

The POS N
trabeculectomy POS N
group POS N
required POS N
less POS N
postoperative POS N
topical POS N
IOP-lowering POS N
medication POS N
(P=0.011). POS N

Forty-two POS N
percent POS N
(n=10) POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
a POS N
successful POS N
outcome POS N
(IOP<18 POS N
mm POS N
Hg POS N
with POS N
no POS N
treatment) POS N
at POS N
last POS N
follow-up POS N
visit, POS N
compared POS N
to POS N
21% POS N
(n=5) POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

we POS N
found POS N
trabeculectomy POS N
to POS N
be POS N
more POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

IOP POS N
was POS N
lower POS N
in POS N
the POS N
trab POS N
group POS N
with POS N
differences POS N
in POS N
IOP POS N
being POS N
statistically POS N
significant POS N
at POS N
month POS N
12 POS N
(P=<0.001), POS N
24 POS N
(P=<0.001), POS N
30 POS N
(P=0.030), POS N
36 POS N
(P=<0.001), POS N
and POS N
48 POS N
(P=0.018). POS N

Forty-two POS N
percent POS N
(n=10) POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
a POS N
successful POS N
outcome POS N
(IOP<18 POS N
mm POS N
Hg POS N
with POS N
no POS N
treatment) POS N
at POS N
last POS N
follow-up POS N
visit, POS N
compared POS N
to POS N
21% POS N
(n=5) POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

IOP POS N
was POS N
lower POS N
in POS N
the POS N
trab POS N
group POS N
with POS N
differences POS N
in POS N
IOP POS N
being POS N
statistically POS N
significant POS N
at POS N
month POS N
12 POS N
(P=<0.001), POS N
24 POS N
(P=<0.001), POS N
30 POS N
(P=0.030), POS N
36 POS N
(P=<0.001), POS N
and POS N
48 POS N
(P=0.018). POS N

The POS N
trabeculectomy POS N
group POS N
required POS N
less POS N
postoperative POS N
topical POS N
IOP-lowering POS N
medication POS N
(P=0.011). POS N

IOP POS N
was POS N
lower POS N
in POS N
the POS N
trab POS N
group POS N
with POS N
differences POS N
in POS N
IOP POS N
being POS N
statistically POS N
significant POS N
at POS N
month POS N
12 POS N
(P=<0.001), POS N
24 POS N
(P=<0.001), POS N
30 POS N
(P=0.030), POS N
36 POS N
(P=<0.001), POS N
and POS N
48 POS N
(P=0.018). POS N

we POS N
found POS N
trabeculectomy POS N
to POS N
be POS N
more POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

The POS N
trabeculectomy POS N
group POS N
required POS N
less POS N
postoperative POS N
topical POS N
IOP-lowering POS N
medication POS N
(P=0.011). POS N

Forty-two POS N
percent POS N
(n=10) POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
a POS N
successful POS N
outcome POS N
(IOP<18 POS N
mm POS N
Hg POS N
with POS N
no POS N
treatment) POS N
at POS N
last POS N
follow-up POS N
visit, POS N
compared POS N
to POS N
21% POS N
(n=5) POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

The POS N
trabeculectomy POS N
group POS N
required POS N
less POS N
postoperative POS N
topical POS N
IOP-lowering POS N
medication POS N
(P=0.011). POS N

IOP POS N
was POS N
lower POS N
in POS N
the POS N
trab POS N
group POS N
with POS N
differences POS N
in POS N
IOP POS N
being POS N
statistically POS N
significant POS N
at POS N
month POS N
12 POS N
(P=<0.001), POS N
24 POS N
(P=<0.001), POS N
30 POS N
(P=0.030), POS N
36 POS N
(P=<0.001), POS N
and POS N
48 POS N
(P=0.018). POS N

The POS N
trabeculectomy POS N
group POS N
required POS N
less POS N
postoperative POS N
topical POS N
IOP-lowering POS N
medication POS N
(P=0.011). POS N

we POS N
found POS N
trabeculectomy POS N
to POS N
be POS N
more POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

we POS N
found POS N
trabeculectomy POS N
to POS N
be POS N
more POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Forty-two POS N
percent POS N
(n=10) POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
a POS N
successful POS N
outcome POS N
(IOP<18 POS N
mm POS N
Hg POS N
with POS N
no POS N
treatment) POS N
at POS N
last POS N
follow-up POS N
visit, POS N
compared POS N
to POS N
21% POS N
(n=5) POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

we POS N
found POS N
trabeculectomy POS N
to POS N
be POS N
more POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

IOP POS N
was POS N
lower POS N
in POS N
the POS N
trab POS N
group POS N
with POS N
differences POS N
in POS N
IOP POS N
being POS N
statistically POS N
significant POS N
at POS N
month POS N
12 POS N
(P=<0.001), POS N
24 POS N
(P=<0.001), POS N
30 POS N
(P=0.030), POS N
36 POS N
(P=<0.001), POS N
and POS N
48 POS N
(P=0.018). POS N

we POS N
found POS N
trabeculectomy POS N
to POS N
be POS N
more POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

The POS N
trabeculectomy POS N
group POS N
required POS N
less POS N
postoperative POS N
topical POS N
IOP-lowering POS N
medication POS N
(P=0.011). POS N

Tafluprost POS N
is POS N
a POS N
new POS N
effective POS N
and POS N
well-tolerated POS N
treatment POS N
for POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

the POS N
IOP-lowering POS N
effect POS N
during POS N
the POS N
study POS N
was POS N
slightly POS N
larger POS N
with POS N
latanoprost, POS N

Tafluprost POS N
is POS N
a POS N
new POS N
effective POS N
and POS N
well-tolerated POS N
treatment POS N
for POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
treatments POS N
had POS N
a POS N
substantial POS N
IOP-lowering POS N
effect POS N
which POS N
persisted POS N
throughout POS N
the POS N
study POS N
(-7.1 POS N
mmHg POS N
for POS N
tafluprost POS N
and POS N
-7.7 POS N
mmHg POS N
for POS N
latanoprost POS N
at POS N
24 POS N
months). POS N

Tafluprost POS N
is POS N
a POS N
new POS N
effective POS N
and POS N
well-tolerated POS N
treatment POS N
for POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

this POS N
difference POS N
was POS N
clinically POS N
small POS N
and POS N
the POS N
noninferiority POS N
of POS N
tafluprost POS N
to POS N
latanoprost POS N
over POS N
all POS N
diurnal POS N
IOP POS N
measurements POS N
was POS N
shown POS N
with POS N
anova POS N
and POS N
almost POS N
reached POS N
with POS N
ancova POS N
(upper POS N
limits POS N
of POS N
the POS N
95% POS N
confidence POS N
intervals POS N
1.38 POS N
and POS N
1.52 POS N
for POS N
the POS N
overall POS N
period, POS N
respectively). POS N

the POS N
IOP-lowering POS N
effect POS N
during POS N
the POS N
study POS N
was POS N
slightly POS N
larger POS N
with POS N
latanoprost, POS N

Tafluprost POS N
is POS N
a POS N
new POS N
effective POS N
and POS N
well-tolerated POS N
treatment POS N
for POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

the POS N
IOP-lowering POS N
effect POS N
during POS N
the POS N
study POS N
was POS N
slightly POS N
larger POS N
with POS N
latanoprost, POS N

Both POS N
treatments POS N
had POS N
a POS N
substantial POS N
IOP-lowering POS N
effect POS N
which POS N
persisted POS N
throughout POS N
the POS N
study POS N
(-7.1 POS N
mmHg POS N
for POS N
tafluprost POS N
and POS N
-7.7 POS N
mmHg POS N
for POS N
latanoprost POS N
at POS N
24 POS N
months). POS N

the POS N
IOP-lowering POS N
effect POS N
during POS N
the POS N
study POS N
was POS N
slightly POS N
larger POS N
with POS N
latanoprost, POS N

this POS N
difference POS N
was POS N
clinically POS N
small POS N
and POS N
the POS N
noninferiority POS N
of POS N
tafluprost POS N
to POS N
latanoprost POS N
over POS N
all POS N
diurnal POS N
IOP POS N
measurements POS N
was POS N
shown POS N
with POS N
anova POS N
and POS N
almost POS N
reached POS N
with POS N
ancova POS N
(upper POS N
limits POS N
of POS N
the POS N
95% POS N
confidence POS N
intervals POS N
1.38 POS N
and POS N
1.52 POS N
for POS N
the POS N
overall POS N
period, POS N
respectively). POS N

Both POS N
treatments POS N
had POS N
a POS N
substantial POS N
IOP-lowering POS N
effect POS N
which POS N
persisted POS N
throughout POS N
the POS N
study POS N
(-7.1 POS N
mmHg POS N
for POS N
tafluprost POS N
and POS N
-7.7 POS N
mmHg POS N
for POS N
latanoprost POS N
at POS N
24 POS N
months). POS N

Tafluprost POS N
is POS N
a POS N
new POS N
effective POS N
and POS N
well-tolerated POS N
treatment POS N
for POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
treatments POS N
had POS N
a POS N
substantial POS N
IOP-lowering POS N
effect POS N
which POS N
persisted POS N
throughout POS N
the POS N
study POS N
(-7.1 POS N
mmHg POS N
for POS N
tafluprost POS N
and POS N
-7.7 POS N
mmHg POS N
for POS N
latanoprost POS N
at POS N
24 POS N
months). POS N

the POS N
IOP-lowering POS N
effect POS N
during POS N
the POS N
study POS N
was POS N
slightly POS N
larger POS N
with POS N
latanoprost, POS N

Both POS N
treatments POS N
had POS N
a POS N
substantial POS N
IOP-lowering POS N
effect POS N
which POS N
persisted POS N
throughout POS N
the POS N
study POS N
(-7.1 POS N
mmHg POS N
for POS N
tafluprost POS N
and POS N
-7.7 POS N
mmHg POS N
for POS N
latanoprost POS N
at POS N
24 POS N
months). POS N

this POS N
difference POS N
was POS N
clinically POS N
small POS N
and POS N
the POS N
noninferiority POS N
of POS N
tafluprost POS N
to POS N
latanoprost POS N
over POS N
all POS N
diurnal POS N
IOP POS N
measurements POS N
was POS N
shown POS N
with POS N
anova POS N
and POS N
almost POS N
reached POS N
with POS N
ancova POS N
(upper POS N
limits POS N
of POS N
the POS N
95% POS N
confidence POS N
intervals POS N
1.38 POS N
and POS N
1.52 POS N
for POS N
the POS N
overall POS N
period, POS N
respectively). POS N

this POS N
difference POS N
was POS N
clinically POS N
small POS N
and POS N
the POS N
noninferiority POS N
of POS N
tafluprost POS N
to POS N
latanoprost POS N
over POS N
all POS N
diurnal POS N
IOP POS N
measurements POS N
was POS N
shown POS N
with POS N
anova POS N
and POS N
almost POS N
reached POS N
with POS N
ancova POS N
(upper POS N
limits POS N
of POS N
the POS N
95% POS N
confidence POS N
intervals POS N
1.38 POS N
and POS N
1.52 POS N
for POS N
the POS N
overall POS N
period, POS N
respectively). POS N

Tafluprost POS N
is POS N
a POS N
new POS N
effective POS N
and POS N
well-tolerated POS N
treatment POS N
for POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

this POS N
difference POS N
was POS N
clinically POS N
small POS N
and POS N
the POS N
noninferiority POS N
of POS N
tafluprost POS N
to POS N
latanoprost POS N
over POS N
all POS N
diurnal POS N
IOP POS N
measurements POS N
was POS N
shown POS N
with POS N
anova POS N
and POS N
almost POS N
reached POS N
with POS N
ancova POS N
(upper POS N
limits POS N
of POS N
the POS N
95% POS N
confidence POS N
intervals POS N
1.38 POS N
and POS N
1.52 POS N
for POS N
the POS N
overall POS N
period, POS N
respectively). POS N

the POS N
IOP-lowering POS N
effect POS N
during POS N
the POS N
study POS N
was POS N
slightly POS N
larger POS N
with POS N
latanoprost, POS N

this POS N
difference POS N
was POS N
clinically POS N
small POS N
and POS N
the POS N
noninferiority POS N
of POS N
tafluprost POS N
to POS N
latanoprost POS N
over POS N
all POS N
diurnal POS N
IOP POS N
measurements POS N
was POS N
shown POS N
with POS N
anova POS N
and POS N
almost POS N
reached POS N
with POS N
ancova POS N
(upper POS N
limits POS N
of POS N
the POS N
95% POS N
confidence POS N
intervals POS N
1.38 POS N
and POS N
1.52 POS N
for POS N
the POS N
overall POS N
period, POS N
respectively). POS N

Both POS N
treatments POS N
had POS N
a POS N
substantial POS N
IOP-lowering POS N
effect POS N
which POS N
persisted POS N
throughout POS N
the POS N
study POS N
(-7.1 POS N
mmHg POS N
for POS N
tafluprost POS N
and POS N
-7.7 POS N
mmHg POS N
for POS N
latanoprost POS N
at POS N
24 POS N
months). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

The POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
were POS N
similar POS N
between POS N
groups POS N
(p POS N
= POS N
0.232). POS N

No POS N
additional POS N
IOP-lowering POS N
surgical POS N
procedures POS N
were POS N
required POS N
in POS N
the POS N
combined POS N
group, POS N
while POS N
13 POS N
(54%) POS N
eyes POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
required POS N
either POS N
cataract POS N
extraction POS N
or POS N
further POS N
IOP-lowering POS N
surgical POS N
procedures POS N
(p POS N
<0.001). POS N

The POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
were POS N
similar POS N
between POS N
groups POS N
(p POS N
= POS N
0.232). POS N

In POS N
patients POS N
with POS N
PACG, POS N
the POS N
long-term POS N
IOP-lowering POS N
effect POS N
and POS N
surgical POS N
complications POS N
of POS N
combined POS N
trabeculectomy POS N
and POS N
cataract POS N
extraction POS N
are POS N
comparable POS N
with POS N
those POS N
of POS N
trabeculectomy POS N
alone. POS N

The POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
were POS N
similar POS N
between POS N
groups POS N
(p POS N
= POS N
0.232). POS N

However, POS N
the POS N
combined POS N
surgery POS N
incurred POS N
fewer POS N
subsequent POS N
surgical POS N
interventions. POS N

No POS N
additional POS N
IOP-lowering POS N
surgical POS N
procedures POS N
were POS N
required POS N
in POS N
the POS N
combined POS N
group, POS N
while POS N
13 POS N
(54%) POS N
eyes POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
required POS N
either POS N
cataract POS N
extraction POS N
or POS N
further POS N
IOP-lowering POS N
surgical POS N
procedures POS N
(p POS N
<0.001). POS N

The POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
were POS N
similar POS N
between POS N
groups POS N
(p POS N
= POS N
0.232). POS N

No POS N
additional POS N
IOP-lowering POS N
surgical POS N
procedures POS N
were POS N
required POS N
in POS N
the POS N
combined POS N
group, POS N
while POS N
13 POS N
(54%) POS N
eyes POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
required POS N
either POS N
cataract POS N
extraction POS N
or POS N
further POS N
IOP-lowering POS N
surgical POS N
procedures POS N
(p POS N
<0.001). POS N

In POS N
patients POS N
with POS N
PACG, POS N
the POS N
long-term POS N
IOP-lowering POS N
effect POS N
and POS N
surgical POS N
complications POS N
of POS N
combined POS N
trabeculectomy POS N
and POS N
cataract POS N
extraction POS N
are POS N
comparable POS N
with POS N
those POS N
of POS N
trabeculectomy POS N
alone. POS N

No POS N
additional POS N
IOP-lowering POS N
surgical POS N
procedures POS N
were POS N
required POS N
in POS N
the POS N
combined POS N
group, POS N
while POS N
13 POS N
(54%) POS N
eyes POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
required POS N
either POS N
cataract POS N
extraction POS N
or POS N
further POS N
IOP-lowering POS N
surgical POS N
procedures POS N
(p POS N
<0.001). POS N

However, POS N
the POS N
combined POS N
surgery POS N
incurred POS N
fewer POS N
subsequent POS N
surgical POS N
interventions. POS N

In POS N
patients POS N
with POS N
PACG, POS N
the POS N
long-term POS N
IOP-lowering POS N
effect POS N
and POS N
surgical POS N
complications POS N
of POS N
combined POS N
trabeculectomy POS N
and POS N
cataract POS N
extraction POS N
are POS N
comparable POS N
with POS N
those POS N
of POS N
trabeculectomy POS N
alone. POS N

The POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
were POS N
similar POS N
between POS N
groups POS N
(p POS N
= POS N
0.232). POS N

In POS N
patients POS N
with POS N
PACG, POS N
the POS N
long-term POS N
IOP-lowering POS N
effect POS N
and POS N
surgical POS N
complications POS N
of POS N
combined POS N
trabeculectomy POS N
and POS N
cataract POS N
extraction POS N
are POS N
comparable POS N
with POS N
those POS N
of POS N
trabeculectomy POS N
alone. POS N

No POS N
additional POS N
IOP-lowering POS N
surgical POS N
procedures POS N
were POS N
required POS N
in POS N
the POS N
combined POS N
group, POS N
while POS N
13 POS N
(54%) POS N
eyes POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
required POS N
either POS N
cataract POS N
extraction POS N
or POS N
further POS N
IOP-lowering POS N
surgical POS N
procedures POS N
(p POS N
<0.001). POS N

In POS N
patients POS N
with POS N
PACG, POS N
the POS N
long-term POS N
IOP-lowering POS N
effect POS N
and POS N
surgical POS N
complications POS N
of POS N
combined POS N
trabeculectomy POS N
and POS N
cataract POS N
extraction POS N
are POS N
comparable POS N
with POS N
those POS N
of POS N
trabeculectomy POS N
alone. POS N

However, POS N
the POS N
combined POS N
surgery POS N
incurred POS N
fewer POS N
subsequent POS N
surgical POS N
interventions. POS N

However, POS N
the POS N
combined POS N
surgery POS N
incurred POS N
fewer POS N
subsequent POS N
surgical POS N
interventions. POS N

The POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
were POS N
similar POS N
between POS N
groups POS N
(p POS N
= POS N
0.232). POS N

However, POS N
the POS N
combined POS N
surgery POS N
incurred POS N
fewer POS N
subsequent POS N
surgical POS N
interventions. POS N

No POS N
additional POS N
IOP-lowering POS N
surgical POS N
procedures POS N
were POS N
required POS N
in POS N
the POS N
combined POS N
group, POS N
while POS N
13 POS N
(54%) POS N
eyes POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
required POS N
either POS N
cataract POS N
extraction POS N
or POS N
further POS N
IOP-lowering POS N
surgical POS N
procedures POS N
(p POS N
<0.001). POS N

However, POS N
the POS N
combined POS N
surgery POS N
incurred POS N
fewer POS N
subsequent POS N
surgical POS N
interventions. POS N

In POS N
patients POS N
with POS N
PACG, POS N
the POS N
long-term POS N
IOP-lowering POS N
effect POS N
and POS N
surgical POS N
complications POS N
of POS N
combined POS N
trabeculectomy POS N
and POS N
cataract POS N
extraction POS N
are POS N
comparable POS N
with POS N
those POS N
of POS N
trabeculectomy POS N
alone. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

At POS N
1 POS N
year, POS N
IOP POS N
in POS N
both POS N
treatment POS N
groups POS N
was POS N
statistically POS N
significantly POS N
lower POS N
from POS N
baseline POS N
values. POS N

Sixty-six POS N
percent POS N
of POS N
treatment POS N
eyes POS N
versus POS N
48% POS N
of POS N
control POS N
eyes POS N
achieved POS N
=20% POS N
IOP POS N
reduction POS N
without POS N
medication POS N
(P POS N
= POS N
0.003). POS N

At POS N
1 POS N
year, POS N
IOP POS N
in POS N
both POS N
treatment POS N
groups POS N
was POS N
statistically POS N
significantly POS N
lower POS N
from POS N
baseline POS N
values. POS N

The POS N
overall POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
similar POS N
between POS N
groups POS N
with POS N
no POS N
unanticipated POS N
adverse POS N
device POS N
effects. POS N

At POS N
1 POS N
year, POS N
IOP POS N
in POS N
both POS N
treatment POS N
groups POS N
was POS N
statistically POS N
significantly POS N
lower POS N
from POS N
baseline POS N
values. POS N

Pressure POS N
reduction POS N
on POS N
fewer POS N
medications POS N
was POS N
clinically POS N
and POS N
statistically POS N
significantly POS N
better POS N
1 POS N
year POS N
after POS N
stent POS N
plus POS N
cataract POS N
surgery POS N
versus POS N
cataract POS N
surgery POS N
alone, POS N
with POS N
an POS N
overall POS N
safety POS N
profile POS N
similar POS N
to POS N
that POS N
of POS N
cataract POS N
surgery POS N
alone. POS N

Sixty-six POS N
percent POS N
of POS N
treatment POS N
eyes POS N
versus POS N
48% POS N
of POS N
control POS N
eyes POS N
achieved POS N
=20% POS N
IOP POS N
reduction POS N
without POS N
medication POS N
(P POS N
= POS N
0.003). POS N

At POS N
1 POS N
year, POS N
IOP POS N
in POS N
both POS N
treatment POS N
groups POS N
was POS N
statistically POS N
significantly POS N
lower POS N
from POS N
baseline POS N
values. POS N

Sixty-six POS N
percent POS N
of POS N
treatment POS N
eyes POS N
versus POS N
48% POS N
of POS N
control POS N
eyes POS N
achieved POS N
=20% POS N
IOP POS N
reduction POS N
without POS N
medication POS N
(P POS N
= POS N
0.003). POS N

The POS N
overall POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
similar POS N
between POS N
groups POS N
with POS N
no POS N
unanticipated POS N
adverse POS N
device POS N
effects. POS N

Sixty-six POS N
percent POS N
of POS N
treatment POS N
eyes POS N
versus POS N
48% POS N
of POS N
control POS N
eyes POS N
achieved POS N
=20% POS N
IOP POS N
reduction POS N
without POS N
medication POS N
(P POS N
= POS N
0.003). POS N

Pressure POS N
reduction POS N
on POS N
fewer POS N
medications POS N
was POS N
clinically POS N
and POS N
statistically POS N
significantly POS N
better POS N
1 POS N
year POS N
after POS N
stent POS N
plus POS N
cataract POS N
surgery POS N
versus POS N
cataract POS N
surgery POS N
alone, POS N
with POS N
an POS N
overall POS N
safety POS N
profile POS N
similar POS N
to POS N
that POS N
of POS N
cataract POS N
surgery POS N
alone. POS N

The POS N
overall POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
similar POS N
between POS N
groups POS N
with POS N
no POS N
unanticipated POS N
adverse POS N
device POS N
effects. POS N

At POS N
1 POS N
year, POS N
IOP POS N
in POS N
both POS N
treatment POS N
groups POS N
was POS N
statistically POS N
significantly POS N
lower POS N
from POS N
baseline POS N
values. POS N

The POS N
overall POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
similar POS N
between POS N
groups POS N
with POS N
no POS N
unanticipated POS N
adverse POS N
device POS N
effects. POS N

Sixty-six POS N
percent POS N
of POS N
treatment POS N
eyes POS N
versus POS N
48% POS N
of POS N
control POS N
eyes POS N
achieved POS N
=20% POS N
IOP POS N
reduction POS N
without POS N
medication POS N
(P POS N
= POS N
0.003). POS N

The POS N
overall POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
similar POS N
between POS N
groups POS N
with POS N
no POS N
unanticipated POS N
adverse POS N
device POS N
effects. POS N

Pressure POS N
reduction POS N
on POS N
fewer POS N
medications POS N
was POS N
clinically POS N
and POS N
statistically POS N
significantly POS N
better POS N
1 POS N
year POS N
after POS N
stent POS N
plus POS N
cataract POS N
surgery POS N
versus POS N
cataract POS N
surgery POS N
alone, POS N
with POS N
an POS N
overall POS N
safety POS N
profile POS N
similar POS N
to POS N
that POS N
of POS N
cataract POS N
surgery POS N
alone. POS N

Pressure POS N
reduction POS N
on POS N
fewer POS N
medications POS N
was POS N
clinically POS N
and POS N
statistically POS N
significantly POS N
better POS N
1 POS N
year POS N
after POS N
stent POS N
plus POS N
cataract POS N
surgery POS N
versus POS N
cataract POS N
surgery POS N
alone, POS N
with POS N
an POS N
overall POS N
safety POS N
profile POS N
similar POS N
to POS N
that POS N
of POS N
cataract POS N
surgery POS N
alone. POS N

At POS N
1 POS N
year, POS N
IOP POS N
in POS N
both POS N
treatment POS N
groups POS N
was POS N
statistically POS N
significantly POS N
lower POS N
from POS N
baseline POS N
values. POS N

Pressure POS N
reduction POS N
on POS N
fewer POS N
medications POS N
was POS N
clinically POS N
and POS N
statistically POS N
significantly POS N
better POS N
1 POS N
year POS N
after POS N
stent POS N
plus POS N
cataract POS N
surgery POS N
versus POS N
cataract POS N
surgery POS N
alone, POS N
with POS N
an POS N
overall POS N
safety POS N
profile POS N
similar POS N
to POS N
that POS N
of POS N
cataract POS N
surgery POS N
alone. POS N

Sixty-six POS N
percent POS N
of POS N
treatment POS N
eyes POS N
versus POS N
48% POS N
of POS N
control POS N
eyes POS N
achieved POS N
=20% POS N
IOP POS N
reduction POS N
without POS N
medication POS N
(P POS N
= POS N
0.003). POS N

Pressure POS N
reduction POS N
on POS N
fewer POS N
medications POS N
was POS N
clinically POS N
and POS N
statistically POS N
significantly POS N
better POS N
1 POS N
year POS N
after POS N
stent POS N
plus POS N
cataract POS N
surgery POS N
versus POS N
cataract POS N
surgery POS N
alone, POS N
with POS N
an POS N
overall POS N
safety POS N
profile POS N
similar POS N
to POS N
that POS N
of POS N
cataract POS N
surgery POS N
alone. POS N

The POS N
overall POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
similar POS N
between POS N
groups POS N
with POS N
no POS N
unanticipated POS N
adverse POS N
device POS N
effects. POS N

The POS N
mean POS N
IOP POS N
reduction POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
BTFC POS N
group POS N
than POS N
in POS N
the POS N
LTFC POS N
group POS N
(-21.4% POS N
vs POS N
-13.7%, POS N
p<0.001). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
in POS N
the POS N
BTFC POS N
group POS N
showed POS N
a POS N
mean POS N
IOP POS N
reduction POS N
from POS N
baseline POS N
>or=15% POS N
(72.3% POS N
vs POS N
40.0%) POS N
and POS N
>or=20% POS N
(61.7% POS N
vs POS N
17.1%) POS N
compared POS N
to POS N
patients POS N
in POS N
the POS N
LTFC POS N
group. POS N

The POS N
mean POS N
IOP POS N
reduction POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
BTFC POS N
group POS N
than POS N
in POS N
the POS N
LTFC POS N
group POS N
(-21.4% POS N
vs POS N
-13.7%, POS N
p<0.001). POS N

Both POS N
BTFC POS N
and POS N
LTFC POS N
were POS N
more POS N
effective POS N
versus POS N
the POS N
monotherapy POS N
with POS N
prostaglandin POS N
analogues. POS N

The POS N
mean POS N
IOP POS N
reduction POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
BTFC POS N
group POS N
than POS N
in POS N
the POS N
LTFC POS N
group POS N
(-21.4% POS N
vs POS N
-13.7%, POS N
p<0.001). POS N

BTFC POS N
demonstrated POS N
higher POS N
performance POS N
than POS N
LTFC POS N
in POS N
terms POS N
of POS N
relative POS N
IOP POS N
reduction. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
in POS N
the POS N
BTFC POS N
group POS N
showed POS N
a POS N
mean POS N
IOP POS N
reduction POS N
from POS N
baseline POS N
>or=15% POS N
(72.3% POS N
vs POS N
40.0%) POS N
and POS N
>or=20% POS N
(61.7% POS N
vs POS N
17.1%) POS N
compared POS N
to POS N
patients POS N
in POS N
the POS N
LTFC POS N
group. POS N

The POS N
mean POS N
IOP POS N
reduction POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
BTFC POS N
group POS N
than POS N
in POS N
the POS N
LTFC POS N
group POS N
(-21.4% POS N
vs POS N
-13.7%, POS N
p<0.001). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
in POS N
the POS N
BTFC POS N
group POS N
showed POS N
a POS N
mean POS N
IOP POS N
reduction POS N
from POS N
baseline POS N
>or=15% POS N
(72.3% POS N
vs POS N
40.0%) POS N
and POS N
>or=20% POS N
(61.7% POS N
vs POS N
17.1%) POS N
compared POS N
to POS N
patients POS N
in POS N
the POS N
LTFC POS N
group. POS N

Both POS N
BTFC POS N
and POS N
LTFC POS N
were POS N
more POS N
effective POS N
versus POS N
the POS N
monotherapy POS N
with POS N
prostaglandin POS N
analogues. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
in POS N
the POS N
BTFC POS N
group POS N
showed POS N
a POS N
mean POS N
IOP POS N
reduction POS N
from POS N
baseline POS N
>or=15% POS N
(72.3% POS N
vs POS N
40.0%) POS N
and POS N
>or=20% POS N
(61.7% POS N
vs POS N
17.1%) POS N
compared POS N
to POS N
patients POS N
in POS N
the POS N
LTFC POS N
group. POS N

BTFC POS N
demonstrated POS N
higher POS N
performance POS N
than POS N
LTFC POS N
in POS N
terms POS N
of POS N
relative POS N
IOP POS N
reduction. POS N

Both POS N
BTFC POS N
and POS N
LTFC POS N
were POS N
more POS N
effective POS N
versus POS N
the POS N
monotherapy POS N
with POS N
prostaglandin POS N
analogues. POS N

The POS N
mean POS N
IOP POS N
reduction POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
BTFC POS N
group POS N
than POS N
in POS N
the POS N
LTFC POS N
group POS N
(-21.4% POS N
vs POS N
-13.7%, POS N
p<0.001). POS N

Both POS N
BTFC POS N
and POS N
LTFC POS N
were POS N
more POS N
effective POS N
versus POS N
the POS N
monotherapy POS N
with POS N
prostaglandin POS N
analogues. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
in POS N
the POS N
BTFC POS N
group POS N
showed POS N
a POS N
mean POS N
IOP POS N
reduction POS N
from POS N
baseline POS N
>or=15% POS N
(72.3% POS N
vs POS N
40.0%) POS N
and POS N
>or=20% POS N
(61.7% POS N
vs POS N
17.1%) POS N
compared POS N
to POS N
patients POS N
in POS N
the POS N
LTFC POS N
group. POS N

Both POS N
BTFC POS N
and POS N
LTFC POS N
were POS N
more POS N
effective POS N
versus POS N
the POS N
monotherapy POS N
with POS N
prostaglandin POS N
analogues. POS N

BTFC POS N
demonstrated POS N
higher POS N
performance POS N
than POS N
LTFC POS N
in POS N
terms POS N
of POS N
relative POS N
IOP POS N
reduction. POS N

BTFC POS N
demonstrated POS N
higher POS N
performance POS N
than POS N
LTFC POS N
in POS N
terms POS N
of POS N
relative POS N
IOP POS N
reduction. POS N

The POS N
mean POS N
IOP POS N
reduction POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
BTFC POS N
group POS N
than POS N
in POS N
the POS N
LTFC POS N
group POS N
(-21.4% POS N
vs POS N
-13.7%, POS N
p<0.001). POS N

BTFC POS N
demonstrated POS N
higher POS N
performance POS N
than POS N
LTFC POS N
in POS N
terms POS N
of POS N
relative POS N
IOP POS N
reduction. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
in POS N
the POS N
BTFC POS N
group POS N
showed POS N
a POS N
mean POS N
IOP POS N
reduction POS N
from POS N
baseline POS N
>or=15% POS N
(72.3% POS N
vs POS N
40.0%) POS N
and POS N
>or=20% POS N
(61.7% POS N
vs POS N
17.1%) POS N
compared POS N
to POS N
patients POS N
in POS N
the POS N
LTFC POS N
group. POS N

BTFC POS N
demonstrated POS N
higher POS N
performance POS N
than POS N
LTFC POS N
in POS N
terms POS N
of POS N
relative POS N
IOP POS N
reduction. POS N

Both POS N
BTFC POS N
and POS N
LTFC POS N
were POS N
more POS N
effective POS N
versus POS N
the POS N
monotherapy POS N
with POS N
prostaglandin POS N
analogues. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
plus POS N
dorzolamide POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

Latanoprost POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
1.09 POS N
and POS N
1.58 POS N
mm POS N
Hg POS N
more POS N
than POS N
timolol POS N
plus POS N
dorzolamide POS N
after POS N
2 POS N
weeks POS N
and POS N
3 POS N
months POS N
of POS N
treatment, POS N
respectively. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
plus POS N
dorzolamide POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

These POS N
differences POS N
were POS N
statistically POS N
significant POS N
(p<0.05) POS N
at POS N
the POS N
end POS N
of POS N
the POS N
study. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
plus POS N
dorzolamide POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
32.3% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
latanoprost POS N
group POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
in POS N
30% POS N
or POS N
more POS N
with POS N
respect POS N
to POS N
baseline, POS N
while POS N
15.6% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
timolol POS N
plus POS N
dorzolamide POS N
group POS N
achieved POS N
this POS N
reduction. POS N

Latanoprost POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
1.09 POS N
and POS N
1.58 POS N
mm POS N
Hg POS N
more POS N
than POS N
timolol POS N
plus POS N
dorzolamide POS N
after POS N
2 POS N
weeks POS N
and POS N
3 POS N
months POS N
of POS N
treatment, POS N
respectively. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
plus POS N
dorzolamide POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

Latanoprost POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
1.09 POS N
and POS N
1.58 POS N
mm POS N
Hg POS N
more POS N
than POS N
timolol POS N
plus POS N
dorzolamide POS N
after POS N
2 POS N
weeks POS N
and POS N
3 POS N
months POS N
of POS N
treatment, POS N
respectively. POS N

These POS N
differences POS N
were POS N
statistically POS N
significant POS N
(p<0.05) POS N
at POS N
the POS N
end POS N
of POS N
the POS N
study. POS N

Latanoprost POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
1.09 POS N
and POS N
1.58 POS N
mm POS N
Hg POS N
more POS N
than POS N
timolol POS N
plus POS N
dorzolamide POS N
after POS N
2 POS N
weeks POS N
and POS N
3 POS N
months POS N
of POS N
treatment, POS N
respectively. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
32.3% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
latanoprost POS N
group POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
in POS N
30% POS N
or POS N
more POS N
with POS N
respect POS N
to POS N
baseline, POS N
while POS N
15.6% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
timolol POS N
plus POS N
dorzolamide POS N
group POS N
achieved POS N
this POS N
reduction. POS N

These POS N
differences POS N
were POS N
statistically POS N
significant POS N
(p<0.05) POS N
at POS N
the POS N
end POS N
of POS N
the POS N
study. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
plus POS N
dorzolamide POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

These POS N
differences POS N
were POS N
statistically POS N
significant POS N
(p<0.05) POS N
at POS N
the POS N
end POS N
of POS N
the POS N
study. POS N

Latanoprost POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
1.09 POS N
and POS N
1.58 POS N
mm POS N
Hg POS N
more POS N
than POS N
timolol POS N
plus POS N
dorzolamide POS N
after POS N
2 POS N
weeks POS N
and POS N
3 POS N
months POS N
of POS N
treatment, POS N
respectively. POS N

These POS N
differences POS N
were POS N
statistically POS N
significant POS N
(p<0.05) POS N
at POS N
the POS N
end POS N
of POS N
the POS N
study. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
32.3% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
latanoprost POS N
group POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
in POS N
30% POS N
or POS N
more POS N
with POS N
respect POS N
to POS N
baseline, POS N
while POS N
15.6% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
timolol POS N
plus POS N
dorzolamide POS N
group POS N
achieved POS N
this POS N
reduction. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
32.3% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
latanoprost POS N
group POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
in POS N
30% POS N
or POS N
more POS N
with POS N
respect POS N
to POS N
baseline, POS N
while POS N
15.6% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
timolol POS N
plus POS N
dorzolamide POS N
group POS N
achieved POS N
this POS N
reduction. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
plus POS N
dorzolamide POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
32.3% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
latanoprost POS N
group POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
in POS N
30% POS N
or POS N
more POS N
with POS N
respect POS N
to POS N
baseline, POS N
while POS N
15.6% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
timolol POS N
plus POS N
dorzolamide POS N
group POS N
achieved POS N
this POS N
reduction. POS N

Latanoprost POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
1.09 POS N
and POS N
1.58 POS N
mm POS N
Hg POS N
more POS N
than POS N
timolol POS N
plus POS N
dorzolamide POS N
after POS N
2 POS N
weeks POS N
and POS N
3 POS N
months POS N
of POS N
treatment, POS N
respectively. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
32.3% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
latanoprost POS N
group POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
in POS N
30% POS N
or POS N
more POS N
with POS N
respect POS N
to POS N
baseline, POS N
while POS N
15.6% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
timolol POS N
plus POS N
dorzolamide POS N
group POS N
achieved POS N
this POS N
reduction. POS N

These POS N
differences POS N
were POS N
statistically POS N
significant POS N
(p<0.05) POS N
at POS N
the POS N
end POS N
of POS N
the POS N
study. POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP POS N
reduction POS N
between POS N
viscocanalostomy POS N
and POS N
trabeculectomy POS N
with POS N
mitomycin POS N
C POS N
in POS N
combination POS N
with POS N
phacoemulsification POS N
and POS N
intraocular POS N
lens POS N
implantation POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma. POS N

At POS N
12 POS N
months, POS N
17 POS N
patients POS N
(85%) POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
16 POS N
patients POS N
(80%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
achieved POS N
an POS N
IOP POS N
of POS N
20 POS N
mmHg POS N
or POS N
less POS N
without POS N
medication POS N
(P POS N
= POS N
0.7). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP POS N
reduction POS N
between POS N
viscocanalostomy POS N
and POS N
trabeculectomy POS N
with POS N
mitomycin POS N
C POS N
in POS N
combination POS N
with POS N
phacoemulsification POS N
and POS N
intraocular POS N
lens POS N
implantation POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma. POS N

Mean POS N
baseline POS N
IOP POS N
was POS N
24.0+/-2.0 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
23.7+/-2.6 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.7). POS N
Mean POS N
postoperative POS N
IOP POS N
was POS N
13.7+/-2.2 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
14.8+/-3.3 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.9+/-3.0 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
12.1+/-4.0 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
13.8+/-4.7 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.1+/-4.4 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

At POS N
12 POS N
months, POS N
17 POS N
patients POS N
(85%) POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
16 POS N
patients POS N
(80%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
achieved POS N
an POS N
IOP POS N
of POS N
20 POS N
mmHg POS N
or POS N
less POS N
without POS N
medication POS N
(P POS N
= POS N
0.7). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP POS N
reduction POS N
between POS N
viscocanalostomy POS N
and POS N
trabeculectomy POS N
with POS N
mitomycin POS N
C POS N
in POS N
combination POS N
with POS N
phacoemulsification POS N
and POS N
intraocular POS N
lens POS N
implantation POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma. POS N

At POS N
12 POS N
months, POS N
17 POS N
patients POS N
(85%) POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
16 POS N
patients POS N
(80%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
achieved POS N
an POS N
IOP POS N
of POS N
20 POS N
mmHg POS N
or POS N
less POS N
without POS N
medication POS N
(P POS N
= POS N
0.7). POS N

Mean POS N
baseline POS N
IOP POS N
was POS N
24.0+/-2.0 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
23.7+/-2.6 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.7). POS N
Mean POS N
postoperative POS N
IOP POS N
was POS N
13.7+/-2.2 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
14.8+/-3.3 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.9+/-3.0 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
12.1+/-4.0 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
13.8+/-4.7 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.1+/-4.4 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

Mean POS N
baseline POS N
IOP POS N
was POS N
24.0+/-2.0 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
23.7+/-2.6 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.7). POS N
Mean POS N
postoperative POS N
IOP POS N
was POS N
13.7+/-2.2 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
14.8+/-3.3 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.9+/-3.0 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
12.1+/-4.0 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
13.8+/-4.7 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.1+/-4.4 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP POS N
reduction POS N
between POS N
viscocanalostomy POS N
and POS N
trabeculectomy POS N
with POS N
mitomycin POS N
C POS N
in POS N
combination POS N
with POS N
phacoemulsification POS N
and POS N
intraocular POS N
lens POS N
implantation POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma. POS N

Mean POS N
baseline POS N
IOP POS N
was POS N
24.0+/-2.0 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
23.7+/-2.6 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.7). POS N
Mean POS N
postoperative POS N
IOP POS N
was POS N
13.7+/-2.2 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
14.8+/-3.3 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.9+/-3.0 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
12.1+/-4.0 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
13.8+/-4.7 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.1+/-4.4 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

At POS N
12 POS N
months, POS N
17 POS N
patients POS N
(85%) POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
16 POS N
patients POS N
(80%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
achieved POS N
an POS N
IOP POS N
of POS N
20 POS N
mmHg POS N
or POS N
less POS N
without POS N
medication POS N
(P POS N
= POS N
0.7). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

In POS N
a POS N
case-controlled POS N
comparison, POS N
the POS N
Baerveldt-350 POS N
implant POS N
and POS N
the POS N
Ahmed POS N
valve POS N
had POS N
similar POS N
IOP POS N
control POS N
and POS N
surgical POS N
outcomes POS N
in POS N
patients POS N
with POS N
refractory POS N
glaucoma POS N
at POS N
1-year POS N
follow-up. POS N

Over POS N
a POS N
follow-up POS N
period POS N
of POS N
1 POS N
year, POS N
no POS N
statistically POS N
significant POS N
differences POS N
were POS N
detected POS N
between POS N
the POS N
Baerveldt-350 POS N
implant POS N
versus POS N
Ahmed POS N
valve POS N
for POS N
IOP POS N
control POS N
(12.1 POS N
+/- POS N
5.3 POS N
mm POS N
Hg POS N
vs POS N
13.6 POS N
+/- POS N
5.6 POS N
mm POS N
Hg POS N
respectively, POS N
at POS N
a POS N
power POS N
of POS N
90% POS N
to POS N
detect POS N
a POS N
difference POS N
of POS N
3.2 POS N
mm POS N
Hg POS N
between POS N
the POS N
two POS N
groups POS N
and POS N
P POS N
= POS N
0.05), POS N
surgical POS N
success POS N
rate POS N
(65.6% POS N
vs. POS N
65.6% POS N
respectively, POS N
complete POS N
and POS N
qualified POS N
combined), POS N
postoperative POS N
hypotony POS N
rate POS N
(37.5% POS N
vs. POS N
34.4% POS N
respectively), POS N
and POS N
visual POS N
acuity POS N
changes POS N
of POS N
more POS N
than POS N
1 POS N
line POS N
in POS N
Snellen POS N
visual POS N
acuity POS N
(43.3% POS N
vs. POS N
29.0% POS N
respectively). POS N

In POS N
a POS N
case-controlled POS N
comparison, POS N
the POS N
Baerveldt-350 POS N
implant POS N
and POS N
the POS N
Ahmed POS N
valve POS N
had POS N
similar POS N
IOP POS N
control POS N
and POS N
surgical POS N
outcomes POS N
in POS N
patients POS N
with POS N
refractory POS N
glaucoma POS N
at POS N
1-year POS N
follow-up. POS N

Surgical POS N
success POS N
rate POS N
was POS N
defined POS N
as POS N
an POS N
IOP POS N
reduction POS N
greater POS N
than POS N
or POS N
equal POS N
to POS N
30% POS N
and POS N
final POS N
IOP POS N
more POS N
than POS N
5 POS N
mm POS N
Hg POS N
and POS N
less POS N
than POS N
22 POS N
mm POS N
Hg, POS N
without POS N
devastating POS N
complications. POS N

Over POS N
a POS N
follow-up POS N
period POS N
of POS N
1 POS N
year, POS N
no POS N
statistically POS N
significant POS N
differences POS N
were POS N
detected POS N
between POS N
the POS N
Baerveldt-350 POS N
implant POS N
versus POS N
Ahmed POS N
valve POS N
for POS N
IOP POS N
control POS N
(12.1 POS N
+/- POS N
5.3 POS N
mm POS N
Hg POS N
vs POS N
13.6 POS N
+/- POS N
5.6 POS N
mm POS N
Hg POS N
respectively, POS N
at POS N
a POS N
power POS N
of POS N
90% POS N
to POS N
detect POS N
a POS N
difference POS N
of POS N
3.2 POS N
mm POS N
Hg POS N
between POS N
the POS N
two POS N
groups POS N
and POS N
P POS N
= POS N
0.05), POS N
surgical POS N
success POS N
rate POS N
(65.6% POS N
vs. POS N
65.6% POS N
respectively, POS N
complete POS N
and POS N
qualified POS N
combined), POS N
postoperative POS N
hypotony POS N
rate POS N
(37.5% POS N
vs. POS N
34.4% POS N
respectively), POS N
and POS N
visual POS N
acuity POS N
changes POS N
of POS N
more POS N
than POS N
1 POS N
line POS N
in POS N
Snellen POS N
visual POS N
acuity POS N
(43.3% POS N
vs. POS N
29.0% POS N
respectively). POS N

In POS N
a POS N
case-controlled POS N
comparison, POS N
the POS N
Baerveldt-350 POS N
implant POS N
and POS N
the POS N
Ahmed POS N
valve POS N
had POS N
similar POS N
IOP POS N
control POS N
and POS N
surgical POS N
outcomes POS N
in POS N
patients POS N
with POS N
refractory POS N
glaucoma POS N
at POS N
1-year POS N
follow-up. POS N

Over POS N
a POS N
follow-up POS N
period POS N
of POS N
1 POS N
year, POS N
no POS N
statistically POS N
significant POS N
differences POS N
were POS N
detected POS N
between POS N
the POS N
Baerveldt-350 POS N
implant POS N
versus POS N
Ahmed POS N
valve POS N
for POS N
IOP POS N
control POS N
(12.1 POS N
+/- POS N
5.3 POS N
mm POS N
Hg POS N
vs POS N
13.6 POS N
+/- POS N
5.6 POS N
mm POS N
Hg POS N
respectively, POS N
at POS N
a POS N
power POS N
of POS N
90% POS N
to POS N
detect POS N
a POS N
difference POS N
of POS N
3.2 POS N
mm POS N
Hg POS N
between POS N
the POS N
two POS N
groups POS N
and POS N
P POS N
= POS N
0.05), POS N
surgical POS N
success POS N
rate POS N
(65.6% POS N
vs. POS N
65.6% POS N
respectively, POS N
complete POS N
and POS N
qualified POS N
combined), POS N
postoperative POS N
hypotony POS N
rate POS N
(37.5% POS N
vs. POS N
34.4% POS N
respectively), POS N
and POS N
visual POS N
acuity POS N
changes POS N
of POS N
more POS N
than POS N
1 POS N
line POS N
in POS N
Snellen POS N
visual POS N
acuity POS N
(43.3% POS N
vs. POS N
29.0% POS N
respectively). POS N

Surgical POS N
success POS N
rate POS N
was POS N
defined POS N
as POS N
an POS N
IOP POS N
reduction POS N
greater POS N
than POS N
or POS N
equal POS N
to POS N
30% POS N
and POS N
final POS N
IOP POS N
more POS N
than POS N
5 POS N
mm POS N
Hg POS N
and POS N
less POS N
than POS N
22 POS N
mm POS N
Hg, POS N
without POS N
devastating POS N
complications. POS N

Surgical POS N
success POS N
rate POS N
was POS N
defined POS N
as POS N
an POS N
IOP POS N
reduction POS N
greater POS N
than POS N
or POS N
equal POS N
to POS N
30% POS N
and POS N
final POS N
IOP POS N
more POS N
than POS N
5 POS N
mm POS N
Hg POS N
and POS N
less POS N
than POS N
22 POS N
mm POS N
Hg, POS N
without POS N
devastating POS N
complications. POS N

In POS N
a POS N
case-controlled POS N
comparison, POS N
the POS N
Baerveldt-350 POS N
implant POS N
and POS N
the POS N
Ahmed POS N
valve POS N
had POS N
similar POS N
IOP POS N
control POS N
and POS N
surgical POS N
outcomes POS N
in POS N
patients POS N
with POS N
refractory POS N
glaucoma POS N
at POS N
1-year POS N
follow-up. POS N

Surgical POS N
success POS N
rate POS N
was POS N
defined POS N
as POS N
an POS N
IOP POS N
reduction POS N
greater POS N
than POS N
or POS N
equal POS N
to POS N
30% POS N
and POS N
final POS N
IOP POS N
more POS N
than POS N
5 POS N
mm POS N
Hg POS N
and POS N
less POS N
than POS N
22 POS N
mm POS N
Hg, POS N
without POS N
devastating POS N
complications. POS N

Over POS N
a POS N
follow-up POS N
period POS N
of POS N
1 POS N
year, POS N
no POS N
statistically POS N
significant POS N
differences POS N
were POS N
detected POS N
between POS N
the POS N
Baerveldt-350 POS N
implant POS N
versus POS N
Ahmed POS N
valve POS N
for POS N
IOP POS N
control POS N
(12.1 POS N
+/- POS N
5.3 POS N
mm POS N
Hg POS N
vs POS N
13.6 POS N
+/- POS N
5.6 POS N
mm POS N
Hg POS N
respectively, POS N
at POS N
a POS N
power POS N
of POS N
90% POS N
to POS N
detect POS N
a POS N
difference POS N
of POS N
3.2 POS N
mm POS N
Hg POS N
between POS N
the POS N
two POS N
groups POS N
and POS N
P POS N
= POS N
0.05), POS N
surgical POS N
success POS N
rate POS N
(65.6% POS N
vs. POS N
65.6% POS N
respectively, POS N
complete POS N
and POS N
qualified POS N
combined), POS N
postoperative POS N
hypotony POS N
rate POS N
(37.5% POS N
vs. POS N
34.4% POS N
respectively), POS N
and POS N
visual POS N
acuity POS N
changes POS N
of POS N
more POS N
than POS N
1 POS N
line POS N
in POS N
Snellen POS N
visual POS N
acuity POS N
(43.3% POS N
vs. POS N
29.0% POS N
respectively). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
period POS N
when POS N
all POS N
patients POS N
were POS N
dosed POS N
in POS N
the POS N
evening POS N
was POS N
assessed POS N
12 POS N
h POS N
after POS N
dosing POS N
at POS N
09:00 POS N
and POS N
it POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
treatment POS N
groups POS N
(mean POS N
+/- POS N
standard POS N
deviation: POS N
17.9 POS N
+/- POS N
2.7 POS N
mmHg POS N
for POS N
travoprost POS N
versus POS N
17.7 POS N
+/- POS N
2.5 POS N
mmHg POS N
for POS N
latanoprost, POS N
p POS N
= POS N
0.812). POS N

In POS N
the POS N
a.m.-dosing POS N
crossover POS N
comparison, POS N
the POS N
24-h POS N
post-dose POS N
IOP POS N
was POS N
significantly POS N
lower POS N
( POS N
p POS N
< POS N
0.001) POS N
on POS N
travoprost POS N
(16.9 POS N
+/- POS N
3.1 POS N
mmHg) POS N
compared POS N
to POS N
latanoprost POS N
(18.6 POS N
+/- POS N
3.3 POS N
mmHg). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
period POS N
when POS N
all POS N
patients POS N
were POS N
dosed POS N
in POS N
the POS N
evening POS N
was POS N
assessed POS N
12 POS N
h POS N
after POS N
dosing POS N
at POS N
09:00 POS N
and POS N
it POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
treatment POS N
groups POS N
(mean POS N
+/- POS N
standard POS N
deviation: POS N
17.9 POS N
+/- POS N
2.7 POS N
mmHg POS N
for POS N
travoprost POS N
versus POS N
17.7 POS N
+/- POS N
2.5 POS N
mmHg POS N
for POS N
latanoprost, POS N
p POS N
= POS N
0.812). POS N

a.m.-dosed POS N
travoprost POS N
is POS N
superior POS N
to POS N
a.m.-dosed POS N
latanoprost POS N
by POS N
1.7 POS N
mmHg POS N
at POS N
24-h POS N
post-dose. POS N

In POS N
the POS N
a.m.-dosing POS N
crossover POS N
comparison, POS N
the POS N
24-h POS N
post-dose POS N
IOP POS N
was POS N
significantly POS N
lower POS N
( POS N
p POS N
< POS N
0.001) POS N
on POS N
travoprost POS N
(16.9 POS N
+/- POS N
3.1 POS N
mmHg) POS N
compared POS N
to POS N
latanoprost POS N
(18.6 POS N
+/- POS N
3.3 POS N
mmHg). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
period POS N
when POS N
all POS N
patients POS N
were POS N
dosed POS N
in POS N
the POS N
evening POS N
was POS N
assessed POS N
12 POS N
h POS N
after POS N
dosing POS N
at POS N
09:00 POS N
and POS N
it POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
treatment POS N
groups POS N
(mean POS N
+/- POS N
standard POS N
deviation: POS N
17.9 POS N
+/- POS N
2.7 POS N
mmHg POS N
for POS N
travoprost POS N
versus POS N
17.7 POS N
+/- POS N
2.5 POS N
mmHg POS N
for POS N
latanoprost, POS N
p POS N
= POS N
0.812). POS N

In POS N
the POS N
a.m.-dosing POS N
crossover POS N
comparison, POS N
the POS N
24-h POS N
post-dose POS N
IOP POS N
was POS N
significantly POS N
lower POS N
( POS N
p POS N
< POS N
0.001) POS N
on POS N
travoprost POS N
(16.9 POS N
+/- POS N
3.1 POS N
mmHg) POS N
compared POS N
to POS N
latanoprost POS N
(18.6 POS N
+/- POS N
3.3 POS N
mmHg). POS N

a.m.-dosed POS N
travoprost POS N
is POS N
superior POS N
to POS N
a.m.-dosed POS N
latanoprost POS N
by POS N
1.7 POS N
mmHg POS N
at POS N
24-h POS N
post-dose. POS N

a.m.-dosed POS N
travoprost POS N
is POS N
superior POS N
to POS N
a.m.-dosed POS N
latanoprost POS N
by POS N
1.7 POS N
mmHg POS N
at POS N
24-h POS N
post-dose. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
period POS N
when POS N
all POS N
patients POS N
were POS N
dosed POS N
in POS N
the POS N
evening POS N
was POS N
assessed POS N
12 POS N
h POS N
after POS N
dosing POS N
at POS N
09:00 POS N
and POS N
it POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
treatment POS N
groups POS N
(mean POS N
+/- POS N
standard POS N
deviation: POS N
17.9 POS N
+/- POS N
2.7 POS N
mmHg POS N
for POS N
travoprost POS N
versus POS N
17.7 POS N
+/- POS N
2.5 POS N
mmHg POS N
for POS N
latanoprost, POS N
p POS N
= POS N
0.812). POS N

a.m.-dosed POS N
travoprost POS N
is POS N
superior POS N
to POS N
a.m.-dosed POS N
latanoprost POS N
by POS N
1.7 POS N
mmHg POS N
at POS N
24-h POS N
post-dose. POS N

In POS N
the POS N
a.m.-dosing POS N
crossover POS N
comparison, POS N
the POS N
24-h POS N
post-dose POS N
IOP POS N
was POS N
significantly POS N
lower POS N
( POS N
p POS N
< POS N
0.001) POS N
on POS N
travoprost POS N
(16.9 POS N
+/- POS N
3.1 POS N
mmHg) POS N
compared POS N
to POS N
latanoprost POS N
(18.6 POS N
+/- POS N
3.3 POS N
mmHg). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
unoprostone POS N
administered POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
OH. POS N

From POS N
an POS N
overall POS N
baseline POS N
of POS N
24.1 POS N
mmHg, POS N
latanoprost POS N
reduced POS N
IOP POS N
by POS N
6.7 POS N
mmHg POS N
(28%) POS N
and POS N
unoprostone POS N
reduced POS N
IOP POS N
by POS N
3.3 POS N
mmHg POS N
(14%). POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
unoprostone POS N
administered POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
OH. POS N

The POS N
difference POS N
between POS N
the POS N
groups POS N
of POS N
3.4 POS N
mmHg POS N
was POS N
significant POS N
(P: POS N
< POS N
0.001, POS N
analysis POS N
of POS N
covariance; POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
-4.7 POS N
to POS N
-2.1) POS N
in POS N
favor POS N
of POS N
latanoprost. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
unoprostone POS N
administered POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
OH. POS N

A POS N
>/=30% POS N
reduction POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline POS N
was POS N
achieved POS N
by POS N
44% POS N
of POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
8% POS N
of POS N
unoprostone-treated POS N
patients. POS N

From POS N
an POS N
overall POS N
baseline POS N
of POS N
24.1 POS N
mmHg, POS N
latanoprost POS N
reduced POS N
IOP POS N
by POS N
6.7 POS N
mmHg POS N
(28%) POS N
and POS N
unoprostone POS N
reduced POS N
IOP POS N
by POS N
3.3 POS N
mmHg POS N
(14%). POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
unoprostone POS N
administered POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
OH. POS N

From POS N
an POS N
overall POS N
baseline POS N
of POS N
24.1 POS N
mmHg, POS N
latanoprost POS N
reduced POS N
IOP POS N
by POS N
6.7 POS N
mmHg POS N
(28%) POS N
and POS N
unoprostone POS N
reduced POS N
IOP POS N
by POS N
3.3 POS N
mmHg POS N
(14%). POS N

The POS N
difference POS N
between POS N
the POS N
groups POS N
of POS N
3.4 POS N
mmHg POS N
was POS N
significant POS N
(P: POS N
< POS N
0.001, POS N
analysis POS N
of POS N
covariance; POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
-4.7 POS N
to POS N
-2.1) POS N
in POS N
favor POS N
of POS N
latanoprost. POS N

From POS N
an POS N
overall POS N
baseline POS N
of POS N
24.1 POS N
mmHg, POS N
latanoprost POS N
reduced POS N
IOP POS N
by POS N
6.7 POS N
mmHg POS N
(28%) POS N
and POS N
unoprostone POS N
reduced POS N
IOP POS N
by POS N
3.3 POS N
mmHg POS N
(14%). POS N

A POS N
>/=30% POS N
reduction POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline POS N
was POS N
achieved POS N
by POS N
44% POS N
of POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
8% POS N
of POS N
unoprostone-treated POS N
patients. POS N

The POS N
difference POS N
between POS N
the POS N
groups POS N
of POS N
3.4 POS N
mmHg POS N
was POS N
significant POS N
(P: POS N
< POS N
0.001, POS N
analysis POS N
of POS N
covariance; POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
-4.7 POS N
to POS N
-2.1) POS N
in POS N
favor POS N
of POS N
latanoprost. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
unoprostone POS N
administered POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
OH. POS N

The POS N
difference POS N
between POS N
the POS N
groups POS N
of POS N
3.4 POS N
mmHg POS N
was POS N
significant POS N
(P: POS N
< POS N
0.001, POS N
analysis POS N
of POS N
covariance; POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
-4.7 POS N
to POS N
-2.1) POS N
in POS N
favor POS N
of POS N
latanoprost. POS N

From POS N
an POS N
overall POS N
baseline POS N
of POS N
24.1 POS N
mmHg, POS N
latanoprost POS N
reduced POS N
IOP POS N
by POS N
6.7 POS N
mmHg POS N
(28%) POS N
and POS N
unoprostone POS N
reduced POS N
IOP POS N
by POS N
3.3 POS N
mmHg POS N
(14%). POS N

The POS N
difference POS N
between POS N
the POS N
groups POS N
of POS N
3.4 POS N
mmHg POS N
was POS N
significant POS N
(P: POS N
< POS N
0.001, POS N
analysis POS N
of POS N
covariance; POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
-4.7 POS N
to POS N
-2.1) POS N
in POS N
favor POS N
of POS N
latanoprost. POS N

A POS N
>/=30% POS N
reduction POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline POS N
was POS N
achieved POS N
by POS N
44% POS N
of POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
8% POS N
of POS N
unoprostone-treated POS N
patients. POS N

A POS N
>/=30% POS N
reduction POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline POS N
was POS N
achieved POS N
by POS N
44% POS N
of POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
8% POS N
of POS N
unoprostone-treated POS N
patients. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
unoprostone POS N
administered POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
OH. POS N

A POS N
>/=30% POS N
reduction POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline POS N
was POS N
achieved POS N
by POS N
44% POS N
of POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
8% POS N
of POS N
unoprostone-treated POS N
patients. POS N

From POS N
an POS N
overall POS N
baseline POS N
of POS N
24.1 POS N
mmHg, POS N
latanoprost POS N
reduced POS N
IOP POS N
by POS N
6.7 POS N
mmHg POS N
(28%) POS N
and POS N
unoprostone POS N
reduced POS N
IOP POS N
by POS N
3.3 POS N
mmHg POS N
(14%). POS N

A POS N
>/=30% POS N
reduction POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline POS N
was POS N
achieved POS N
by POS N
44% POS N
of POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
8% POS N
of POS N
unoprostone-treated POS N
patients. POS N

The POS N
difference POS N
between POS N
the POS N
groups POS N
of POS N
3.4 POS N
mmHg POS N
was POS N
significant POS N
(P: POS N
< POS N
0.001, POS N
analysis POS N
of POS N
covariance; POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
-4.7 POS N
to POS N
-2.1) POS N
in POS N
favor POS N
of POS N
latanoprost. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
6 POS N
months POS N
(range, POS N
6-8 POS N
months), POS N
success POS N
was POS N
obtained POS N
in POS N
5 POS N
of POS N
10 POS N
cases POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
0 POS N
of POS N
10 POS N
case POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

With POS N
Kaplan-Meier's POS N
method, POS N
subjects POS N
with POS N
viscocanalostomy POS N
showed POS N
shorter POS N
postoperative POS N
IOP-reduction POS N
periods POS N
than POS N
subjects POS N
undergoing POS N
trabeculectomy. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
6 POS N
months POS N
(range, POS N
6-8 POS N
months), POS N
success POS N
was POS N
obtained POS N
in POS N
5 POS N
of POS N
10 POS N
cases POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
0 POS N
of POS N
10 POS N
case POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

According POS N
to POS N
the POS N
results POS N
of POS N
this POS N
short-term POS N
study, POS N
trabeculectomy POS N
was POS N
more POS N
effective POS N
than POS N
viscocanalostomy POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes POS N
of POS N
white POS N
patients. POS N

With POS N
Kaplan-Meier's POS N
method, POS N
subjects POS N
with POS N
viscocanalostomy POS N
showed POS N
shorter POS N
postoperative POS N
IOP-reduction POS N
periods POS N
than POS N
subjects POS N
undergoing POS N
trabeculectomy. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
6 POS N
months POS N
(range, POS N
6-8 POS N
months), POS N
success POS N
was POS N
obtained POS N
in POS N
5 POS N
of POS N
10 POS N
cases POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
0 POS N
of POS N
10 POS N
case POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

With POS N
Kaplan-Meier's POS N
method, POS N
subjects POS N
with POS N
viscocanalostomy POS N
showed POS N
shorter POS N
postoperative POS N
IOP-reduction POS N
periods POS N
than POS N
subjects POS N
undergoing POS N
trabeculectomy. POS N

According POS N
to POS N
the POS N
results POS N
of POS N
this POS N
short-term POS N
study, POS N
trabeculectomy POS N
was POS N
more POS N
effective POS N
than POS N
viscocanalostomy POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes POS N
of POS N
white POS N
patients. POS N

According POS N
to POS N
the POS N
results POS N
of POS N
this POS N
short-term POS N
study, POS N
trabeculectomy POS N
was POS N
more POS N
effective POS N
than POS N
viscocanalostomy POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes POS N
of POS N
white POS N
patients. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
6 POS N
months POS N
(range, POS N
6-8 POS N
months), POS N
success POS N
was POS N
obtained POS N
in POS N
5 POS N
of POS N
10 POS N
cases POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
0 POS N
of POS N
10 POS N
case POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

According POS N
to POS N
the POS N
results POS N
of POS N
this POS N
short-term POS N
study, POS N
trabeculectomy POS N
was POS N
more POS N
effective POS N
than POS N
viscocanalostomy POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes POS N
of POS N
white POS N
patients. POS N

With POS N
Kaplan-Meier's POS N
method, POS N
subjects POS N
with POS N
viscocanalostomy POS N
showed POS N
shorter POS N
postoperative POS N
IOP-reduction POS N
periods POS N
than POS N
subjects POS N
undergoing POS N
trabeculectomy. POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

Both POS N
agents POS N
were POS N
safe POS N
and POS N
well POS N
tolerated. POS N

Over POS N
an POS N
8-week POS N
period, POS N
latanoprost POS N
0.005% POS N
once POS N
daily POS N
lowered POS N
IOP POS N
more POS N
than POS N
unoprostone POS N
0.15% POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP. POS N

Both POS N
agents POS N
were POS N
safe POS N
and POS N
well POS N
tolerated. POS N

The POS N
change POS N
in POS N
the POS N
mean POS N
+/- POS N
SD POS N
of POS N
the POS N
IOPs POS N
measured POS N
at POS N
8:00 POS N
AM, POS N
12 POS N
noon, POS N
and POS N
4:00 POS N
PM POS N
was POS N
-7.2 POS N
+/- POS N
3.2 POS N
mm POS N
Hg POS N
(28%) POS N
for POS N
latanoprost POS N
(25.3 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
18.2 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
8 POS N
weeks) POS N
and POS N
-3.9 POS N
+/- POS N
2.6 POS N
mm POS N
Hg POS N
(15%) POS N
for POS N
unoprostone POS N
(25.5 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
21.6 POS N
+/- POS N
4.0 POS N
mm POS N
Hg; POS N
P POS N
<or=.001. POS N

Both POS N
agents POS N
were POS N
safe POS N
and POS N
well POS N
tolerated. POS N

No POS N
serious POS N
adverse POS N
event POS N
related POS N
to POS N
either POS N
medication POS N
was POS N
reported. POS N

Over POS N
an POS N
8-week POS N
period, POS N
latanoprost POS N
0.005% POS N
once POS N
daily POS N
lowered POS N
IOP POS N
more POS N
than POS N
unoprostone POS N
0.15% POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP. POS N

Both POS N
agents POS N
were POS N
safe POS N
and POS N
well POS N
tolerated. POS N

Over POS N
an POS N
8-week POS N
period, POS N
latanoprost POS N
0.005% POS N
once POS N
daily POS N
lowered POS N
IOP POS N
more POS N
than POS N
unoprostone POS N
0.15% POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP. POS N

The POS N
change POS N
in POS N
the POS N
mean POS N
+/- POS N
SD POS N
of POS N
the POS N
IOPs POS N
measured POS N
at POS N
8:00 POS N
AM, POS N
12 POS N
noon, POS N
and POS N
4:00 POS N
PM POS N
was POS N
-7.2 POS N
+/- POS N
3.2 POS N
mm POS N
Hg POS N
(28%) POS N
for POS N
latanoprost POS N
(25.3 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
18.2 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
8 POS N
weeks) POS N
and POS N
-3.9 POS N
+/- POS N
2.6 POS N
mm POS N
Hg POS N
(15%) POS N
for POS N
unoprostone POS N
(25.5 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
21.6 POS N
+/- POS N
4.0 POS N
mm POS N
Hg; POS N
P POS N
<or=.001. POS N

Over POS N
an POS N
8-week POS N
period, POS N
latanoprost POS N
0.005% POS N
once POS N
daily POS N
lowered POS N
IOP POS N
more POS N
than POS N
unoprostone POS N
0.15% POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP. POS N

No POS N
serious POS N
adverse POS N
event POS N
related POS N
to POS N
either POS N
medication POS N
was POS N
reported. POS N

The POS N
change POS N
in POS N
the POS N
mean POS N
+/- POS N
SD POS N
of POS N
the POS N
IOPs POS N
measured POS N
at POS N
8:00 POS N
AM, POS N
12 POS N
noon, POS N
and POS N
4:00 POS N
PM POS N
was POS N
-7.2 POS N
+/- POS N
3.2 POS N
mm POS N
Hg POS N
(28%) POS N
for POS N
latanoprost POS N
(25.3 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
18.2 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
8 POS N
weeks) POS N
and POS N
-3.9 POS N
+/- POS N
2.6 POS N
mm POS N
Hg POS N
(15%) POS N
for POS N
unoprostone POS N
(25.5 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
21.6 POS N
+/- POS N
4.0 POS N
mm POS N
Hg; POS N
P POS N
<or=.001. POS N

Both POS N
agents POS N
were POS N
safe POS N
and POS N
well POS N
tolerated. POS N

The POS N
change POS N
in POS N
the POS N
mean POS N
+/- POS N
SD POS N
of POS N
the POS N
IOPs POS N
measured POS N
at POS N
8:00 POS N
AM, POS N
12 POS N
noon, POS N
and POS N
4:00 POS N
PM POS N
was POS N
-7.2 POS N
+/- POS N
3.2 POS N
mm POS N
Hg POS N
(28%) POS N
for POS N
latanoprost POS N
(25.3 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
18.2 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
8 POS N
weeks) POS N
and POS N
-3.9 POS N
+/- POS N
2.6 POS N
mm POS N
Hg POS N
(15%) POS N
for POS N
unoprostone POS N
(25.5 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
21.6 POS N
+/- POS N
4.0 POS N
mm POS N
Hg; POS N
P POS N
<or=.001. POS N

Over POS N
an POS N
8-week POS N
period, POS N
latanoprost POS N
0.005% POS N
once POS N
daily POS N
lowered POS N
IOP POS N
more POS N
than POS N
unoprostone POS N
0.15% POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP. POS N

The POS N
change POS N
in POS N
the POS N
mean POS N
+/- POS N
SD POS N
of POS N
the POS N
IOPs POS N
measured POS N
at POS N
8:00 POS N
AM, POS N
12 POS N
noon, POS N
and POS N
4:00 POS N
PM POS N
was POS N
-7.2 POS N
+/- POS N
3.2 POS N
mm POS N
Hg POS N
(28%) POS N
for POS N
latanoprost POS N
(25.3 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
18.2 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
8 POS N
weeks) POS N
and POS N
-3.9 POS N
+/- POS N
2.6 POS N
mm POS N
Hg POS N
(15%) POS N
for POS N
unoprostone POS N
(25.5 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
21.6 POS N
+/- POS N
4.0 POS N
mm POS N
Hg; POS N
P POS N
<or=.001. POS N

No POS N
serious POS N
adverse POS N
event POS N
related POS N
to POS N
either POS N
medication POS N
was POS N
reported. POS N

No POS N
serious POS N
adverse POS N
event POS N
related POS N
to POS N
either POS N
medication POS N
was POS N
reported. POS N

Both POS N
agents POS N
were POS N
safe POS N
and POS N
well POS N
tolerated. POS N

No POS N
serious POS N
adverse POS N
event POS N
related POS N
to POS N
either POS N
medication POS N
was POS N
reported. POS N

Over POS N
an POS N
8-week POS N
period, POS N
latanoprost POS N
0.005% POS N
once POS N
daily POS N
lowered POS N
IOP POS N
more POS N
than POS N
unoprostone POS N
0.15% POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP. POS N

No POS N
serious POS N
adverse POS N
event POS N
related POS N
to POS N
either POS N
medication POS N
was POS N
reported. POS N

The POS N
change POS N
in POS N
the POS N
mean POS N
+/- POS N
SD POS N
of POS N
the POS N
IOPs POS N
measured POS N
at POS N
8:00 POS N
AM, POS N
12 POS N
noon, POS N
and POS N
4:00 POS N
PM POS N
was POS N
-7.2 POS N
+/- POS N
3.2 POS N
mm POS N
Hg POS N
(28%) POS N
for POS N
latanoprost POS N
(25.3 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
18.2 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
8 POS N
weeks) POS N
and POS N
-3.9 POS N
+/- POS N
2.6 POS N
mm POS N
Hg POS N
(15%) POS N
for POS N
unoprostone POS N
(25.5 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
21.6 POS N
+/- POS N
4.0 POS N
mm POS N
Hg; POS N
P POS N
<or=.001. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

Study POS N
attrition POS N
was POS N
large. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Study POS N
attrition POS N
was POS N
large. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Study POS N
attrition POS N
was POS N
large. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

Study POS N
attrition POS N
was POS N
large. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Study POS N
attrition POS N
was POS N
large. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

Study POS N
attrition POS N
was POS N
large. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Study POS N
attrition POS N
was POS N
large. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Study POS N
attrition POS N
was POS N
large. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

Study POS N
attrition POS N
was POS N
large. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

Study POS N
attrition POS N
was POS N
large. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Study POS N
attrition POS N
was POS N
large. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Study POS N
attrition POS N
was POS N
large. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Study POS N
attrition POS N
was POS N
large. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

Study POS N
attrition POS N
was POS N
large. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Study POS N
attrition POS N
was POS N
large. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Study POS N
attrition POS N
was POS N
large. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Study POS N
attrition POS N
was POS N
large. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Study POS N
attrition POS N
was POS N
large. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Mean POS N
intraocular POS N
pressure POS N
(IOP) POS N
changes POS N
from POS N
baseline POS N
were POS N
-4.0 POS N
+/- POS N
1.7 POS N
mmHg POS N
in POS N
Tafluprost POS N
administered POS N
patients POS N
and POS N
-1.4 POS N
+/- POS N
1.8 POS N
mmHg POS N
in POS N
Placebo POS N
administered POS N
patients POS N
at POS N
4 POS N
weeks, POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(p<0.001). POS N

IOP POS N
change POS N
at POS N
4 POS N
weeks, POS N
% POS N
IOP POS N
reduction POS N
at POS N
2 POS N
and POS N
4 POS N
weeks POS N
were POS N
also POS N
significantly POS N
greater POS N
in POS N
Tafluprost POS N
than POS N
in POS N
Placebo. POS N

Mean POS N
intraocular POS N
pressure POS N
(IOP) POS N
changes POS N
from POS N
baseline POS N
were POS N
-4.0 POS N
+/- POS N
1.7 POS N
mmHg POS N
in POS N
Tafluprost POS N
administered POS N
patients POS N
and POS N
-1.4 POS N
+/- POS N
1.8 POS N
mmHg POS N
in POS N
Placebo POS N
administered POS N
patients POS N
at POS N
4 POS N
weeks, POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(p<0.001). POS N

A POS N
total POS N
of POS N
51.0% POS N
in POS N
Tafluprost POS N
treated POS N
group POS N
and POS N
8.9% POS N
in POS N
Placebo POS N
treated POS N
group POS N
reported POS N
adverse POS N
drug POS N
reactions. POS N

Mean POS N
intraocular POS N
pressure POS N
(IOP) POS N
changes POS N
from POS N
baseline POS N
were POS N
-4.0 POS N
+/- POS N
1.7 POS N
mmHg POS N
in POS N
Tafluprost POS N
administered POS N
patients POS N
and POS N
-1.4 POS N
+/- POS N
1.8 POS N
mmHg POS N
in POS N
Placebo POS N
administered POS N
patients POS N
at POS N
4 POS N
weeks, POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(p<0.001). POS N

These POS N
results POS N
indicate POS N
that POS N
Tafluprost POS N
is POS N
clinically POS N
useful POS N
in POS N
the POS N
treatment POS N
of POS N
NTG. POS N

IOP POS N
change POS N
at POS N
4 POS N
weeks, POS N
% POS N
IOP POS N
reduction POS N
at POS N
2 POS N
and POS N
4 POS N
weeks POS N
were POS N
also POS N
significantly POS N
greater POS N
in POS N
Tafluprost POS N
than POS N
in POS N
Placebo. POS N

Mean POS N
intraocular POS N
pressure POS N
(IOP) POS N
changes POS N
from POS N
baseline POS N
were POS N
-4.0 POS N
+/- POS N
1.7 POS N
mmHg POS N
in POS N
Tafluprost POS N
administered POS N
patients POS N
and POS N
-1.4 POS N
+/- POS N
1.8 POS N
mmHg POS N
in POS N
Placebo POS N
administered POS N
patients POS N
at POS N
4 POS N
weeks, POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(p<0.001). POS N

IOP POS N
change POS N
at POS N
4 POS N
weeks, POS N
% POS N
IOP POS N
reduction POS N
at POS N
2 POS N
and POS N
4 POS N
weeks POS N
were POS N
also POS N
significantly POS N
greater POS N
in POS N
Tafluprost POS N
than POS N
in POS N
Placebo. POS N

A POS N
total POS N
of POS N
51.0% POS N
in POS N
Tafluprost POS N
treated POS N
group POS N
and POS N
8.9% POS N
in POS N
Placebo POS N
treated POS N
group POS N
reported POS N
adverse POS N
drug POS N
reactions. POS N

IOP POS N
change POS N
at POS N
4 POS N
weeks, POS N
% POS N
IOP POS N
reduction POS N
at POS N
2 POS N
and POS N
4 POS N
weeks POS N
were POS N
also POS N
significantly POS N
greater POS N
in POS N
Tafluprost POS N
than POS N
in POS N
Placebo. POS N

These POS N
results POS N
indicate POS N
that POS N
Tafluprost POS N
is POS N
clinically POS N
useful POS N
in POS N
the POS N
treatment POS N
of POS N
NTG. POS N

A POS N
total POS N
of POS N
51.0% POS N
in POS N
Tafluprost POS N
treated POS N
group POS N
and POS N
8.9% POS N
in POS N
Placebo POS N
treated POS N
group POS N
reported POS N
adverse POS N
drug POS N
reactions. POS N

Mean POS N
intraocular POS N
pressure POS N
(IOP) POS N
changes POS N
from POS N
baseline POS N
were POS N
-4.0 POS N
+/- POS N
1.7 POS N
mmHg POS N
in POS N
Tafluprost POS N
administered POS N
patients POS N
and POS N
-1.4 POS N
+/- POS N
1.8 POS N
mmHg POS N
in POS N
Placebo POS N
administered POS N
patients POS N
at POS N
4 POS N
weeks, POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(p<0.001). POS N

A POS N
total POS N
of POS N
51.0% POS N
in POS N
Tafluprost POS N
treated POS N
group POS N
and POS N
8.9% POS N
in POS N
Placebo POS N
treated POS N
group POS N
reported POS N
adverse POS N
drug POS N
reactions. POS N

IOP POS N
change POS N
at POS N
4 POS N
weeks, POS N
% POS N
IOP POS N
reduction POS N
at POS N
2 POS N
and POS N
4 POS N
weeks POS N
were POS N
also POS N
significantly POS N
greater POS N
in POS N
Tafluprost POS N
than POS N
in POS N
Placebo. POS N

A POS N
total POS N
of POS N
51.0% POS N
in POS N
Tafluprost POS N
treated POS N
group POS N
and POS N
8.9% POS N
in POS N
Placebo POS N
treated POS N
group POS N
reported POS N
adverse POS N
drug POS N
reactions. POS N

These POS N
results POS N
indicate POS N
that POS N
Tafluprost POS N
is POS N
clinically POS N
useful POS N
in POS N
the POS N
treatment POS N
of POS N
NTG. POS N

These POS N
results POS N
indicate POS N
that POS N
Tafluprost POS N
is POS N
clinically POS N
useful POS N
in POS N
the POS N
treatment POS N
of POS N
NTG. POS N

Mean POS N
intraocular POS N
pressure POS N
(IOP) POS N
changes POS N
from POS N
baseline POS N
were POS N
-4.0 POS N
+/- POS N
1.7 POS N
mmHg POS N
in POS N
Tafluprost POS N
administered POS N
patients POS N
and POS N
-1.4 POS N
+/- POS N
1.8 POS N
mmHg POS N
in POS N
Placebo POS N
administered POS N
patients POS N
at POS N
4 POS N
weeks, POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(p<0.001). POS N

These POS N
results POS N
indicate POS N
that POS N
Tafluprost POS N
is POS N
clinically POS N
useful POS N
in POS N
the POS N
treatment POS N
of POS N
NTG. POS N

IOP POS N
change POS N
at POS N
4 POS N
weeks, POS N
% POS N
IOP POS N
reduction POS N
at POS N
2 POS N
and POS N
4 POS N
weeks POS N
were POS N
also POS N
significantly POS N
greater POS N
in POS N
Tafluprost POS N
than POS N
in POS N
Placebo. POS N

These POS N
results POS N
indicate POS N
that POS N
Tafluprost POS N
is POS N
clinically POS N
useful POS N
in POS N
the POS N
treatment POS N
of POS N
NTG. POS N

A POS N
total POS N
of POS N
51.0% POS N
in POS N
Tafluprost POS N
treated POS N
group POS N
and POS N
8.9% POS N
in POS N
Placebo POS N
treated POS N
group POS N
reported POS N
adverse POS N
drug POS N
reactions. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

No POS N
significant POS N
difference POS N
(p POS N
= POS N
0.846) POS N
was POS N
found POS N
in POS N
mean POS N
decrease POS N
in POS N
IOP POS N
between POS N
the POS N
SLT POS N
(5.86 POS N
mm POS N
Hg) POS N
and POS N
ALT POS N
(6.04 POS N
mm POS N
Hg) POS N
groups POS N
at POS N
1 POS N
year POS N
or POS N
at POS N
any POS N
other POS N
time POS N
points, POS N
nor POS N
were POS N
there POS N
any POS N
significant POS N
differences POS N
in POS N
the POS N
rate POS N
of POS N
early POS N
or POS N
late POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

SLT POS N
is POS N
equivalent POS N
to POS N
ALT POS N
in POS N
terms POS N
of POS N
IOP POS N
lowering POS N
at POS N
1 POS N
year, POS N
and POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
procedure POS N
for POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

SLT POS N
is POS N
equivalent POS N
to POS N
ALT POS N
in POS N
terms POS N
of POS N
IOP POS N
lowering POS N
at POS N
1 POS N
year, POS N
and POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
procedure POS N
for POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

No POS N
significant POS N
difference POS N
(p POS N
= POS N
0.846) POS N
was POS N
found POS N
in POS N
mean POS N
decrease POS N
in POS N
IOP POS N
between POS N
the POS N
SLT POS N
(5.86 POS N
mm POS N
Hg) POS N
and POS N
ALT POS N
(6.04 POS N
mm POS N
Hg) POS N
groups POS N
at POS N
1 POS N
year POS N
or POS N
at POS N
any POS N
other POS N
time POS N
points, POS N
nor POS N
were POS N
there POS N
any POS N
significant POS N
differences POS N
in POS N
the POS N
rate POS N
of POS N
early POS N
or POS N
late POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

Percentage POS N
of POS N
IOP POS N
reduction POS N
or POS N
the POS N
magnitude POS N
of POS N
IOP POS N
reduction POS N
showed POS N
no POS N
intergroup POS N
differences POS N
either POS N
at POS N
any POS N
time POS N
point POS N
(13-15%). POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

In POS N
the POS N
visual POS N
field, POS N
the POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
the POS N
MD POS N
value POS N
(dB/year) POS N
was POS N
-0.34+/-0.17 POS N
(SE) POS N
for POS N
the POS N
latanoprost POS N
group, POS N
and POS N
-0.10+/-0.18 POS N
(SE) POS N
for POS N
the POS N
timolol POS N
group. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

The POS N
estimated POS N
rate POS N
of POS N
change POS N
in POS N
MD POS N
showed POS N
no POS N
significant POS N
difference POS N
from POS N
zero POS N
in POS N
both POS N
groups, POS N
and POS N
there POS N
were POS N
no POS N
statistical POS N
intergroup POS N
differences. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

No POS N
changes POS N
in POS N
the POS N
optic POS N
nerve POS N
head POS N
topography POS N
in POS N
the POS N
vertical POS N
cup-to-disc POS N
ratio POS N
and POS N
rim POS N
area POS N
measured POS N
by POS N
image-analysis POS N
techniques POS N
were POS N
observed POS N
in POS N
either POS N
group. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

There POS N
were POS N
no POS N
patients POS N
who POS N
dropped POS N
out POS N
due POS N
to POS N
the POS N
side POS N
effects POS N
of POS N
treatment POS N
regimens. POS N

both POS N
showed POS N
similar POS N
effects POS N
on POS N
visual POS N
field POS N
performance. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
single POS N
treatments POS N
reduced POS N
IOP POS N
by POS N
13-15% POS N
at POS N
their POS N
trough POS N
effects POS N
for POS N
3 POS N
years POS N
in POS N
Japanese POS N
NTG POS N
patients POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Mean POS N
(+/-SD) POS N
preoperative POS N
and POS N
1-year POS N
postoperative POS N
intraocular POS N
pressures POS N
in POS N
the POS N
5-fluorouracil POS N
group POS N
were POS N
26.9 POS N
(+/-9.5) POS N
and POS N
15.3 POS N
(+/-5.8) POS N
mm POS N
Hg, POS N
respectively. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

In POS N
the POS N
control POS N
group POS N
these POS N
were POS N
25.9 POS N
(+/-8.1) POS N
mm POS N
Hg, POS N
and POS N
15.8 POS N
(+/-5.1) POS N
mm POS N
Hg, POS N
respectively. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

The POS N
patients POS N
who POS N
received POS N
5-fluorouracil POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
11.5 POS N
(+/-9.1) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.3 POS N
weeks. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

The POS N
control POS N
group POS N
had POS N
a POS N
mean POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
of POS N
10.2 POS N
(+/-8.7) POS N
mm POS N
Hg POS N
at POS N
a POS N
median POS N
follow-up POS N
of POS N
52.6 POS N
weeks. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Three POS N
postoperative POS N
subconjunctival POS N
5-fluorouracil POS N
injections POS N
of POS N
5 POS N
mg POS N
each POS N
after POS N
trabeculectomy POS N
in POS N
eyes POS N
at POS N
low POS N
risk POS N
for POS N
failure POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
with POS N
1-year POS N
follow-up. POS N

These POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Enhancement POS N
of POS N
success POS N
in POS N
this POS N
group POS N
of POS N
patients POS N
may POS N
require POS N
a POS N
larger POS N
total POS N
dose POS N
of POS N
5-fluorouracil. POS N

Both POS N
treatments POS N
resulted POS N
in POS N
significant POS N
reductions POS N
in POS N
mean POS N
intervisit POS N
IOP POS N
range POS N
during POS N
26 POS N
weeks. POS N

After POS N
treatment, POS N
6% POS N
(19/313) POS N
and POS N
11% POS N
(35/318) POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
and POS N
timolol POS N
groups, POS N
respectively, POS N
had POS N
high POS N
intervisit POS N
IOP POS N
ranges POS N
(P POS N
= POS N
.026). POS N

Both POS N
treatments POS N
resulted POS N
in POS N
significant POS N
reductions POS N
in POS N
mean POS N
intervisit POS N
IOP POS N
range POS N
during POS N
26 POS N
weeks. POS N

Significant POS N
risk POS N
factors POS N
for POS N
high POS N
posttreatment POS N
intervisit POS N
range POS N
(multivariate POS N
logistic POS N
regression) POS N
were POS N
high POS N
pretreatment POS N
intervisit POS N
IOP POS N
range, POS N
treatment POS N
with POS N
timolol, POS N
Black POS N
race, POS N
longer POS N
time POS N
since POS N
diagnosis, POS N
and POS N
higher POS N
mean POS N
pretreatment POS N
IOP. POS N

Both POS N
treatments POS N
resulted POS N
in POS N
significant POS N
reductions POS N
in POS N
mean POS N
intervisit POS N
IOP POS N
range POS N
during POS N
26 POS N
weeks. POS N

Compared POS N
with POS N
timolol, POS N
treatment POS N
with POS N
latanoprost POS N
results POS N
in POS N
significantly POS N
fewer POS N
patients POS N
with POS N
a POS N
high POS N
IOP POS N
fluctuation. POS N

After POS N
treatment, POS N
6% POS N
(19/313) POS N
and POS N
11% POS N
(35/318) POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
and POS N
timolol POS N
groups, POS N
respectively, POS N
had POS N
high POS N
intervisit POS N
IOP POS N
ranges POS N
(P POS N
= POS N
.026). POS N

Both POS N
treatments POS N
resulted POS N
in POS N
significant POS N
reductions POS N
in POS N
mean POS N
intervisit POS N
IOP POS N
range POS N
during POS N
26 POS N
weeks. POS N

After POS N
treatment, POS N
6% POS N
(19/313) POS N
and POS N
11% POS N
(35/318) POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
and POS N
timolol POS N
groups, POS N
respectively, POS N
had POS N
high POS N
intervisit POS N
IOP POS N
ranges POS N
(P POS N
= POS N
.026). POS N

Significant POS N
risk POS N
factors POS N
for POS N
high POS N
posttreatment POS N
intervisit POS N
range POS N
(multivariate POS N
logistic POS N
regression) POS N
were POS N
high POS N
pretreatment POS N
intervisit POS N
IOP POS N
range, POS N
treatment POS N
with POS N
timolol, POS N
Black POS N
race, POS N
longer POS N
time POS N
since POS N
diagnosis, POS N
and POS N
higher POS N
mean POS N
pretreatment POS N
IOP. POS N

After POS N
treatment, POS N
6% POS N
(19/313) POS N
and POS N
11% POS N
(35/318) POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
and POS N
timolol POS N
groups, POS N
respectively, POS N
had POS N
high POS N
intervisit POS N
IOP POS N
ranges POS N
(P POS N
= POS N
.026). POS N

Compared POS N
with POS N
timolol, POS N
treatment POS N
with POS N
latanoprost POS N
results POS N
in POS N
significantly POS N
fewer POS N
patients POS N
with POS N
a POS N
high POS N
IOP POS N
fluctuation. POS N

Significant POS N
risk POS N
factors POS N
for POS N
high POS N
posttreatment POS N
intervisit POS N
range POS N
(multivariate POS N
logistic POS N
regression) POS N
were POS N
high POS N
pretreatment POS N
intervisit POS N
IOP POS N
range, POS N
treatment POS N
with POS N
timolol, POS N
Black POS N
race, POS N
longer POS N
time POS N
since POS N
diagnosis, POS N
and POS N
higher POS N
mean POS N
pretreatment POS N
IOP. POS N

Both POS N
treatments POS N
resulted POS N
in POS N
significant POS N
reductions POS N
in POS N
mean POS N
intervisit POS N
IOP POS N
range POS N
during POS N
26 POS N
weeks. POS N

Significant POS N
risk POS N
factors POS N
for POS N
high POS N
posttreatment POS N
intervisit POS N
range POS N
(multivariate POS N
logistic POS N
regression) POS N
were POS N
high POS N
pretreatment POS N
intervisit POS N
IOP POS N
range, POS N
treatment POS N
with POS N
timolol, POS N
Black POS N
race, POS N
longer POS N
time POS N
since POS N
diagnosis, POS N
and POS N
higher POS N
mean POS N
pretreatment POS N
IOP. POS N

After POS N
treatment, POS N
6% POS N
(19/313) POS N
and POS N
11% POS N
(35/318) POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
and POS N
timolol POS N
groups, POS N
respectively, POS N
had POS N
high POS N
intervisit POS N
IOP POS N
ranges POS N
(P POS N
= POS N
.026). POS N

Significant POS N
risk POS N
factors POS N
for POS N
high POS N
posttreatment POS N
intervisit POS N
range POS N
(multivariate POS N
logistic POS N
regression) POS N
were POS N
high POS N
pretreatment POS N
intervisit POS N
IOP POS N
range, POS N
treatment POS N
with POS N
timolol, POS N
Black POS N
race, POS N
longer POS N
time POS N
since POS N
diagnosis, POS N
and POS N
higher POS N
mean POS N
pretreatment POS N
IOP. POS N

Compared POS N
with POS N
timolol, POS N
treatment POS N
with POS N
latanoprost POS N
results POS N
in POS N
significantly POS N
fewer POS N
patients POS N
with POS N
a POS N
high POS N
IOP POS N
fluctuation. POS N

Compared POS N
with POS N
timolol, POS N
treatment POS N
with POS N
latanoprost POS N
results POS N
in POS N
significantly POS N
fewer POS N
patients POS N
with POS N
a POS N
high POS N
IOP POS N
fluctuation. POS N

Both POS N
treatments POS N
resulted POS N
in POS N
significant POS N
reductions POS N
in POS N
mean POS N
intervisit POS N
IOP POS N
range POS N
during POS N
26 POS N
weeks. POS N

Compared POS N
with POS N
timolol, POS N
treatment POS N
with POS N
latanoprost POS N
results POS N
in POS N
significantly POS N
fewer POS N
patients POS N
with POS N
a POS N
high POS N
IOP POS N
fluctuation. POS N

After POS N
treatment, POS N
6% POS N
(19/313) POS N
and POS N
11% POS N
(35/318) POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
and POS N
timolol POS N
groups, POS N
respectively, POS N
had POS N
high POS N
intervisit POS N
IOP POS N
ranges POS N
(P POS N
= POS N
.026). POS N

Compared POS N
with POS N
timolol, POS N
treatment POS N
with POS N
latanoprost POS N
results POS N
in POS N
significantly POS N
fewer POS N
patients POS N
with POS N
a POS N
high POS N
IOP POS N
fluctuation. POS N

Significant POS N
risk POS N
factors POS N
for POS N
high POS N
posttreatment POS N
intervisit POS N
range POS N
(multivariate POS N
logistic POS N
regression) POS N
were POS N
high POS N
pretreatment POS N
intervisit POS N
IOP POS N
range, POS N
treatment POS N
with POS N
timolol, POS N
Black POS N
race, POS N
longer POS N
time POS N
since POS N
diagnosis, POS N
and POS N
higher POS N
mean POS N
pretreatment POS N
IOP. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

After POS N
1 POS N
month POS N
of POS N
treatment, POS N
latanoprost POS N
significantly POS N
reduced POS N
intraocular POS N
pressure POS N
(mean POS N
+/- POS N
SEM) POS N
by POS N
6.1 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
and POS N
unoprostone POS N
by POS N
4.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg POS N
(P POS N
<.001) POS N
adjusted POS N
from POS N
an POS N
overall POS N
baseline POS N
of POS N
22.3 POS N
+/- POS N
0.5 POS N
mm POS N
Hg POS N
and POS N
23.2 POS N
+/- POS N
0.4 POS N
mm POS N
Hg, POS N
respectively. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

The POS N
difference POS N
of POS N
1.9 POS N
mm POS N
Hg POS N
between POS N
treatments POS N
was POS N
statistically POS N
significant POS N
in POS N
favor POS N
of POS N
latanoprost POS N
[P POS N
=.003, POS N
analysis POS N
of POS N
covariance POS N
(ANCOVA)]. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Unadjusted POS N
analysis POS N
of POS N
responders POS N
using POS N
the POS N
percentage POS N
decrease POS N
in POS N
intraocular POS N
pressure POS N
showed POS N
that POS N
the POS N
proportion POS N
of POS N
responders POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
was POS N
greater POS N
than POS N
in POS N
the POS N
unoprostone-treated POS N
group. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Adverse POS N
ocular POS N
symptoms POS N
and POS N
findings POS N
were POS N
mild POS N
in POS N
both POS N
treatment POS N
groups. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Eye POS N
redness POS N
and POS N
ocular POS N
irritation POS N
were POS N
the POS N
most POS N
frequently POS N
reported POS N
events. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
few POS N
ocular POS N
adverse POS N
events. POS N

Latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
compared POS N
with POS N
unoprostone POS N
twice POS N
daily POS N
after POS N
1 POS N
month POS N
of POS N
treatment POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

the POS N
overall POS N
probability POS N
of POS N
success POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
was POS N
0.613 POS N
and POS N
0.733 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

The POS N
success POS N
probability POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
in POS N
reducing POS N
IOP POS N
below POS N
18 POS N
mm POS N
Hg POS N
was POS N
0.748 POS N
and POS N
0.825 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

the POS N
overall POS N
probability POS N
of POS N
success POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
was POS N
0.613 POS N
and POS N
0.733 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

In POS N
POAG POS N
and POS N
CPACG POS N
patients, POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
were POS N
effective POS N
in POS N
reducing POS N
IOP POS N
for POS N
up POS N
to POS N
15 POS N
years POS N
after POS N
surgery. POS N

The POS N
success POS N
probability POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
in POS N
reducing POS N
IOP POS N
below POS N
18 POS N
mm POS N
Hg POS N
was POS N
0.748 POS N
and POS N
0.825 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

the POS N
overall POS N
probability POS N
of POS N
success POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
was POS N
0.613 POS N
and POS N
0.733 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

The POS N
success POS N
probability POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
in POS N
reducing POS N
IOP POS N
below POS N
18 POS N
mm POS N
Hg POS N
was POS N
0.748 POS N
and POS N
0.825 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

In POS N
POAG POS N
and POS N
CPACG POS N
patients, POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
were POS N
effective POS N
in POS N
reducing POS N
IOP POS N
for POS N
up POS N
to POS N
15 POS N
years POS N
after POS N
surgery. POS N

In POS N
POAG POS N
and POS N
CPACG POS N
patients, POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
were POS N
effective POS N
in POS N
reducing POS N
IOP POS N
for POS N
up POS N
to POS N
15 POS N
years POS N
after POS N
surgery. POS N

the POS N
overall POS N
probability POS N
of POS N
success POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
was POS N
0.613 POS N
and POS N
0.733 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

In POS N
POAG POS N
and POS N
CPACG POS N
patients, POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
were POS N
effective POS N
in POS N
reducing POS N
IOP POS N
for POS N
up POS N
to POS N
15 POS N
years POS N
after POS N
surgery. POS N

The POS N
success POS N
probability POS N
of POS N
trabeculectomy POS N
and POS N
triple POS N
procedure POS N
in POS N
reducing POS N
IOP POS N
below POS N
18 POS N
mm POS N
Hg POS N
was POS N
0.748 POS N
and POS N
0.825 POS N
at POS N
15 POS N
years, POS N
respectively. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
study POS N
groups POS N
regarding POS N
the POS N
baseline POS N
characteristics POS N
and POS N
the POS N
baseline POS N
IOP POS N
(P=0.628). POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

Patients POS N
who POS N
received POS N
placebo POS N
as POS N
premedication POS N
had POS N
significantly POS N
higher POS N
IOP POS N
at POS N
6 POS N
(17.96±5.49 POS N
vs POS N
13.61±4.09; POS N
P<0.001) POS N
and POS N
12 POS N
(16.90±4.11 POS N
vs POS N
13.96±3.25; POS N
P=0.003) POS N
h POS N
postoperatively POS N
compared POS N
with POS N
those POS N
who POS N
received POS N
oral POS N
clonidine. POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
2 POS N
groups POS N
regarding POS N
the POS N
IOP POS N
at POS N
24h POS N
after POS N
operation POS N
(15.41±3.96 POS N
vs POS N
16.01±3.41; POS N
P=0.0539). POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

The POS N
prevalence POS N
of POS N
acute POS N
IOP POS N
rise POS N
(>21 POS N
mmHg) POS N
was POS N
significantly POS N
higher POS N
in POS N
placebo POS N
group POS N
compared POS N
with POS N
clonidine POS N
group POS N
(25.8% POS N
vs POS N
9.6%; POS N
P=0.091). POS N

Oral POS N
clonidine POS N
is POS N
safe, POS N
cheap, POS N
and POS N
easily POS N
accessible POS N
and, POS N
thus, POS N
it POS N
is POS N
recommended POS N
for POS N
controlling POS N
the POS N
IOP POS N
after POS N
phacoemulsification, POS N
especially POS N
in POS N
high-risk POS N
patients. POS N

Administering POS N
preoperative POS N
oral POS N
clonidine POS N
in POS N
a POS N
dosage POS N
of POS N
5g/kg, POS N
2h POS N
before POS N
phacoemulsification, POS N
significantly POS N
decreases POS N
the POS N
prevalence POS N
and POS N
intensity POS N
of POS N
acute POS N
postoperative POS N
IOP POS N
rise POS N
in POS N
those POS N
undergoing POS N
general POS N
anesthesia. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Diurnal POS N
IOP POS N
(9:00 POS N
am, POS N
1:00 POS N
pm, POS N
5:00 POS N
pm) POS N
was POS N
reduced POS N
from POS N
25.2 POS N
to POS N
16.7 POS N
mmHg POS N
(33.7%) POS N
with POS N
lantanoprost POS N
and POS N
from POS N
25.4 POS N
to POS N
17.1 POS N
mmHg POS N
(32.7%) POS N
with POS N
timolol POS N
as POS N
determined POS N
at POS N
the POS N
end POS N
of POS N
the POS N
6-month POS N
treatment POS N
period. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Latanoprost POS N
caused POS N
a POS N
somewhat POS N
more POS N
conjunctival POS N
hyperemia POS N
than POS N
timolol POS N
and POS N
more POS N
corneal POS N
punctuate POS N
epithelial POS N
erosions. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

both POS N
drugs POS N
were POS N
generally POS N
well POS N
tolerated. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

The POS N
most POS N
significant POS N
side POS N
effect POS N
of POS N
latanoprost POS N
was POS N
increased POS N
pigmentation POS N
of POS N
the POS N
iris POS N
which POS N
was POS N
observed POS N
in POS N
15 POS N
patients POS N
(10.1%). POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Timolol POS N
caused POS N
more POS N
systemic POS N
side POS N
effects POS N
than POS N
latanoprost. POS N

Latanoprost POS N
was POS N
generally POS N
well POS N
tolerated POS N
systemically POS N
and POS N
in POS N
the POS N
eye. POS N

Latanoprost POS N
0.005% POS N
administered POS N
once POS N
daily POS N
in POS N
the POS N
evening POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
administered POS N
twice POS N
daily. POS N

Six POS N
months POS N
after POS N
surgery, POS N
intraocular POS N
pressures POS N
averaged POS N
10.9 POS N
+/- POS N
5.3 POS N
mmHg POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
in POS N
the POS N
MMC-treated POS N
eyes POS N
versus POS N
14.2 POS N
+/- POS N
5.5 POS N
mmHg POS N
in POS N
the POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.08) POS N
and POS N
were POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
12 POS N
mmHg POS N
in POS N
60.0% POS N
of POS N
MMC-treated POS N
eyes POS N
and POS N
21.1% POS N
of POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.03). POS N

Drug-induced POS N
corneal POS N
epithelial POS N
defects POS N
were POS N
seen POS N
in POS N
nine POS N
5-FU-treated POS N
eyes POS N
and POS N
in POS N
no POS N
MMC-treated POS N
eyes POS N
(P POS N
= POS N
0.0004). POS N

Six POS N
months POS N
after POS N
surgery, POS N
intraocular POS N
pressures POS N
averaged POS N
10.9 POS N
+/- POS N
5.3 POS N
mmHg POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
in POS N
the POS N
MMC-treated POS N
eyes POS N
versus POS N
14.2 POS N
+/- POS N
5.5 POS N
mmHg POS N
in POS N
the POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.08) POS N
and POS N
were POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
12 POS N
mmHg POS N
in POS N
60.0% POS N
of POS N
MMC-treated POS N
eyes POS N
and POS N
21.1% POS N
of POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.03). POS N

These POS N
results POS N
suggest POS N
that POS N
intraoperative POS N
MMC POS N
may POS N
be POS N
a POS N
viable POS N
alternative POS N
to POS N
postoperative POS N
5-FU, POS N
with POS N
lower POS N
overall POS N
intraocular POS N
pressures, POS N
decreased POS N
dependence POS N
on POS N
postoperative POS N
ocular POS N
antihypertensive POS N
medications, POS N
and POS N
decreased POS N
corneal POS N
toxicity. POS N

Drug-induced POS N
corneal POS N
epithelial POS N
defects POS N
were POS N
seen POS N
in POS N
nine POS N
5-FU-treated POS N
eyes POS N
and POS N
in POS N
no POS N
MMC-treated POS N
eyes POS N
(P POS N
= POS N
0.0004). POS N

Six POS N
months POS N
after POS N
surgery, POS N
intraocular POS N
pressures POS N
averaged POS N
10.9 POS N
+/- POS N
5.3 POS N
mmHg POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
in POS N
the POS N
MMC-treated POS N
eyes POS N
versus POS N
14.2 POS N
+/- POS N
5.5 POS N
mmHg POS N
in POS N
the POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.08) POS N
and POS N
were POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
12 POS N
mmHg POS N
in POS N
60.0% POS N
of POS N
MMC-treated POS N
eyes POS N
and POS N
21.1% POS N
of POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.03). POS N

Drug-induced POS N
corneal POS N
epithelial POS N
defects POS N
were POS N
seen POS N
in POS N
nine POS N
5-FU-treated POS N
eyes POS N
and POS N
in POS N
no POS N
MMC-treated POS N
eyes POS N
(P POS N
= POS N
0.0004). POS N

These POS N
results POS N
suggest POS N
that POS N
intraoperative POS N
MMC POS N
may POS N
be POS N
a POS N
viable POS N
alternative POS N
to POS N
postoperative POS N
5-FU, POS N
with POS N
lower POS N
overall POS N
intraocular POS N
pressures, POS N
decreased POS N
dependence POS N
on POS N
postoperative POS N
ocular POS N
antihypertensive POS N
medications, POS N
and POS N
decreased POS N
corneal POS N
toxicity. POS N

These POS N
results POS N
suggest POS N
that POS N
intraoperative POS N
MMC POS N
may POS N
be POS N
a POS N
viable POS N
alternative POS N
to POS N
postoperative POS N
5-FU, POS N
with POS N
lower POS N
overall POS N
intraocular POS N
pressures, POS N
decreased POS N
dependence POS N
on POS N
postoperative POS N
ocular POS N
antihypertensive POS N
medications, POS N
and POS N
decreased POS N
corneal POS N
toxicity. POS N

Six POS N
months POS N
after POS N
surgery, POS N
intraocular POS N
pressures POS N
averaged POS N
10.9 POS N
+/- POS N
5.3 POS N
mmHg POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
in POS N
the POS N
MMC-treated POS N
eyes POS N
versus POS N
14.2 POS N
+/- POS N
5.5 POS N
mmHg POS N
in POS N
the POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.08) POS N
and POS N
were POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
12 POS N
mmHg POS N
in POS N
60.0% POS N
of POS N
MMC-treated POS N
eyes POS N
and POS N
21.1% POS N
of POS N
5-FU-treated POS N
eyes POS N
(P POS N
= POS N
0.03). POS N

These POS N
results POS N
suggest POS N
that POS N
intraoperative POS N
MMC POS N
may POS N
be POS N
a POS N
viable POS N
alternative POS N
to POS N
postoperative POS N
5-FU, POS N
with POS N
lower POS N
overall POS N
intraocular POS N
pressures, POS N
decreased POS N
dependence POS N
on POS N
postoperative POS N
ocular POS N
antihypertensive POS N
medications, POS N
and POS N
decreased POS N
corneal POS N
toxicity. POS N

Drug-induced POS N
corneal POS N
epithelial POS N
defects POS N
were POS N
seen POS N
in POS N
nine POS N
5-FU-treated POS N
eyes POS N
and POS N
in POS N
no POS N
MMC-treated POS N
eyes POS N
(P POS N
= POS N
0.0004). POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

The POS N
postoperative POS N
percentage POS N
of POS N
IOP POS N
reduction POS N
(Group POS N
A POS N
68.9%; POS N
Group POS N
B POS N
66.51%) POS N
was POS N
statically POS N
significant POS N
in POS N
both POS N
the POS N
groups POS N
(p=0.001). POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

Trabeculectomy POS N
was POS N
almost POS N
equally POS N
effective POS N
with POS N
complete POS N
surgical POS N
success POS N
of POS N
91% POS N
in POS N
group POS N
A, POS N
and POS N
82% POS N
in POS N
group POS N
B POS N
(p=0.534). POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

Final POS N
bleb POS N
scores POS N
were POS N
almost POS N
similar POS N
in POS N
both POS N
the POS N
groups POS N
with POS N
3.27 POS N
+/- POS N
1.5 POS N
in POS N
group POS N
A POS N
and POS N
3.36 POS N
+/- POS N
1.21 POS N
in POS N
group POS N
B POS N
(p=0.877). POS N

both POS N
triangular POS N
and POS N
rectangular POS N
scleral POS N
flaps POS N
in POS N
trabeculectomy POS N
are POS N
equally POS N
effective POS N
in POS N
terms POS N
of POS N
post POS N
surgical POS N
IOP POS N
control, POS N
bleb POS N
characteristics POS N
and POS N
complications. POS N

Hypotony POS N
with POS N
the POS N
IOP POS N
less POS N
than POS N
6 POS N
mmHg POS N
was POS N
found POS N
in POS N
the POS N
first POS N
post-operative POS N
day POS N
in POS N
2 POS N
patients POS N
in POS N
Group POS N
A POS N
and POS N
in POS N
1 POS N
in POS N
Group POS N
B. POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

In POS N
individuals POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension, POS N
uncontrolled POS N
on POS N
a POS N
topical POS N
beta-blocker POS N
alone, POS N
bimatoprost POS N
lowered POS N
IOP POS N
more POS N
consistently POS N
than POS N
did POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

Bimatoprost POS N
provided POS N
significantly POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

At POS N
the POS N
8 POS N
AM POS N
measurements, POS N
bimatoprost POS N
lowered POS N
mean POS N
IOP POS N
6.8 POS N
mmHg POS N
to POS N
7.6 POS N
mmHg POS N
from POS N
baseline, POS N
whereas POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
lowered POS N
mean POS N
IOP POS N
4.4 POS N
to POS N
5.0 POS N
mmHg POS N
from POS N
baseline POS N
(P<0.001). POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

At POS N
the POS N
last POS N
follow-up, POS N
patients POS N
had POS N
better POS N
diurnal POS N
IOP POS N
control POS N
with POS N
bimatoprost POS N
than POS N
combined POS N
timolol POS N
and POS N
dorzolamide. POS N

Taste POS N
perversion, POS N
ocular POS N
burning, POS N
and POS N
stinging POS N
with POS N
instillation POS N
were POS N
more POS N
common POS N
with POS N
combined POS N
timolol POS N
and POS N
dorzolamide, POS N
whereas POS N
conjunctival POS N
hyperemia POS N
was POS N
more POS N
common POS N
with POS N
bimatoprost. POS N

At POS N
8 POS N
AM POS N
at POS N
the POS N
3-month POS N
visit, POS N
the POS N
percentages POS N
of POS N
patients POS N
achieving POS N
IOPs POS N
of POS N
<or POS N
=13 POS N
mmHg, POS N
< POS N
or POS N
=14 POS N
mmHg, POS N
< POS N
or POS N
=15 POS N
mmHg, POS N
or POS N
< POS N
or POS N
=16 POS N
mmHg POS N
were POS N
more POS N
than POS N
twice POS N
as POS N
high POS N
for POS N
bimatoprost POS N
than POS N
for POS N
combined POS N
timolol POS N
and POS N
dorzolamide POS N
(all POS N
P< POS N
or POS N
=0.008). POS N

Fifteen POS N
eyes POS N
(88%) POS N
in POS N
the POS N
mitomycin POS N
group POS N
and POS N
seven POS N
(47%) POS N
in POS N
the POS N
fluorouracil POS N
group POS N
achieved POS N
an POS N
intraocular POS N
pressure POS N
of POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
20 POS N
mm POS N
Hg POS N
without POS N
antiglaucoma POS N
medication. POS N

Corneal POS N
complications POS N
were POS N
less POS N
common POS N
in POS N
the POS N
group POS N
given POS N
mitomycin POS N
than POS N
in POS N
that POS N
given POS N
fluorouracil POS N
(12% POS N
vs POS N
53%). POS N

Fifteen POS N
eyes POS N
(88%) POS N
in POS N
the POS N
mitomycin POS N
group POS N
and POS N
seven POS N
(47%) POS N
in POS N
the POS N
fluorouracil POS N
group POS N
achieved POS N
an POS N
intraocular POS N
pressure POS N
of POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
20 POS N
mm POS N
Hg POS N
without POS N
antiglaucoma POS N
medication. POS N

The POS N
incidence POS N
of POS N
other POS N
complications POS N
was POS N
similar POS N
between POS N
the POS N
two POS N
groups. POS N

Corneal POS N
complications POS N
were POS N
less POS N
common POS N
in POS N
the POS N
group POS N
given POS N
mitomycin POS N
than POS N
in POS N
that POS N
given POS N
fluorouracil POS N
(12% POS N
vs POS N
53%). POS N

Fifteen POS N
eyes POS N
(88%) POS N
in POS N
the POS N
mitomycin POS N
group POS N
and POS N
seven POS N
(47%) POS N
in POS N
the POS N
fluorouracil POS N
group POS N
achieved POS N
an POS N
intraocular POS N
pressure POS N
of POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
20 POS N
mm POS N
Hg POS N
without POS N
antiglaucoma POS N
medication. POS N

Corneal POS N
complications POS N
were POS N
less POS N
common POS N
in POS N
the POS N
group POS N
given POS N
mitomycin POS N
than POS N
in POS N
that POS N
given POS N
fluorouracil POS N
(12% POS N
vs POS N
53%). POS N

The POS N
incidence POS N
of POS N
other POS N
complications POS N
was POS N
similar POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
incidence POS N
of POS N
other POS N
complications POS N
was POS N
similar POS N
between POS N
the POS N
two POS N
groups. POS N

Fifteen POS N
eyes POS N
(88%) POS N
in POS N
the POS N
mitomycin POS N
group POS N
and POS N
seven POS N
(47%) POS N
in POS N
the POS N
fluorouracil POS N
group POS N
achieved POS N
an POS N
intraocular POS N
pressure POS N
of POS N
less POS N
than POS N
or POS N
equal POS N
to POS N
20 POS N
mm POS N
Hg POS N
without POS N
antiglaucoma POS N
medication. POS N

The POS N
incidence POS N
of POS N
other POS N
complications POS N
was POS N
similar POS N
between POS N
the POS N
two POS N
groups. POS N

Corneal POS N
complications POS N
were POS N
less POS N
common POS N
in POS N
the POS N
group POS N
given POS N
mitomycin POS N
than POS N
in POS N
that POS N
given POS N
fluorouracil POS N
(12% POS N
vs POS N
53%). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
(+/- POS N
SEM) POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(9.8 POS N
+/- POS N
0.9 POS N
mm POS N
Hg POS N
and POS N
6.7 POS N
+/- POS N
0.9 POS N
mm POS N
Hg, POS N
respectively). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
increase POS N
in POS N
the POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
within POS N
the POS N
timolol POS N
group POS N
(P POS N
= POS N
0.004), POS N
but POS N
not POS N
within POS N
the POS N
latanoprost POS N
group POS N
(P POS N
= POS N
0.97). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

No POS N
statistically POS N
significant POS N
difference POS N
in POS N
conjunctival POS N
hyperemia POS N
between POS N
the POS N
two POS N
latanoprost POS N
regimens POS N
was POS N
found POS N
(P POS N
= POS N
0.37). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
hyperemia POS N
between POS N
the POS N
two POS N
regimens. POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

Both POS N
concentrations POS N
of POS N
latanoprost POS N
reduced POS N
IOP POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
0.5% POS N
eye POS N
drops. POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

Latanoprost POS N
0.005% POS N
once POS N
daily POS N
reduced POS N
IOP POS N
more POS N
effectively POS N
than POS N
latanoprost POS N
0.0015% POS N
twice POS N
daily POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
had POS N
no POS N
statistically POS N
or POS N
clinically POS N
significant POS N
effect POS N
on POS N
the POS N
blood-aqueous POS N
barrier. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
change POS N
in POS N
aqueous POS N
humour POS N
protein POS N
concentration POS N
from POS N
baseline POS N
between POS N
latanoprost POS N
and POS N
timolol POS N
groups POS N
(P POS N
= POS N
0.08). POS N

At POS N
15 POS N
months, POS N
the POS N
mean POS N
number POS N
of POS N
medications POS N
was POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(0.4 POS N
+/- POS N
0.7 POS N
and POS N
1.3 POS N
+/- POS N
1.0, POS N
respectively; POS N
P POS N
= POS N
.007), POS N
as POS N
was POS N
the POS N
proportion POS N
of POS N
patients POS N
on POS N
ocular POS N
hypotensive POS N
medication POS N
(33% POS N
and POS N
76%, POS N
respectively). POS N

Phacoemulsification POS N
with POS N
stent POS N
implantation POS N
was POS N
more POS N
effective POS N
in POS N
controlling POS N
IOP POS N
than POS N
phacoemulsification POS N
alone; POS N

At POS N
15 POS N
months, POS N
the POS N
mean POS N
number POS N
of POS N
medications POS N
was POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(0.4 POS N
+/- POS N
0.7 POS N
and POS N
1.3 POS N
+/- POS N
1.0, POS N
respectively; POS N
P POS N
= POS N
.007), POS N
as POS N
was POS N
the POS N
proportion POS N
of POS N
patients POS N
on POS N
ocular POS N
hypotensive POS N
medication POS N
(33% POS N
and POS N
76%, POS N
respectively). POS N

the POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
at POS N
both POS N
time POS N
points POS N
(P POS N
= POS N
.031 POS N
and POS N
P POS N
= POS N
.042, POS N
respectively). POS N

At POS N
15 POS N
months, POS N
the POS N
mean POS N
number POS N
of POS N
medications POS N
was POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(0.4 POS N
+/- POS N
0.7 POS N
and POS N
1.3 POS N
+/- POS N
1.0, POS N
respectively; POS N
P POS N
= POS N
.007), POS N
as POS N
was POS N
the POS N
proportion POS N
of POS N
patients POS N
on POS N
ocular POS N
hypotensive POS N
medication POS N
(33% POS N
and POS N
76%, POS N
respectively). POS N

The POS N
mean POS N
IOP POS N
was POS N
14.8 POS N
+/- POS N
1.2 POS N
mm POS N
Hg POS N
in POS N
the POS N
combined POS N
group POS N
and POS N
15.7 POS N
+/- POS N
1.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
control POS N
group POS N
at POS N
15 POS N
months POS N
and POS N
16.6 POS N
+/- POS N
3.1 POS N
mm POS N
Hg POS N
and POS N
19.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg, POS N
respectively, POS N
after POS N
washout; POS N

Phacoemulsification POS N
with POS N
stent POS N
implantation POS N
was POS N
more POS N
effective POS N
in POS N
controlling POS N
IOP POS N
than POS N
phacoemulsification POS N
alone; POS N

At POS N
15 POS N
months, POS N
the POS N
mean POS N
number POS N
of POS N
medications POS N
was POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(0.4 POS N
+/- POS N
0.7 POS N
and POS N
1.3 POS N
+/- POS N
1.0, POS N
respectively; POS N
P POS N
= POS N
.007), POS N
as POS N
was POS N
the POS N
proportion POS N
of POS N
patients POS N
on POS N
ocular POS N
hypotensive POS N
medication POS N
(33% POS N
and POS N
76%, POS N
respectively). POS N

Phacoemulsification POS N
with POS N
stent POS N
implantation POS N
was POS N
more POS N
effective POS N
in POS N
controlling POS N
IOP POS N
than POS N
phacoemulsification POS N
alone; POS N

the POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
at POS N
both POS N
time POS N
points POS N
(P POS N
= POS N
.031 POS N
and POS N
P POS N
= POS N
.042, POS N
respectively). POS N

Phacoemulsification POS N
with POS N
stent POS N
implantation POS N
was POS N
more POS N
effective POS N
in POS N
controlling POS N
IOP POS N
than POS N
phacoemulsification POS N
alone; POS N

The POS N
mean POS N
IOP POS N
was POS N
14.8 POS N
+/- POS N
1.2 POS N
mm POS N
Hg POS N
in POS N
the POS N
combined POS N
group POS N
and POS N
15.7 POS N
+/- POS N
1.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
control POS N
group POS N
at POS N
15 POS N
months POS N
and POS N
16.6 POS N
+/- POS N
3.1 POS N
mm POS N
Hg POS N
and POS N
19.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg, POS N
respectively, POS N
after POS N
washout; POS N

the POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
at POS N
both POS N
time POS N
points POS N
(P POS N
= POS N
.031 POS N
and POS N
P POS N
= POS N
.042, POS N
respectively). POS N

At POS N
15 POS N
months, POS N
the POS N
mean POS N
number POS N
of POS N
medications POS N
was POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(0.4 POS N
+/- POS N
0.7 POS N
and POS N
1.3 POS N
+/- POS N
1.0, POS N
respectively; POS N
P POS N
= POS N
.007), POS N
as POS N
was POS N
the POS N
proportion POS N
of POS N
patients POS N
on POS N
ocular POS N
hypotensive POS N
medication POS N
(33% POS N
and POS N
76%, POS N
respectively). POS N

the POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
at POS N
both POS N
time POS N
points POS N
(P POS N
= POS N
.031 POS N
and POS N
P POS N
= POS N
.042, POS N
respectively). POS N

Phacoemulsification POS N
with POS N
stent POS N
implantation POS N
was POS N
more POS N
effective POS N
in POS N
controlling POS N
IOP POS N
than POS N
phacoemulsification POS N
alone; POS N

the POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
at POS N
both POS N
time POS N
points POS N
(P POS N
= POS N
.031 POS N
and POS N
P POS N
= POS N
.042, POS N
respectively). POS N

The POS N
mean POS N
IOP POS N
was POS N
14.8 POS N
+/- POS N
1.2 POS N
mm POS N
Hg POS N
in POS N
the POS N
combined POS N
group POS N
and POS N
15.7 POS N
+/- POS N
1.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
control POS N
group POS N
at POS N
15 POS N
months POS N
and POS N
16.6 POS N
+/- POS N
3.1 POS N
mm POS N
Hg POS N
and POS N
19.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg, POS N
respectively, POS N
after POS N
washout; POS N

The POS N
mean POS N
IOP POS N
was POS N
14.8 POS N
+/- POS N
1.2 POS N
mm POS N
Hg POS N
in POS N
the POS N
combined POS N
group POS N
and POS N
15.7 POS N
+/- POS N
1.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
control POS N
group POS N
at POS N
15 POS N
months POS N
and POS N
16.6 POS N
+/- POS N
3.1 POS N
mm POS N
Hg POS N
and POS N
19.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg, POS N
respectively, POS N
after POS N
washout; POS N

At POS N
15 POS N
months, POS N
the POS N
mean POS N
number POS N
of POS N
medications POS N
was POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(0.4 POS N
+/- POS N
0.7 POS N
and POS N
1.3 POS N
+/- POS N
1.0, POS N
respectively; POS N
P POS N
= POS N
.007), POS N
as POS N
was POS N
the POS N
proportion POS N
of POS N
patients POS N
on POS N
ocular POS N
hypotensive POS N
medication POS N
(33% POS N
and POS N
76%, POS N
respectively). POS N

The POS N
mean POS N
IOP POS N
was POS N
14.8 POS N
+/- POS N
1.2 POS N
mm POS N
Hg POS N
in POS N
the POS N
combined POS N
group POS N
and POS N
15.7 POS N
+/- POS N
1.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
control POS N
group POS N
at POS N
15 POS N
months POS N
and POS N
16.6 POS N
+/- POS N
3.1 POS N
mm POS N
Hg POS N
and POS N
19.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg, POS N
respectively, POS N
after POS N
washout; POS N

Phacoemulsification POS N
with POS N
stent POS N
implantation POS N
was POS N
more POS N
effective POS N
in POS N
controlling POS N
IOP POS N
than POS N
phacoemulsification POS N
alone; POS N

The POS N
mean POS N
IOP POS N
was POS N
14.8 POS N
+/- POS N
1.2 POS N
mm POS N
Hg POS N
in POS N
the POS N
combined POS N
group POS N
and POS N
15.7 POS N
+/- POS N
1.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
control POS N
group POS N
at POS N
15 POS N
months POS N
and POS N
16.6 POS N
+/- POS N
3.1 POS N
mm POS N
Hg POS N
and POS N
19.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg, POS N
respectively, POS N
after POS N
washout; POS N

the POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
combined POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
at POS N
both POS N
time POS N
points POS N
(P POS N
= POS N
.031 POS N
and POS N
P POS N
= POS N
.042, POS N
respectively). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine-treated POS N
subjects POS N
showed POS N
an POS N
overall POS N
mean POS N
peak POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
(IOP) POS N
of POS N
6.5 POS N
mm POS N
Hg; POS N
timolol-treated POS N
subjects POS N
had POS N
a POS N
mean POS N
peak POS N
reduction POS N
in POS N
IOP POS N
of POS N
6.1 POS N
mm POS N
Hg. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine POS N
lowered POS N
mean POS N
peak POS N
IOP POS N
significantly POS N
more POS N
than POS N
timolol POS N
at POS N
week POS N
2 POS N
and POS N
month POS N
3 POS N
(P POS N
< POS N
.03) POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

No POS N
evidence POS N
of POS N
tachyphylaxis POS N
was POS N
seen POS N
in POS N
either POS N
group. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Allergy POS N
was POS N
seen POS N
in POS N
9% POS N
of POS N
subjects POS N
treated POS N
with POS N
brimonidine. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Dry POS N
mouth POS N
was POS N
more POS N
common POS N
in POS N
the POS N
brimonidine-treated POS N
group POS N
than POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(33.0% POS N
vs POS N
19.4%), POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Headache, POS N
fatigue, POS N
and POS N
drowsiness POS N
were POS N
similar POS N
in POS N
the POS N
2 POS N
groups. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine POS N
is POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes. POS N

complaints POS N
of POS N
burning POS N
and POS N
stinging POS N
were POS N
more POS N
common POS N
in POS N
the POS N
timolol-treated POS N
group POS N
(41.9%) POS N
than POS N
in POS N
the POS N
brimonidine-treated POS N
patients POS N
(28.1%). POS N

Brimonidine POS N
provides POS N
a POS N
sustained POS N
long-term POS N
ocular POS N
hypotensive POS N
effect, POS N
is POS N
well POS N
tolerated, POS N
and POS N
has POS N
a POS N
low POS N
rate POS N
of POS N
allergic POS N
response. POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

At POS N
month POS N
6, POS N
the POS N
adjusted POS N
mean POS N
(+/- POS N
SEM) POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
5.7 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
3.1 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
in POS N
patients POS N
receiving POS N
brimonidine POS N
(P POS N
< POS N
0.001). POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

The POS N
mean POS N
difference POS N
in POS N
diurnal POS N
IOP POS N
reduction POS N
was POS N
2.5 POS N
+/- POS N
0.3 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
1.9, POS N
3.2; POS N
P POS N
< POS N
0.001). POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

Five POS N
times POS N
more POS N
patients POS N
receiving POS N
brimonidine POS N
than POS N
latanoprost POS N
were POS N
withdrawn POS N
from POS N
the POS N
study POS N
due POS N
to POS N
adverse POS N
events. POS N

During POS N
therapy, POS N
the POS N
range POS N
of POS N
daily POS N
fluctuation POS N
of POS N
IOP POS N
is POS N
less POS N
for POS N
latanoprost POS N
compared POS N
with POS N
brimonidine. POS N

Latanoprost POS N
instilled POS N
once POS N
daily POS N
is POS N
more POS N
effective POS N
and POS N
better POS N
tolerated POS N
than POS N
brimonidine POS N
administered POS N
twice POS N
daily POS N
for POS N
the POS N
treatment POS N
of POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

The POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
was POS N
significant POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
0.001). POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

The POS N
mean POS N
intraocular POS N
pressure POS N
reduction POS N
from POS N
baseline POS N
was POS N
32% POS N
for POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
20% POS N
for POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group. POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

The POS N
least POS N
square POS N
estimate POS N
of POS N
the POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
reduction POS N
after POS N
3 POS N
months POS N
was POS N
-7.06 POS N
mm POS N
Hg POS N
in POS N
the POS N
latanoprost POS N
plus POS N
timolol POS N
group POS N
and POS N
-4.44 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide POS N
plus POS N
timolol POS N
group POS N
(P POS N
< POS N
0.001). POS N

This POS N
study POS N
clearly POS N
showed POS N
that POS N
the POS N
additive POS N
diurnal POS N
intraocular POS N
pressure-lowering POS N
effect POS N
of POS N
latanoprost POS N
is POS N
superior POS N
to POS N
that POS N
of POS N
dorzolamide POS N
in POS N
patients POS N
treated POS N
with POS N
timolol. POS N

Drugs POS N
administered POS N
in POS N
both POS N
treatment POS N
groups POS N
were POS N
well POS N
tolerated. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

Our POS N
results POS N
suggest POS N
that POS N
OLO POS N
implant POS N
could POS N
be POS N
a POS N
new, POS N
safe, POS N
and POS N
effective POS N
alternative POS N
to POS N
MMC, POS N
with POS N
similar POS N
long-term POS N
success POS N
rate. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

No POS N
adverse POS N
reaction POS N
to POS N
OLO POS N
was POS N
noted. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

One-day POS N
postoperatively, POS N
the POS N
IOP POS N
dropped POS N
to POS N
5.2 POS N
(±3.5) POS N
and POS N
9.2 POS N
(±5.5) POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.009). POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

The POS N
IOP POS N
reduction POS N
was POS N
significant POS N
at POS N
end POS N
point POS N
in POS N
all POS N
groups POS N
(P=0.01), POS N
with POS N
a POS N
mean POS N
IOP POS N
of POS N
16.0 POS N
(±2.9) POS N
and POS N
16.5 POS N
(±2.1) POS N
mm POS N
Hg POS N
in POS N
MMC POS N
and POS N
OLO, POS N
respectively. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

The POS N
rates POS N
and POS N
Kaplan-Meier POS N
curves POS N
did POS N
not POS N
differ POS N
for POS N
both POS N
complete POS N
and POS N
qualified POS N
success POS N
at POS N
any POS N
target POS N
IOP. POS N

SD-OCT POS N
analysis POS N
of POS N
successful/unsuccessful POS N
bleb POS N
in POS N
patients POS N
with POS N
or POS N
without POS N
complete POS N
success POS N
at POS N
IOP POS N
=17 POS N
 POS N
mm POS N
Hg POS N
indicated POS N
a POS N
sensitivity POS N
of POS N
83% POS N
and POS N
73% POS N
and POS N
a POS N
specificity POS N
of POS N
75% POS N
and POS N
67%, POS N
respectively, POS N
for POS N
MMC POS N
and POS N
OLO POS N
groups. POS N

The POS N
bleb POS N
height POS N
in POS N
OLO POS N
group POS N
was POS N
higher POS N
than POS N
MMC POS N
one POS N
(P<0.05). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
receiving POS N
the POS N
fixed POS N
combination POS N
had POS N
IOP POS N
decreases POS N
of POS N
2 POS N
mm POS N
Hg POS N
on POS N
day POS N
21 POS N
relative POS N
to POS N
baseline POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(79.4% POS N
vs POS N
51.4%, POS N
respectively; POS N
P POS N
< POS N
0.001). POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

PP POS N
analyses POS N
found POS N
that POS N
more POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
group POS N
had POS N
IOP POS N
decreases POS N
>or=3, POS N
>or=4, POS N
or POS N
>or=5 POS N
mm POS N
Hg POS N
(for POS N
each POS N
target POS N
level, POS N
P POS N
< POS N
0.001 POS N
vs POS N
latanoprost POS N
group) POS N
or POS N
final POS N
IOP POS N
18 POS N
mm POS N
Hg POS N
(fixed POS N
-combination, POS N
35.1%; POS N
latanoprost, POS N
17.8%; POS N
P POS N
< POS N
0.001). POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

patients POS N
with POS N
an POS N
inadequate POS N
initial POS N
IOP POS N
response POS N
to POS N
latanoprost, POS N
switching POS N
to POS N
fixed-combination POS N
latanoprosttimolol POS N
resulted POS N
in POS N
a POS N
greater POS N
decrease POS N
in POS N
IOP POS N
and POS N
similar POS N
tolerability POS N
compared POS N
with POS N
continuing POS N
latanoprost POS N
therapy. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated. POS N

Similar POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
fixed-combination POS N
and POS N
latanoprost POS N
groups POS N
reported POS N
at POS N
least POS N
1 POS N
treatment-emergent POS N
AE POS N
(10.9% POS N
and POS N
12.1%, POS N
respectively). POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
for POS N
dorzolamide POS N
were POS N
27.2 POS N
(3.4) POS N
and POS N
5.6 POS N
(2.6) POS N
mm POS N
Hg. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

After POS N
3 POS N
months, POS N
latanoprost POS N
reduced POS N
mean POS N
baseline POS N
diurnal POS N
IOP POS N
from POS N
27.2 POS N
(SD POS N
3.0) POS N
mm POS N
Hg POS N
by POS N
8.5 POS N
(3.3) POS N
mm POS N
Hg. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
difference POS N
of POS N
2.9 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
2.3-3.6) POS N
was POS N
highly POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

The POS N
corresponding POS N
figures POS N
at POS N
trough POS N
were POS N
8.1 POS N
mm POS N
Hg POS N
(31%) POS N
for POS N
latanoprost POS N
and POS N
4.7 POS N
mm POS N
Hg POS N
(17%) POS N
for POS N
dorzolamide, POS N
a POS N
significant POS N
difference POS N
of POS N
3.4 POS N
mm POS N
Hg POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
systemically POS N
and POS N
locally. POS N

Latanoprost POS N
reduced POS N
IOP POS N
at POS N
peak POS N
by POS N
8.6 POS N
mm POS N
Hg POS N
(32%) POS N
compared POS N
with POS N
6.2 POS N
mm POS N
Hg POS N
(23%) POS N
for POS N
dorzolamide, POS N
and POS N
the POS N
difference POS N
of POS N
2.4 POS N
mm POS N
Hg POS N
was POS N
significant POS N
(p<0.001, POS N
ANCOVA). POS N

Latanoprost POS N
was POS N
superior POS N
to POS N
dorzolamide POS N
in POS N
reducing POS N
the POS N
IOP, POS N
judged POS N
both POS N
from POS N
the POS N
effect POS N
on POS N
IOP POS N
at POS N
peak POS N
and POS N
trough POS N
and POS N
by POS N
the POS N
effect POS N
on POS N
diurnal POS N
IOP. POS N

At POS N
1-year POS N
follow-up, POS N
complete POS N
success POS N
rates POS N
were POS N
81.8% POS N
for POS N
Ex-PRESS POS N
and POS N
47.5% POS N
for POS N
trabeculectomy POS N
(P=0.0020), POS N
and POS N
71.7% POS N
and POS N
37.5% POS N
(P=0.0070), POS N
respectively, POS N
for POS N
the POS N
more POS N
stringent POS N
target. POS N

There POS N
was POS N
a POS N
similar POS N
level POS N
of POS N
postoperative POS N
interventions POS N
and POS N
complications POS N
for POS N
each POS N
group. POS N

At POS N
1-year POS N
follow-up, POS N
complete POS N
success POS N
rates POS N
were POS N
81.8% POS N
for POS N
Ex-PRESS POS N
and POS N
47.5% POS N
for POS N
trabeculectomy POS N
(P=0.0020), POS N
and POS N
71.7% POS N
and POS N
37.5% POS N
(P=0.0070), POS N
respectively, POS N
for POS N
the POS N
more POS N
stringent POS N
target. POS N

In POS N
open-angle POS N
glaucoma, POS N
the POS N
Ex-PRESS POS N
mini POS N
glaucoma POS N
shunt POS N
implanted POS N
under POS N
a POS N
superficial POS N
scleral POS N
flap POS N
produces POS N
significantly POS N
higher POS N
success POS N
rates, POS N
and POS N
a POS N
similar POS N
complication POS N
rate, POS N
compared POS N
with POS N
trabeculectomy. POS N

At POS N
1-year POS N
follow-up, POS N
complete POS N
success POS N
rates POS N
were POS N
81.8% POS N
for POS N
Ex-PRESS POS N
and POS N
47.5% POS N
for POS N
trabeculectomy POS N
(P=0.0020), POS N
and POS N
71.7% POS N
and POS N
37.5% POS N
(P=0.0070), POS N
respectively, POS N
for POS N
the POS N
more POS N
stringent POS N
target. POS N

The POS N
Ex-PRESS POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
device POS N
for POS N
treating POS N
open-angle POS N
glaucoma. POS N

There POS N
was POS N
a POS N
similar POS N
level POS N
of POS N
postoperative POS N
interventions POS N
and POS N
complications POS N
for POS N
each POS N
group. POS N

At POS N
1-year POS N
follow-up, POS N
complete POS N
success POS N
rates POS N
were POS N
81.8% POS N
for POS N
Ex-PRESS POS N
and POS N
47.5% POS N
for POS N
trabeculectomy POS N
(P=0.0020), POS N
and POS N
71.7% POS N
and POS N
37.5% POS N
(P=0.0070), POS N
respectively, POS N
for POS N
the POS N
more POS N
stringent POS N
target. POS N

There POS N
was POS N
a POS N
similar POS N
level POS N
of POS N
postoperative POS N
interventions POS N
and POS N
complications POS N
for POS N
each POS N
group. POS N

In POS N
open-angle POS N
glaucoma, POS N
the POS N
Ex-PRESS POS N
mini POS N
glaucoma POS N
shunt POS N
implanted POS N
under POS N
a POS N
superficial POS N
scleral POS N
flap POS N
produces POS N
significantly POS N
higher POS N
success POS N
rates, POS N
and POS N
a POS N
similar POS N
complication POS N
rate, POS N
compared POS N
with POS N
trabeculectomy. POS N

There POS N
was POS N
a POS N
similar POS N
level POS N
of POS N
postoperative POS N
interventions POS N
and POS N
complications POS N
for POS N
each POS N
group. POS N

The POS N
Ex-PRESS POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
device POS N
for POS N
treating POS N
open-angle POS N
glaucoma. POS N

In POS N
open-angle POS N
glaucoma, POS N
the POS N
Ex-PRESS POS N
mini POS N
glaucoma POS N
shunt POS N
implanted POS N
under POS N
a POS N
superficial POS N
scleral POS N
flap POS N
produces POS N
significantly POS N
higher POS N
success POS N
rates, POS N
and POS N
a POS N
similar POS N
complication POS N
rate, POS N
compared POS N
with POS N
trabeculectomy. POS N

At POS N
1-year POS N
follow-up, POS N
complete POS N
success POS N
rates POS N
were POS N
81.8% POS N
for POS N
Ex-PRESS POS N
and POS N
47.5% POS N
for POS N
trabeculectomy POS N
(P=0.0020), POS N
and POS N
71.7% POS N
and POS N
37.5% POS N
(P=0.0070), POS N
respectively, POS N
for POS N
the POS N
more POS N
stringent POS N
target. POS N

In POS N
open-angle POS N
glaucoma, POS N
the POS N
Ex-PRESS POS N
mini POS N
glaucoma POS N
shunt POS N
implanted POS N
under POS N
a POS N
superficial POS N
scleral POS N
flap POS N
produces POS N
significantly POS N
higher POS N
success POS N
rates, POS N
and POS N
a POS N
similar POS N
complication POS N
rate, POS N
compared POS N
with POS N
trabeculectomy. POS N

There POS N
was POS N
a POS N
similar POS N
level POS N
of POS N
postoperative POS N
interventions POS N
and POS N
complications POS N
for POS N
each POS N
group. POS N

In POS N
open-angle POS N
glaucoma, POS N
the POS N
Ex-PRESS POS N
mini POS N
glaucoma POS N
shunt POS N
implanted POS N
under POS N
a POS N
superficial POS N
scleral POS N
flap POS N
produces POS N
significantly POS N
higher POS N
success POS N
rates, POS N
and POS N
a POS N
similar POS N
complication POS N
rate, POS N
compared POS N
with POS N
trabeculectomy. POS N

The POS N
Ex-PRESS POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
device POS N
for POS N
treating POS N
open-angle POS N
glaucoma. POS N

The POS N
Ex-PRESS POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
device POS N
for POS N
treating POS N
open-angle POS N
glaucoma. POS N

At POS N
1-year POS N
follow-up, POS N
complete POS N
success POS N
rates POS N
were POS N
81.8% POS N
for POS N
Ex-PRESS POS N
and POS N
47.5% POS N
for POS N
trabeculectomy POS N
(P=0.0020), POS N
and POS N
71.7% POS N
and POS N
37.5% POS N
(P=0.0070), POS N
respectively, POS N
for POS N
the POS N
more POS N
stringent POS N
target. POS N

The POS N
Ex-PRESS POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
device POS N
for POS N
treating POS N
open-angle POS N
glaucoma. POS N

There POS N
was POS N
a POS N
similar POS N
level POS N
of POS N
postoperative POS N
interventions POS N
and POS N
complications POS N
for POS N
each POS N
group. POS N

The POS N
Ex-PRESS POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
device POS N
for POS N
treating POS N
open-angle POS N
glaucoma. POS N

In POS N
open-angle POS N
glaucoma, POS N
the POS N
Ex-PRESS POS N
mini POS N
glaucoma POS N
shunt POS N
implanted POS N
under POS N
a POS N
superficial POS N
scleral POS N
flap POS N
produces POS N
significantly POS N
higher POS N
success POS N
rates, POS N
and POS N
a POS N
similar POS N
complication POS N
rate, POS N
compared POS N
with POS N
trabeculectomy. POS N

TMMC POS N
and POS N
T5-FU POS N
appeared POS N
to POS N
have POS N
similar POS N
efficacy POS N
in POS N
lowering POS N
IOP. POS N

Mean POS N
preoperative POS N
IOPs POS N
in POS N
the POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
were POS N
31.2 POS N
± POS N
9.8 POS N
and POS N
30.6 POS N
± POS N
9.9 POS N
mmHg, POS N
respectively. POS N
Postoperatively, POS N
mean POS N
IOPs POS N
were POS N
11.4 POS N
± POS N
4.9 POS N
and POS N
13.6 POS N
± POS N
3.9 POS N
mmHg, POS N
respectively POS N
for POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
after POS N
6 POS N
months. POS N

TMMC POS N
and POS N
T5-FU POS N
appeared POS N
to POS N
have POS N
similar POS N
efficacy POS N
in POS N
lowering POS N
IOP. POS N

statistical POS N
tests POS N
showed POS N
no POS N
difference POS N
in POS N
mean POS N
and POS N
median POS N
IOP. POS N

TMMC POS N
and POS N
T5-FU POS N
appeared POS N
to POS N
have POS N
similar POS N
efficacy POS N
in POS N
lowering POS N
IOP. POS N

Three POS N
cases POS N
of POS N
hypotonia POS N
(IOP POS N
< POS N
6 POS N
mmHg) POS N
and POS N
1 POS N
case POS N
of POS N
epithelial POS N
keratitis POS N
were POS N
detected. POS N

Mean POS N
preoperative POS N
IOPs POS N
in POS N
the POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
were POS N
31.2 POS N
± POS N
9.8 POS N
and POS N
30.6 POS N
± POS N
9.9 POS N
mmHg, POS N
respectively. POS N
Postoperatively, POS N
mean POS N
IOPs POS N
were POS N
11.4 POS N
± POS N
4.9 POS N
and POS N
13.6 POS N
± POS N
3.9 POS N
mmHg, POS N
respectively POS N
for POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
after POS N
6 POS N
months. POS N

TMMC POS N
and POS N
T5-FU POS N
appeared POS N
to POS N
have POS N
similar POS N
efficacy POS N
in POS N
lowering POS N
IOP. POS N

Mean POS N
preoperative POS N
IOPs POS N
in POS N
the POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
were POS N
31.2 POS N
± POS N
9.8 POS N
and POS N
30.6 POS N
± POS N
9.9 POS N
mmHg, POS N
respectively. POS N
Postoperatively, POS N
mean POS N
IOPs POS N
were POS N
11.4 POS N
± POS N
4.9 POS N
and POS N
13.6 POS N
± POS N
3.9 POS N
mmHg, POS N
respectively POS N
for POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
after POS N
6 POS N
months. POS N

statistical POS N
tests POS N
showed POS N
no POS N
difference POS N
in POS N
mean POS N
and POS N
median POS N
IOP. POS N

Mean POS N
preoperative POS N
IOPs POS N
in POS N
the POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
were POS N
31.2 POS N
± POS N
9.8 POS N
and POS N
30.6 POS N
± POS N
9.9 POS N
mmHg, POS N
respectively. POS N
Postoperatively, POS N
mean POS N
IOPs POS N
were POS N
11.4 POS N
± POS N
4.9 POS N
and POS N
13.6 POS N
± POS N
3.9 POS N
mmHg, POS N
respectively POS N
for POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
after POS N
6 POS N
months. POS N

Three POS N
cases POS N
of POS N
hypotonia POS N
(IOP POS N
< POS N
6 POS N
mmHg) POS N
and POS N
1 POS N
case POS N
of POS N
epithelial POS N
keratitis POS N
were POS N
detected. POS N

statistical POS N
tests POS N
showed POS N
no POS N
difference POS N
in POS N
mean POS N
and POS N
median POS N
IOP. POS N

TMMC POS N
and POS N
T5-FU POS N
appeared POS N
to POS N
have POS N
similar POS N
efficacy POS N
in POS N
lowering POS N
IOP. POS N

statistical POS N
tests POS N
showed POS N
no POS N
difference POS N
in POS N
mean POS N
and POS N
median POS N
IOP. POS N

Mean POS N
preoperative POS N
IOPs POS N
in POS N
the POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
were POS N
31.2 POS N
± POS N
9.8 POS N
and POS N
30.6 POS N
± POS N
9.9 POS N
mmHg, POS N
respectively. POS N
Postoperatively, POS N
mean POS N
IOPs POS N
were POS N
11.4 POS N
± POS N
4.9 POS N
and POS N
13.6 POS N
± POS N
3.9 POS N
mmHg, POS N
respectively POS N
for POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
after POS N
6 POS N
months. POS N

statistical POS N
tests POS N
showed POS N
no POS N
difference POS N
in POS N
mean POS N
and POS N
median POS N
IOP. POS N

Three POS N
cases POS N
of POS N
hypotonia POS N
(IOP POS N
< POS N
6 POS N
mmHg) POS N
and POS N
1 POS N
case POS N
of POS N
epithelial POS N
keratitis POS N
were POS N
detected. POS N

Three POS N
cases POS N
of POS N
hypotonia POS N
(IOP POS N
< POS N
6 POS N
mmHg) POS N
and POS N
1 POS N
case POS N
of POS N
epithelial POS N
keratitis POS N
were POS N
detected. POS N

TMMC POS N
and POS N
T5-FU POS N
appeared POS N
to POS N
have POS N
similar POS N
efficacy POS N
in POS N
lowering POS N
IOP. POS N

Three POS N
cases POS N
of POS N
hypotonia POS N
(IOP POS N
< POS N
6 POS N
mmHg) POS N
and POS N
1 POS N
case POS N
of POS N
epithelial POS N
keratitis POS N
were POS N
detected. POS N

Mean POS N
preoperative POS N
IOPs POS N
in POS N
the POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
were POS N
31.2 POS N
± POS N
9.8 POS N
and POS N
30.6 POS N
± POS N
9.9 POS N
mmHg, POS N
respectively. POS N
Postoperatively, POS N
mean POS N
IOPs POS N
were POS N
11.4 POS N
± POS N
4.9 POS N
and POS N
13.6 POS N
± POS N
3.9 POS N
mmHg, POS N
respectively POS N
for POS N
TMMC POS N
and POS N
T5-FU POS N
groups POS N
after POS N
6 POS N
months. POS N

Three POS N
cases POS N
of POS N
hypotonia POS N
(IOP POS N
< POS N
6 POS N
mmHg) POS N
and POS N
1 POS N
case POS N
of POS N
epithelial POS N
keratitis POS N
were POS N
detected. POS N

statistical POS N
tests POS N
showed POS N
no POS N
difference POS N
in POS N
mean POS N
and POS N
median POS N
IOP. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
ECD POS N
reduction POS N
in POS N
group POS N
BSS POS N
Plus POS N
13.1 POS N
± POS N
2.0% POS N
and POS N
Ringer POS N
9.2 POS N
± POS N
1.9% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
CV POS N
increase POS N
in POS N
group POS N
BSS POS N
Plus POS N
23.0 POS N
± POS N
3.0% POS N
and POS N
Ringer POS N
20.2 POS N
± POS N
4.0% POS N
(p<0.05) POS N
at POS N
day POS N
60 POS N
or POS N
in POS N
any POS N
study POS N
visit. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

CCT POS N
was POS N
significantly POS N
increased POS N
(p<0.05) POS N
at POS N
1, POS N
8, POS N
15 POS N
and POS N
30 POS N
days POS N
postoperatively, POS N
returning POS N
to POS N
baseline POS N
at POS N
60 POS N
days POS N
in POS N
both POS N
groups. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
CCT POS N
increase POS N
in POS N
both POS N
groups POS N
at POS N
any POS N
visit. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

there POS N
were POS N
statistically POS N
significant POS N
correlations POS N
between POS N
ECD POS N
loss POS N
and POS N
phacoemulsification POS N
time POS N
(p<0.0001) POS N
and POS N
ECD POS N
loss POS N
and POS N
irrigation POS N
solution POS N
volume POS N
(p<0.0001) POS N
in POS N
the POS N
Ringer POS N
group, POS N
but POS N
not POS N
in POS N
the POS N
BSS POS N
Plus POS N
group. POS N

However, POS N
our POS N
study POS N
demonstrates POS N
that POS N
there POS N
is POS N
a POS N
trend POS N
towards POS N
lower POS N
postoperative POS N
endothelial POS N
cell POS N
density POS N
for POS N
surgeries POS N
with POS N
longer POS N
phacoemulsification POS N
time POS N
and POS N
higher POS N
irrigation POS N
volumes POS N
if POS N
Ringer POS N
is POS N
used. POS N

Ringers POS N
solution POS N
was POS N
similar POS N
to POS N
BSS POS N
Plus POS N
for POS N
corneal POS N
preservation POS N
in POS N
atraumatic POS N
cataract POS N
surgery. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

Mean POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
8 POS N
weeks POS N
were POS N
7.02+/-3.06 POS N
mm POS N
Hg POS N
and POS N
6.91+/-3.67 POS N
mm POS N
Hg, POS N
respectively POS N
(P=0.811). POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

The POS N
adjusted POS N
difference POS N
between POS N
groups POS N
(analysis POS N
of POS N
covariance) POS N
at POS N
week POS N
8 POS N
was POS N
not POS N
statistically POS N
significant POS N
(P=0.847). POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

No POS N
statistical POS N
difference POS N
in POS N
terms POS N
of POS N
adverse POS N
events POS N
was POS N
found POS N
between POS N
groups. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

both POS N
fixed POS N
combinations POS N
are POS N
well POS N
tolerated POS N
with POS N
few POS N
side POS N
effects. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

Mean POS N
baseline POS N
WDT POS N
peak POS N
was POS N
27.79+/-4.29 POS N
mm POS N
Hg POS N
in POS N
the POS N
brimonidine/timolol POS N
group POS N
and POS N
27.68+/-5.46 POS N
mm POS N
Hg POS N
in POS N
the POS N
dorzolamide/timolol POS N
group. POS N

After POS N
8 POS N
weeks POS N
of POS N
treatment, POS N
mean POS N
WDT POS N
peaks POS N
were POS N
20.94+/-3.76 POS N
mm POS N
Hg POS N
(P<0.001) POS N
and POS N
20.98+/-4.19 POS N
(P<0.001), POS N
respectively. POS N

Both POS N
fixed POS N
combinations POS N
were POS N
capable POS N
of POS N
significantly POS N
reducing POS N
the POS N
mean POS N
diurnal POS N
IOP, POS N
mean POS N
diurnal POS N
peak, POS N
and POS N
mean POS N
WDT POS N
peak POS N
after POS N
8 POS N
weeks POS N
of POS N
treatment. POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

Low-pressure POS N
glaucoma POS N
patients POS N
treated POS N
with POS N
brimonidine POS N
0.2% POS N
who POS N
do POS N
not POS N
develop POS N
ocular POS N
allergy POS N
are POS N
less POS N
likely POS N
to POS N
have POS N
field POS N
progression POS N
than POS N
patients POS N
treated POS N
with POS N
timolol POS N
0.5%. POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

Statistically POS N
fewer POS N
brimonidine-treated POS N
patients POS N
(9, POS N
9.1%) POS N
had POS N
visual POS N
field POS N
progression POS N
by POS N
pointwise POS N
linear POS N
regression POS N
than POS N
timolol-treated POS N
patients POS N
(31, POS N
39.2%, POS N
log-rank POS N
12.4, POS N
P=.001). POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

Mean POS N
treated POS N
IOP POS N
was POS N
similar POS N
for POS N
brimonidine- POS N
and POS N
timolol-treated POS N
patients POS N
at POS N
all POS N
time POS N
points. POS N

Similar POS N
differences POS N
in POS N
progression POS N
were POS N
observed POS N
when POS N
analyzed POS N
by POS N
GCPM POS N
and POS N
the POS N
3-omitting POS N
method. POS N

More POS N
brimonidine-treated POS N
(28, POS N
28.3%) POS N
than POS N
timolol-treated POS N
(9, POS N
11.4%) POS N
patients POS N
discontinued POS N
study POS N
participation POS N
because POS N
of POS N
drug-related POS N
adverse POS N
events POS N
(P=.008). POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Clinical POS N
success POS N
was POS N
71% POS N
(75/106) POS N
with POS N
brimonidine POS N
and POS N
70% POS N
(73/105) POS N
with POS N
timolol POS N
as POS N
initial POS N
treatment. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
overall POS N
mean POS N
decrease POS N
in POS N
IOP POS N
was POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.2 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Few POS N
patients POS N
reported POS N
a POS N
specific POS N
adverse POS N
event POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

with POS N
the POS N
exception POS N
of POS N
a POS N
slightly POS N
higher POS N
rate POS N
of POS N
ocular POS N
burning POS N
and POS N
stinging POS N
in POS N
the POS N
brimonidine POS N
group, POS N
there POS N
were POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

No POS N
significant POS N
chronotropic POS N
effects POS N
on POS N
the POS N
heart POS N
were POS N
seen POS N
with POS N
brimonidine POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

small POS N
but POS N
significant POS N
mean POS N
decreases POS N
in POS N
heart POS N
rate POS N
were POS N
seen POS N
at POS N
months POS N
1 POS N
and POS N
4 POS N
with POS N
timolol. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Quality POS N
of POS N
life POS N
remained POS N
stable, POS N
with POS N
no POS N
significant POS N
between-group POS N
differences. POS N

Brimonidine POS N
is POS N
a POS N
viable POS N
alternative POS N
to POS N
timolol POS N
for POS N
first-line POS N
therapy POS N
in POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

As POS N
a POS N
first-line POS N
agent POS N
for POS N
the POS N
treatment POS N
of POS N
glaucoma POS N
and POS N
ocular POS N
hypertension, POS N
brimonidine POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol, POS N
but POS N
with POS N
less POS N
chronotropic POS N
effect POS N
on POS N
the POS N
heart. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
fixed-combination POS N
dorzolamide POS N
and POS N
timolol. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Mean POS N
(SD) POS N
diurnal POS N
IOP POS N
reductions POS N
at POS N
week POS N
8 POS N
before POS N
the POS N
water-drinking POS N
test POS N
were POS N
6.9 POS N
(3.0) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
6.4 POS N
(3.2) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Mean POS N
baseline POS N
diurnal POS N
IOP POS N
values POS N
were POS N
similar POS N
between POS N
the POS N
2 POS N
groups. POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Mean POS N
IOP POS N
values POS N
were POS N
similar POS N
at POS N
all POS N
time POS N
points POS N
except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
levels POS N
were POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
(P POS N
= POS N
0.025). POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

After POS N
the POS N
water-drinking POS N
test, POS N
the POS N
increase POS N
in POS N
IOP POS N
values POS N
was POS N
similar POS N
between POS N
groups POS N
at POS N
baseline POS N
but POS N
lower POS N
in POS N
latanoprost-treated POS N
patients POS N
at POS N
week POS N
8 POS N
(adjusted POS N
difference, POS N
1.08 POS N
mm POS N
Hg; POS N
P POS N
= POS N
0.012). POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

Fewer POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
reported POS N
ocular POS N
or POS N
systemic POS N
AEs POS N
(P POS N
= POS N
0.025 POS N
and POS N
P POS N
< POS N
0.001, POS N
respectively). POS N

except POS N
at POS N
5:00 POS N
pm, POS N
when POS N
the POS N
mean POS N
IOP POS N
level POS N
was POS N
significantly POS N
lower POS N
in POS N
latanoprost-treated POS N
patients. POS N

In POS N
this POS N
study POS N
of POS N
patients POS N
with POS N
unilateral POS N
or POS N
bilateral POS N
primary POS N
open-angle, POS N
pigmentary, POS N
or POS N
exfoliative POS N
glaucoma POS N
or POS N
OHT POS N
IOP POS N
reductions POS N
generally POS N
were POS N
similar POS N
between POS N
treatment POS N
groups, POS N

At POS N
24 POS N
months, POS N
complete POS N
success POS N
rates POS N
were POS N
53.3% POS N
for POS N
the POS N
ELT POS N
group POS N
and POS N
40% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.35, POS N
Fisher's POS N
exact POS N
test); POS N

Both POS N
ELT POS N
and POS N
SLT POS N
proved POS N
to POS N
be POS N
effective POS N
techniques POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
refractory POS N
to POS N
medical POS N
therapy. POS N

At POS N
24 POS N
months, POS N
complete POS N
success POS N
rates POS N
were POS N
53.3% POS N
for POS N
the POS N
ELT POS N
group POS N
and POS N
40% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.35, POS N
Fisher's POS N
exact POS N
test); POS N

qualified POS N
success POS N
rates POS N
were POS N
33.3% POS N
for POS N
the POS N
ELT POS N
and POS N
26.6% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.5, POS N
Fisher's POS N
exact POS N
test). POS N

At POS N
24 POS N
months, POS N
complete POS N
success POS N
rates POS N
were POS N
53.3% POS N
for POS N
the POS N
ELT POS N
group POS N
and POS N
40% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.35, POS N
Fisher's POS N
exact POS N
test); POS N

Mean POS N
IOP POS N
decreased POS N
from POS N
25.0+/-1.9 POS N
to POS N
17.6+/-2.2 POS N
mmHg POS N
(-29.6%; POS N
P<0.0001) POS N
in POS N
the POS N
ELT POS N
group POS N
and POS N
from POS N
23.9+/-0.9 POS N
to POS N
19.1+/-1.8 POS N
mmHg POS N
(-21%; POS N
P<0.0001) POS N
in POS N
the POS N
SLT POS N
group. POS N

Both POS N
ELT POS N
and POS N
SLT POS N
proved POS N
to POS N
be POS N
effective POS N
techniques POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
refractory POS N
to POS N
medical POS N
therapy. POS N

At POS N
24 POS N
months, POS N
complete POS N
success POS N
rates POS N
were POS N
53.3% POS N
for POS N
the POS N
ELT POS N
group POS N
and POS N
40% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.35, POS N
Fisher's POS N
exact POS N
test); POS N

Both POS N
ELT POS N
and POS N
SLT POS N
proved POS N
to POS N
be POS N
effective POS N
techniques POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
refractory POS N
to POS N
medical POS N
therapy. POS N

qualified POS N
success POS N
rates POS N
were POS N
33.3% POS N
for POS N
the POS N
ELT POS N
and POS N
26.6% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.5, POS N
Fisher's POS N
exact POS N
test). POS N

Both POS N
ELT POS N
and POS N
SLT POS N
proved POS N
to POS N
be POS N
effective POS N
techniques POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
refractory POS N
to POS N
medical POS N
therapy. POS N

Mean POS N
IOP POS N
decreased POS N
from POS N
25.0+/-1.9 POS N
to POS N
17.6+/-2.2 POS N
mmHg POS N
(-29.6%; POS N
P<0.0001) POS N
in POS N
the POS N
ELT POS N
group POS N
and POS N
from POS N
23.9+/-0.9 POS N
to POS N
19.1+/-1.8 POS N
mmHg POS N
(-21%; POS N
P<0.0001) POS N
in POS N
the POS N
SLT POS N
group. POS N

qualified POS N
success POS N
rates POS N
were POS N
33.3% POS N
for POS N
the POS N
ELT POS N
and POS N
26.6% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.5, POS N
Fisher's POS N
exact POS N
test). POS N

At POS N
24 POS N
months, POS N
complete POS N
success POS N
rates POS N
were POS N
53.3% POS N
for POS N
the POS N
ELT POS N
group POS N
and POS N
40% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.35, POS N
Fisher's POS N
exact POS N
test); POS N

qualified POS N
success POS N
rates POS N
were POS N
33.3% POS N
for POS N
the POS N
ELT POS N
and POS N
26.6% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.5, POS N
Fisher's POS N
exact POS N
test). POS N

Both POS N
ELT POS N
and POS N
SLT POS N
proved POS N
to POS N
be POS N
effective POS N
techniques POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
refractory POS N
to POS N
medical POS N
therapy. POS N

qualified POS N
success POS N
rates POS N
were POS N
33.3% POS N
for POS N
the POS N
ELT POS N
and POS N
26.6% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.5, POS N
Fisher's POS N
exact POS N
test). POS N

Mean POS N
IOP POS N
decreased POS N
from POS N
25.0+/-1.9 POS N
to POS N
17.6+/-2.2 POS N
mmHg POS N
(-29.6%; POS N
P<0.0001) POS N
in POS N
the POS N
ELT POS N
group POS N
and POS N
from POS N
23.9+/-0.9 POS N
to POS N
19.1+/-1.8 POS N
mmHg POS N
(-21%; POS N
P<0.0001) POS N
in POS N
the POS N
SLT POS N
group. POS N

Mean POS N
IOP POS N
decreased POS N
from POS N
25.0+/-1.9 POS N
to POS N
17.6+/-2.2 POS N
mmHg POS N
(-29.6%; POS N
P<0.0001) POS N
in POS N
the POS N
ELT POS N
group POS N
and POS N
from POS N
23.9+/-0.9 POS N
to POS N
19.1+/-1.8 POS N
mmHg POS N
(-21%; POS N
P<0.0001) POS N
in POS N
the POS N
SLT POS N
group. POS N

At POS N
24 POS N
months, POS N
complete POS N
success POS N
rates POS N
were POS N
53.3% POS N
for POS N
the POS N
ELT POS N
group POS N
and POS N
40% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.35, POS N
Fisher's POS N
exact POS N
test); POS N

Mean POS N
IOP POS N
decreased POS N
from POS N
25.0+/-1.9 POS N
to POS N
17.6+/-2.2 POS N
mmHg POS N
(-29.6%; POS N
P<0.0001) POS N
in POS N
the POS N
ELT POS N
group POS N
and POS N
from POS N
23.9+/-0.9 POS N
to POS N
19.1+/-1.8 POS N
mmHg POS N
(-21%; POS N
P<0.0001) POS N
in POS N
the POS N
SLT POS N
group. POS N

Both POS N
ELT POS N
and POS N
SLT POS N
proved POS N
to POS N
be POS N
effective POS N
techniques POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
refractory POS N
to POS N
medical POS N
therapy. POS N

Mean POS N
IOP POS N
decreased POS N
from POS N
25.0+/-1.9 POS N
to POS N
17.6+/-2.2 POS N
mmHg POS N
(-29.6%; POS N
P<0.0001) POS N
in POS N
the POS N
ELT POS N
group POS N
and POS N
from POS N
23.9+/-0.9 POS N
to POS N
19.1+/-1.8 POS N
mmHg POS N
(-21%; POS N
P<0.0001) POS N
in POS N
the POS N
SLT POS N
group. POS N

qualified POS N
success POS N
rates POS N
were POS N
33.3% POS N
for POS N
the POS N
ELT POS N
and POS N
26.6% POS N
for POS N
the POS N
SLT POS N
group POS N
(P=0.5, POS N
Fisher's POS N
exact POS N
test). POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

Intraocular POS N
pressure POS N
was POS N
significantly POS N
reduced POS N
during POS N
the POS N
entire POS N
follow-up POS N
period POS N
in POS N
both POS N
groups. POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

In POS N
the POS N
long-acting POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-3.5 POS N
+/- POS N
0.2, POS N
-4.3 POS N
+/- POS N
0.2 POS N
and POS N
-4.6 POS N
+/- POS N
0.3 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks, POS N
respectively POS N
(paired POS N
t POS N
test). POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

The POS N
safety POS N
profile POS N
was POS N
similar POS N
in POS N
both POS N
groups, POS N
and POS N
the POS N
tolerance POS N
for POS N
the POS N
long-acting POS N
eye POS N
drops POS N
was POS N
as POS N
good POS N
as POS N
for POS N
the POS N
currently-prescribed POS N
eye POS N
drops. POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

the POS N
long-acting POS N
eye POS N
drops POS N
seem POS N
to POS N
be POS N
an POS N
efficacious POS N
formulation POS N
for POS N
clinical POS N
use POS N
in POS N
Japanese POS N
glaucoma POS N
patients. POS N

In POS N
the POS N
currently-prescribed POS N
drug POS N
group, POS N
the POS N
reduction POS N
of POS N
intraocular POS N
pressure POS N
was POS N
-4.1 POS N
+/- POS N
0.2, POS N
-4.4 POS N
+/- POS N
0.3 POS N
and--4.6 POS N
+/- POS N
0.2 POS N
mmHg POS N
at POS N
2, POS N
4, POS N
and POS N
8 POS N
weeks(paired POS N
t POS N
test). POS N

Because POS N
the POS N
efficacy POS N
of POS N
both POS N
drugs POS N
was POS N
equivalent, POS N
with POS N
an POS N
identical POS N
safety POS N
profile, POS N

The POS N
mean POS N
(standard POS N
error POS N
of POS N
mean POS N
[SE]) POS N
IOP POS N
reductions POS N
at POS N
months POS N
one POS N
was POS N
7.2 POS N
(0.4), POS N
at POS N
month POS N
3 POS N
was POS N
7.3 POS N
(0.4), POS N
and POS N
at POS N
month POS N
6 POS N
was POS N
7.1 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
7.5 POS N
(0.3), POS N
7.8 POS N
(0.3), POS N
and POS N
7.4 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

The POS N
latanoprost POS N
and POS N
dorzolamide/timolol POS N
combination POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP POS N
compared POS N
to POS N
untreated POS N
baseline. POS N

The POS N
mean POS N
(standard POS N
error POS N
of POS N
mean POS N
[SE]) POS N
IOP POS N
reductions POS N
at POS N
months POS N
one POS N
was POS N
7.2 POS N
(0.4), POS N
at POS N
month POS N
3 POS N
was POS N
7.3 POS N
(0.4), POS N
and POS N
at POS N
month POS N
6 POS N
was POS N
7.1 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
7.5 POS N
(0.3), POS N
7.8 POS N
(0.3), POS N
and POS N
7.4 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

The POS N
2 POS N
therapies POS N
were POS N
similarly POS N
effective. POS N

The POS N
latanoprost POS N
and POS N
dorzolamide/timolol POS N
combination POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP POS N
compared POS N
to POS N
untreated POS N
baseline. POS N

The POS N
mean POS N
(standard POS N
error POS N
of POS N
mean POS N
[SE]) POS N
IOP POS N
reductions POS N
at POS N
months POS N
one POS N
was POS N
7.2 POS N
(0.4), POS N
at POS N
month POS N
3 POS N
was POS N
7.3 POS N
(0.4), POS N
and POS N
at POS N
month POS N
6 POS N
was POS N
7.1 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
7.5 POS N
(0.3), POS N
7.8 POS N
(0.3), POS N
and POS N
7.4 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

The POS N
latanoprost POS N
and POS N
dorzolamide/timolol POS N
combination POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP POS N
compared POS N
to POS N
untreated POS N
baseline. POS N

The POS N
2 POS N
therapies POS N
were POS N
similarly POS N
effective. POS N

The POS N
2 POS N
therapies POS N
were POS N
similarly POS N
effective. POS N

The POS N
mean POS N
(standard POS N
error POS N
of POS N
mean POS N
[SE]) POS N
IOP POS N
reductions POS N
at POS N
months POS N
one POS N
was POS N
7.2 POS N
(0.4), POS N
at POS N
month POS N
3 POS N
was POS N
7.3 POS N
(0.4), POS N
and POS N
at POS N
month POS N
6 POS N
was POS N
7.1 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
latanoprost POS N
group POS N
and POS N
7.5 POS N
(0.3), POS N
7.8 POS N
(0.3), POS N
and POS N
7.4 POS N
(0.3) POS N
mm POS N
Hg POS N
for POS N
the POS N
dorzolamide/timolol POS N
group. POS N

The POS N
2 POS N
therapies POS N
were POS N
similarly POS N
effective. POS N

The POS N
latanoprost POS N
and POS N
dorzolamide/timolol POS N
combination POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP POS N
compared POS N
to POS N
untreated POS N
baseline. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Pulse POS N
rate POS N
was POS N
significantly POS N
reduced POS N
with POS N
timolol, POS N
but POS N
not POS N
with POS N
latanoprost. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Slightly POS N
more POS N
conjunctival POS N
hyperemia POS N
appeared POS N
in POS N
latanoprost-treated POS N
compared POS N
with POS N
timolol-treated POS N
eyes. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Fewer POS N
subjective POS N
side POS N
effects POS N
occurred POS N
in POS N
latanoprost-treated POS N
eyes. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

no POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
occurred POS N
visual POS N
acuity, POS N
slit-lamp POS N
examination, POS N
blood POS N
pressure, POS N
and POS N
laboratory POS N
values. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Latanoprost POS N
has POS N
the POS N
potential POS N
for POS N
becoming POS N
a POS N
new POS N
first-line POS N
treatment POS N
for POS N
glaucoma. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Intraocular POS N
pressure POS N
(IOP) POS N
was POS N
significantly POS N
(P<0.001) POS N
reduced POS N
and POS N
maintained POS N
by POS N
both POS N
medications POS N
without POS N
evidence POS N
of POS N
a POS N
long-term POS N
drift POS N
over POS N
6 POS N
months. POS N

Both POS N
eyes POS N
of POS N
a POS N
patient POS N
with POS N
a POS N
characteristic, POS N
concentric POS N
iris POS N
heterochromia POS N
(darker POS N
centrally) POS N
at POS N
baseline POS N
showed POS N
a POS N
definite, POS N
photographically POS N
documented POS N
increase POS N
in POS N
pigmentation POS N
during POS N
latanoprost POS N
treatment, POS N
making POS N
the POS N
irides POS N
uniformly POS N
darker. POS N

Comparing POS N
6-month POS N
with POS N
baseline POS N
diurnal POS N
IOP POS N
values, POS N
the POS N
IOP POS N
reduction POS N
(mean POS N
+/- POS N
standard POS N
deviation) POS N
achieved POS N
with POS N
latanoprost POS N
(-6.7 POS N
+/- POS N
3.4 POS N
mmHg) POS N
was POS N
significantly POS N
(P<0.001) POS N
greater POS N
than POS N
that POS N
produced POS N
with POS N
timolol POS N
(4.9 POS N
+/- POS N
2.9 POS N
mmHg). POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

Latanoprost POS N
reduced POS N
IOP POS N
(mean POS N
(SD)) POS N
by POS N
8.4 POS N
(3.8) POS N
mm POS N
Hg POS N
and POS N
bimatoprost POS N
by POS N
8.9 POS N
(3.9) POS N
mm POS N
Hg POS N
from POS N
a POS N
baseline POS N
of POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
and POS N
25.2 POS N
(3.6) POS N
mm POS N
Hg POS N
respectively POS N
(p POS N
= POS N
0.23). POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

however POS N
there POS N
were POS N
twice POS N
as POS N
many POS N
reports POS N
of POS N
an POS N
adverse POS N
event POS N
in POS N
the POS N
bimatoprost POS N
group POS N
(81%) POS N
compared POS N
with POS N
the POS N
latanoprost POS N
group POS N
(40%, POS N
p<0.01). POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

22 POS N
subjects POS N
(37.9%) POS N
treated POS N
with POS N
bimatoprost POS N
experienced POS N
ocular POS N
hyperaemia POS N
as POS N
compared POS N
with POS N
13 POS N
subjects POS N
(22.4%) POS N
treated POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.11). POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

Bimatoprost POS N
once POS N
daily POS N
was POS N
similarly POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
latanoprost POS N
once POS N
daily POS N
in POS N
subjects POS N
with POS N
chronic POS N
PACG. POS N

Adverse POS N
events POS N
were POS N
mild POS N
in POS N
both POS N
groups; POS N

Both POS N
drugs POS N
were POS N
well POS N
tolerated POS N
with POS N
mild POS N
ocular POS N
adverse POS N
events. POS N

A POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
at POS N
6 POS N
months POS N
was POS N
achieved POS N
in POS N
53 POS N
of POS N
56 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
and POS N
54 POS N
of POS N
57 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
(P POS N
= POS N
1.00). POS N

At POS N
12 POS N
months, POS N
45 POS N
of POS N
48 POS N
(94%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
met POS N
a POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
while POS N
48 POS N
of POS N
54 POS N
(89%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
did POS N
(P POS N
=.49). POS N

A POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
at POS N
6 POS N
months POS N
was POS N
achieved POS N
in POS N
53 POS N
of POS N
56 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
and POS N
54 POS N
of POS N
57 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
(P POS N
= POS N
1.00). POS N

The POS N
most POS N
common POS N
complications POS N
in POS N
each POS N
group POS N
were POS N
persistent POS N
choroidal POS N
effusions POS N
and POS N
bleb POS N
leak. POS N

A POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
at POS N
6 POS N
months POS N
was POS N
achieved POS N
in POS N
53 POS N
of POS N
56 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
and POS N
54 POS N
of POS N
57 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
(P POS N
= POS N
1.00). POS N

Our POS N
study POS N
suggests POS N
that POS N
intraoperative POS N
topical POS N
5-FU POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
intraoperative POS N
topical POS N
MMC POS N
in POS N
reducing POS N
IOP POS N
of POS N
eyes POS N
undergoing POS N
primary POS N
trabeculectomy. POS N

At POS N
12 POS N
months, POS N
45 POS N
of POS N
48 POS N
(94%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
met POS N
a POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
while POS N
48 POS N
of POS N
54 POS N
(89%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
did POS N
(P POS N
=.49). POS N

A POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
at POS N
6 POS N
months POS N
was POS N
achieved POS N
in POS N
53 POS N
of POS N
56 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
and POS N
54 POS N
of POS N
57 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
(P POS N
= POS N
1.00). POS N

At POS N
12 POS N
months, POS N
45 POS N
of POS N
48 POS N
(94%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
met POS N
a POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
while POS N
48 POS N
of POS N
54 POS N
(89%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
did POS N
(P POS N
=.49). POS N

The POS N
most POS N
common POS N
complications POS N
in POS N
each POS N
group POS N
were POS N
persistent POS N
choroidal POS N
effusions POS N
and POS N
bleb POS N
leak. POS N

At POS N
12 POS N
months, POS N
45 POS N
of POS N
48 POS N
(94%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
met POS N
a POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
while POS N
48 POS N
of POS N
54 POS N
(89%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
did POS N
(P POS N
=.49). POS N

Our POS N
study POS N
suggests POS N
that POS N
intraoperative POS N
topical POS N
5-FU POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
intraoperative POS N
topical POS N
MMC POS N
in POS N
reducing POS N
IOP POS N
of POS N
eyes POS N
undergoing POS N
primary POS N
trabeculectomy. POS N

The POS N
most POS N
common POS N
complications POS N
in POS N
each POS N
group POS N
were POS N
persistent POS N
choroidal POS N
effusions POS N
and POS N
bleb POS N
leak. POS N

A POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
at POS N
6 POS N
months POS N
was POS N
achieved POS N
in POS N
53 POS N
of POS N
56 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
and POS N
54 POS N
of POS N
57 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
(P POS N
= POS N
1.00). POS N

The POS N
most POS N
common POS N
complications POS N
in POS N
each POS N
group POS N
were POS N
persistent POS N
choroidal POS N
effusions POS N
and POS N
bleb POS N
leak. POS N

At POS N
12 POS N
months, POS N
45 POS N
of POS N
48 POS N
(94%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
met POS N
a POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
while POS N
48 POS N
of POS N
54 POS N
(89%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
did POS N
(P POS N
=.49). POS N

The POS N
most POS N
common POS N
complications POS N
in POS N
each POS N
group POS N
were POS N
persistent POS N
choroidal POS N
effusions POS N
and POS N
bleb POS N
leak. POS N

Our POS N
study POS N
suggests POS N
that POS N
intraoperative POS N
topical POS N
5-FU POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
intraoperative POS N
topical POS N
MMC POS N
in POS N
reducing POS N
IOP POS N
of POS N
eyes POS N
undergoing POS N
primary POS N
trabeculectomy. POS N

Our POS N
study POS N
suggests POS N
that POS N
intraoperative POS N
topical POS N
5-FU POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
intraoperative POS N
topical POS N
MMC POS N
in POS N
reducing POS N
IOP POS N
of POS N
eyes POS N
undergoing POS N
primary POS N
trabeculectomy. POS N

A POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
at POS N
6 POS N
months POS N
was POS N
achieved POS N
in POS N
53 POS N
of POS N
56 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
and POS N
54 POS N
of POS N
57 POS N
(95%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
(P POS N
= POS N
1.00). POS N

Our POS N
study POS N
suggests POS N
that POS N
intraoperative POS N
topical POS N
5-FU POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
intraoperative POS N
topical POS N
MMC POS N
in POS N
reducing POS N
IOP POS N
of POS N
eyes POS N
undergoing POS N
primary POS N
trabeculectomy. POS N

At POS N
12 POS N
months, POS N
45 POS N
of POS N
48 POS N
(94%) POS N
eyes POS N
in POS N
the POS N
5-FU POS N
group POS N
met POS N
a POS N
target POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
while POS N
48 POS N
of POS N
54 POS N
(89%) POS N
eyes POS N
in POS N
the POS N
MMC POS N
group POS N
did POS N
(P POS N
=.49). POS N

Our POS N
study POS N
suggests POS N
that POS N
intraoperative POS N
topical POS N
5-FU POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
intraoperative POS N
topical POS N
MMC POS N
in POS N
reducing POS N
IOP POS N
of POS N
eyes POS N
undergoing POS N
primary POS N
trabeculectomy. POS N

The POS N
most POS N
common POS N
complications POS N
in POS N
each POS N
group POS N
were POS N
persistent POS N
choroidal POS N
effusions POS N
and POS N
bleb POS N
leak. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

The POS N
dorzolamide/timolol POS N
combination POS N
and POS N
latanoprost POS N
were POS N
equally POS N
effective POS N
at POS N
lowering POS N
IOP. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

At POS N
baseline, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
26.1 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
25.6 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
1, POS N
and POS N
25.3 POS N
mmHg POS N
in POS N
the POS N
dorzolamide/timolol POS N
combination POS N
group POS N
versus POS N
24.7 POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
group POS N
in POS N
Study POS N
2. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

After POS N
3 POS N
months, POS N
the POS N
mean POS N
daytime POS N
diurnal POS N
IOP POS N
was POS N
18.9 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
18.4 POS N
mmHg POS N
for POS N
latanoprost POS N
in POS N
Study POS N
1, POS N
and POS N
17.4 POS N
mmHg POS N
for POS N
the POS N
dorzolamide/timolol POS N
combination POS N
versus POS N
17.5 POS N
for POS N
latanoprost POS N
in POS N
Study POS N
2. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

The POS N
difference POS N
between POS N
treatments POS N
in POS N
mean POS N
IOP POS N
change POS N
at POS N
3 POS N
months POS N
was POS N
-0.04 POS N
mmHg POS N
[95% POS N
confidence POS N
interval POS N
(CI) POS N
-0.85, POS N
0.77] POS N
in POS N
Study POS N
1, POS N
and POS N
-0.57 POS N
mmHg POS N
(95% POS N
CI POS N
-1.31, POS N
0.16) POS N
in POS N
Study POS N
2. POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

Both POS N
treatments POS N
were POS N
well POS N
tolerated POS N
over POS N
3 POS N
months, POS N

although POS N
ocular POS N
stinging POS N
occurred POS N
more POS N
frequently POS N
with POS N
the POS N
dorzolamide/timolol POS N
combination. POS N

The POS N
probability POS N
that POS N
the POS N
true POS N
difference POS N
lay POS N
between POS N
-1.5 POS N
and POS N
1.5 POS N
mmHg, POS N
the POS N
predefined POS N
bounds POS N
for POS N
equivalence, POS N
was POS N
>0.950 POS N
in POS N
both POS N
studies. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

Mitomycin POS N
C POS N
did POS N
not POS N
increase POS N
the POS N
short- POS N
or POS N
intermediate-term POS N
success POS N
rates POS N
of POS N
Ahmed POS N
Glaucoma POS N
Valve POS N
implantation. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
12.3 POS N
months, POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
showed POS N
a POS N
probability POS N
of POS N
success POS N
of POS N
59% POS N
at POS N
18 POS N
months POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
61% POS N
for POS N
the POS N
control POS N
group POS N
when POS N
the POS N
first POS N
criterion POS N
for POS N
success POS N
was POS N
used POS N
(IOP POS N
between POS N
6 POS N
and POS N
21 POS N
mmHg). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

When POS N
an POS N
IOP POS N
reduction POS N
of POS N
at POS N
least POS N
30% POS N
was POS N
used POS N
as POS N
the POS N
criterion POS N
to POS N
define POS N
success, POS N
the POS N
Kaplan-Meier POS N
survival POS N
analysis POS N
demonstrated POS N
a POS N
probability POS N
of POS N
success POS N
at POS N
18 POS N
months POS N
of POS N
62% POS N
for POS N
the POS N
MMC POS N
group POS N
and POS N
67% POS N
for POS N
the POS N
control POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
survival POS N
rates POS N
between POS N
the POS N
2 POS N
groups POS N
with POS N
either POS N
criterion POS N
(P POS N
= POS N
0.75 POS N
and POS N
P POS N
= POS N
0.37, POS N
respectively). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

After POS N
15 POS N
days POS N
postoperatively, POS N
the POS N
mean POS N
IOP POS N
did POS N
not POS N
significantly POS N
differ POS N
for POS N
both POS N
MMC POS N
and POS N
control POS N
eyes. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
in POS N
both POS N
groups. POS N

Mean POS N
numbers POS N
of POS N
postoperative POS N
antiglaucoma POS N
medications POS N
were POS N
similar POS N
in POS N
MMC-treated POS N
eyes POS N
and POS N
controls. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

It POS N
has POS N
a POS N
safe POS N
systemic POS N
profile POS N
with POS N
minimum POS N
effect POS N
on POS N
the POS N
heart. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

The POS N
IOP POS N
readings POS N
after POS N
treatment POS N
were POS N
significantly POS N
lower POS N
than POS N
their POS N
baseline POS N
levels POS N
in POS N
both POS N
groups POS N
at POS N
all POS N
visits POS N
(p POS N
< POS N
0.001). POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

At POS N
baseline, POS N
the POS N
mean POS N
IOP POS N
was POS N
24.48 POS N
+/- POS N
2.29 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
23.32 POS N
+/- POS N
0.82 POS N
mmHg POS N
in POS N
the POS N
timolol POS N
group. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

At POS N
peak, POS N
the POS N
mean POS N
decreases POS N
from POS N
the POS N
baseline POS N
IOP POS N
ranged POS N
from POS N
5.22 POS N
+/- POS N
0.30 POS N
mmHg POS N
to POS N
6.96 POS N
+/- POS N
0.33 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
from POS N
4.55 POS N
+/- POS N
0.49 POS N
mmHg POS N
to POS N
6.64 POS N
+/- POS N
0.53 POS N
mmHg POS N
for POS N
timolol. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

At POS N
trough, POS N
the POS N
mean POS N
decreases POS N
from POS N
baseline POS N
ranged POS N
from POS N
3.72 POS N
+/- POS N
0.32 POS N
mmHg POS N
to POS N
4.55 POS N
+/- POS N
0.32 POS N
mmHg POS N
for POS N
brimonidine POS N
and POS N
3.82 POS N
+/- POS N
0.52 POS N
mmHg POS N
to POS N
4.27 POS N
+/- POS N
0.51 POS N
mmHg POS N
for POS N
timolol. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

The POS N
clinical POS N
success POS N
rate POS N
was POS N
86.2% POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
81.8% POS N
in POS N
the POS N
timolol POS N
group, POS N
making POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
them POS N
(p POS N
= POS N
0.817). POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

17.2% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group POS N
and POS N
9.0% POS N
patients POS N
in POS N
timolol POS N
group POS N
reported POS N
mild POS N
adverse POS N
events. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Ocular POS N
allergy POS N
occurred POS N
in POS N
10.3% POS N
of POS N
patients POS N
in POS N
brimonidine POS N
group. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

No POS N
significant POS N
changes POS N
in POS N
visual POS N
acuity, POS N
biomicroscopy POS N
or POS N
ophthalmoscopy POS N
were POS N
observed POS N
in POS N
both POS N
groups. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Mean POS N
systolic POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
remained POS N
relatively POS N
stable POS N
in POS N
both POS N
groups POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Patients POS N
receiving POS N
timolol POS N
experienced POS N
statistically POS N
significant POS N
mean POS N
heart POS N
rate POS N
decreases POS N
from POS N
baseline POS N
(p POS N
= POS N
0.020) POS N
in POS N
week POS N
4. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

Topically POS N
applied POS N
twice POS N
daily POS N
for POS N
one POS N
month, POS N
brimonidine POS N
tartrate POS N
0.2% POS N
has POS N
clinical POS N
effectiveness POS N
equivalent POS N
to POS N
timolol POS N
0.5% POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
glaucoma. POS N

except POS N
in POS N
week POS N
2 POS N
(p POS N
= POS N
0.016) POS N
when POS N
brimonidine POS N
had POS N
lower POS N
systolic POS N
blood POS N
pressure. POS N

The POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
brimonidine POS N
group POS N
was POS N
relatively POS N
unchanged POS N
over POS N
the POS N
study POS N
period. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

This POS N
study POS N
suggests POS N
that POS N
there POS N
was POS N
no POS N
benefit POS N
of POS N
Nd:YAG POS N
LPI POS N
in POS N
preventing POS N
progression POS N
from POS N
PDS POS N
with POS N
OHT POS N
to POS N
PG POS N
within POS N
3 POS N
years POS N
of POS N
follow-up. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

neodymium:yttrium-aluminum-garnet POS N
(Nd:YAG) POS N
laser POS N
peripheral POS N
iridotomy POS N
(LPI) POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
conversion POS N
from POS N
pigment POS N
dispersion POS N
syndrome POS N
(PDS) POS N
with POS N
ocular POS N
hypertension POS N
(OHT) POS N
to POS N
pigmentary POS N
glaucoma POS N
(PG). POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

Eight POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
3 POS N
eyes POS N
(6%) POS N
in POS N
the POS N
control POS N
group POS N
converted POS N
to POS N
glaucoma POS N
in POS N
the POS N
study POS N
period. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

The POS N
proportion POS N
of POS N
eyes POS N
started POS N
on POS N
medical POS N
treatment POS N
was POS N
similar POS N
in POS N
the POS N
2 POS N
groups: POS N
8 POS N
eyes POS N
(15%) POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
9 POS N
eyes POS N
(17%) POS N
in POS N
the POS N
control POS N
group. POS N

Cataract POS N
extraction POS N
was POS N
performed POS N
on POS N
1 POS N
patient POS N
in POS N
the POS N
laser POS N
group POS N
and POS N
in POS N
1 POS N
patient POS N
in POS N
the POS N
control POS N
group POS N
during POS N
the POS N
study POS N
period POS N
(laser POS N
eye POS N
at POS N
18 POS N
months; POS N
control POS N
eye POS N
at POS N
34 POS N
months). POS N

Survival POS N
analyses POS N
showed POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
time POS N
to POS N
VF POS N
progression POS N
or POS N
commencement POS N
of POS N
topical POS N
therapy POS N
between POS N
the POS N
2 POS N
groups. POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

125 POS N
of POS N
277 POS N
patients POS N
(45.1%) POS N
experienced POS N
pain POS N
in POS N
the POS N
lidocaine POS N
group, POS N
compared POS N
with POS N
123 POS N
of POS N
229 POS N
patients POS N
(53.7%) POS N
in POS N
the POS N
BSS POS N
group. POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

The POS N
proportion POS N
of POS N
patients POS N
who POS N
experienced POS N
pain POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
the POS N
BSS POS N
group POS N
(multivariate POS N
OR POS N
0.68, POS N
95% POS N
CI POS N
0.47 POS N
to POS N
0.97; POS N
p=0.034). POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

The POS N
median POS N
pain POS N
score POS N
(range) POS N
was POS N
0.0 POS N
for POS N
intracameral POS N
lidocaine POS N
group POS N
compared POS N
with POS N
1.0 POS N
for POS N
BSS POS N
group POS N
(p=0.039). POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

Pain POS N
was POS N
more POS N
common POS N
in POS N
females POS N
(54.3% POS N
vs POS N
43.6%; POS N
OR POS N
1.56), POS N
non-Chinese POS N
(62.3% POS N
vs POS N
46.9%; POS N
OR POS N
2.13) POS N
and POS N
those POS N
who POS N
had POS N
previous POS N
cataract POS N
surgery POS N
to POS N
the POS N
fellow POS N
eye POS N
(55.3% POS N
vs POS N
44.7%; POS N
OR POS N
1.61). POS N

Risk POS N
factors POS N
for POS N
pain POS N
include POS N
females, POS N
non-Chinese POS N
and POS N
previous POS N
cataract POS N
surgery. POS N

The POS N
use POS N
of POS N
0.5 POS N
cc POS N
of POS N
1% POS N
intracameral POS N
lidocaine POS N
during POS N
phacoemulsification POS N
under POS N
topical POS N
anaesthesia POS N
significantly POS N
reduces POS N
pain POS N
experienced POS N
by POS N
patients. POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

Fixed POS N
combinations POS N
of POS N
0.2% POS N
brimonidine-0.5% POS N
timolol POS N
and POS N
2% POS N
dorzolamide-0.5% POS N
timolol POS N
are POS N
used POS N
to POS N
lower POS N
intraocular POS N
pressure POS N
(IOP). POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

At POS N
month POS N
3, POS N
the POS N
mean POS N
(SD) POS N
reduction POS N
from POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
monotherapy POS N
was POS N
7.7 POS N
(4.2) POS N
mmHg POS N
(32.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
6.7 POS N
(5.0) POS N
mmHg POS N
(26.1%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.040). POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

The POS N
mean POS N
reduction POS N
from POS N
PGA-treated POS N
baseline POS N
IOP POS N
for POS N
patients POS N
on POS N
fixed-combination POS N
adjunctive POS N
therapy POS N
was POS N
6.9 POS N
(4.8) POS N
mmHg POS N
(29.3%) POS N
with POS N
brimonidine-timolol POS N
versus POS N
5.2 POS N
(3.7) POS N
mmHg POS N
(23.5%) POS N
with POS N
dorzolamide-timolol POS N
(p POS N
= POS N
0.213). POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

Patients POS N
on POS N
brimonidine-timolol POS N
reported POS N
less POS N
burning POS N
(p POS N
< POS N
0.001), POS N
stinging POS N
(p POS N
< POS N
0.001), POS N
and POS N
unusual POS N
taste POS N
(p POS N
< POS N
0.001) POS N
than POS N
patients POS N
on POS N
dorzolamide-timolol. POS N

Both POS N
fixed-combination POS N
medications POS N
were POS N
safe POS N
and POS N
well-tolerated. POS N

Fixed-combination POS N
brimonidine-timolol POS N
provided POS N
the POS N
same POS N
or POS N
greater POS N
IOP POS N
lowering POS N
compared POS N
with POS N
fixed-combination POS N
dorzolamide-timolol. POS N

Cumulative POS N
successes POS N
in POS N
the POS N
Ahmed POS N
group POS N
were POS N
0.73 POS N
at POS N
1 POS N
year POS N
and POS N
0.62 POS N
at POS N
2 POS N
years, POS N
whereas POS N
cumulative POS N
successes POS N
in POS N
the POS N
Baerveldt POS N
group POS N
were POS N
0.92 POS N
at POS N
1 POS N
year POS N
and POS N
0.85 POS N
at POS N
2 POS N
years POS N
(Kaplan-Meier POS N
survival POS N
functions: POS N
P POS N
= POS N
0.03, POS N
log POS N
rank POS N
test). POS N

Male POS N
gender, POS N
African POS N
descent, POS N
neovascular POS N
glaucoma, POS N
and POS N
Ahmed POS N
implantation POS N
were POS N
found POS N
to POS N
be POS N
significant POS N
predictors POS N
of POS N
failure. POS N

Cumulative POS N
successes POS N
in POS N
the POS N
Ahmed POS N
group POS N
were POS N
0.73 POS N
at POS N
1 POS N
year POS N
and POS N
0.62 POS N
at POS N
2 POS N
years, POS N
whereas POS N
cumulative POS N
successes POS N
in POS N
the POS N
Baerveldt POS N
group POS N
were POS N
0.92 POS N
at POS N
1 POS N
year POS N
and POS N
0.85 POS N
at POS N
2 POS N
years POS N
(Kaplan-Meier POS N
survival POS N
functions: POS N
P POS N
= POS N
0.03, POS N
log POS N
rank POS N
test). POS N

At POS N
last POS N
follow-up POS N
visit, POS N
eyes POS N
in POS N
the POS N
Ahmed POS N
group POS N
had POS N
a POS N
significantly POS N
higher POS N
mean POS N
IOP POS N
(19.8+/-9.5 POS N
vs. POS N
15.8+/-7.9 POS N
mmHg, POS N
P POS N
= POS N
0.003, POS N
t POS N
test) POS N
and POS N
more POS N
antiglaucoma POS N
medications POS N
(1.4+/-1.2 POS N
vs. POS N
0.9+/-1.1 POS N
medications, POS N
P POS N
= POS N
0.008, POS N
Mann-Whitney POS N
test) POS N
than POS N
eyes POS N
in POS N
the POS N
Baerveldt POS N
group. POS N

Cumulative POS N
successes POS N
in POS N
the POS N
Ahmed POS N
group POS N
were POS N
0.73 POS N
at POS N
1 POS N
year POS N
and POS N
0.62 POS N
at POS N
2 POS N
years, POS N
whereas POS N
cumulative POS N
successes POS N
in POS N
the POS N
Baerveldt POS N
group POS N
were POS N
0.92 POS N
at POS N
1 POS N
year POS N
and POS N
0.85 POS N
at POS N
2 POS N
years POS N
(Kaplan-Meier POS N
survival POS N
functions: POS N
P POS N
= POS N
0.03, POS N
log POS N
rank POS N
test). POS N

Our POS N
study POS N
suggests POS N
that POS N
the POS N
Ahmed POS N
S2 POS N
Glaucoma POS N
Valve POS N
may POS N
be POS N
less POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
the POS N
Baerveldt POS N
250-mm(2) POS N
Glaucoma POS N
Implant. POS N

Male POS N
gender, POS N
African POS N
descent, POS N
neovascular POS N
glaucoma, POS N
and POS N
Ahmed POS N
implantation POS N
were POS N
found POS N
to POS N
be POS N
significant POS N
predictors POS N
of POS N
failure. POS N

Cumulative POS N
successes POS N
in POS N
the POS N
Ahmed POS N
group POS N
were POS N
0.73 POS N
at POS N
1 POS N
year POS N
and POS N
0.62 POS N
at POS N
2 POS N
years, POS N
whereas POS N
cumulative POS N
successes POS N
in POS N
the POS N
Baerveldt POS N
group POS N
were POS N
0.92 POS N
at POS N
1 POS N
year POS N
and POS N
0.85 POS N
at POS N
2 POS N
years POS N
(Kaplan-Meier POS N
survival POS N
functions: POS N
P POS N
= POS N
0.03, POS N
log POS N
rank POS N
test). POS N

Male POS N
gender, POS N
African POS N
descent, POS N
neovascular POS N
glaucoma, POS N
and POS N
Ahmed POS N
implantation POS N
were POS N
found POS N
to POS N
be POS N
significant POS N
predictors POS N
of POS N
failure. POS N

At POS N
last POS N
follow-up POS N
visit, POS N
eyes POS N
in POS N
the POS N
Ahmed POS N
group POS N
had POS N
a POS N
significantly POS N
higher POS N
mean POS N
IOP POS N
(19.8+/-9.5 POS N
vs. POS N
15.8+/-7.9 POS N
mmHg, POS N
P POS N
= POS N
0.003, POS N
t POS N
test) POS N
and POS N
more POS N
antiglaucoma POS N
medications POS N
(1.4+/-1.2 POS N
vs. POS N
0.9+/-1.1 POS N
medications, POS N
P POS N
= POS N
0.008, POS N
Mann-Whitney POS N
test) POS N
than POS N
eyes POS N
in POS N
the POS N
Baerveldt POS N
group. POS N

Male POS N
gender, POS N
African POS N
descent, POS N
neovascular POS N
glaucoma, POS N
and POS N
Ahmed POS N
implantation POS N
were POS N
found POS N
to POS N
be POS N
significant POS N
predictors POS N
of POS N
failure. POS N

Our POS N
study POS N
suggests POS N
that POS N
the POS N
Ahmed POS N
S2 POS N
Glaucoma POS N
Valve POS N
may POS N
be POS N
less POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
the POS N
Baerveldt POS N
250-mm(2) POS N
Glaucoma POS N
Implant. POS N

At POS N
last POS N
follow-up POS N
visit, POS N
eyes POS N
in POS N
the POS N
Ahmed POS N
group POS N
had POS N
a POS N
significantly POS N
higher POS N
mean POS N
IOP POS N
(19.8+/-9.5 POS N
vs. POS N
15.8+/-7.9 POS N
mmHg, POS N
P POS N
= POS N
0.003, POS N
t POS N
test) POS N
and POS N
more POS N
antiglaucoma POS N
medications POS N
(1.4+/-1.2 POS N
vs. POS N
0.9+/-1.1 POS N
medications, POS N
P POS N
= POS N
0.008, POS N
Mann-Whitney POS N
test) POS N
than POS N
eyes POS N
in POS N
the POS N
Baerveldt POS N
group. POS N

Cumulative POS N
successes POS N
in POS N
the POS N
Ahmed POS N
group POS N
were POS N
0.73 POS N
at POS N
1 POS N
year POS N
and POS N
0.62 POS N
at POS N
2 POS N
years, POS N
whereas POS N
cumulative POS N
successes POS N
in POS N
the POS N
Baerveldt POS N
group POS N
were POS N
0.92 POS N
at POS N
1 POS N
year POS N
and POS N
0.85 POS N
at POS N
2 POS N
years POS N
(Kaplan-Meier POS N
survival POS N
functions: POS N
P POS N
= POS N
0.03, POS N
log POS N
rank POS N
test). POS N

At POS N
last POS N
follow-up POS N
visit, POS N
eyes POS N
in POS N
the POS N
Ahmed POS N
group POS N
had POS N
a POS N
significantly POS N
higher POS N
mean POS N
IOP POS N
(19.8+/-9.5 POS N
vs. POS N
15.8+/-7.9 POS N
mmHg, POS N
P POS N
= POS N
0.003, POS N
t POS N
test) POS N
and POS N
more POS N
antiglaucoma POS N
medications POS N
(1.4+/-1.2 POS N
vs. POS N
0.9+/-1.1 POS N
medications, POS N
P POS N
= POS N
0.008, POS N
Mann-Whitney POS N
test) POS N
than POS N
eyes POS N
in POS N
the POS N
Baerveldt POS N
group. POS N

Male POS N
gender, POS N
African POS N
descent, POS N
neovascular POS N
glaucoma, POS N
and POS N
Ahmed POS N
implantation POS N
were POS N
found POS N
to POS N
be POS N
significant POS N
predictors POS N
of POS N
failure. POS N

At POS N
last POS N
follow-up POS N
visit, POS N
eyes POS N
in POS N
the POS N
Ahmed POS N
group POS N
had POS N
a POS N
significantly POS N
higher POS N
mean POS N
IOP POS N
(19.8+/-9.5 POS N
vs. POS N
15.8+/-7.9 POS N
mmHg, POS N
P POS N
= POS N
0.003, POS N
t POS N
test) POS N
and POS N
more POS N
antiglaucoma POS N
medications POS N
(1.4+/-1.2 POS N
vs. POS N
0.9+/-1.1 POS N
medications, POS N
P POS N
= POS N
0.008, POS N
Mann-Whitney POS N
test) POS N
than POS N
eyes POS N
in POS N
the POS N
Baerveldt POS N
group. POS N

Our POS N
study POS N
suggests POS N
that POS N
the POS N
Ahmed POS N
S2 POS N
Glaucoma POS N
Valve POS N
may POS N
be POS N
less POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
the POS N
Baerveldt POS N
250-mm(2) POS N
Glaucoma POS N
Implant. POS N

Our POS N
study POS N
suggests POS N
that POS N
the POS N
Ahmed POS N
S2 POS N
Glaucoma POS N
Valve POS N
may POS N
be POS N
less POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
the POS N
Baerveldt POS N
250-mm(2) POS N
Glaucoma POS N
Implant. POS N

Cumulative POS N
successes POS N
in POS N
the POS N
Ahmed POS N
group POS N
were POS N
0.73 POS N
at POS N
1 POS N
year POS N
and POS N
0.62 POS N
at POS N
2 POS N
years, POS N
whereas POS N
cumulative POS N
successes POS N
in POS N
the POS N
Baerveldt POS N
group POS N
were POS N
0.92 POS N
at POS N
1 POS N
year POS N
and POS N
0.85 POS N
at POS N
2 POS N
years POS N
(Kaplan-Meier POS N
survival POS N
functions: POS N
P POS N
= POS N
0.03, POS N
log POS N
rank POS N
test). POS N

Our POS N
study POS N
suggests POS N
that POS N
the POS N
Ahmed POS N
S2 POS N
Glaucoma POS N
Valve POS N
may POS N
be POS N
less POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
the POS N
Baerveldt POS N
250-mm(2) POS N
Glaucoma POS N
Implant. POS N

Male POS N
gender, POS N
African POS N
descent, POS N
neovascular POS N
glaucoma, POS N
and POS N
Ahmed POS N
implantation POS N
were POS N
found POS N
to POS N
be POS N
significant POS N
predictors POS N
of POS N
failure. POS N

Our POS N
study POS N
suggests POS N
that POS N
the POS N
Ahmed POS N
S2 POS N
Glaucoma POS N
Valve POS N
may POS N
be POS N
less POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
the POS N
Baerveldt POS N
250-mm(2) POS N
Glaucoma POS N
Implant. POS N

At POS N
last POS N
follow-up POS N
visit, POS N
eyes POS N
in POS N
the POS N
Ahmed POS N
group POS N
had POS N
a POS N
significantly POS N
higher POS N
mean POS N
IOP POS N
(19.8+/-9.5 POS N
vs. POS N
15.8+/-7.9 POS N
mmHg, POS N
P POS N
= POS N
0.003, POS N
t POS N
test) POS N
and POS N
more POS N
antiglaucoma POS N
medications POS N
(1.4+/-1.2 POS N
vs. POS N
0.9+/-1.1 POS N
medications, POS N
P POS N
= POS N
0.008, POS N
Mann-Whitney POS N
test) POS N
than POS N
eyes POS N
in POS N
the POS N
Baerveldt POS N
group. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Both POS N
Baerveldt POS N
and POS N
Ahmed POS N
glaucoma POS N
drainage POS N
implants POS N
performed POS N
well POS N
in POS N
terms POS N
of POS N
IOP POS N
control, POS N
preservation POS N
of POS N
visual POS N
function, POS N
and POS N
having POS N
low POS N
complication POS N
rates. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Both POS N
drainage POS N
implants POS N
achieved POS N
remarkable POS N
reductions POS N
in POS N
IOP; POS N
from POS N
pretreatment POS N
IOP POS N
of POS N
40.1+/-13.8 POS N
mmHg POS N
and POS N
43.7+/-9.3 POS N
mmHg POS N
to POS N
postoperative POS N
IOP POS N
of POS N
17.4+/-6.2 POS N
and POS N
14.9+/-5.5 POS N
mmHg POS N
in POS N
the POS N
Baerveldt POS N
and POS N
Ahmed POS N
groups, POS N
respectively. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

A POS N
decrease POS N
in POS N
IOP POS N
of POS N
56.6% POS N
and POS N
65.9% POS N
had POS N
been POS N
achieved. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Success POS N
rates POS N
were POS N
20 POS N
(83.3%) POS N
for POS N
Baerveldt POS N
and POS N
12 POS N
(66.7%) POS N
for POS N
Ahmed POS N
implants, POS N
whereas POS N
qualified POS N
success POS N
occurred POS N
in POS N
1 POS N
(4.2%) POS N
Baerveldt POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

More POS N
than POS N
80% POS N
of POS N
the POS N
patients POS N
had POS N
maintained POS N
or POS N
improved POS N
visual POS N
function, POS N
whereas POS N
only POS N
4 POS N
(16.0%) POS N
of POS N
the POS N
patients POS N
with POS N
Baerveldt POS N
implants POS N
and POS N
2 POS N
(16.7%) POS N
patients POS N
with POS N
Ahmed POS N
implants POS N
had POS N
loss POS N
of POS N
more POS N
than POS N
1 POS N
Snellen POS N
line. POS N

Conversely, POS N
failure POS N
to POS N
control POS N
IOP POS N
occurred POS N
in POS N
3 POS N
(12.5%) POS N
Baerveldt POS N
implants POS N
and POS N
3 POS N
(16.7%) POS N
Ahmed POS N
implants. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

No POS N
patient POS N
required POS N
reoperation. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

No POS N
patient POS N
required POS N
reoperation. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

No POS N
patient POS N
required POS N
reoperation. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
24-month POS N
follow-up, POS N
IOP POS N
of POS N
21 POS N
mmHg POS N
or POS N
less POS N
and POS N
more POS N
than POS N
6 POS N
mmHg POS N
was POS N
achieved POS N
in POS N
76% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
19) POS N
and POS N
in POS N
80% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
20; POS N
log-rank POS N
P POS N
= POS N
0.60); POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

an POS N
IOP POS N
between POS N
6 POS N
and POS N
16 POS N
mmHg POS N
was POS N
obtained POS N
in POS N
56% POS N
in POS N
group POS N
1 POS N
(n POS N
= POS N
14) POS N
and POS N
in POS N
72% POS N
in POS N
group POS N
2 POS N
(n POS N
= POS N
18; POS N
log-rank POS N
P POS N
= POS N
0.17; POS N
Kaplan-Meier POS N
cumulative POS N
probability POS N
of POS N
success). POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Complications POS N
of POS N
viscocanalostomy POS N
included POS N
one POS N
intraoperative POS N
conversion POS N
into POS N
trabeculectomy; POS N
microruptures POS N
in POS N
Descemet's POS N
membrane POS N
in POS N
five POS N
eyes; POS N
three POS N
cases POS N
of POS N
iris POS N
incarceration POS N
in POS N
the POS N
Decemet's POS N
window, POS N
two POS N
of POS N
which POS N
caused POS N
early POS N
failure POS N
of POS N
the POS N
procedure POS N
requiring POS N
reoperation; POS N
and POS N
a POS N
1-mm POS N
to POS N
2-mm POS N
transient POS N
self-resolving POS N
hyphema POS N
in POS N
three POS N
cases POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Complications POS N
of POS N
trabeculectomy POS N
included POS N
one POS N
case POS N
of POS N
postoperative POS N
bleb POS N
bleeding POS N
with POS N
early POS N
transient POS N
IOP POS N
spike; POS N
one POS N
early POS N
hyphema; POS N
five POS N
cases POS N
of POS N
postoperative POS N
hypotony, POS N
two POS N
of POS N
which POS N
had POS N
a POS N
positive POS N
Seidel POS N
test POS N
from POS N
the POS N
conjunctival POS N
suture; POS N
three POS N
cases POS N
of POS N
transient POS N
choroidal POS N
detachment, POS N
two POS N
of POS N
which POS N
had POS N
shallow POS N
anterior POS N
chamber. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

No POS N
patient POS N
required POS N
reoperation. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Two POS N
eyes POS N
required POS N
argon POS N
laser POS N
suture POS N
lysis, POS N
and POS N
nine POS N
underwent POS N
one POS N
or POS N
more POS N
5-FU POS N
injections, POS N
which POS N
caused POS N
punctate POS N
keratopathy POS N
in POS N
three POS N
eyes. POS N

Trabeculectomy POS N
with POS N
postoperative POS N
5-FU POS N
can POS N
probably POS N
provides POS N
lower POS N
IOPs POS N
but, POS N
with POS N
more POS N
numerous POS N
complications, POS N
greater POS N
discomfort, POS N
and POS N
more POS N
intensive POS N
postoperative POS N
management. POS N

Viscocanalostomy POS N
is POS N
an POS N
effective POS N
IOP-lowering POS N
procedure POS N
in POS N
white POS N
adults POS N
affected POS N
by POS N
open-angle POS N
glaucoma. POS N

Forty-two POS N
percent POS N
(n=10) POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
a POS N
successful POS N
outcome POS N
(IOP<18 POS N
mm POS N
Hg POS N
with POS N
no POS N
treatment) POS N
at POS N
last POS N
follow-up POS N
visit, POS N
compared POS N
to POS N
21% POS N
(n=5) POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

IOP POS N
was POS N
lower POS N
in POS N
the POS N
trab POS N
group POS N
with POS N
differences POS N
in POS N
IOP POS N
being POS N
statistically POS N
significant POS N
at POS N
month POS N
12 POS N
(P=<0.001), POS N
24 POS N
(P=<0.001), POS N
30 POS N
(P=0.030), POS N
36 POS N
(P=<0.001), POS N
and POS N
48 POS N
(P=0.018). POS N

Forty-two POS N
percent POS N
(n=10) POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
a POS N
successful POS N
outcome POS N
(IOP<18 POS N
mm POS N
Hg POS N
with POS N
no POS N
treatment) POS N
at POS N
last POS N
follow-up POS N
visit, POS N
compared POS N
to POS N
21% POS N
(n=5) POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

The POS N
trabeculectomy POS N
group POS N
required POS N
less POS N
postoperative POS N
topical POS N
IOP-lowering POS N
medication POS N
(P=0.011). POS N

Forty-two POS N
percent POS N
(n=10) POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
a POS N
successful POS N
outcome POS N
(IOP<18 POS N
mm POS N
Hg POS N
with POS N
no POS N
treatment) POS N
at POS N
last POS N
follow-up POS N
visit, POS N
compared POS N
to POS N
21% POS N
(n=5) POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

we POS N
found POS N
trabeculectomy POS N
to POS N
be POS N
more POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

IOP POS N
was POS N
lower POS N
in POS N
the POS N
trab POS N
group POS N
with POS N
differences POS N
in POS N
IOP POS N
being POS N
statistically POS N
significant POS N
at POS N
month POS N
12 POS N
(P=<0.001), POS N
24 POS N
(P=<0.001), POS N
30 POS N
(P=0.030), POS N
36 POS N
(P=<0.001), POS N
and POS N
48 POS N
(P=0.018). POS N

Forty-two POS N
percent POS N
(n=10) POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
a POS N
successful POS N
outcome POS N
(IOP<18 POS N
mm POS N
Hg POS N
with POS N
no POS N
treatment) POS N
at POS N
last POS N
follow-up POS N
visit, POS N
compared POS N
to POS N
21% POS N
(n=5) POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

IOP POS N
was POS N
lower POS N
in POS N
the POS N
trab POS N
group POS N
with POS N
differences POS N
in POS N
IOP POS N
being POS N
statistically POS N
significant POS N
at POS N
month POS N
12 POS N
(P=<0.001), POS N
24 POS N
(P=<0.001), POS N
30 POS N
(P=0.030), POS N
36 POS N
(P=<0.001), POS N
and POS N
48 POS N
(P=0.018). POS N

The POS N
trabeculectomy POS N
group POS N
required POS N
less POS N
postoperative POS N
topical POS N
IOP-lowering POS N
medication POS N
(P=0.011). POS N

IOP POS N
was POS N
lower POS N
in POS N
the POS N
trab POS N
group POS N
with POS N
differences POS N
in POS N
IOP POS N
being POS N
statistically POS N
significant POS N
at POS N
month POS N
12 POS N
(P=<0.001), POS N
24 POS N
(P=<0.001), POS N
30 POS N
(P=0.030), POS N
36 POS N
(P=<0.001), POS N
and POS N
48 POS N
(P=0.018). POS N

we POS N
found POS N
trabeculectomy POS N
to POS N
be POS N
more POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

The POS N
trabeculectomy POS N
group POS N
required POS N
less POS N
postoperative POS N
topical POS N
IOP-lowering POS N
medication POS N
(P=0.011). POS N

Forty-two POS N
percent POS N
(n=10) POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
a POS N
successful POS N
outcome POS N
(IOP<18 POS N
mm POS N
Hg POS N
with POS N
no POS N
treatment) POS N
at POS N
last POS N
follow-up POS N
visit, POS N
compared POS N
to POS N
21% POS N
(n=5) POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

The POS N
trabeculectomy POS N
group POS N
required POS N
less POS N
postoperative POS N
topical POS N
IOP-lowering POS N
medication POS N
(P=0.011). POS N

IOP POS N
was POS N
lower POS N
in POS N
the POS N
trab POS N
group POS N
with POS N
differences POS N
in POS N
IOP POS N
being POS N
statistically POS N
significant POS N
at POS N
month POS N
12 POS N
(P=<0.001), POS N
24 POS N
(P=<0.001), POS N
30 POS N
(P=0.030), POS N
36 POS N
(P=<0.001), POS N
and POS N
48 POS N
(P=0.018). POS N

The POS N
trabeculectomy POS N
group POS N
required POS N
less POS N
postoperative POS N
topical POS N
IOP-lowering POS N
medication POS N
(P=0.011). POS N

we POS N
found POS N
trabeculectomy POS N
to POS N
be POS N
more POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

we POS N
found POS N
trabeculectomy POS N
to POS N
be POS N
more POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Forty-two POS N
percent POS N
(n=10) POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
a POS N
successful POS N
outcome POS N
(IOP<18 POS N
mm POS N
Hg POS N
with POS N
no POS N
treatment) POS N
at POS N
last POS N
follow-up POS N
visit, POS N
compared POS N
to POS N
21% POS N
(n=5) POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

we POS N
found POS N
trabeculectomy POS N
to POS N
be POS N
more POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

IOP POS N
was POS N
lower POS N
in POS N
the POS N
trab POS N
group POS N
with POS N
differences POS N
in POS N
IOP POS N
being POS N
statistically POS N
significant POS N
at POS N
month POS N
12 POS N
(P=<0.001), POS N
24 POS N
(P=<0.001), POS N
30 POS N
(P=0.030), POS N
36 POS N
(P=<0.001), POS N
and POS N
48 POS N
(P=0.018). POS N

we POS N
found POS N
trabeculectomy POS N
to POS N
be POS N
more POS N
effective POS N
at POS N
lowering POS N
IOP POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

The POS N
trabeculectomy POS N
group POS N
required POS N
less POS N
postoperative POS N
topical POS N
IOP-lowering POS N
medication POS N
(P=0.011). POS N

Tafluprost POS N
is POS N
a POS N
new POS N
effective POS N
and POS N
well-tolerated POS N
treatment POS N
for POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

the POS N
IOP-lowering POS N
effect POS N
during POS N
the POS N
study POS N
was POS N
slightly POS N
larger POS N
with POS N
latanoprost, POS N

Tafluprost POS N
is POS N
a POS N
new POS N
effective POS N
and POS N
well-tolerated POS N
treatment POS N
for POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
treatments POS N
had POS N
a POS N
substantial POS N
IOP-lowering POS N
effect POS N
which POS N
persisted POS N
throughout POS N
the POS N
study POS N
(-7.1 POS N
mmHg POS N
for POS N
tafluprost POS N
and POS N
-7.7 POS N
mmHg POS N
for POS N
latanoprost POS N
at POS N
24 POS N
months). POS N

Tafluprost POS N
is POS N
a POS N
new POS N
effective POS N
and POS N
well-tolerated POS N
treatment POS N
for POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

this POS N
difference POS N
was POS N
clinically POS N
small POS N
and POS N
the POS N
noninferiority POS N
of POS N
tafluprost POS N
to POS N
latanoprost POS N
over POS N
all POS N
diurnal POS N
IOP POS N
measurements POS N
was POS N
shown POS N
with POS N
anova POS N
and POS N
almost POS N
reached POS N
with POS N
ancova POS N
(upper POS N
limits POS N
of POS N
the POS N
95% POS N
confidence POS N
intervals POS N
1.38 POS N
and POS N
1.52 POS N
for POS N
the POS N
overall POS N
period, POS N
respectively). POS N

the POS N
IOP-lowering POS N
effect POS N
during POS N
the POS N
study POS N
was POS N
slightly POS N
larger POS N
with POS N
latanoprost, POS N

Tafluprost POS N
is POS N
a POS N
new POS N
effective POS N
and POS N
well-tolerated POS N
treatment POS N
for POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

the POS N
IOP-lowering POS N
effect POS N
during POS N
the POS N
study POS N
was POS N
slightly POS N
larger POS N
with POS N
latanoprost, POS N

Both POS N
treatments POS N
had POS N
a POS N
substantial POS N
IOP-lowering POS N
effect POS N
which POS N
persisted POS N
throughout POS N
the POS N
study POS N
(-7.1 POS N
mmHg POS N
for POS N
tafluprost POS N
and POS N
-7.7 POS N
mmHg POS N
for POS N
latanoprost POS N
at POS N
24 POS N
months). POS N

the POS N
IOP-lowering POS N
effect POS N
during POS N
the POS N
study POS N
was POS N
slightly POS N
larger POS N
with POS N
latanoprost, POS N

this POS N
difference POS N
was POS N
clinically POS N
small POS N
and POS N
the POS N
noninferiority POS N
of POS N
tafluprost POS N
to POS N
latanoprost POS N
over POS N
all POS N
diurnal POS N
IOP POS N
measurements POS N
was POS N
shown POS N
with POS N
anova POS N
and POS N
almost POS N
reached POS N
with POS N
ancova POS N
(upper POS N
limits POS N
of POS N
the POS N
95% POS N
confidence POS N
intervals POS N
1.38 POS N
and POS N
1.52 POS N
for POS N
the POS N
overall POS N
period, POS N
respectively). POS N

Both POS N
treatments POS N
had POS N
a POS N
substantial POS N
IOP-lowering POS N
effect POS N
which POS N
persisted POS N
throughout POS N
the POS N
study POS N
(-7.1 POS N
mmHg POS N
for POS N
tafluprost POS N
and POS N
-7.7 POS N
mmHg POS N
for POS N
latanoprost POS N
at POS N
24 POS N
months). POS N

Tafluprost POS N
is POS N
a POS N
new POS N
effective POS N
and POS N
well-tolerated POS N
treatment POS N
for POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
treatments POS N
had POS N
a POS N
substantial POS N
IOP-lowering POS N
effect POS N
which POS N
persisted POS N
throughout POS N
the POS N
study POS N
(-7.1 POS N
mmHg POS N
for POS N
tafluprost POS N
and POS N
-7.7 POS N
mmHg POS N
for POS N
latanoprost POS N
at POS N
24 POS N
months). POS N

the POS N
IOP-lowering POS N
effect POS N
during POS N
the POS N
study POS N
was POS N
slightly POS N
larger POS N
with POS N
latanoprost, POS N

Both POS N
treatments POS N
had POS N
a POS N
substantial POS N
IOP-lowering POS N
effect POS N
which POS N
persisted POS N
throughout POS N
the POS N
study POS N
(-7.1 POS N
mmHg POS N
for POS N
tafluprost POS N
and POS N
-7.7 POS N
mmHg POS N
for POS N
latanoprost POS N
at POS N
24 POS N
months). POS N

this POS N
difference POS N
was POS N
clinically POS N
small POS N
and POS N
the POS N
noninferiority POS N
of POS N
tafluprost POS N
to POS N
latanoprost POS N
over POS N
all POS N
diurnal POS N
IOP POS N
measurements POS N
was POS N
shown POS N
with POS N
anova POS N
and POS N
almost POS N
reached POS N
with POS N
ancova POS N
(upper POS N
limits POS N
of POS N
the POS N
95% POS N
confidence POS N
intervals POS N
1.38 POS N
and POS N
1.52 POS N
for POS N
the POS N
overall POS N
period, POS N
respectively). POS N

this POS N
difference POS N
was POS N
clinically POS N
small POS N
and POS N
the POS N
noninferiority POS N
of POS N
tafluprost POS N
to POS N
latanoprost POS N
over POS N
all POS N
diurnal POS N
IOP POS N
measurements POS N
was POS N
shown POS N
with POS N
anova POS N
and POS N
almost POS N
reached POS N
with POS N
ancova POS N
(upper POS N
limits POS N
of POS N
the POS N
95% POS N
confidence POS N
intervals POS N
1.38 POS N
and POS N
1.52 POS N
for POS N
the POS N
overall POS N
period, POS N
respectively). POS N

Tafluprost POS N
is POS N
a POS N
new POS N
effective POS N
and POS N
well-tolerated POS N
treatment POS N
for POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

this POS N
difference POS N
was POS N
clinically POS N
small POS N
and POS N
the POS N
noninferiority POS N
of POS N
tafluprost POS N
to POS N
latanoprost POS N
over POS N
all POS N
diurnal POS N
IOP POS N
measurements POS N
was POS N
shown POS N
with POS N
anova POS N
and POS N
almost POS N
reached POS N
with POS N
ancova POS N
(upper POS N
limits POS N
of POS N
the POS N
95% POS N
confidence POS N
intervals POS N
1.38 POS N
and POS N
1.52 POS N
for POS N
the POS N
overall POS N
period, POS N
respectively). POS N

the POS N
IOP-lowering POS N
effect POS N
during POS N
the POS N
study POS N
was POS N
slightly POS N
larger POS N
with POS N
latanoprost, POS N

this POS N
difference POS N
was POS N
clinically POS N
small POS N
and POS N
the POS N
noninferiority POS N
of POS N
tafluprost POS N
to POS N
latanoprost POS N
over POS N
all POS N
diurnal POS N
IOP POS N
measurements POS N
was POS N
shown POS N
with POS N
anova POS N
and POS N
almost POS N
reached POS N
with POS N
ancova POS N
(upper POS N
limits POS N
of POS N
the POS N
95% POS N
confidence POS N
intervals POS N
1.38 POS N
and POS N
1.52 POS N
for POS N
the POS N
overall POS N
period, POS N
respectively). POS N

Both POS N
treatments POS N
had POS N
a POS N
substantial POS N
IOP-lowering POS N
effect POS N
which POS N
persisted POS N
throughout POS N
the POS N
study POS N
(-7.1 POS N
mmHg POS N
for POS N
tafluprost POS N
and POS N
-7.7 POS N
mmHg POS N
for POS N
latanoprost POS N
at POS N
24 POS N
months). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

At POS N
09.00 POS N
hours POS N
(presumed POS N
trough) POS N
on POS N
day POS N
60, POS N
mean POS N
reductions POS N
from POS N
baseline POS N
in POS N
intraocular POS N
pressure POS N
were POS N
6.32+/-2.87 POS N
and POS N
5.67+/-3.30 POS N
mmHg POS N
for POS N
the POS N
alginate POS N
carteolol POS N
and POS N
standard POS N
groups, POS N
respectively. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

At POS N
11.00 POS N
hours POS N
(presumed POS N
peak), POS N
mean POS N
reductions POS N
were POS N
6.70+/-2.81 POS N
and POS N
6.55+/-3.35 POS N
mmHg, POS N
respectively. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

At POS N
each POS N
evaluation POS N
time, POS N
the POS N
two POS N
unilateral POS N
t POS N
tests POS N
were POS N
highly POS N
significant POS N
(p<0.005), POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Safety- POS N
Slight POS N
decreases POS N
in POS N
heart POS N
rate POS N
and POS N
blood POS N
pressure POS N
means POS N
were POS N
observed POS N
in POS N
both POS N
groups POS N
at POS N
follow-up POS N
visits POS N
with POS N
no POS N
significant POS N
difference POS N
between POS N
groups. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Subjective POS N
tolerance POS N
upon POS N
instillation POS N
was POS N
judged POS N
good POS N
or POS N
very POS N
good POS N
at POS N
day POS N
60 POS N
by POS N
100% POS N
of POS N
alginate POS N
patients POS N
and POS N
by POS N
98.7% POS N
of POS N
standard POS N
patients. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Transient POS N
discomfort POS N
(mainly POS N
stinging POS N
or POS N
burning POS N
sensation) POS N
was POS N
reported POS N
by POS N
approximately POS N
4% POS N
- POS N
6% POS N
of POS N
patients POS N
in POS N
each POS N
treatment POS N
group POS N
at POS N
each POS N
visit. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

A POS N
blurred POS N
vision POS N
sensation POS N
was POS N
reported POS N
by POS N
2 POS N
out POS N
of POS N
74 POS N
patients POS N
of POS N
the POS N
alginate POS N
group. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

Among POS N
the POS N
17 POS N
reported POS N
adverse POS N
events, POS N
three POS N
were POS N
assessed POS N
as POS N
drug-related: POS N
one POS N
vertigo, POS N
one POS N
superficial POS N
punctate POS N
keratitis POS N
in POS N
the POS N
alginate POS N
group POS N
and POS N
one POS N
decrease POS N
in POS N
blood POS N
pressure POS N
in POS N
the POS N
standard POS N
group. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
daily POS N
is POS N
as POS N
effective POS N
as POS N
standard POS N
1% POS N
carteolol POS N
given POS N
twice POS N
daily, POS N
with POS N
no POS N
meaningful POS N
differences POS N
regarding POS N
safety. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
reported. POS N

The POS N
new POS N
alginate POS N
formulation POS N
of POS N
long-acting POS N
carteolol POS N
1% POS N
given POS N
once POS N
a POS N
day POS N
is POS N
effective POS N
and POS N
well POS N
tolerated POS N
by POS N
glaucoma POS N
patients POS N
who POS N
require POS N
chronic POS N
treatment. POS N

The POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
were POS N
similar POS N
between POS N
groups POS N
(p POS N
= POS N
0.232). POS N

No POS N
additional POS N
IOP-lowering POS N
surgical POS N
procedures POS N
were POS N
required POS N
in POS N
the POS N
combined POS N
group, POS N
while POS N
13 POS N
(54%) POS N
eyes POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
required POS N
either POS N
cataract POS N
extraction POS N
or POS N
further POS N
IOP-lowering POS N
surgical POS N
procedures POS N
(p POS N
<0.001). POS N

The POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
were POS N
similar POS N
between POS N
groups POS N
(p POS N
= POS N
0.232). POS N

In POS N
patients POS N
with POS N
PACG, POS N
the POS N
long-term POS N
IOP-lowering POS N
effect POS N
and POS N
surgical POS N
complications POS N
of POS N
combined POS N
trabeculectomy POS N
and POS N
cataract POS N
extraction POS N
are POS N
comparable POS N
with POS N
those POS N
of POS N
trabeculectomy POS N
alone. POS N

The POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
were POS N
similar POS N
between POS N
groups POS N
(p POS N
= POS N
0.232). POS N

However, POS N
the POS N
combined POS N
surgery POS N
incurred POS N
fewer POS N
subsequent POS N
surgical POS N
interventions. POS N

No POS N
additional POS N
IOP-lowering POS N
surgical POS N
procedures POS N
were POS N
required POS N
in POS N
the POS N
combined POS N
group, POS N
while POS N
13 POS N
(54%) POS N
eyes POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
required POS N
either POS N
cataract POS N
extraction POS N
or POS N
further POS N
IOP-lowering POS N
surgical POS N
procedures POS N
(p POS N
<0.001). POS N

The POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
were POS N
similar POS N
between POS N
groups POS N
(p POS N
= POS N
0.232). POS N

No POS N
additional POS N
IOP-lowering POS N
surgical POS N
procedures POS N
were POS N
required POS N
in POS N
the POS N
combined POS N
group, POS N
while POS N
13 POS N
(54%) POS N
eyes POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
required POS N
either POS N
cataract POS N
extraction POS N
or POS N
further POS N
IOP-lowering POS N
surgical POS N
procedures POS N
(p POS N
<0.001). POS N

In POS N
patients POS N
with POS N
PACG, POS N
the POS N
long-term POS N
IOP-lowering POS N
effect POS N
and POS N
surgical POS N
complications POS N
of POS N
combined POS N
trabeculectomy POS N
and POS N
cataract POS N
extraction POS N
are POS N
comparable POS N
with POS N
those POS N
of POS N
trabeculectomy POS N
alone. POS N

No POS N
additional POS N
IOP-lowering POS N
surgical POS N
procedures POS N
were POS N
required POS N
in POS N
the POS N
combined POS N
group, POS N
while POS N
13 POS N
(54%) POS N
eyes POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
required POS N
either POS N
cataract POS N
extraction POS N
or POS N
further POS N
IOP-lowering POS N
surgical POS N
procedures POS N
(p POS N
<0.001). POS N

However, POS N
the POS N
combined POS N
surgery POS N
incurred POS N
fewer POS N
subsequent POS N
surgical POS N
interventions. POS N

In POS N
patients POS N
with POS N
PACG, POS N
the POS N
long-term POS N
IOP-lowering POS N
effect POS N
and POS N
surgical POS N
complications POS N
of POS N
combined POS N
trabeculectomy POS N
and POS N
cataract POS N
extraction POS N
are POS N
comparable POS N
with POS N
those POS N
of POS N
trabeculectomy POS N
alone. POS N

The POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
were POS N
similar POS N
between POS N
groups POS N
(p POS N
= POS N
0.232). POS N

In POS N
patients POS N
with POS N
PACG, POS N
the POS N
long-term POS N
IOP-lowering POS N
effect POS N
and POS N
surgical POS N
complications POS N
of POS N
combined POS N
trabeculectomy POS N
and POS N
cataract POS N
extraction POS N
are POS N
comparable POS N
with POS N
those POS N
of POS N
trabeculectomy POS N
alone. POS N

No POS N
additional POS N
IOP-lowering POS N
surgical POS N
procedures POS N
were POS N
required POS N
in POS N
the POS N
combined POS N
group, POS N
while POS N
13 POS N
(54%) POS N
eyes POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
required POS N
either POS N
cataract POS N
extraction POS N
or POS N
further POS N
IOP-lowering POS N
surgical POS N
procedures POS N
(p POS N
<0.001). POS N

In POS N
patients POS N
with POS N
PACG, POS N
the POS N
long-term POS N
IOP-lowering POS N
effect POS N
and POS N
surgical POS N
complications POS N
of POS N
combined POS N
trabeculectomy POS N
and POS N
cataract POS N
extraction POS N
are POS N
comparable POS N
with POS N
those POS N
of POS N
trabeculectomy POS N
alone. POS N

However, POS N
the POS N
combined POS N
surgery POS N
incurred POS N
fewer POS N
subsequent POS N
surgical POS N
interventions. POS N

However, POS N
the POS N
combined POS N
surgery POS N
incurred POS N
fewer POS N
subsequent POS N
surgical POS N
interventions. POS N

The POS N
incidences POS N
of POS N
postoperative POS N
complications POS N
were POS N
similar POS N
between POS N
groups POS N
(p POS N
= POS N
0.232). POS N

However, POS N
the POS N
combined POS N
surgery POS N
incurred POS N
fewer POS N
subsequent POS N
surgical POS N
interventions. POS N

No POS N
additional POS N
IOP-lowering POS N
surgical POS N
procedures POS N
were POS N
required POS N
in POS N
the POS N
combined POS N
group, POS N
while POS N
13 POS N
(54%) POS N
eyes POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
required POS N
either POS N
cataract POS N
extraction POS N
or POS N
further POS N
IOP-lowering POS N
surgical POS N
procedures POS N
(p POS N
<0.001). POS N

However, POS N
the POS N
combined POS N
surgery POS N
incurred POS N
fewer POS N
subsequent POS N
surgical POS N
interventions. POS N

In POS N
patients POS N
with POS N
PACG, POS N
the POS N
long-term POS N
IOP-lowering POS N
effect POS N
and POS N
surgical POS N
complications POS N
of POS N
combined POS N
trabeculectomy POS N
and POS N
cataract POS N
extraction POS N
are POS N
comparable POS N
with POS N
those POS N
of POS N
trabeculectomy POS N
alone. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Brinzolamide POS N
produced POS N
less POS N
ocular POS N
discomfort POS N
(burning/stinging) POS N
than POS N
timolol, POS N
and POS N
total POS N
carbonic POS N
anhydrase POS N
inhibition POS N
levels POS N
remained POS N
below POS N
that POS N
known POS N
to POS N
cause POS N
systemic POS N
side POS N
effects. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Brinzolamide POS N
produced POS N
significant POS N
and POS N
equivalent POS N
reductions POS N
in POS N
intraocular POS N
pressure POS N
when POS N
dosed POS N
two POS N
and POS N
three POS N
times POS N
daily POS N
for POS N
18 POS N
months. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Brinzolamide POS N
was POS N
safe POS N
and POS N
well POS N
tolerated POS N
by POS N
patients, POS N
with POS N
minimal POS N
ocular POS N
discomfort. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Mean POS N
changes POS N
in POS N
intraocular POS N
pressure POS N
trough POS N
measurements POS N
ranged POS N
from POS N
-2.7 POS N
to POS N
-3.9 POS N
mm POS N
Hg POS N
with POS N
brinzolamide POS N
twice-daily POS N
dosing POS N
and POS N
-2.8 POS N
to POS N
-3.8 POS N
mm POS N
Hg POS N
three POS N
times POS N
daily POS N
dosing POS N
compared POS N
with POS N
-4.7 POS N
to POS N
-5.6 POS N
mm POS N
Hg POS N
with POS N
timolol. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

Oral POS N
carbonic POS N
anhydrase POS N
inhibitors POS N
used POS N
to POS N
treat POS N
glaucoma POS N
have POS N
significant POS N
systemic POS N
side POS N
effects. POS N

Adverse POS N
events POS N
were POS N
nonserious POS N
and POS N
resolved POS N
without POS N
sequelae. POS N

All POS N
regimens POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
(P<.05) POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline. POS N

At POS N
1 POS N
year, POS N
IOP POS N
in POS N
both POS N
treatment POS N
groups POS N
was POS N
statistically POS N
significantly POS N
lower POS N
from POS N
baseline POS N
values. POS N

Sixty-six POS N
percent POS N
of POS N
treatment POS N
eyes POS N
versus POS N
48% POS N
of POS N
control POS N
eyes POS N
achieved POS N
=20% POS N
IOP POS N
reduction POS N
without POS N
medication POS N
(P POS N
= POS N
0.003). POS N

At POS N
1 POS N
year, POS N
IOP POS N
in POS N
both POS N
treatment POS N
groups POS N
was POS N
statistically POS N
significantly POS N
lower POS N
from POS N
baseline POS N
values. POS N

The POS N
overall POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
similar POS N
between POS N
groups POS N
with POS N
no POS N
unanticipated POS N
adverse POS N
device POS N
effects. POS N

At POS N
1 POS N
year, POS N
IOP POS N
in POS N
both POS N
treatment POS N
groups POS N
was POS N
statistically POS N
significantly POS N
lower POS N
from POS N
baseline POS N
values. POS N

Pressure POS N
reduction POS N
on POS N
fewer POS N
medications POS N
was POS N
clinically POS N
and POS N
statistically POS N
significantly POS N
better POS N
1 POS N
year POS N
after POS N
stent POS N
plus POS N
cataract POS N
surgery POS N
versus POS N
cataract POS N
surgery POS N
alone, POS N
with POS N
an POS N
overall POS N
safety POS N
profile POS N
similar POS N
to POS N
that POS N
of POS N
cataract POS N
surgery POS N
alone. POS N

Sixty-six POS N
percent POS N
of POS N
treatment POS N
eyes POS N
versus POS N
48% POS N
of POS N
control POS N
eyes POS N
achieved POS N
=20% POS N
IOP POS N
reduction POS N
without POS N
medication POS N
(P POS N
= POS N
0.003). POS N

At POS N
1 POS N
year, POS N
IOP POS N
in POS N
both POS N
treatment POS N
groups POS N
was POS N
statistically POS N
significantly POS N
lower POS N
from POS N
baseline POS N
values. POS N

Sixty-six POS N
percent POS N
of POS N
treatment POS N
eyes POS N
versus POS N
48% POS N
of POS N
control POS N
eyes POS N
achieved POS N
=20% POS N
IOP POS N
reduction POS N
without POS N
medication POS N
(P POS N
= POS N
0.003). POS N

The POS N
overall POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
similar POS N
between POS N
groups POS N
with POS N
no POS N
unanticipated POS N
adverse POS N
device POS N
effects. POS N

Sixty-six POS N
percent POS N
of POS N
treatment POS N
eyes POS N
versus POS N
48% POS N
of POS N
control POS N
eyes POS N
achieved POS N
=20% POS N
IOP POS N
reduction POS N
without POS N
medication POS N
(P POS N
= POS N
0.003). POS N

Pressure POS N
reduction POS N
on POS N
fewer POS N
medications POS N
was POS N
clinically POS N
and POS N
statistically POS N
significantly POS N
better POS N
1 POS N
year POS N
after POS N
stent POS N
plus POS N
cataract POS N
surgery POS N
versus POS N
cataract POS N
surgery POS N
alone, POS N
with POS N
an POS N
overall POS N
safety POS N
profile POS N
similar POS N
to POS N
that POS N
of POS N
cataract POS N
surgery POS N
alone. POS N

The POS N
overall POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
similar POS N
between POS N
groups POS N
with POS N
no POS N
unanticipated POS N
adverse POS N
device POS N
effects. POS N

At POS N
1 POS N
year, POS N
IOP POS N
in POS N
both POS N
treatment POS N
groups POS N
was POS N
statistically POS N
significantly POS N
lower POS N
from POS N
baseline POS N
values. POS N

The POS N
overall POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
similar POS N
between POS N
groups POS N
with POS N
no POS N
unanticipated POS N
adverse POS N
device POS N
effects. POS N

Sixty-six POS N
percent POS N
of POS N
treatment POS N
eyes POS N
versus POS N
48% POS N
of POS N
control POS N
eyes POS N
achieved POS N
=20% POS N
IOP POS N
reduction POS N
without POS N
medication POS N
(P POS N
= POS N
0.003). POS N

The POS N
overall POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
similar POS N
between POS N
groups POS N
with POS N
no POS N
unanticipated POS N
adverse POS N
device POS N
effects. POS N

Pressure POS N
reduction POS N
on POS N
fewer POS N
medications POS N
was POS N
clinically POS N
and POS N
statistically POS N
significantly POS N
better POS N
1 POS N
year POS N
after POS N
stent POS N
plus POS N
cataract POS N
surgery POS N
versus POS N
cataract POS N
surgery POS N
alone, POS N
with POS N
an POS N
overall POS N
safety POS N
profile POS N
similar POS N
to POS N
that POS N
of POS N
cataract POS N
surgery POS N
alone. POS N

Pressure POS N
reduction POS N
on POS N
fewer POS N
medications POS N
was POS N
clinically POS N
and POS N
statistically POS N
significantly POS N
better POS N
1 POS N
year POS N
after POS N
stent POS N
plus POS N
cataract POS N
surgery POS N
versus POS N
cataract POS N
surgery POS N
alone, POS N
with POS N
an POS N
overall POS N
safety POS N
profile POS N
similar POS N
to POS N
that POS N
of POS N
cataract POS N
surgery POS N
alone. POS N

At POS N
1 POS N
year, POS N
IOP POS N
in POS N
both POS N
treatment POS N
groups POS N
was POS N
statistically POS N
significantly POS N
lower POS N
from POS N
baseline POS N
values. POS N

Pressure POS N
reduction POS N
on POS N
fewer POS N
medications POS N
was POS N
clinically POS N
and POS N
statistically POS N
significantly POS N
better POS N
1 POS N
year POS N
after POS N
stent POS N
plus POS N
cataract POS N
surgery POS N
versus POS N
cataract POS N
surgery POS N
alone, POS N
with POS N
an POS N
overall POS N
safety POS N
profile POS N
similar POS N
to POS N
that POS N
of POS N
cataract POS N
surgery POS N
alone. POS N

Sixty-six POS N
percent POS N
of POS N
treatment POS N
eyes POS N
versus POS N
48% POS N
of POS N
control POS N
eyes POS N
achieved POS N
=20% POS N
IOP POS N
reduction POS N
without POS N
medication POS N
(P POS N
= POS N
0.003). POS N

Pressure POS N
reduction POS N
on POS N
fewer POS N
medications POS N
was POS N
clinically POS N
and POS N
statistically POS N
significantly POS N
better POS N
1 POS N
year POS N
after POS N
stent POS N
plus POS N
cataract POS N
surgery POS N
versus POS N
cataract POS N
surgery POS N
alone, POS N
with POS N
an POS N
overall POS N
safety POS N
profile POS N
similar POS N
to POS N
that POS N
of POS N
cataract POS N
surgery POS N
alone. POS N

The POS N
overall POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
similar POS N
between POS N
groups POS N
with POS N
no POS N
unanticipated POS N
adverse POS N
device POS N
effects. POS N

The POS N
mean POS N
IOP POS N
reduction POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
BTFC POS N
group POS N
than POS N
in POS N
the POS N
LTFC POS N
group POS N
(-21.4% POS N
vs POS N
-13.7%, POS N
p<0.001). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
in POS N
the POS N
BTFC POS N
group POS N
showed POS N
a POS N
mean POS N
IOP POS N
reduction POS N
from POS N
baseline POS N
>or=15% POS N
(72.3% POS N
vs POS N
40.0%) POS N
and POS N
>or=20% POS N
(61.7% POS N
vs POS N
17.1%) POS N
compared POS N
to POS N
patients POS N
in POS N
the POS N
LTFC POS N
group. POS N

The POS N
mean POS N
IOP POS N
reduction POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
BTFC POS N
group POS N
than POS N
in POS N
the POS N
LTFC POS N
group POS N
(-21.4% POS N
vs POS N
-13.7%, POS N
p<0.001). POS N

Both POS N
BTFC POS N
and POS N
LTFC POS N
were POS N
more POS N
effective POS N
versus POS N
the POS N
monotherapy POS N
with POS N
prostaglandin POS N
analogues. POS N

The POS N
mean POS N
IOP POS N
reduction POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
BTFC POS N
group POS N
than POS N
in POS N
the POS N
LTFC POS N
group POS N
(-21.4% POS N
vs POS N
-13.7%, POS N
p<0.001). POS N

BTFC POS N
demonstrated POS N
higher POS N
performance POS N
than POS N
LTFC POS N
in POS N
terms POS N
of POS N
relative POS N
IOP POS N
reduction. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
in POS N
the POS N
BTFC POS N
group POS N
showed POS N
a POS N
mean POS N
IOP POS N
reduction POS N
from POS N
baseline POS N
>or=15% POS N
(72.3% POS N
vs POS N
40.0%) POS N
and POS N
>or=20% POS N
(61.7% POS N
vs POS N
17.1%) POS N
compared POS N
to POS N
patients POS N
in POS N
the POS N
LTFC POS N
group. POS N

The POS N
mean POS N
IOP POS N
reduction POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
BTFC POS N
group POS N
than POS N
in POS N
the POS N
LTFC POS N
group POS N
(-21.4% POS N
vs POS N
-13.7%, POS N
p<0.001). POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
in POS N
the POS N
BTFC POS N
group POS N
showed POS N
a POS N
mean POS N
IOP POS N
reduction POS N
from POS N
baseline POS N
>or=15% POS N
(72.3% POS N
vs POS N
40.0%) POS N
and POS N
>or=20% POS N
(61.7% POS N
vs POS N
17.1%) POS N
compared POS N
to POS N
patients POS N
in POS N
the POS N
LTFC POS N
group. POS N

Both POS N
BTFC POS N
and POS N
LTFC POS N
were POS N
more POS N
effective POS N
versus POS N
the POS N
monotherapy POS N
with POS N
prostaglandin POS N
analogues. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
in POS N
the POS N
BTFC POS N
group POS N
showed POS N
a POS N
mean POS N
IOP POS N
reduction POS N
from POS N
baseline POS N
>or=15% POS N
(72.3% POS N
vs POS N
40.0%) POS N
and POS N
>or=20% POS N
(61.7% POS N
vs POS N
17.1%) POS N
compared POS N
to POS N
patients POS N
in POS N
the POS N
LTFC POS N
group. POS N

BTFC POS N
demonstrated POS N
higher POS N
performance POS N
than POS N
LTFC POS N
in POS N
terms POS N
of POS N
relative POS N
IOP POS N
reduction. POS N

Both POS N
BTFC POS N
and POS N
LTFC POS N
were POS N
more POS N
effective POS N
versus POS N
the POS N
monotherapy POS N
with POS N
prostaglandin POS N
analogues. POS N

The POS N
mean POS N
IOP POS N
reduction POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
BTFC POS N
group POS N
than POS N
in POS N
the POS N
LTFC POS N
group POS N
(-21.4% POS N
vs POS N
-13.7%, POS N
p<0.001). POS N

Both POS N
BTFC POS N
and POS N
LTFC POS N
were POS N
more POS N
effective POS N
versus POS N
the POS N
monotherapy POS N
with POS N
prostaglandin POS N
analogues. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
in POS N
the POS N
BTFC POS N
group POS N
showed POS N
a POS N
mean POS N
IOP POS N
reduction POS N
from POS N
baseline POS N
>or=15% POS N
(72.3% POS N
vs POS N
40.0%) POS N
and POS N
>or=20% POS N
(61.7% POS N
vs POS N
17.1%) POS N
compared POS N
to POS N
patients POS N
in POS N
the POS N
LTFC POS N
group. POS N

Both POS N
BTFC POS N
and POS N
LTFC POS N
were POS N
more POS N
effective POS N
versus POS N
the POS N
monotherapy POS N
with POS N
prostaglandin POS N
analogues. POS N

BTFC POS N
demonstrated POS N
higher POS N
performance POS N
than POS N
LTFC POS N
in POS N
terms POS N
of POS N
relative POS N
IOP POS N
reduction. POS N

BTFC POS N
demonstrated POS N
higher POS N
performance POS N
than POS N
LTFC POS N
in POS N
terms POS N
of POS N
relative POS N
IOP POS N
reduction. POS N

The POS N
mean POS N
IOP POS N
reduction POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
BTFC POS N
group POS N
than POS N
in POS N
the POS N
LTFC POS N
group POS N
(-21.4% POS N
vs POS N
-13.7%, POS N
p<0.001). POS N

BTFC POS N
demonstrated POS N
higher POS N
performance POS N
than POS N
LTFC POS N
in POS N
terms POS N
of POS N
relative POS N
IOP POS N
reduction. POS N

A POS N
higher POS N
percentage POS N
of POS N
patients POS N
in POS N
the POS N
BTFC POS N
group POS N
showed POS N
a POS N
mean POS N
IOP POS N
reduction POS N
from POS N
baseline POS N
>or=15% POS N
(72.3% POS N
vs POS N
40.0%) POS N
and POS N
>or=20% POS N
(61.7% POS N
vs POS N
17.1%) POS N
compared POS N
to POS N
patients POS N
in POS N
the POS N
LTFC POS N
group. POS N

BTFC POS N
demonstrated POS N
higher POS N
performance POS N
than POS N
LTFC POS N
in POS N
terms POS N
of POS N
relative POS N
IOP POS N
reduction. POS N

Both POS N
BTFC POS N
and POS N
LTFC POS N
were POS N
more POS N
effective POS N
versus POS N
the POS N
monotherapy POS N
with POS N
prostaglandin POS N
analogues. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Bimatoprost POS N
provided POS N
greater POS N
(nonsignificant) POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
travoprost POS N
at POS N
each POS N
visit. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reduction POS N
was POS N
8.77 POS N
mm POS N
Hg POS N
(33.39%) POS N
and POS N
8.42 POS N
mm POS N
Hg POS N
(31.54%) POS N
at POS N
2 POS N
weeks POS N
(P POS N
= POS N
0.703), POS N
and POS N
8.47 POS N
mm POS N
Hg POS N
(31.61%) POS N
and POS N
7.84 POS N
mm POS N
Hg POS N
(29.50%) POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.536) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
20 POS N
(58.8%) POS N
versus POS N
19 POS N
(50%) POS N
eyes POS N
(P POS N
= POS N
0.603), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
12 POS N
(32%) POS N
eyes POS N
(P POS N
= POS N
0.456); POS N
and POS N
at POS N
6 POS N
months POS N
18 POS N
mm POS N
Hg POS N
in POS N
22 POS N
(65%) POS N
versus POS N
14 POS N
(37%) POS N
eyes POS N
(P POS N
= POS N
0.045), POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
12 POS N
(35%) POS N
versus POS N
7 POS N
(18%) POS N
eyes POS N
(P POS N
= POS N
0.037) POS N
for POS N
bimatoprost POS N
and POS N
travoprost, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Ocular POS N
adverse POS N
and POS N
clinical POS N
success POS N
occurred POS N
equally POS N
with POS N
both POS N
drops. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
lowered POS N
IOP POS N
effectively POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

but POS N
bimatoprost POS N
showed POS N
a POS N
greater POS N
non-significant POS N
reductions POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Adjunctive POS N
use POS N
of POS N
brimonidine POS N
purite POS N
provided POS N
greater POS N
IOP POS N
lowering POS N
than POS N
brinzolamide POS N
at POS N
10 POS N
a.m. POS N
(p POS N
< POS N
0.001) POS N
and POS N
4 POS N
p.m. POS N
(p POS N
= POS N
0.050) POS N
and POS N
equivalent POS N
IOP POS N
lowering POS N
to POS N
brinzolamide POS N
at POS N
8 POS N
a.m. POS N
(p POS N
= POS N
0.716). POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Baseline POS N
mean POS N
diurnal POS N
IOP POS N
(+/- POS N
standard POS N
deviation, POS N
mmHg) POS N
on POS N
latanoprost POS N
was POS N
comparable POS N
between POS N
groups POS N
(brimonidine POS N
purite: POS N
19.6 POS N
+/- POS N
2.94; POS N
brinzolamide: POS N
19.8 POS N
+/- POS N
3.25; POS N
p POS N
= POS N
0.846). POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Blurred POS N
vision POS N
at POS N
Month POS N
1 POS N
and POS N
bitter POS N
taste POS N
at POS N
Months POS N
1 POS N
and POS N
3 POS N
were POS N
more POS N
common POS N
upon POS N
instillation POS N
of POS N
brinzolamide POS N
eye POS N
drops. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Brimonidine POS N
purite POS N
0.1% POS N
provided POS N
significantly POS N
lower POS N
IOP POS N
compared POS N
with POS N
brinzolamide POS N
1% POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Both POS N
adjunctive POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Limitations POS N
of POS N
this POS N
study POS N
include POS N
the POS N
use POS N
of POS N
a POS N
single POS N
site POS N
and POS N
the POS N
sample POS N
size. POS N

Mean POS N
diurnal POS N
IOP POS N
at POS N
Month POS N
3 POS N
was POS N
16.3 POS N
+/- POS N
2.63 POS N
mmHg POS N
with POS N
brimonidine POS N
purite POS N
and POS N
17.8 POS N
+/- POS N
2.19 POS N
mmHg POS N
with POS N
brinzolamide POS N
(p POS N
= POS N
0.028). POS N

Additional POS N
studies POS N
are POS N
needed POS N
to POS N
further POS N
evaluate POS N
these POS N
drugs POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
prostaglandin POS N
analogs. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

There POS N
were POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
need POS N
for POS N
digital POS N
pressure, POS N
postoperative POS N
bleb POS N
needling POS N
with POS N
5-fluorouracil, POS N
or POS N
number POS N
of POS N
postoperative POS N
visits. POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

Early POS N
leaks POS N
of POS N
the POS N
conjunctival POS N
wound POS N
closure POS N
occurred POS N
in POS N
6 POS N
eyes POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
in POS N
0 POS N
eyes POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.03). POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

One-site POS N
fornix-based POS N
and POS N
2-site POS N
limbus-based POS N
phacotrabeculectomy POS N
were POS N
similarly POS N
effective POS N
in POS N
lowering POS N
IOP POS N
and POS N
reducing POS N
the POS N
need POS N
for POS N
antiglaucoma POS N
medications POS N
over POS N
a POS N
3-year POS N
follow-up POS N
period. POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
73% POS N
of POS N
1-site POS N
eyes POS N
and POS N
78.4% POS N
of POS N
2-site POS N
eyes POS N
had POS N
IOPs POS N
of POS N
less POS N
than POS N
18 POS N
mmHg POS N
while POS N
receiving POS N
no POS N
antiglaucoma POS N
medications POS N
(P POS N
= POS N
0.59). POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

Visual POS N
acuity POS N
was POS N
similar POS N
for POS N
both POS N
groups POS N
at POS N
3 POS N
months POS N
after POS N
surgery. POS N

After POS N
3 POS N
years POS N
of POS N
follow-up, POS N
the POS N
mean POS N
IOP POS N
was POS N
12.6+/-4.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
11.7+/-4.0 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.40), POS N
receiving POS N
a POS N
mean POS N
of POS N
0.3+/-0.7 POS N
and POS N
0.4+/-0.9 POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.59). POS N

Mean POS N
preoperative POS N
IOP POS N
was POS N
20.1+/-3.8 POS N
mmHg POS N
in POS N
the POS N
1-site POS N
group POS N
and POS N
19.5+/-5.3 POS N
mmHg POS N
in POS N
the POS N
2-site POS N
group POS N
(P POS N
= POS N
0.56) POS N
using POS N
a POS N
mean POS N
of POS N
2.3+/-0.9 POS N
and POS N
2.5+/-0.9 POS N
antiglaucoma POS N
medications, POS N
respectively POS N
(P POS N
= POS N
0.27). POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
plus POS N
dorzolamide POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

Latanoprost POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
1.09 POS N
and POS N
1.58 POS N
mm POS N
Hg POS N
more POS N
than POS N
timolol POS N
plus POS N
dorzolamide POS N
after POS N
2 POS N
weeks POS N
and POS N
3 POS N
months POS N
of POS N
treatment, POS N
respectively. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
plus POS N
dorzolamide POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

These POS N
differences POS N
were POS N
statistically POS N
significant POS N
(p<0.05) POS N
at POS N
the POS N
end POS N
of POS N
the POS N
study. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
plus POS N
dorzolamide POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
32.3% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
latanoprost POS N
group POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
in POS N
30% POS N
or POS N
more POS N
with POS N
respect POS N
to POS N
baseline, POS N
while POS N
15.6% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
timolol POS N
plus POS N
dorzolamide POS N
group POS N
achieved POS N
this POS N
reduction. POS N

Latanoprost POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
1.09 POS N
and POS N
1.58 POS N
mm POS N
Hg POS N
more POS N
than POS N
timolol POS N
plus POS N
dorzolamide POS N
after POS N
2 POS N
weeks POS N
and POS N
3 POS N
months POS N
of POS N
treatment, POS N
respectively. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
plus POS N
dorzolamide POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

Latanoprost POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
1.09 POS N
and POS N
1.58 POS N
mm POS N
Hg POS N
more POS N
than POS N
timolol POS N
plus POS N
dorzolamide POS N
after POS N
2 POS N
weeks POS N
and POS N
3 POS N
months POS N
of POS N
treatment, POS N
respectively. POS N

These POS N
differences POS N
were POS N
statistically POS N
significant POS N
(p<0.05) POS N
at POS N
the POS N
end POS N
of POS N
the POS N
study. POS N

Latanoprost POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
1.09 POS N
and POS N
1.58 POS N
mm POS N
Hg POS N
more POS N
than POS N
timolol POS N
plus POS N
dorzolamide POS N
after POS N
2 POS N
weeks POS N
and POS N
3 POS N
months POS N
of POS N
treatment, POS N
respectively. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
32.3% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
latanoprost POS N
group POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
in POS N
30% POS N
or POS N
more POS N
with POS N
respect POS N
to POS N
baseline, POS N
while POS N
15.6% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
timolol POS N
plus POS N
dorzolamide POS N
group POS N
achieved POS N
this POS N
reduction. POS N

These POS N
differences POS N
were POS N
statistically POS N
significant POS N
(p<0.05) POS N
at POS N
the POS N
end POS N
of POS N
the POS N
study. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
plus POS N
dorzolamide POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

These POS N
differences POS N
were POS N
statistically POS N
significant POS N
(p<0.05) POS N
at POS N
the POS N
end POS N
of POS N
the POS N
study. POS N

Latanoprost POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
1.09 POS N
and POS N
1.58 POS N
mm POS N
Hg POS N
more POS N
than POS N
timolol POS N
plus POS N
dorzolamide POS N
after POS N
2 POS N
weeks POS N
and POS N
3 POS N
months POS N
of POS N
treatment, POS N
respectively. POS N

These POS N
differences POS N
were POS N
statistically POS N
significant POS N
(p<0.05) POS N
at POS N
the POS N
end POS N
of POS N
the POS N
study. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
32.3% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
latanoprost POS N
group POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
in POS N
30% POS N
or POS N
more POS N
with POS N
respect POS N
to POS N
baseline, POS N
while POS N
15.6% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
timolol POS N
plus POS N
dorzolamide POS N
group POS N
achieved POS N
this POS N
reduction. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
32.3% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
latanoprost POS N
group POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
in POS N
30% POS N
or POS N
more POS N
with POS N
respect POS N
to POS N
baseline, POS N
while POS N
15.6% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
timolol POS N
plus POS N
dorzolamide POS N
group POS N
achieved POS N
this POS N
reduction. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
at POS N
least POS N
as POS N
well POS N
as POS N
timolol POS N
plus POS N
dorzolamide POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
32.3% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
latanoprost POS N
group POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
in POS N
30% POS N
or POS N
more POS N
with POS N
respect POS N
to POS N
baseline, POS N
while POS N
15.6% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
timolol POS N
plus POS N
dorzolamide POS N
group POS N
achieved POS N
this POS N
reduction. POS N

Latanoprost POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
1.09 POS N
and POS N
1.58 POS N
mm POS N
Hg POS N
more POS N
than POS N
timolol POS N
plus POS N
dorzolamide POS N
after POS N
2 POS N
weeks POS N
and POS N
3 POS N
months POS N
of POS N
treatment, POS N
respectively. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
32.3% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
latanoprost POS N
group POS N
reduced POS N
the POS N
intraocular POS N
pressure POS N
in POS N
30% POS N
or POS N
more POS N
with POS N
respect POS N
to POS N
baseline, POS N
while POS N
15.6% POS N
of POS N
the POS N
eyes POS N
in POS N
the POS N
timolol POS N
plus POS N
dorzolamide POS N
group POS N
achieved POS N
this POS N
reduction. POS N

These POS N
differences POS N
were POS N
statistically POS N
significant POS N
(p<0.05) POS N
at POS N
the POS N
end POS N
of POS N
the POS N
study. POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

At POS N
1 POS N
year POS N
after POS N
surgery, POS N
the POS N
mean POS N
IOP POS N
was POS N
15.6+/-2.4mm POS N
Hg POS N
in POS N
the POS N
ologen POS N
group POS N
(P<0.01, POS N
43% POS N
reduction) POS N
and POS N
11.5+/-4.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.01, POS N
50% POS N
reduction). POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

However, POS N
the POS N
bleb POS N
morphology POS N
caused POS N
more POS N
problems POS N
in POS N
the POS N
MMC POS N
group POS N
(avascularity POS N
score). POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

The POS N
complete POS N
success POS N
rate POS N
using POS N
trabeculectomy POS N
with POS N
the POS N
ologen POS N
implant POS N
is POS N
lower POS N
than POS N
that POS N
achieved POS N
by POS N
trabeculectomy POS N
with POS N
MMC. POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

No POS N
anti-glaucomatous POS N
medication POS N
was POS N
necessary POS N
in POS N
the POS N
MMC POS N
group POS N
in POS N
the POS N
first POS N
year POS N
of POS N
follow-up, POS N
whereas POS N
five POS N
patients POS N
in POS N
the POS N
ologen POS N
group POS N
required POS N
topical POS N
treatment. POS N

After POS N
1 POS N
year, POS N
filtering POS N
blebs POS N
developed POS N
significantly POS N
more POS N
avascular POS N
areas POS N
in POS N
the POS N
MMC POS N
group POS N
(score=1.4) POS N
than POS N
in POS N
the POS N
ologen POS N
group POS N
(score=2.8; POS N
P<0.01). POS N

The POS N
absolute POS N
success POS N
rate POS N
was POS N
100% POS N
in POS N
the POS N
MMC POS N
group POS N
and POS N
50% POS N
in POS N
the POS N
ologen POS N
group POS N
(P=0.01). POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

In POS N
the POS N
bimatoprost-treated POS N
group, POS N
the POS N
IOP POS N
reduction POS N
was POS N
6.2 POS N
+/- POS N
1.8 POS N
mmHg, POS N
whereas POS N
it POS N
was POS N
6.5 POS N
+/- POS N
2.3 POS N
mmHg POS N
in POS N
the POS N
timolol-dorzolamide POS N
group POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

The POS N
IOP-lowering POS N
efficacies POS N
of POS N
bimatoprost POS N
and POS N
timolol-dorzolamide POS N
combination POS N
were POS N
similar POS N
over POS N
a POS N
6-month POS N
follow-up. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

Both POS N
bimatoprost POS N
and POS N
the POS N
timolol-dorzolamide POS N
combination POS N
were POS N
well POS N
tolerated. POS N

The POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(p POS N
= POS N
0.48). POS N

Bimatoprost POS N
can POS N
be POS N
used POS N
as POS N
a POS N
longterm POS N
monotherapy POS N
agent POS N
in POS N
the POS N
treatment POS N
of POS N
POAG POS N
and POS N
ocular POS N
hypertension. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP POS N
reduction POS N
between POS N
viscocanalostomy POS N
and POS N
trabeculectomy POS N
with POS N
mitomycin POS N
C POS N
in POS N
combination POS N
with POS N
phacoemulsification POS N
and POS N
intraocular POS N
lens POS N
implantation POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma. POS N

At POS N
12 POS N
months, POS N
17 POS N
patients POS N
(85%) POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
16 POS N
patients POS N
(80%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
achieved POS N
an POS N
IOP POS N
of POS N
20 POS N
mmHg POS N
or POS N
less POS N
without POS N
medication POS N
(P POS N
= POS N
0.7). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP POS N
reduction POS N
between POS N
viscocanalostomy POS N
and POS N
trabeculectomy POS N
with POS N
mitomycin POS N
C POS N
in POS N
combination POS N
with POS N
phacoemulsification POS N
and POS N
intraocular POS N
lens POS N
implantation POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma. POS N

Mean POS N
baseline POS N
IOP POS N
was POS N
24.0+/-2.0 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
23.7+/-2.6 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.7). POS N
Mean POS N
postoperative POS N
IOP POS N
was POS N
13.7+/-2.2 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
14.8+/-3.3 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.9+/-3.0 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
12.1+/-4.0 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
13.8+/-4.7 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.1+/-4.4 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

At POS N
12 POS N
months, POS N
17 POS N
patients POS N
(85%) POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
16 POS N
patients POS N
(80%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
achieved POS N
an POS N
IOP POS N
of POS N
20 POS N
mmHg POS N
or POS N
less POS N
without POS N
medication POS N
(P POS N
= POS N
0.7). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP POS N
reduction POS N
between POS N
viscocanalostomy POS N
and POS N
trabeculectomy POS N
with POS N
mitomycin POS N
C POS N
in POS N
combination POS N
with POS N
phacoemulsification POS N
and POS N
intraocular POS N
lens POS N
implantation POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma. POS N

At POS N
12 POS N
months, POS N
17 POS N
patients POS N
(85%) POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
16 POS N
patients POS N
(80%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
achieved POS N
an POS N
IOP POS N
of POS N
20 POS N
mmHg POS N
or POS N
less POS N
without POS N
medication POS N
(P POS N
= POS N
0.7). POS N

Mean POS N
baseline POS N
IOP POS N
was POS N
24.0+/-2.0 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
23.7+/-2.6 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.7). POS N
Mean POS N
postoperative POS N
IOP POS N
was POS N
13.7+/-2.2 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
14.8+/-3.3 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.9+/-3.0 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
12.1+/-4.0 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
13.8+/-4.7 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.1+/-4.4 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

Mean POS N
baseline POS N
IOP POS N
was POS N
24.0+/-2.0 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
23.7+/-2.6 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.7). POS N
Mean POS N
postoperative POS N
IOP POS N
was POS N
13.7+/-2.2 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
14.8+/-3.3 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.9+/-3.0 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
12.1+/-4.0 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
13.8+/-4.7 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.1+/-4.4 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP POS N
reduction POS N
between POS N
viscocanalostomy POS N
and POS N
trabeculectomy POS N
with POS N
mitomycin POS N
C POS N
in POS N
combination POS N
with POS N
phacoemulsification POS N
and POS N
intraocular POS N
lens POS N
implantation POS N
in POS N
patients POS N
with POS N
primary POS N
open-angle POS N
glaucoma. POS N

Mean POS N
baseline POS N
IOP POS N
was POS N
24.0+/-2.0 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
23.7+/-2.6 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.7). POS N
Mean POS N
postoperative POS N
IOP POS N
was POS N
13.7+/-2.2 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
14.8+/-3.3 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.9+/-3.0 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
12.1+/-4.0 POS N
mmHg POS N
at POS N
3 POS N
months, POS N
13.8+/-4.7 POS N
mmHg POS N
at POS N
6 POS N
months, POS N
and POS N
14.1+/-4.4 POS N
mmHg POS N
at POS N
12 POS N
months POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

At POS N
12 POS N
months, POS N
17 POS N
patients POS N
(85%) POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
and POS N
16 POS N
patients POS N
(80%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
achieved POS N
an POS N
IOP POS N
of POS N
20 POS N
mmHg POS N
or POS N
less POS N
without POS N
medication POS N
(P POS N
= POS N
0.7). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
mean POS N
IOP POS N
was POS N
significantly POS N
lower POS N
after POS N
1 POS N
year POS N
in POS N
both POS N
the POS N
groups POS N
(P<0.001). POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
month POS N
of POS N
follow-up POS N
was POS N
lower POS N
in POS N
the POS N
study POS N
group POS N
(control; POS N
20.4±9.7, POS N
study; POS N
13.6±6.5, POS N
P<0.01). POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
success POS N
rate POS N
at POS N
1 POS N
year POS N
was POS N
78% POS N
for POS N
the POS N
study POS N
group POS N
and POS N
76% POS N
for POS N
the POS N
control POS N
group POS N
(P=0.82). POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

Intravitreal POS N
injection POS N
of POS N
triamcinolone POS N
acetonide POS N
in POS N
neovascular POS N
glaucoma POS N
did POS N
not POS N
affect POS N
the POS N
intermediate-term POS N
success POS N
of POS N
the POS N
silicone POS N
Ahmed POS N
valve POS N
nor POS N
reduce POS N
the POS N
incidence POS N
of POS N
complications. POS N

Complication POS N
rates POS N
were POS N
not POS N
different POS N
between POS N
the POS N
groups. POS N

The POS N
mean POS N
IOP POS N
spike POS N
in POS N
the POS N
first POS N
month POS N
was POS N
lower POS N
in POS N
the POS N
triamcinolone POS N
group. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

The POS N
mean POS N
IOP POS N
levels POS N
of POS N
latanoprost/timolol POS N
(13.83, POS N
SD POS N
= POS N
2.54) POS N
was POS N
significantly POS N
lower POS N
than POS N
of POS N
bimatoprost POS N
(16.16, POS N
SD POS N
= POS N
3.28; POS N
P POS N
< POS N
0.0001) POS N
at POS N
week POS N
8. POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

the POS N
change POS N
in POS N
mean POS N
IOP POS N
values POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N
at POS N
10:00 POS N
am POS N
(P POS N
= POS N
0.013) POS N
and POS N
12:00 POS N
pm POS N
(P POS N
= POS N
0.01), POS N
but POS N
not POS N
at POS N
8:00 POS N
am POS N
(P POS N
= POS N
ns). POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

there POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
mean POS N
heart POS N
rate POS N
in POS N
the POS N
latanoprost/timolol POS N
group POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

no POS N
significant POS N
changes POS N
in POS N
blood POS N
pressure POS N
and POS N
lung POS N
spirometry POS N
were POS N
observed POS N
in POS N
either POS N
groups. POS N

Further POS N
studies POS N
with POS N
large POS N
sample POS N
sizes POS N
should POS N
be POS N
taken POS N
to POS N
support POS N
the POS N
superior POS N
efficacy POS N
of POS N
latanoprost/timolol, POS N
as POS N
well POS N
as POS N
to POS N
better POS N
assess POS N
its POS N
profile POS N
of POS N
side POS N
effects. POS N

The POS N
fixed POS N
combination POS N
of POS N
latanoprost/timolol POS N
was POS N
significantly POS N
superior POS N
to POS N
bimatoprost POS N
alone POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
or POS N
OHT. POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

In POS N
eyes POS N
with POS N
synechial POS N
primary POS N
angle-closure POS N
or POS N
primary POS N
angle-closure POS N
glaucoma, POS N
both POS N
iridotomy POS N
alone POS N
or POS N
combined POS N
with POS N
iridoplasty POS N
provide POS N
a POS N
significant POS N
and POS N
equivalent POS N
reduction POS N
in POS N
IOP. POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

IOP POS N
was POS N
reduced POS N
from POS N
24.66 POS N
+/- POS N
13.76 POS N
mm POS N
Hg POS N
to POS N
19.03 POS N
+/- POS N
6.21 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
group POS N
(P POS N
< POS N
.001) POS N
and POS N
from POS N
27.96 POS N
+/- POS N
13.06 POS N
mm POS N
Hg POS N
to POS N
20.45 POS N
+/- POS N
7.26 POS N
mm POS N
Hg POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

Extent POS N
of POS N
peripheral POS N
anterior POS N
synechiae POS N
was POS N
decreased POS N
by POS N
1 POS N
more POS N
clock-hour POS N
after POS N
iridoplasty POS N
compared POS N
with POS N
that POS N
after POS N
iridotomy POS N
in POS N
the POS N
iridotomy POS N
plus POS N
iridoplasty POS N
group POS N
(P POS N
< POS N
.001). POS N

There POS N
is POS N
also POS N
a POS N
possible POS N
reduction POS N
in POS N
peripheral POS N
anterior POS N
synechiae, POS N
more POS N
so POS N
in POS N
the POS N
iridoplasty POS N
group. POS N

There POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
IOP, POS N
medications, POS N
need POS N
for POS N
surgery, POS N
or POS N
visual POS N
function POS N
between POS N
groups POS N
at POS N
the POS N
1-year POS N
visit. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

Of POS N
patients POS N
with POS N
350- POS N
and POS N
500-mm2 POS N
implants, POS N
93% POS N
and POS N
88%, POS N
respectively, POS N
achieved POS N
surgical POS N
success POS N
(18-month POS N
life-table POS N
analysis, POS N
P POS N
= POS N
0.93). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
500-mm2 POS N
implants POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
significantly POS N
fewer POS N
medications POS N
(0.7 POS N
versus POS N
1.3; POS N
P POS N
= POS N
0.006). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
postoperative POS N
visual POS N
acuities POS N
remained POS N
within POS N
one POS N
line POS N
of POS N
the POS N
preoperative POS N
visual POS N
acuities POS N
or POS N
improved POS N
in POS N
62% POS N
and POS N
66% POS N
of POS N
patients POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively POS N
(P POS N
= POS N
0.93). POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

Complication POS N
rates POS N
were POS N
statistically POS N
similar. POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

The POS N
intermediate-term POS N
results POS N
of POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
Baerveldt POS N
implants POS N
were POS N
statistically POS N
comparable POS N
with POS N
respect POS N
to POS N
surgical POS N
and POS N
visual POS N
outcomes, POS N
as POS N
well POS N
as POS N
complications POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

although POS N
the POS N
larger POS N
implant POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
rate POS N
of POS N
some POS N
complications. POS N

The POS N
most POS N
frequent POS N
ones POS N
in POS N
the POS N
350- POS N
and POS N
500-mm2 POS N
groups, POS N
respectively, POS N
were POS N
serous POS N
choroidal POS N
effusion POS N
(16% POS N
and POS N
32%), POS N
strabismus POS N
(16% POS N
and POS N
19%), POS N
anterior POS N
uveitis POS N
(14% POS N
and POS N
11%), POS N
and POS N
corneal POS N
or POS N
corneal POS N
graft POS N
edema POS N
(11% POS N
each). POS N

the POS N
500-mm2 POS N
Baerveldt POS N
implant POS N
afforded POS N
intraocular POS N
pressure POS N
control POS N
with POS N
fewer POS N
medications POS N
than POS N
the POS N
350-mm2 POS N
implant. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

For POS N
both POS N
treatments POS N
the POS N
diurnal POS N
IOP POS N
reduction POS N
after POS N
6 POS N
months POS N
was POS N
statistically POS N
significant POS N
(P<0.001). POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

IOP POS N
(mean+/-SD) POS N
was POS N
reduced POS N
from POS N
23.3+/-2.8 POS N
to POS N
17.8+/-2.8 POS N
(-5.6) POS N
mmHg POS N
in POS N
the POS N
latanoprost POS N
0.005% POS N
group POS N
and POS N
from POS N
23.0+/-3.2 POS N
to POS N
18.5+/-2.4 POS N
(-4.8) POS N
mmHg POS N
in POS N
pilocarpine POS N
2% POS N
t.i.d.-treated POS N
eyes. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

The POS N
mean POS N
difference POS N
of POS N
-0.8 POS N
mmHg POS N
(per POS N
protocol, POS N
PP) POS N
and POS N
-1.6 POS N
mmHg POS N
(intend-to-treat, POS N
ITT) POS N
was POS N
statistically POS N
significant POS N
(P<0.04, POS N
PP; POS N
P<0.001, POS N
ITT) POS N
in POS N
favor POS N
of POS N
latanoprost POS N
0.005%. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

Two POS N
eyes POS N
treated POS N
with POS N
latanoprost POS N
showed POS N
an POS N
iris POS N
color POS N
change. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

Thirty-six POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
and POS N
106 POS N
in POS N
the POS N
pilocarpine POS N
2% POS N
group POS N
reported POS N
ocular POS N
adverse POS N
events POS N
(P<0.001). POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

From POS N
the POS N
data POS N
we POS N
conclude POS N
that POS N
the POS N
additivity POS N
of POS N
latanoprost POS N
0.005% POS N
is POS N
at POS N
least POS N
as POS N
effective POS N
as POS N
pilocarpine POS N
2% POS N
t.i.d. POS N
in POS N
reducing POS N
IOP POS N
when POS N
added POS N
to POS N
eyes POS N
currently POS N
on POS N
monotherapy POS N
with POS N
timolol POS N
0.5% POS N
b.i.d. POS N

The POS N
increase POS N
in POS N
iris POS N
pigmentation POS N
requires POS N
further POS N
investigation. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
than POS N
pilocarpine POS N
2% POS N
eye POS N
drops POS N
in POS N
this POS N
study. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
lower POS N
mean POS N
postoperative POS N
IOP POS N
than POS N
phacoemulsification POS N
alone POS N
at POS N
3 POS N
months POS N
(14.0 POS N
vs POS N
17.0 POS N
mmHg, POS N
P POS N
= POS N
0.01), POS N
15 POS N
months POS N
(13.2 POS N
vs POS N
15.4 POS N
mmHg, POS N
P POS N
= POS N
0.02), POS N
and POS N
18 POS N
months POS N
(13.6 POS N
vs POS N
15.9 POS N
mmHg, POS N
P POS N
= POS N
0.01). POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
phacotrabeculectomy POS N
resulted POS N
in POS N
1.25 POS N
fewer POS N
topical POS N
glaucoma POS N
drugs POS N
(P<0.001) POS N
in POS N
the POS N
24-month POS N
postoperative POS N
period, POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
surgery POS N
was POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications POS N
(P<0.001) POS N
and POS N
more POS N
progression POS N
of POS N
optic POS N
neuropathy POS N
(P POS N
= POS N
0.03), POS N
compared POS N
with POS N
phacoemulsification POS N
alone. POS N

Combined POS N
phacotrabeculectomy POS N
is POS N
associated POS N
with POS N
more POS N
postoperative POS N
complications. POS N

Combined POS N
phacotrabeculectomy POS N
with POS N
adjunctive POS N
mitomycin POS N
C POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
alone POS N
in POS N
controlling POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
with POS N
coexisting POS N
cataract. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

the POS N
intent-to-treat POS N
analysis POS N
did POS N
not POS N
demonstrate POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
the POS N
conversion POS N
rate POS N
in POS N
the POS N
betaxolol-treated POS N
group. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Sixteen POS N
(13.2%) POS N
of POS N
121 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
converted POS N
to POS N
glaucoma, POS N
compared POS N
with POS N
12 POS N
(9.0%) POS N
of POS N
134 POS N
patients POS N
in POS N
the POS N
betaxolol POS N
group. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

The POS N
intent-to-treat POS N
analysis POS N
demonstrated POS N
no POS N
evidence POS N
of POS N
any POS N
difference POS N
in POS N
conversion POS N
rates POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups POS N
after POS N
3 POS N
years. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Visual POS N
field POS N
survival POS N
analysis POS N
demonstrated POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
betaxolol POS N
and POS N
placebo POS N
groups. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

The POS N
betaxolol-treated POS N
group POS N
had POS N
significantly POS N
lower POS N
post-treatment POS N
IOP POS N
values. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Converters POS N
had POS N
significantly POS N
higher POS N
pre- POS N
and POS N
post-treatment POS N
IOP POS N
values POS N
than POS N
non-converters. POS N

Conversion POS N
to POS N
glaucoma POS N
was POS N
found POS N
to POS N
be POS N
related POS N
to POS N
both POS N
the POS N
baseline POS N
and POS N
post-treatment POS N
IOP POS N
levels. POS N

Betaxolol POS N
significantly POS N
lowered POS N
the POS N
IOP POS N
level POS N
compared POS N
with POS N
placebo. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

The POS N
overall POS N
success POS N
rates POS N
were POS N
87% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
70% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
(P POS N
= POS N
0.05). POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

The POS N
life-table POS N
success POS N
rates POS N
declined POS N
over POS N
time POS N
for POS N
both POS N
implant POS N
groups, POS N
from POS N
a POS N
high POS N
of POS N
98% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
92% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
1 POS N
year POS N
to POS N
a POS N
cumulative POS N
success POS N
rate POS N
of POS N
79% POS N
for POS N
the POS N
350-mm2 POS N
group POS N
and POS N
66% POS N
for POS N
the POS N
500-mm2 POS N
group POS N
at POS N
5 POS N
years. POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

Visual POS N
acuities POS N
were POS N
better POS N
or POS N
remained POS N
the POS N
same POS N
in POS N
50% POS N
of POS N
the POS N
patients POS N
in POS N
the POS N
350-mm2 POS N
group POS N
and POS N
46% POS N
of POS N
those POS N
in POS N
the POS N
500-mm2 POS N
group. POS N

Interval POS N
comparisons POS N
indicate POS N
a POS N
higher POS N
rate POS N
of POS N
success POS N
for POS N
the POS N
350-mm2 POS N
implant POS N
in POS N
the POS N
first, POS N
second, POS N
third, POS N
fourth, POS N
and POS N
fifth POS N
years POS N
of POS N
implantation. POS N

The POS N
longer POS N
term POS N
results POS N
show POS N
that POS N
the POS N
350-mm2 POS N
Baerveldt POS N
implant POS N
is POS N
more POS N
successful POS N
than POS N
the POS N
500-mm2 POS N
implant POS N
for POS N
overall POS N
IOP POS N
control. POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

Nonvalved POS N
tube POS N
shunt POS N
surgery POS N
was POS N
more POS N
likely POS N
to POS N
maintain POS N
IOP POS N
control POS N
and POS N
avoid POS N
persistent POS N
hypotony POS N
or POS N
reoperation POS N
for POS N
glaucoma POS N
than POS N
trabeculectomy POS N
with POS N
MMC POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
in POS N
the POS N
TVT POS N
Study. POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

there POS N
was POS N
less POS N
need POS N
for POS N
supplemental POS N
medical POS N
therapy POS N
following POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
3.9% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
13.5% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
.017). POS N

The POS N
number POS N
of POS N
glaucoma POS N
medications POS N
(mean POS N
+/- POS N
SD) POS N
was POS N
1.3 POS N
+/- POS N
1.3 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.5 POS N
+/- POS N
0.9 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
.001). POS N

Both POS N
surgical POS N
procedures POS N
produced POS N
similar POS N
IOP POS N
reduction POS N
at POS N
one POS N
year POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

PF POS N
tafluprost POS N
is POS N
an POS N
efficacious POS N
and POS N
generally POS N
well-tolerated POS N
ocular POS N
hypotensive POS N
agent. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

The POS N
IOP-lowering POS N
effect POS N
of POS N
PF POS N
tafluprost POS N
was POS N
noninferior POS N
to POS N
that POS N
of POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

The POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reporting POS N
conjunctival POS N
hyperemia POS N
were POS N
4.4% POS N
vs POS N
1.2% POS N
(nominal POS N
P POS N
= POS N
.016). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

Similar POS N
percentages POS N
of POS N
PF POS N
tafluprost POS N
and POS N
PF POS N
timolol POS N
patients POS N
reported POS N
ocular POS N
pain/stinging/irritation POS N
(4.4% POS N
vs POS N
4.6%) POS N
and POS N
pruritus POS N
(2.5% POS N
vs POS N
1.5%). POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
12-week POS N
visit POS N
ranged POS N
from POS N
17.4 POS N
to POS N
18.6 POS N
mm POS N
Hg POS N
for POS N
PF POS N
tafluprost POS N
and POS N
17.9 POS N
to POS N
18.5 POS N
mm POS N
Hg POS N
for POS N
PF POS N
timolol. POS N

IOPs POS N
at POS N
the POS N
3 POS N
time POS N
points POS N
assessed POS N
during POS N
the POS N
baseline POS N
visit POS N
ranged POS N
from POS N
23.8 POS N
to POS N
26.1 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
tafluprost POS N
group POS N
and POS N
23.5 POS N
to POS N
26.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
PF POS N
timolol POS N
group. POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

Scleral POS N
flap POS N
size POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
medium-term POS N
intraocular POS N
pressure POS N
control POS N
and POS N
complication POS N
profile. POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

At POS N
2 POS N
years, POS N
the POS N
mean POS N
intraocular POS N
pressure POS N
and POS N
cumulative POS N
probability POS N
of POS N
failure POS N
was POS N
12.4 POS N
± POS N
4.6 POS N
mmHg POS N
and POS N
0.28 POS N
for POS N
standard POS N
trabeculectomy, POS N
and POS N
11.5 POS N
± POS N
3.6 POS N
mmHg POS N
and POS N
0.27 POS N
for POS N
microtrabeculectomy POS N
(P POS N
= POS N
0.50 POS N
and POS N
0.89, POS N
respectively). POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

One POS N
patient POS N
in POS N
each POS N
group POS N
required POS N
Baerveldt POS N
device POS N
implantation. POS N

Both POS N
trabeculectomy POS N
techniques POS N
achieved POS N
good POS N
intraocular POS N
pressure POS N
reduction POS N
and POS N
had POS N
similar POS N
complication POS N
rates. POS N

Vision POS N
reduced POS N
≥2 POS N
Snellen POS N
lines POS N
in POS N
15% POS N
in POS N
the POS N
standard POS N
trabeculectomy POS N
group POS N
and POS N
25% POS N
in POS N
the POS N
microtrabeculectomy POS N
group, POS N
mainly POS N
from POS N
cataract POS N
(P POS N
= POS N
0.48). POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Diurnal POS N
IOP POS N
reductions POS N
of POS N
30% POS N
or POS N
more POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
achieved POS N
by POS N
73.5%, POS N
57.5%, POS N
and POS N
32.8% POS N
of POS N
those POS N
treated POS N
with POS N
FCLT, POS N
latanoprost, POS N
and POS N
timolol, POS N
respectively POS N
(P POS N
= POS N
.007 POS N
for POS N
FCLT POS N
vs POS N
timolol; POS N
P POS N
< POS N
.001 POS N
for POS N
FCLT POS N
vs POS N
latanoprost). POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

FCLT POS N
was POS N
associated POS N
with POS N
greater POS N
percentage POS N
reductions POS N
in POS N
diurnal POS N
IOP POS N
levels POS N
and POS N
a POS N
greater POS N
likelihood POS N
of POS N
achieving POS N
lower POS N
mean POS N
diurnal POS N
IOP POS N
levels. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

FCLT POS N
was POS N
statistically POS N
superior POS N
to POS N
latanoprost POS N
at POS N
7 POS N
of POS N
9 POS N
time POS N
points POS N
and POS N
at POS N
all POS N
9 POS N
time POS N
points POS N
when POS N
compared POS N
with POS N
timolol. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Fixed-combination POS N
latanoprost-timolol POS N
therapy POS N
is POS N
as POS N
safe POS N
and POS N
effective POS N
in POS N
lowering POS N
IOP POS N
in POS N
patients POS N
with POS N
either POS N
ocular POS N
hypertension POS N
or POS N
glaucoma POS N
as POS N
monotherapy POS N
with POS N
latanoprost POS N
or POS N
timolol. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Combination POS N
therapy POS N
can POS N
be POS N
used POS N
to POS N
treat POS N
patients POS N
for POS N
whom POS N
monotherapy POS N
does POS N
not POS N
provide POS N
sufficient POS N
IOP POS N
reduction. POS N

All POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

The POS N
simplicity, POS N
efficacy, POS N
and POS N
tolerability POS N
of POS N
FCLT POS N
contribute POS N
to POS N
its POS N
utility POS N
in POS N
clinical POS N
practice. POS N

In POS N
a POS N
case-controlled POS N
comparison, POS N
the POS N
Baerveldt-350 POS N
implant POS N
and POS N
the POS N
Ahmed POS N
valve POS N
had POS N
similar POS N
IOP POS N
control POS N
and POS N
surgical POS N
outcomes POS N
in POS N
patients POS N
with POS N
refractory POS N
glaucoma POS N
at POS N
1-year POS N
follow-up. POS N

Over POS N
a POS N
follow-up POS N
period POS N
of POS N
1 POS N
year, POS N
no POS N
statistically POS N
significant POS N
differences POS N
were POS N
detected POS N
between POS N
the POS N
Baerveldt-350 POS N
implant POS N
versus POS N
Ahmed POS N
valve POS N
for POS N
IOP POS N
control POS N
(12.1 POS N
+/- POS N
5.3 POS N
mm POS N
Hg POS N
vs POS N
13.6 POS N
+/- POS N
5.6 POS N
mm POS N
Hg POS N
respectively, POS N
at POS N
a POS N
power POS N
of POS N
90% POS N
to POS N
detect POS N
a POS N
difference POS N
of POS N
3.2 POS N
mm POS N
Hg POS N
between POS N
the POS N
two POS N
groups POS N
and POS N
P POS N
= POS N
0.05), POS N
surgical POS N
success POS N
rate POS N
(65.6% POS N
vs. POS N
65.6% POS N
respectively, POS N
complete POS N
and POS N
qualified POS N
combined), POS N
postoperative POS N
hypotony POS N
rate POS N
(37.5% POS N
vs. POS N
34.4% POS N
respectively), POS N
and POS N
visual POS N
acuity POS N
changes POS N
of POS N
more POS N
than POS N
1 POS N
line POS N
in POS N
Snellen POS N
visual POS N
acuity POS N
(43.3% POS N
vs. POS N
29.0% POS N
respectively). POS N

In POS N
a POS N
case-controlled POS N
comparison, POS N
the POS N
Baerveldt-350 POS N
implant POS N
and POS N
the POS N
Ahmed POS N
valve POS N
had POS N
similar POS N
IOP POS N
control POS N
and POS N
surgical POS N
outcomes POS N
in POS N
patients POS N
with POS N
refractory POS N
glaucoma POS N
at POS N
1-year POS N
follow-up. POS N

Surgical POS N
success POS N
rate POS N
was POS N
defined POS N
as POS N
an POS N
IOP POS N
reduction POS N
greater POS N
than POS N
or POS N
equal POS N
to POS N
30% POS N
and POS N
final POS N
IOP POS N
more POS N
than POS N
5 POS N
mm POS N
Hg POS N
and POS N
less POS N
than POS N
22 POS N
mm POS N
Hg, POS N
without POS N
devastating POS N
complications. POS N

Over POS N
a POS N
follow-up POS N
period POS N
of POS N
1 POS N
year, POS N
no POS N
statistically POS N
significant POS N
differences POS N
were POS N
detected POS N
between POS N
the POS N
Baerveldt-350 POS N
implant POS N
versus POS N
Ahmed POS N
valve POS N
for POS N
IOP POS N
control POS N
(12.1 POS N
+/- POS N
5.3 POS N
mm POS N
Hg POS N
vs POS N
13.6 POS N
+/- POS N
5.6 POS N
mm POS N
Hg POS N
respectively, POS N
at POS N
a POS N
power POS N
of POS N
90% POS N
to POS N
detect POS N
a POS N
difference POS N
of POS N
3.2 POS N
mm POS N
Hg POS N
between POS N
the POS N
two POS N
groups POS N
and POS N
P POS N
= POS N
0.05), POS N
surgical POS N
success POS N
rate POS N
(65.6% POS N
vs. POS N
65.6% POS N
respectively, POS N
complete POS N
and POS N
qualified POS N
combined), POS N
postoperative POS N
hypotony POS N
rate POS N
(37.5% POS N
vs. POS N
34.4% POS N
respectively), POS N
and POS N
visual POS N
acuity POS N
changes POS N
of POS N
more POS N
than POS N
1 POS N
line POS N
in POS N
Snellen POS N
visual POS N
acuity POS N
(43.3% POS N
vs. POS N
29.0% POS N
respectively). POS N

In POS N
a POS N
case-controlled POS N
comparison, POS N
the POS N
Baerveldt-350 POS N
implant POS N
and POS N
the POS N
Ahmed POS N
valve POS N
had POS N
similar POS N
IOP POS N
control POS N
and POS N
surgical POS N
outcomes POS N
in POS N
patients POS N
with POS N
refractory POS N
glaucoma POS N
at POS N
1-year POS N
follow-up. POS N

Over POS N
a POS N
follow-up POS N
period POS N
of POS N
1 POS N
year, POS N
no POS N
statistically POS N
significant POS N
differences POS N
were POS N
detected POS N
between POS N
the POS N
Baerveldt-350 POS N
implant POS N
versus POS N
Ahmed POS N
valve POS N
for POS N
IOP POS N
control POS N
(12.1 POS N
+/- POS N
5.3 POS N
mm POS N
Hg POS N
vs POS N
13.6 POS N
+/- POS N
5.6 POS N
mm POS N
Hg POS N
respectively, POS N
at POS N
a POS N
power POS N
of POS N
90% POS N
to POS N
detect POS N
a POS N
difference POS N
of POS N
3.2 POS N
mm POS N
Hg POS N
between POS N
the POS N
two POS N
groups POS N
and POS N
P POS N
= POS N
0.05), POS N
surgical POS N
success POS N
rate POS N
(65.6% POS N
vs. POS N
65.6% POS N
respectively, POS N
complete POS N
and POS N
qualified POS N
combined), POS N
postoperative POS N
hypotony POS N
rate POS N
(37.5% POS N
vs. POS N
34.4% POS N
respectively), POS N
and POS N
visual POS N
acuity POS N
changes POS N
of POS N
more POS N
than POS N
1 POS N
line POS N
in POS N
Snellen POS N
visual POS N
acuity POS N
(43.3% POS N
vs. POS N
29.0% POS N
respectively). POS N

Surgical POS N
success POS N
rate POS N
was POS N
defined POS N
as POS N
an POS N
IOP POS N
reduction POS N
greater POS N
than POS N
or POS N
equal POS N
to POS N
30% POS N
and POS N
final POS N
IOP POS N
more POS N
than POS N
5 POS N
mm POS N
Hg POS N
and POS N
less POS N
than POS N
22 POS N
mm POS N
Hg, POS N
without POS N
devastating POS N
complications. POS N

Surgical POS N
success POS N
rate POS N
was POS N
defined POS N
as POS N
an POS N
IOP POS N
reduction POS N
greater POS N
than POS N
or POS N
equal POS N
to POS N
30% POS N
and POS N
final POS N
IOP POS N
more POS N
than POS N
5 POS N
mm POS N
Hg POS N
and POS N
less POS N
than POS N
22 POS N
mm POS N
Hg, POS N
without POS N
devastating POS N
complications. POS N

In POS N
a POS N
case-controlled POS N
comparison, POS N
the POS N
Baerveldt-350 POS N
implant POS N
and POS N
the POS N
Ahmed POS N
valve POS N
had POS N
similar POS N
IOP POS N
control POS N
and POS N
surgical POS N
outcomes POS N
in POS N
patients POS N
with POS N
refractory POS N
glaucoma POS N
at POS N
1-year POS N
follow-up. POS N

Surgical POS N
success POS N
rate POS N
was POS N
defined POS N
as POS N
an POS N
IOP POS N
reduction POS N
greater POS N
than POS N
or POS N
equal POS N
to POS N
30% POS N
and POS N
final POS N
IOP POS N
more POS N
than POS N
5 POS N
mm POS N
Hg POS N
and POS N
less POS N
than POS N
22 POS N
mm POS N
Hg, POS N
without POS N
devastating POS N
complications. POS N

Over POS N
a POS N
follow-up POS N
period POS N
of POS N
1 POS N
year, POS N
no POS N
statistically POS N
significant POS N
differences POS N
were POS N
detected POS N
between POS N
the POS N
Baerveldt-350 POS N
implant POS N
versus POS N
Ahmed POS N
valve POS N
for POS N
IOP POS N
control POS N
(12.1 POS N
+/- POS N
5.3 POS N
mm POS N
Hg POS N
vs POS N
13.6 POS N
+/- POS N
5.6 POS N
mm POS N
Hg POS N
respectively, POS N
at POS N
a POS N
power POS N
of POS N
90% POS N
to POS N
detect POS N
a POS N
difference POS N
of POS N
3.2 POS N
mm POS N
Hg POS N
between POS N
the POS N
two POS N
groups POS N
and POS N
P POS N
= POS N
0.05), POS N
surgical POS N
success POS N
rate POS N
(65.6% POS N
vs. POS N
65.6% POS N
respectively, POS N
complete POS N
and POS N
qualified POS N
combined), POS N
postoperative POS N
hypotony POS N
rate POS N
(37.5% POS N
vs. POS N
34.4% POS N
respectively), POS N
and POS N
visual POS N
acuity POS N
changes POS N
of POS N
more POS N
than POS N
1 POS N
line POS N
in POS N
Snellen POS N
visual POS N
acuity POS N
(43.3% POS N
vs. POS N
29.0% POS N
respectively). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
period POS N
when POS N
all POS N
patients POS N
were POS N
dosed POS N
in POS N
the POS N
evening POS N
was POS N
assessed POS N
12 POS N
h POS N
after POS N
dosing POS N
at POS N
09:00 POS N
and POS N
it POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
treatment POS N
groups POS N
(mean POS N
+/- POS N
standard POS N
deviation: POS N
17.9 POS N
+/- POS N
2.7 POS N
mmHg POS N
for POS N
travoprost POS N
versus POS N
17.7 POS N
+/- POS N
2.5 POS N
mmHg POS N
for POS N
latanoprost, POS N
p POS N
= POS N
0.812). POS N

In POS N
the POS N
a.m.-dosing POS N
crossover POS N
comparison, POS N
the POS N
24-h POS N
post-dose POS N
IOP POS N
was POS N
significantly POS N
lower POS N
( POS N
p POS N
< POS N
0.001) POS N
on POS N
travoprost POS N
(16.9 POS N
+/- POS N
3.1 POS N
mmHg) POS N
compared POS N
to POS N
latanoprost POS N
(18.6 POS N
+/- POS N
3.3 POS N
mmHg). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
period POS N
when POS N
all POS N
patients POS N
were POS N
dosed POS N
in POS N
the POS N
evening POS N
was POS N
assessed POS N
12 POS N
h POS N
after POS N
dosing POS N
at POS N
09:00 POS N
and POS N
it POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
treatment POS N
groups POS N
(mean POS N
+/- POS N
standard POS N
deviation: POS N
17.9 POS N
+/- POS N
2.7 POS N
mmHg POS N
for POS N
travoprost POS N
versus POS N
17.7 POS N
+/- POS N
2.5 POS N
mmHg POS N
for POS N
latanoprost, POS N
p POS N
= POS N
0.812). POS N

a.m.-dosed POS N
travoprost POS N
is POS N
superior POS N
to POS N
a.m.-dosed POS N
latanoprost POS N
by POS N
1.7 POS N
mmHg POS N
at POS N
24-h POS N
post-dose. POS N

In POS N
the POS N
a.m.-dosing POS N
crossover POS N
comparison, POS N
the POS N
24-h POS N
post-dose POS N
IOP POS N
was POS N
significantly POS N
lower POS N
( POS N
p POS N
< POS N
0.001) POS N
on POS N
travoprost POS N
(16.9 POS N
+/- POS N
3.1 POS N
mmHg) POS N
compared POS N
to POS N
latanoprost POS N
(18.6 POS N
+/- POS N
3.3 POS N
mmHg). POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
period POS N
when POS N
all POS N
patients POS N
were POS N
dosed POS N
in POS N
the POS N
evening POS N
was POS N
assessed POS N
12 POS N
h POS N
after POS N
dosing POS N
at POS N
09:00 POS N
and POS N
it POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
treatment POS N
groups POS N
(mean POS N
+/- POS N
standard POS N
deviation: POS N
17.9 POS N
+/- POS N
2.7 POS N
mmHg POS N
for POS N
travoprost POS N
versus POS N
17.7 POS N
+/- POS N
2.5 POS N
mmHg POS N
for POS N
latanoprost, POS N
p POS N
= POS N
0.812). POS N

In POS N
the POS N
a.m.-dosing POS N
crossover POS N
comparison, POS N
the POS N
24-h POS N
post-dose POS N
IOP POS N
was POS N
significantly POS N
lower POS N
( POS N
p POS N
< POS N
0.001) POS N
on POS N
travoprost POS N
(16.9 POS N
+/- POS N
3.1 POS N
mmHg) POS N
compared POS N
to POS N
latanoprost POS N
(18.6 POS N
+/- POS N
3.3 POS N
mmHg). POS N

a.m.-dosed POS N
travoprost POS N
is POS N
superior POS N
to POS N
a.m.-dosed POS N
latanoprost POS N
by POS N
1.7 POS N
mmHg POS N
at POS N
24-h POS N
post-dose. POS N

a.m.-dosed POS N
travoprost POS N
is POS N
superior POS N
to POS N
a.m.-dosed POS N
latanoprost POS N
by POS N
1.7 POS N
mmHg POS N
at POS N
24-h POS N
post-dose. POS N

The POS N
mean POS N
IOP POS N
in POS N
the POS N
first POS N
period POS N
when POS N
all POS N
patients POS N
were POS N
dosed POS N
in POS N
the POS N
evening POS N
was POS N
assessed POS N
12 POS N
h POS N
after POS N
dosing POS N
at POS N
09:00 POS N
and POS N
it POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
treatment POS N
groups POS N
(mean POS N
+/- POS N
standard POS N
deviation: POS N
17.9 POS N
+/- POS N
2.7 POS N
mmHg POS N
for POS N
travoprost POS N
versus POS N
17.7 POS N
+/- POS N
2.5 POS N
mmHg POS N
for POS N
latanoprost, POS N
p POS N
= POS N
0.812). POS N

a.m.-dosed POS N
travoprost POS N
is POS N
superior POS N
to POS N
a.m.-dosed POS N
latanoprost POS N
by POS N
1.7 POS N
mmHg POS N
at POS N
24-h POS N
post-dose. POS N

In POS N
the POS N
a.m.-dosing POS N
crossover POS N
comparison, POS N
the POS N
24-h POS N
post-dose POS N
IOP POS N
was POS N
significantly POS N
lower POS N
( POS N
p POS N
< POS N
0.001) POS N
on POS N
travoprost POS N
(16.9 POS N
+/- POS N
3.1 POS N
mmHg) POS N
compared POS N
to POS N
latanoprost POS N
(18.6 POS N
+/- POS N
3.3 POS N
mmHg). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Both POS N
fixed POS N
brimonidine-timolol POS N
and POS N
timolol POS N
were POS N
well POS N
tolerated POS N
as POS N
agents POS N
adjunctive POS N
to POS N
latanoprost. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Fixed-combination POS N
brimonidine-timolol POS N
reduced POS N
IOP POS N
significantly POS N
more POS N
effectively POS N
than POS N
timolol POS N
when POS N
used POS N
as POS N
adjunctive POS N
therapy POS N
to POS N
latanoprost POS N
in POS N
patients POS N
with POS N
glaucoma POS N
and POS N
ocular POS N
hypertension. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Biomicroscopy POS N
findings POS N
were POS N
similar POS N
between POS N
the POS N
treatment POS N
groups POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Adverse POS N
events POS N
occurred POS N
in POS N
14.7% POS N
of POS N
fixed POS N
brimonidine-timolol POS N
patients POS N
and POS N
12.7% POS N
of POS N
timolol POS N
patients. POS N

The POS N
mean POS N
additional POS N
reduction POS N
from POS N
latanoprost-treated POS N
baseline POS N
IOP POS N
was POS N
8.3 POS N
mmHg POS N
(35.5%) POS N
with POS N
fixed POS N
brimonidine-timolol POS N
and POS N
6.2 POS N
mmHg POS N
(27.0%) POS N
with POS N
timolol POS N
at POS N
10 POS N
am, POS N
week POS N
12 POS N
(P POS N
< POS N
0.001). POS N

Patients POS N
treated POS N
with POS N
fixed POS N
brimonidine-timolol POS N
adjunctive POS N
to POS N
latanoprost POS N
were POS N
significantly POS N
more POS N
likely POS N
than POS N
patients POS N
treated POS N
with POS N
adjunctive POS N
timolol POS N
to POS N
achieve POS N
an POS N
IOP POS N
<18 POS N
mmHg POS N
(P POS N
= POS N
0.028) POS N
and POS N
a POS N
 POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
(P POS N
= POS N
0.047) POS N
at POS N
both POS N
8 POS N
am POS N
and POS N
10 POS N
am POS N
in POS N
week POS N
12. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

From POS N
an POS N
overall POS N
baseline POS N
mean POS N
intraocular POS N
pressure POS N
of POS N
25.0 POS N
mm POS N
Hg, POS N
latanoprost POS N
monotherapy POS N
reduced POS N
mean POS N
diurnal POS N
intraocular POS N
pressure POS N
by POS N
7.1 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
(mean POS N
+/- POS N
SD, POS N
P POS N
< POS N
0.001), POS N
whereas POS N
brimonidine POS N
monotherapy POS N
yielded POS N
an POS N
intraocular-pressure POS N
reduction POS N
of POS N
5.2 POS N
+/- POS N
3.5 POS N
mm POS N
Hg POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

This POS N
1.9 POS N
mm POS N
Hg POS N
difference POS N
in POS N
intraocular-pressure POS N
reduction POS N
was POS N
significantly POS N
in POS N
favor POS N
of POS N
latanoprost POS N
(P POS N
< POS N
0.001). POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

Ocular POS N
allergy POS N
(P POS N
< POS N
0.001) POS N
and POS N
systemic POS N
side POS N
effects POS N
(P POS N
= POS N
0.005) POS N
were POS N
reported POS N
significantly POS N
less POS N
frequently POS N
by POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
brimonidine-treated POS N
patients. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

Both POS N
latanoprost POS N
and POS N
brimonidine POS N
reduced POS N
intraocular POS N
pressure POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension POS N
after POS N
6 POS N
months POS N
of POS N
treatment. POS N

Latanoprost POS N
was POS N
better POS N
tolerated POS N
with POS N
less POS N
frequently POS N
occurring POS N
ocular POS N
allergy POS N
and POS N
systemic POS N
side POS N
effects. POS N

However, POS N
latanoprost POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
than POS N
brimonidine POS N
twice POS N
daily POS N
in POS N
reducing POS N
mean POS N
diurnal POS N
intraocular POS N
pressure. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Both POS N
latanoprost POS N
and POS N
timolol POS N
had POS N
favorable POS N
safety POS N
profiles POS N
over POS N
the POS N
duration POS N
of POS N
this POS N
3-month POS N
trial. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Mean POS N
IOP POS N
reductions POS N
for POS N
latanoprost POS N
and POS N
timolol POS N
at POS N
week POS N
12 POS N
were POS N
7.2 POS N
and POS N
5.7 POS N
mmHg, POS N
respectively, POS N
with POS N
a POS N
difference POS N
of POS N
1.5 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
3.7; POS N
P=0.21). POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Responder POS N
rates POS N
were POS N
60% POS N
for POS N
latanoprost POS N
and POS N
52% POS N
for POS N
timolol POS N
(P=0.33). POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Between-treatment POS N
differences POS N
in POS N
mean POS N
IOP POS N
reduction POS N
for POS N
PCG POS N
and POS N
non-PCG POS N
subgroups POS N
were POS N
0.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-2.3 POS N
to POS N
3.4) POS N
and POS N
2.6 POS N
mmHg POS N
(95% POS N
CI, POS N
-0.8 POS N
to POS N
6.1), POS N
respectively. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Responder POS N
rates POS N
for POS N
latanoprost POS N
versus POS N
timolol POS N
were POS N
50% POS N
versus POS N
46% POS N
for POS N
the POS N
PCG POS N
group POS N
and POS N
72% POS N
versus POS N
57% POS N
for POS N
the POS N
non-PCG POS N
group. POS N

Both POS N
therapies POS N
were POS N
well POS N
tolerated. POS N

Latanoprost POS N
0.005% POS N
is POS N
not POS N
inferior POS N
(i.e., POS N
is POS N
either POS N
more POS N
or POS N
similarly POS N
effective) POS N
to POS N
timolol POS N
and POS N
produces POS N
clinically POS N
relevant POS N
IOP POS N
reductions POS N
across POS N
pediatric POS N
patients POS N
with POS N
and POS N
without POS N
PCG. POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

No POS N
clinically POS N
relevant POS N
differences POS N
in POS N
the POS N
safety POS N
profiles POS N
of POS N
travoprost/timolol POS N
BAK-free POS N
and POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
were POS N
identified. POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

Travoprost/timolol POS N
BAK-free POS N
demonstrated POS N
equivalence POS N
to POS N
travoprost/timolol POS N
preserved POS N
with POS N
BAK POS N
in POS N
efficacy. POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

Mean POS N
IOP POS N
reduction POS N
across POS N
all POS N
visits POS N
and POS N
time POS N
points POS N
was POS N
8.0 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
8.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
TRA/TIM POS N
group POS N
(P=0.0943). POS N

The POS N
most POS N
common POS N
drug-related POS N
adverse POS N
event POS N
was POS N
hyperemia POS N
of POS N
the POS N
eye POS N
(ocular POS N
hyperemia POS N
and POS N
conjunctival POS N
hyperemia POS N
combined), POS N
occurring POS N
in POS N
11.8% POS N
of POS N
the POS N
TRA/TIM POS N
BAK-free POS N
group POS N
and POS N
13.0% POS N
of POS N
the POS N
TRA/TIM POS N
group. POS N

The POS N
difference POS N
in POS N
mean POS N
IOP POS N
between POS N
groups POS N
ranged POS N
from POS N
0.2 POS N
to POS N
0.7 POS N
 POS N
mm POS N
Hg POS N
across POS N
visits POS N
and POS N
time POS N
points, POS N
with POS N
a POS N
mean POS N
pooled POS N
difference POS N
of POS N
0.4 POS N
 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-0.1 POS N
to POS N
0.8), POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
unoprostone POS N
administered POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
OH. POS N

From POS N
an POS N
overall POS N
baseline POS N
of POS N
24.1 POS N
mmHg, POS N
latanoprost POS N
reduced POS N
IOP POS N
by POS N
6.7 POS N
mmHg POS N
(28%) POS N
and POS N
unoprostone POS N
reduced POS N
IOP POS N
by POS N
3.3 POS N
mmHg POS N
(14%). POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
unoprostone POS N
administered POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
OH. POS N

The POS N
difference POS N
between POS N
the POS N
groups POS N
of POS N
3.4 POS N
mmHg POS N
was POS N
significant POS N
(P: POS N
< POS N
0.001, POS N
analysis POS N
of POS N
covariance; POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
-4.7 POS N
to POS N
-2.1) POS N
in POS N
favor POS N
of POS N
latanoprost. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
unoprostone POS N
administered POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
OH. POS N

A POS N
>/=30% POS N
reduction POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline POS N
was POS N
achieved POS N
by POS N
44% POS N
of POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
8% POS N
of POS N
unoprostone-treated POS N
patients. POS N

From POS N
an POS N
overall POS N
baseline POS N
of POS N
24.1 POS N
mmHg, POS N
latanoprost POS N
reduced POS N
IOP POS N
by POS N
6.7 POS N
mmHg POS N
(28%) POS N
and POS N
unoprostone POS N
reduced POS N
IOP POS N
by POS N
3.3 POS N
mmHg POS N
(14%). POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
unoprostone POS N
administered POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
OH. POS N

From POS N
an POS N
overall POS N
baseline POS N
of POS N
24.1 POS N
mmHg, POS N
latanoprost POS N
reduced POS N
IOP POS N
by POS N
6.7 POS N
mmHg POS N
(28%) POS N
and POS N
unoprostone POS N
reduced POS N
IOP POS N
by POS N
3.3 POS N
mmHg POS N
(14%). POS N

The POS N
difference POS N
between POS N
the POS N
groups POS N
of POS N
3.4 POS N
mmHg POS N
was POS N
significant POS N
(P: POS N
< POS N
0.001, POS N
analysis POS N
of POS N
covariance; POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
-4.7 POS N
to POS N
-2.1) POS N
in POS N
favor POS N
of POS N
latanoprost. POS N

From POS N
an POS N
overall POS N
baseline POS N
of POS N
24.1 POS N
mmHg, POS N
latanoprost POS N
reduced POS N
IOP POS N
by POS N
6.7 POS N
mmHg POS N
(28%) POS N
and POS N
unoprostone POS N
reduced POS N
IOP POS N
by POS N
3.3 POS N
mmHg POS N
(14%). POS N

A POS N
>/=30% POS N
reduction POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline POS N
was POS N
achieved POS N
by POS N
44% POS N
of POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
8% POS N
of POS N
unoprostone-treated POS N
patients. POS N

The POS N
difference POS N
between POS N
the POS N
groups POS N
of POS N
3.4 POS N
mmHg POS N
was POS N
significant POS N
(P: POS N
< POS N
0.001, POS N
analysis POS N
of POS N
covariance; POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
-4.7 POS N
to POS N
-2.1) POS N
in POS N
favor POS N
of POS N
latanoprost. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
unoprostone POS N
administered POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
OH. POS N

The POS N
difference POS N
between POS N
the POS N
groups POS N
of POS N
3.4 POS N
mmHg POS N
was POS N
significant POS N
(P: POS N
< POS N
0.001, POS N
analysis POS N
of POS N
covariance; POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
-4.7 POS N
to POS N
-2.1) POS N
in POS N
favor POS N
of POS N
latanoprost. POS N

From POS N
an POS N
overall POS N
baseline POS N
of POS N
24.1 POS N
mmHg, POS N
latanoprost POS N
reduced POS N
IOP POS N
by POS N
6.7 POS N
mmHg POS N
(28%) POS N
and POS N
unoprostone POS N
reduced POS N
IOP POS N
by POS N
3.3 POS N
mmHg POS N
(14%). POS N

The POS N
difference POS N
between POS N
the POS N
groups POS N
of POS N
3.4 POS N
mmHg POS N
was POS N
significant POS N
(P: POS N
< POS N
0.001, POS N
analysis POS N
of POS N
covariance; POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
-4.7 POS N
to POS N
-2.1) POS N
in POS N
favor POS N
of POS N
latanoprost. POS N

A POS N
>/=30% POS N
reduction POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline POS N
was POS N
achieved POS N
by POS N
44% POS N
of POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
8% POS N
of POS N
unoprostone-treated POS N
patients. POS N

A POS N
>/=30% POS N
reduction POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline POS N
was POS N
achieved POS N
by POS N
44% POS N
of POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
8% POS N
of POS N
unoprostone-treated POS N
patients. POS N

Latanoprost POS N
administered POS N
once POS N
daily POS N
was POS N
significantly POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
compared POS N
with POS N
unoprostone POS N
administered POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
OH. POS N

A POS N
>/=30% POS N
reduction POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline POS N
was POS N
achieved POS N
by POS N
44% POS N
of POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
8% POS N
of POS N
unoprostone-treated POS N
patients. POS N

From POS N
an POS N
overall POS N
baseline POS N
of POS N
24.1 POS N
mmHg, POS N
latanoprost POS N
reduced POS N
IOP POS N
by POS N
6.7 POS N
mmHg POS N
(28%) POS N
and POS N
unoprostone POS N
reduced POS N
IOP POS N
by POS N
3.3 POS N
mmHg POS N
(14%). POS N

A POS N
>/=30% POS N
reduction POS N
in POS N
mean POS N
IOP POS N
from POS N
baseline POS N
was POS N
achieved POS N
by POS N
44% POS N
of POS N
latanoprost-treated POS N
patients POS N
compared POS N
with POS N
8% POS N
of POS N
unoprostone-treated POS N
patients. POS N

The POS N
difference POS N
between POS N
the POS N
groups POS N
of POS N
3.4 POS N
mmHg POS N
was POS N
significant POS N
(P: POS N
< POS N
0.001, POS N
analysis POS N
of POS N
covariance; POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
-4.7 POS N
to POS N
-2.1) POS N
in POS N
favor POS N
of POS N
latanoprost. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

Decreases POS N
in POS N
mean POS N
diurnal POS N
IOP POS N
from POS N
baseline POS N
were POS N
significantly POS N
greater POS N
for POS N
latanoprost POS N
than POS N
for POS N
non-PGs POS N
at POS N
months POS N
6 POS N
and POS N
12 POS N
(p POS N
< POS N
0.01). POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

No POS N
serious POS N
adverse POS N
events POS N
were POS N
judged POS N
to POS N
be POS N
treatment-related POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

Mean POS N
total POS N
36-month POS N
direct POS N
costs POS N
were POS N
similar POS N
in POS N
patients POS N
initiated POS N
with POS N
latanoprost POS N
and POS N
non-PGs. POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

Patients POS N
who POS N
failed POS N
previous POS N
monotherapy POS N
remained POS N
on POS N
therapy POS N
longer POS N
when POS N
switched POS N
to POS N
latanoprost. POS N

Resource POS N
utilization POS N
and POS N
costs POS N
were POS N
generally POS N
similar POS N
in POS N
those POS N
initiating POS N
latanoprost POS N
or POS N
non-PG POS N
therapy. POS N

The POS N
IOP-reducing POS N
effect POS N
of POS N
latanoprost POS N
and POS N
tolerability POS N
were POS N
sustained POS N
over POS N
the POS N
long POS N
term. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

the POS N
complication POS N
rate POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

At POS N
3 POS N
years, POS N
the POS N
mean POS N
IOP POS N
was POS N
16.0 POS N
mmHg POS N
+/- POS N
7.07 POS N
(SD) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
17.8 POS N
+/- POS N
4.6 POS N
mmHg POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.694). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Complete POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mm POS N
Hg POS N
without POS N
medication) POS N
was POS N
achieved POS N
in POS N
66.2% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
55.1% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
52.9% POS N
and POS N
35.3%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Qualified POS N
success POS N
(IOP POS N
6 POS N
to POS N
21 POS N
mmHg POS N
with POS N
medication) POS N
was POS N
achieved POS N
in POS N
95.8% POS N
of POS N
eyes POS N
at POS N
6 POS N
months POS N
and POS N
79.2% POS N
at POS N
3 POS N
years POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
90.7% POS N
and POS N
73.9%, POS N
respectively, POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P>.05). POS N

Primary POS N
trabeculectomy POS N
lowered POS N
IOP POS N
more POS N
than POS N
viscocanalostomy POS N
in POS N
POAG POS N
patients. POS N

Postoperative POS N
hypotony POS N
and POS N
cataract POS N
formation POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
than POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
(P=.002). POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

Baseline POS N
mean POS N
IOP POS N
for POS N
all POS N
eyes POS N
was POS N
24.5 POS N
mm POS N
Hg POS N
in POS N
the POS N
SLT POS N
group, POS N
24.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
medical POS N
group. POS N
Mean POS N
IOP POS N
(both POS N
eyes) POS N
at POS N
last POS N
follow-up POS N
was POS N
18.2 POS N
mm POS N
Hg POS N
(6.3 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
SLT POS N
arm, POS N
17.7 POS N
mm POS N
Hg POS N
(7.0 POS N
mm POS N
Hg POS N
reduction) POS N
in POS N
the POS N
medical POS N
arm. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

These POS N
results POS N
support POS N
the POS N
option POS N
of POS N
SLT POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
initial POS N
therapy POS N
in POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

By POS N
last POS N
follow-up, POS N
11% POS N
of POS N
eyes POS N
received POS N
additional POS N
SLT, POS N
27% POS N
required POS N
additional POS N
medication. POS N

IOP POS N
reduction POS N
was POS N
similar POS N
in POS N
both POS N
arms POS N
after POS N
9 POS N
to POS N
12-months POS N
follow-up. POS N

There POS N
was POS N
not POS N
a POS N
statistically POS N
significant POS N
difference POS N
between POS N
the POS N
SLT POS N
and POS N
medication POS N
groups. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
6 POS N
months POS N
(range, POS N
6-8 POS N
months), POS N
success POS N
was POS N
obtained POS N
in POS N
5 POS N
of POS N
10 POS N
cases POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
0 POS N
of POS N
10 POS N
case POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

With POS N
Kaplan-Meier's POS N
method, POS N
subjects POS N
with POS N
viscocanalostomy POS N
showed POS N
shorter POS N
postoperative POS N
IOP-reduction POS N
periods POS N
than POS N
subjects POS N
undergoing POS N
trabeculectomy. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
6 POS N
months POS N
(range, POS N
6-8 POS N
months), POS N
success POS N
was POS N
obtained POS N
in POS N
5 POS N
of POS N
10 POS N
cases POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
0 POS N
of POS N
10 POS N
case POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

According POS N
to POS N
the POS N
results POS N
of POS N
this POS N
short-term POS N
study, POS N
trabeculectomy POS N
was POS N
more POS N
effective POS N
than POS N
viscocanalostomy POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes POS N
of POS N
white POS N
patients. POS N

With POS N
Kaplan-Meier's POS N
method, POS N
subjects POS N
with POS N
viscocanalostomy POS N
showed POS N
shorter POS N
postoperative POS N
IOP-reduction POS N
periods POS N
than POS N
subjects POS N
undergoing POS N
trabeculectomy. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
6 POS N
months POS N
(range, POS N
6-8 POS N
months), POS N
success POS N
was POS N
obtained POS N
in POS N
5 POS N
of POS N
10 POS N
cases POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
0 POS N
of POS N
10 POS N
case POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

With POS N
Kaplan-Meier's POS N
method, POS N
subjects POS N
with POS N
viscocanalostomy POS N
showed POS N
shorter POS N
postoperative POS N
IOP-reduction POS N
periods POS N
than POS N
subjects POS N
undergoing POS N
trabeculectomy. POS N

According POS N
to POS N
the POS N
results POS N
of POS N
this POS N
short-term POS N
study, POS N
trabeculectomy POS N
was POS N
more POS N
effective POS N
than POS N
viscocanalostomy POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes POS N
of POS N
white POS N
patients. POS N

According POS N
to POS N
the POS N
results POS N
of POS N
this POS N
short-term POS N
study, POS N
trabeculectomy POS N
was POS N
more POS N
effective POS N
than POS N
viscocanalostomy POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes POS N
of POS N
white POS N
patients. POS N

After POS N
a POS N
mean POS N
follow-up POS N
of POS N
6 POS N
months POS N
(range, POS N
6-8 POS N
months), POS N
success POS N
was POS N
obtained POS N
in POS N
5 POS N
of POS N
10 POS N
cases POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
in POS N
0 POS N
of POS N
10 POS N
case POS N
in POS N
the POS N
viscocanalostomy POS N
group. POS N

According POS N
to POS N
the POS N
results POS N
of POS N
this POS N
short-term POS N
study, POS N
trabeculectomy POS N
was POS N
more POS N
effective POS N
than POS N
viscocanalostomy POS N
in POS N
lowering POS N
IOP POS N
in POS N
glaucomatous POS N
eyes POS N
of POS N
white POS N
patients. POS N

With POS N
Kaplan-Meier's POS N
method, POS N
subjects POS N
with POS N
viscocanalostomy POS N
showed POS N
shorter POS N
postoperative POS N
IOP-reduction POS N
periods POS N
than POS N
subjects POS N
undergoing POS N
trabeculectomy. POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

In POS N
eyes POS N
with POS N
open-angle POS N
glaucoma, POS N
viscocanalostomy POS N
is POS N
less POS N
effective POS N
in POS N
reducing POS N
intraocular POS N
pressure POS N
than POS N
standard POS N
filtering POS N
surgery. POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

One POS N
day POS N
after POS N
surgery, POS N
mean POS N
(SD) POS N
intraocular POS N
pressure POS N
was POS N
15.9 POS N
(5.2) POS N
for POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
<0.001) POS N
and POS N
15.7 POS N
(3.6) POS N
for POS N
the POS N
viscocanalostomy POS N
group POS N
(P POS N
<0.001), POS N
respectively. POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

The POS N
success POS N
rate, POS N
defined POS N
as POS N
an POS N
intraocular POS N
pressure POS N
lower POS N
than POS N
22 POS N
mm POS N
Hg POS N
without POS N
medication, POS N
was POS N
56.7% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
and POS N
30% POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
at POS N
12 POS N
months POS N
postoperatively POS N
(P POS N
= POS N
0.041). POS N

postoperative POS N
complications POS N
are POS N
more POS N
frequent POS N
after POS N
filtering POS N
surgery. POS N

The POS N
number POS N
of POS N
postoperative POS N
complications POS N
was POS N
lower POS N
in POS N
the POS N
viscocanalostomy POS N
group POS N
than POS N
in POS N
the POS N
trabeculectomy POS N
group. POS N

Both POS N
agents POS N
were POS N
safe POS N
and POS N
well POS N
tolerated. POS N

Over POS N
an POS N
8-week POS N
period, POS N
latanoprost POS N
0.005% POS N
once POS N
daily POS N
lowered POS N
IOP POS N
more POS N
than POS N
unoprostone POS N
0.15% POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP. POS N

Both POS N
agents POS N
were POS N
safe POS N
and POS N
well POS N
tolerated. POS N

The POS N
change POS N
in POS N
the POS N
mean POS N
+/- POS N
SD POS N
of POS N
the POS N
IOPs POS N
measured POS N
at POS N
8:00 POS N
AM, POS N
12 POS N
noon, POS N
and POS N
4:00 POS N
PM POS N
was POS N
-7.2 POS N
+/- POS N
3.2 POS N
mm POS N
Hg POS N
(28%) POS N
for POS N
latanoprost POS N
(25.3 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
18.2 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
8 POS N
weeks) POS N
and POS N
-3.9 POS N
+/- POS N
2.6 POS N
mm POS N
Hg POS N
(15%) POS N
for POS N
unoprostone POS N
(25.5 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
21.6 POS N
+/- POS N
4.0 POS N
mm POS N
Hg; POS N
P POS N
<or=.001. POS N

Both POS N
agents POS N
were POS N
safe POS N
and POS N
well POS N
tolerated. POS N

No POS N
serious POS N
adverse POS N
event POS N
related POS N
to POS N
either POS N
medication POS N
was POS N
reported. POS N

Over POS N
an POS N
8-week POS N
period, POS N
latanoprost POS N
0.005% POS N
once POS N
daily POS N
lowered POS N
IOP POS N
more POS N
than POS N
unoprostone POS N
0.15% POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP. POS N

Both POS N
agents POS N
were POS N
safe POS N
and POS N
well POS N
tolerated. POS N

Over POS N
an POS N
8-week POS N
period, POS N
latanoprost POS N
0.005% POS N
once POS N
daily POS N
lowered POS N
IOP POS N
more POS N
than POS N
unoprostone POS N
0.15% POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP. POS N

The POS N
change POS N
in POS N
the POS N
mean POS N
+/- POS N
SD POS N
of POS N
the POS N
IOPs POS N
measured POS N
at POS N
8:00 POS N
AM, POS N
12 POS N
noon, POS N
and POS N
4:00 POS N
PM POS N
was POS N
-7.2 POS N
+/- POS N
3.2 POS N
mm POS N
Hg POS N
(28%) POS N
for POS N
latanoprost POS N
(25.3 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
18.2 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
8 POS N
weeks) POS N
and POS N
-3.9 POS N
+/- POS N
2.6 POS N
mm POS N
Hg POS N
(15%) POS N
for POS N
unoprostone POS N
(25.5 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
21.6 POS N
+/- POS N
4.0 POS N
mm POS N
Hg; POS N
P POS N
<or=.001. POS N

Over POS N
an POS N
8-week POS N
period, POS N
latanoprost POS N
0.005% POS N
once POS N
daily POS N
lowered POS N
IOP POS N
more POS N
than POS N
unoprostone POS N
0.15% POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP. POS N

No POS N
serious POS N
adverse POS N
event POS N
related POS N
to POS N
either POS N
medication POS N
was POS N
reported. POS N

The POS N
change POS N
in POS N
the POS N
mean POS N
+/- POS N
SD POS N
of POS N
the POS N
IOPs POS N
measured POS N
at POS N
8:00 POS N
AM, POS N
12 POS N
noon, POS N
and POS N
4:00 POS N
PM POS N
was POS N
-7.2 POS N
+/- POS N
3.2 POS N
mm POS N
Hg POS N
(28%) POS N
for POS N
latanoprost POS N
(25.3 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
18.2 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
8 POS N
weeks) POS N
and POS N
-3.9 POS N
+/- POS N
2.6 POS N
mm POS N
Hg POS N
(15%) POS N
for POS N
unoprostone POS N
(25.5 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
21.6 POS N
+/- POS N
4.0 POS N
mm POS N
Hg; POS N
P POS N
<or=.001. POS N

Both POS N
agents POS N
were POS N
safe POS N
and POS N
well POS N
tolerated. POS N

The POS N
change POS N
in POS N
the POS N
mean POS N
+/- POS N
SD POS N
of POS N
the POS N
IOPs POS N
measured POS N
at POS N
8:00 POS N
AM, POS N
12 POS N
noon, POS N
and POS N
4:00 POS N
PM POS N
was POS N
-7.2 POS N
+/- POS N
3.2 POS N
mm POS N
Hg POS N
(28%) POS N
for POS N
latanoprost POS N
(25.3 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
18.2 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
8 POS N
weeks) POS N
and POS N
-3.9 POS N
+/- POS N
2.6 POS N
mm POS N
Hg POS N
(15%) POS N
for POS N
unoprostone POS N
(25.5 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
21.6 POS N
+/- POS N
4.0 POS N
mm POS N
Hg; POS N
P POS N
<or=.001. POS N

Over POS N
an POS N
8-week POS N
period, POS N
latanoprost POS N
0.005% POS N
once POS N
daily POS N
lowered POS N
IOP POS N
more POS N
than POS N
unoprostone POS N
0.15% POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP. POS N

The POS N
change POS N
in POS N
the POS N
mean POS N
+/- POS N
SD POS N
of POS N
the POS N
IOPs POS N
measured POS N
at POS N
8:00 POS N
AM, POS N
12 POS N
noon, POS N
and POS N
4:00 POS N
PM POS N
was POS N
-7.2 POS N
+/- POS N
3.2 POS N
mm POS N
Hg POS N
(28%) POS N
for POS N
latanoprost POS N
(25.3 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
18.2 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
8 POS N
weeks) POS N
and POS N
-3.9 POS N
+/- POS N
2.6 POS N
mm POS N
Hg POS N
(15%) POS N
for POS N
unoprostone POS N
(25.5 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
21.6 POS N
+/- POS N
4.0 POS N
mm POS N
Hg; POS N
P POS N
<or=.001. POS N

No POS N
serious POS N
adverse POS N
event POS N
related POS N
to POS N
either POS N
medication POS N
was POS N
reported. POS N

No POS N
serious POS N
adverse POS N
event POS N
related POS N
to POS N
either POS N
medication POS N
was POS N
reported. POS N

Both POS N
agents POS N
were POS N
safe POS N
and POS N
well POS N
tolerated. POS N

No POS N
serious POS N
adverse POS N
event POS N
related POS N
to POS N
either POS N
medication POS N
was POS N
reported. POS N

Over POS N
an POS N
8-week POS N
period, POS N
latanoprost POS N
0.005% POS N
once POS N
daily POS N
lowered POS N
IOP POS N
more POS N
than POS N
unoprostone POS N
0.15% POS N
twice POS N
daily POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP. POS N

No POS N
serious POS N
adverse POS N
event POS N
related POS N
to POS N
either POS N
medication POS N
was POS N
reported. POS N

The POS N
change POS N
in POS N
the POS N
mean POS N
+/- POS N
SD POS N
of POS N
the POS N
IOPs POS N
measured POS N
at POS N
8:00 POS N
AM, POS N
12 POS N
noon, POS N
and POS N
4:00 POS N
PM POS N
was POS N
-7.2 POS N
+/- POS N
3.2 POS N
mm POS N
Hg POS N
(28%) POS N
for POS N
latanoprost POS N
(25.3 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
18.2 POS N
+/- POS N
2.8 POS N
mm POS N
Hg POS N
at POS N
8 POS N
weeks) POS N
and POS N
-3.9 POS N
+/- POS N
2.6 POS N
mm POS N
Hg POS N
(15%) POS N
for POS N
unoprostone POS N
(25.5 POS N
+/- POS N
3.3 POS N
mm POS N
Hg POS N
at POS N
baseline POS N
to POS N
21.6 POS N
+/- POS N
4.0 POS N
mm POS N
Hg; POS N
P POS N
<or=.001. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Significantly POS N
higher POS N
number POS N
of POS N
eyes POS N
belonging POS N
to POS N
group POS N
A POS N
(14 POS N
eyes) POS N
had POS N
shallower POS N
anterior POS N
chamber POS N
than POS N
group POS N
B POS N
(7 POS N
eyes) POS N
on POS N
first POS N
post POS N
operative POS N
day POS N
(p=0.042). POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Six POS N
eyes POS N
(30%) POS N
in POS N
group POS N
A POS N
had POS N
peripheral POS N
or POS N
central POS N
irido-corneal POS N
touch POS N
in POS N
early POS N
postoperative POS N
period POS N
as POS N
compared POS N
to POS N
only POS N
one POS N
in POS N
Group POS N
B. POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Both POS N
the POS N
groups POS N
had POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
surgery POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

there POS N
was POS N
no POS N
significant POS N
difference POS N
in POS N
the POS N
IOP POS N
between POS N
the POS N
two POS N
groups POS N
after POS N
6 POS N
weeks POS N
(Group POS N
A: POS N
10.95 POS N
+/- POS N
3.03 POS N
mmHg POS N
vs. POS N
Group POS N
B: POS N
12.29 POS N
+/- POS N
4.67 POS N
mmHg; POS N
p=0.87). POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

There POS N
was POS N
a POS N
significant POS N
drop POS N
in POS N
IOP POS N
following POS N
removal POS N
of POS N
sutures POS N
(15.19 POS N
+/- POS N
6.15 POS N
mmHg POS N
to POS N
13.19 POS N
+/- POS N
6.13 POS N
mmHg; POS N
p=006) POS N
in POS N
group POS N
B. POS N

Hypotony POS N
was POS N
noted POS N
in POS N
3 POS N
eyes POS N
in POS N
each POS N
group. POS N

Use POS N
of POS N
combination POS N
of POS N
permanent POS N
and POS N
releasable POS N
scleral POS N
flap POS N
sutures POS N
is POS N
a POS N
safe POS N
technique POS N
that POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
immediate POS N
postoperative POS N
shallow POS N
anterior POS N
chamber POS N
after POS N
trabeculectomy. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

Study POS N
attrition POS N
was POS N
large. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Study POS N
attrition POS N
was POS N
large. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Study POS N
attrition POS N
was POS N
large. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

Study POS N
attrition POS N
was POS N
large. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Study POS N
attrition POS N
was POS N
large. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

Study POS N
attrition POS N
was POS N
large. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Study POS N
attrition POS N
was POS N
large. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Study POS N
attrition POS N
was POS N
large. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

Study POS N
attrition POS N
was POS N
large. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

Study POS N
attrition POS N
was POS N
large. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Study POS N
attrition POS N
was POS N
large. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Study POS N
attrition POS N
was POS N
large. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Study POS N
attrition POS N
was POS N
large. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

Study POS N
attrition POS N
was POS N
large. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Study POS N
attrition POS N
was POS N
large. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Study POS N
attrition POS N
was POS N
large. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Study POS N
attrition POS N
was POS N
large. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Increased POS N
intraocular POS N
pressure POS N
(IOP) POS N
has POS N
been POS N
shown POS N
to POS N
be POS N
one POS N
of POS N
the POS N
most POS N
important POS N
risk POS N
factors POS N
for POS N
developing POS N
glaucoma. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

After POS N
5 POS N
years POS N
of POS N
follow-up POS N
eight POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
five POS N
patients POS N
in POS N
the POS N
timolol POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
(NS); POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

the POS N
corresponding POS N
figures POS N
after POS N
10 POS N
years POS N
were POS N
15 POS N
patients POS N
in POS N
the POS N
placebo POS N
group POS N
and POS N
seven POS N
patients POS N
in POS N
the POS N
timolol POS N
group. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Survival POS N
analysis POS N
showed POS N
a POS N
tendency POS N
but POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
treatment POS N
groups POS N
(P POS N
= POS N
0.07). POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Study POS N
attrition POS N
was POS N
large. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

Eighteen POS N
patients POS N
in POS N
each POS N
group POS N
had POS N
developed POS N
glaucomatous POS N
field POS N
loss POS N
when POS N
also POS N
post-study POS N
data POS N
were POS N
included. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

IOP POS N
reduction POS N
was POS N
greater POS N
in POS N
eyes POS N
passing POS N
the POS N
10-year POS N
visit POS N
without POS N
field POS N
loss POS N
(5.7 POS N
mmHg), POS N
than POS N
in POS N
those POS N
that POS N
reached POS N
an POS N
end-point POS N
(2.3 POS N
mmHg; POS N
P POS N
= POS N
0.0002). POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

In POS N
this POS N
long-term POS N
study POS N
we POS N
found POS N
a POS N
tendency POS N
but POS N
failed POS N
to POS N
prove POS N
a POS N
beneficial POS N
effect POS N
of POS N
topical POS N
timolol POS N
treatment POS N
in POS N
patients POS N
with POS N
elevated POS N
IOP, POS N
normal POS N
visual POS N
fields POS N
and POS N
some POS N
additional POS N
risk POS N
factor. POS N

The POS N
high POS N
attrition POS N
shows POS N
the POS N
difficulties POS N
associated POS N
with POS N
very POS N
long POS N
follow-up. POS N

The POS N
intent-to-treat POS N
analysis POS N
showed POS N
no POS N
difference POS N
between POS N
treatment POS N
groups. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Compared POS N
with POS N
baseline POS N
measurements, POS N
both POS N
latanoprost POS N
and POS N
timolol POS N
caused POS N
a POS N
significant POS N
(P POS N
< POS N
0.001) POS N
reduction POS N
of POS N
IOP POS N
at POS N
each POS N
hour POS N
of POS N
diurnal POS N
curve POS N
throughout POS N
the POS N
duration POS N
of POS N
therapy. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Reduction POS N
of POS N
IOP POS N
was POS N
6.0 POS N
+/- POS N
4.5 POS N
and POS N
5.9 POS N
+/- POS N
4.6 POS N
with POS N
latanoprost POS N
and POS N
4.8 POS N
+/- POS N
3.0 POS N
and POS N
4.6 POS N
+/- POS N
3.1 POS N
with POS N
timolol POS N
after POS N
6 POS N
and POS N
12 POS N
months, POS N
respectively. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Comparison POS N
of POS N
mean POS N
diurnal POS N
measurements POS N
with POS N
latanoprost POS N
and POS N
timolol POS N
showed POS N
a POS N
statistical POS N
significant POS N
(P POS N
< POS N
0.001) POS N
difference POS N
at POS N
3, POS N
6, POS N
and POS N
12 POS N
months. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Mean POS N
C POS N
was POS N
found POS N
to POS N
be POS N
significantly POS N
enhanced POS N
(+30%) POS N
only POS N
in POS N
the POS N
latanoprost-treated POS N
group POS N
compared POS N
with POS N
the POS N
baseline POS N
(P POS N
= POS N
0.017). POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

Mean POS N
conjunctival POS N
hyperemia POS N
was POS N
graded POS N
at POS N
0.3 POS N
in POS N
latanoprost-treated POS N
eyes POS N
and POS N
0.2 POS N
in POS N
timolol-treated POS N
eyes. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

A POS N
remarkable POS N
change POS N
in POS N
iris POS N
color POS N
was POS N
observed POS N
in POS N
both POS N
eyes POS N
of POS N
1 POS N
of POS N
the POS N
18 POS N
patients POS N
treated POS N
with POS N
latanoprost POS N
and POS N
none POS N
of POS N
the POS N
18 POS N
patients POS N
who POS N
received POS N
timolol. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

In POS N
the POS N
timolol POS N
group, POS N
heart POS N
rate POS N
was POS N
significantly POS N
reduced POS N
from POS N
72 POS N
+/- POS N
9 POS N
at POS N
baseline POS N
to POS N
67 POS N
+/- POS N
10 POS N
beats POS N
per POS N
minute POS N
at POS N
12 POS N
months. POS N

further POS N
studies POS N
may POS N
need POS N
to POS N
confirm POS N
these POS N
data POS N
on POS N
a POS N
larger POS N
sample POS N
and POS N
to POS N
evaluate POS N
the POS N
side POS N
effect POS N
of POS N
increased POS N
iris POS N
pigmentation POS N
on POS N
long-term POS N
follow-up, POS N

in POS N
patients POS N
with POS N
pigmentary POS N
glaucoma, POS N
0.005% POS N
latanoprost POS N
taken POS N
once POS N
daily POS N
was POS N
well POS N
tolerated POS N
and POS N
more POS N
effective POS N
in POS N
reducing POS N
IOP POS N
than POS N
0.5% POS N
timolol POS N
taken POS N
twice POS N
daily. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

With POS N
a POS N
mean POS N
follow-up POS N
of POS N
9.7 POS N
months, POS N
the POS N
trabeculectomy POS N
group POS N
had POS N
statistically POS N
lower POS N
intraocular POS N
pressures POS N
at POS N
weeks POS N
6 POS N
to POS N
15 POS N
(12.6 POS N
mm POS N
Hg POS N
vs POS N
16.4 POS N
mm POS N
Hg) POS N
and POS N
months POS N
11 POS N
to POS N
13 POS N
(11.4 POS N
mm POS N
Hg POS N
vs POS N
17.2 POS N
mm POS N
Hg) POS N
than POS N
the POS N
Ahmed POS N
implant POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

Compared POS N
with POS N
preoperative POS N
status, POS N
no POS N
statistically POS N
significant POS N
differences POS N
between POS N
groups POS N
were POS N
noted POS N
for POS N
visual POS N
acuity, POS N
visual POS N
field, POS N
lens POS N
status, POS N
and POS N
final POS N
anterior POS N
chamber POS N
depth. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
cumulative POS N
probabilities POS N
of POS N
success POS N
(intraocular POS N
pressure POS N
<21 POS N
mm POS N
Hg POS N
and POS N
at POS N
least POS N
15% POS N
reduction POS N
in POS N
intraocular POS N
pressure POS N
from POS N
preoperative POS N
level) POS N
were POS N
83.6% POS N
for POS N
trabeculectomy POS N
and POS N
88.1% POS N
for POS N
Ahmed POS N
implant POS N
(P POS N
=.43). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

the POS N
Ahmed POS N
implant POS N
group POS N
had POS N
a POS N
greater POS N
adjunctive POS N
medication POS N
requirement. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

On POS N
the POS N
last POS N
visit, POS N
10 POS N
of POS N
the POS N
trabeculectomy POS N
eyes POS N
and POS N
19 POS N
of POS N
the POS N
Ahmed POS N
implant POS N
eyes POS N
required POS N
at POS N
least POS N
one POS N
topical POS N
medication POS N
(P POS N
=.01). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

Lower POS N
mean POS N
intraocular POS N
pressures POS N
were POS N
noted POS N
for POS N
the POS N
trabeculectomy POS N
group. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
rate POS N
of POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

All POS N
other POS N
results, POS N
including POS N
success POS N
(as POS N
defined POS N
in POS N
this POS N
study) POS N
and POS N
frequency POS N
of POS N
complications, POS N
were POS N
comparable POS N
between POS N
the POS N
two POS N
groups. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

Travoprost POS N
produced POS N
clinically POS N
relevant POS N
and POS N
statistically POS N
significant POS N
additional POS N
intraocular POS N
pressure POS N
reductions POS N
from POS N
baseline POS N
when POS N
used POS N
adjunctively POS N
with POS N
timolol POS N
in POS N
subjects POS N
with POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

Mean POS N
baseline POS N
values POS N
(25 POS N
mm POS N
Hg) POS N
for POS N
subjects POS N
at POS N
eligibility POS N
(while POS N
maintained POS N
on POS N
timolol) POS N
were POS N
not POS N
significantly POS N
different POS N
(P POS N
<.0001) POS N
among POS N
the POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

The POS N
intraocular POS N
pressure POS N
was POS N
lowered POS N
an POS N
additional POS N
-5.7 POS N
to POS N
-7.2 POS N
mm POS N
Hg POS N
and POS N
-5.1 POS N
to POS N
-6.7 POS N
mm POS N
Hg POS N
in POS N
the POS N
travoprost POS N
0.004% POS N
and POS N
0.0015% POS N
concentrations, POS N
respectively. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

These POS N
changes POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
=.0001) POS N
different POS N
from POS N
the POS N
vehicle POS N
group POS N
(-1.3 POS N
to POS N
-2.8 POS N
mm POS N
Hg). POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

The POS N
intraocular POS N
pressure POS N
range POS N
on POS N
treatment POS N
at POS N
all POS N
visit POS N
times POS N
over POS N
the POS N
6-month POS N
treatment POS N
period POS N
ranged POS N
from POS N
17.9 POS N
to POS N
19.2 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.004% POS N
and POS N
18.3 POS N
to POS N
20.1 POS N
mm POS N
Hg POS N
for POS N
travoprost POS N
0.0015% POS N
compared POS N
with POS N
22.4 POS N
to POS N
24.1 POS N
mm POS N
Hg POS N
for POS N
vehicle. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

Average POS N
hyperemia POS N
scores POS N
ranged POS N
from POS N
trace POS N
to POS N
mild POS N
(mean POS N
0.5 POS N
on POS N
a POS N
scale POS N
of POS N
0 POS N
= POS N
none/trace; POS N
1= POS N
mild; POS N
2 POS N
= POS N
moderate; POS N
3 POS N
= POS N
severe) POS N
for POS N
all POS N
treatment POS N
groups. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

No POS N
iris POS N
pigmentation POS N
changes POS N
were POS N
observed POS N
in POS N
any POS N
patient POS N
during POS N
this POS N
study. POS N

There POS N
were POS N
no POS N
serious POS N
adverse POS N
events POS N
reported POS N
for POS N
any POS N
treatment POS N
group. POS N

There POS N
were POS N
no POS N
clinically POS N
or POS N
statistically POS N
significant POS N
changes POS N
from POS N
baseline POS N
in POS N
visual POS N
acuity, POS N
ocular POS N
cells POS N
and POS N
flare, POS N
fundus POS N
parameter, POS N
cup-to-disk POS N
ratio POS N
and POS N
visual POS N
field POS N
between POS N
the POS N
treatment POS N
groups. POS N

Mean POS N
intraocular POS N
pressure POS N
(IOP) POS N
changes POS N
from POS N
baseline POS N
were POS N
-4.0 POS N
+/- POS N
1.7 POS N
mmHg POS N
in POS N
Tafluprost POS N
administered POS N
patients POS N
and POS N
-1.4 POS N
+/- POS N
1.8 POS N
mmHg POS N
in POS N
Placebo POS N
administered POS N
patients POS N
at POS N
4 POS N
weeks, POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(p<0.001). POS N

IOP POS N
change POS N
at POS N
4 POS N
weeks, POS N
% POS N
IOP POS N
reduction POS N
at POS N
2 POS N
and POS N
4 POS N
weeks POS N
were POS N
also POS N
significantly POS N
greater POS N
in POS N
Tafluprost POS N
than POS N
in POS N
Placebo. POS N

Mean POS N
intraocular POS N
pressure POS N
(IOP) POS N
changes POS N
from POS N
baseline POS N
were POS N
-4.0 POS N
+/- POS N
1.7 POS N
mmHg POS N
in POS N
Tafluprost POS N
administered POS N
patients POS N
and POS N
-1.4 POS N
+/- POS N
1.8 POS N
mmHg POS N
in POS N
Placebo POS N
administered POS N
patients POS N
at POS N
4 POS N
weeks, POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(p<0.001). POS N

A POS N
total POS N
of POS N
51.0% POS N
in POS N
Tafluprost POS N
treated POS N
group POS N
and POS N
8.9% POS N
in POS N
Placebo POS N
treated POS N
group POS N
reported POS N
adverse POS N
drug POS N
reactions. POS N

Mean POS N
intraocular POS N
pressure POS N
(IOP) POS N
changes POS N
from POS N
baseline POS N
were POS N
-4.0 POS N
+/- POS N
1.7 POS N
mmHg POS N
in POS N
Tafluprost POS N
administered POS N
patients POS N
and POS N
-1.4 POS N
+/- POS N
1.8 POS N
mmHg POS N
in POS N
Placebo POS N
administered POS N
patients POS N
at POS N
4 POS N
weeks, POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(p<0.001). POS N

These POS N
results POS N
indicate POS N
that POS N
Tafluprost POS N
is POS N
clinically POS N
useful POS N
in POS N
the POS N
treatment POS N
of POS N
NTG. POS N

IOP POS N
change POS N
at POS N
4 POS N
weeks, POS N
% POS N
IOP POS N
reduction POS N
at POS N
2 POS N
and POS N
4 POS N
weeks POS N
were POS N
also POS N
significantly POS N
greater POS N
in POS N
Tafluprost POS N
than POS N
in POS N
Placebo. POS N

Mean POS N
intraocular POS N
pressure POS N
(IOP) POS N
changes POS N
from POS N
baseline POS N
were POS N
-4.0 POS N
+/- POS N
1.7 POS N
mmHg POS N
in POS N
Tafluprost POS N
administered POS N
patients POS N
and POS N
-1.4 POS N
+/- POS N
1.8 POS N
mmHg POS N
in POS N
Placebo POS N
administered POS N
patients POS N
at POS N
4 POS N
weeks, POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(p<0.001). POS N

IOP POS N
change POS N
at POS N
4 POS N
weeks, POS N
% POS N
IOP POS N
reduction POS N
at POS N
2 POS N
and POS N
4 POS N
weeks POS N
were POS N
also POS N
significantly POS N
greater POS N
in POS N
Tafluprost POS N
than POS N
in POS N
Placebo. POS N

A POS N
total POS N
of POS N
51.0% POS N
in POS N
Tafluprost POS N
treated POS N
group POS N
and POS N
8.9% POS N
in POS N
Placebo POS N
treated POS N
group POS N
reported POS N
adverse POS N
drug POS N
reactions. POS N

IOP POS N
change POS N
at POS N
4 POS N
weeks, POS N
% POS N
IOP POS N
reduction POS N
at POS N
2 POS N
and POS N
4 POS N
weeks POS N
were POS N
also POS N
significantly POS N
greater POS N
in POS N
Tafluprost POS N
than POS N
in POS N
Placebo. POS N

These POS N
results POS N
indicate POS N
that POS N
Tafluprost POS N
is POS N
clinically POS N
useful POS N
in POS N
the POS N
treatment POS N
of POS N
NTG. POS N

A POS N
total POS N
of POS N
51.0% POS N
in POS N
Tafluprost POS N
treated POS N
group POS N
and POS N
8.9% POS N
in POS N
Placebo POS N
treated POS N
group POS N
reported POS N
adverse POS N
drug POS N
reactions. POS N

Mean POS N
intraocular POS N
pressure POS N
(IOP) POS N
changes POS N
from POS N
baseline POS N
were POS N
-4.0 POS N
+/- POS N
1.7 POS N
mmHg POS N
in POS N
Tafluprost POS N
administered POS N
patients POS N
and POS N
-1.4 POS N
+/- POS N
1.8 POS N
mmHg POS N
in POS N
Placebo POS N
administered POS N
patients POS N
at POS N
4 POS N
weeks, POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(p<0.001). POS N

A POS N
total POS N
of POS N
51.0% POS N
in POS N
Tafluprost POS N
treated POS N
group POS N
and POS N
8.9% POS N
in POS N
Placebo POS N
treated POS N
group POS N
reported POS N
adverse POS N
drug POS N
reactions. POS N

IOP POS N
change POS N
at POS N
4 POS N
weeks, POS N
% POS N
IOP POS N
reduction POS N
at POS N
2 POS N
and POS N
4 POS N
weeks POS N
were POS N
also POS N
significantly POS N
greater POS N
in POS N
Tafluprost POS N
than POS N
in POS N
Placebo. POS N

A POS N
total POS N
of POS N
51.0% POS N
in POS N
Tafluprost POS N
treated POS N
group POS N
and POS N
8.9% POS N
in POS N
Placebo POS N
treated POS N
group POS N
reported POS N
adverse POS N
drug POS N
reactions. POS N

These POS N
results POS N
indicate POS N
that POS N
Tafluprost POS N
is POS N
clinically POS N
useful POS N
in POS N
the POS N
treatment POS N
of POS N
NTG. POS N

These POS N
results POS N
indicate POS N
that POS N
Tafluprost POS N
is POS N
clinically POS N
useful POS N
in POS N
the POS N
treatment POS N
of POS N
NTG. POS N

Mean POS N
intraocular POS N
pressure POS N
(IOP) POS N
changes POS N
from POS N
baseline POS N
were POS N
-4.0 POS N
+/- POS N
1.7 POS N
mmHg POS N
in POS N
Tafluprost POS N
administered POS N
patients POS N
and POS N
-1.4 POS N
+/- POS N
1.8 POS N
mmHg POS N
in POS N
Placebo POS N
administered POS N
patients POS N
at POS N
4 POS N
weeks, POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(p<0.001). POS N

These POS N
results POS N
indicate POS N
that POS N
Tafluprost POS N
is POS N
clinically POS N
useful POS N
in POS N
the POS N
treatment POS N
of POS N
NTG. POS N

IOP POS N
change POS N
at POS N
4 POS N
weeks, POS N
% POS N
IOP POS N
reduction POS N
at POS N
2 POS N
and POS N
4 POS N
weeks POS N
were POS N
also POS N
significantly POS N
greater POS N
in POS N
Tafluprost POS N
than POS N
in POS N
Placebo. POS N

These POS N
results POS N
indicate POS N
that POS N
Tafluprost POS N
is POS N
clinically POS N
useful POS N
in POS N
the POS N
treatment POS N
of POS N
NTG. POS N

A POS N
total POS N
of POS N
51.0% POS N
in POS N
Tafluprost POS N
treated POS N
group POS N
and POS N
8.9% POS N
in POS N
Placebo POS N
treated POS N
group POS N
reported POS N
adverse POS N
drug POS N
reactions. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

The POS N
mean POS N
baseline POS N
intraocular POS N
pressure POS N
was POS N
23.8 POS N
+/- POS N
12.6 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
25.9 POS N
+/- POS N
10.6 POS N
mmHg POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
= POS N
0.513). POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
the POS N
mean POS N
values POS N
of POS N
Schirmer's POS N
tear POS N
test POS N
1 POS N
and POS N
the POS N
level POS N
of POS N
conjunctival POS N
hyperaemia POS N
between POS N
the POS N
two POS N
groups POS N
at POS N
baseline, POS N
months POS N
1 POS N
and POS N
6 POS N
post POS N
surgery. POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

The POS N
treatment POS N
group POS N
had POS N
a POS N
statistically POS N
significant POS N
decrease POS N
in POS N
ocular POS N
surface POS N
disease POS N
index POS N
score POS N
at POS N
6 POS N
months POS N
(P POS N
= POS N
0.003), POS N
indicating POS N
less POS N
severity POS N
of POS N
dry POS N
eye POS N
symptoms POS N
and POS N
significant POS N
reduction POS N
in POS N
ocular POS N
pain. POS N

Mean POS N
intraocular POS N
pressure POS N
at POS N
postoperative POS N
month POS N
6 POS N
was POS N
14.88 POS N
+/- POS N
6.2 POS N
and POS N
14.62 POS N
+/- POS N
5.46 POS N
mmHg POS N
in POS N
the POS N
study POS N
group POS N
and POS N
control POS N
group, POS N
respectively POS N
(P POS N
= POS N
0.837). POS N

Topical POS N
cyclosporine POS N
0.05% POS N
had POS N
no POS N
effect POS N
on POS N
postoperative POS N
bleb POS N
function POS N
and POS N
intraocular POS N
pressure POS N
following POS N
trabeculectomy, POS N
but POS N
improved POS N
subjective POS N
ocular POS N
surface POS N
symptoms POS N
in POS N
these POS N
patients. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

Significantly POS N
more POS N
patients POS N
achieved POS N
clinical POS N
success POS N
with POS N
brimonidine POS N
monotherapy POS N
than POS N
with POS N
latanoprost POS N
monotherapy. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

After POS N
3 POS N
months POS N
of POS N
treatment, POS N
80% POS N
of POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
and POS N
74% POS N
of POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
had POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

The POS N
mean POS N
reduction POS N
in POS N
IOP POS N
from POS N
baseline POS N
at POS N
month POS N
3 POS N
was POS N
6.8 POS N
mm POS N
Hg POS N
with POS N
brimonidine POS N
and POS N
6.5 POS N
mm POS N
Hg POS N
with POS N
latanoprost POS N
(27.8% POS N
vs POS N
27.0%, POS N
respectively). POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

Among POS N
treatment-naive POS N
patients, POS N
a POS N
significantly POS N
higher POS N
percentage POS N
of POS N
brimonidine-treated POS N
patients POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
decrease POS N
in POS N
IOP POS N
compared POS N
with POS N
latanoprost-treated POS N
patients POS N
(88% POS N
vs POS N
59%, POS N
respectively; POS N
P POS N
= POS N
0.01). POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

In POS N
previously POS N
treated POS N
patients, POS N
a POS N
higher POS N
percentage POS N
of POS N
the POS N
latanoprost POS N
group POS N
achieved POS N
> POS N
or POS N
= POS N
20% POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
brimonidine POS N
group POS N
(88% POS N
vs POS N
74%, POS N
respectively); POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

Significantly POS N
more POS N
patients POS N
in POS N
the POS N
brimonidine POS N
group POS N
achieved POS N
clinical POS N
success POS N
at POS N
month POS N
3 POS N
compared POS N
with POS N
patients POS N
in POS N
the POS N
latanoprost POS N
group POS N
(91% POS N
vs POS N
74%; POS N
P POS N
= POS N
0.01). POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

At POS N
peak POS N
effect, POS N
brimonidine POS N
twice POS N
daily POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
once POS N
daily POS N
in POS N
lowering POS N
IOP. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

In POS N
treatment-naive POS N
patients, POS N
latanoprost POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
rate POS N
of POS N
nonresponse POS N
after POS N
3 POS N
months POS N
of POS N
treatment POS N
compared POS N
with POS N
brimonidine. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

This POS N
suggests POS N
that POS N
brimonidine POS N
may POS N
be POS N
the POS N
more POS N
reliable POS N
choice POS N
for POS N
first-line POS N
therapy POS N
of POS N
newly POS N
diagnosed POS N
open-angle POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

however, POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant. POS N

In POS N
previously POS N
treated POS N
patients, POS N
however, POS N
latanoprost POS N
provided POS N
greater POS N
mean POS N
IOP POS N
reduction POS N
than POS N
did POS N
brimonidine. POS N

No POS N
significant POS N
difference POS N
(p POS N
= POS N
0.846) POS N
was POS N
found POS N
in POS N
mean POS N
decrease POS N
in POS N
IOP POS N
between POS N
the POS N
SLT POS N
(5.86 POS N
mm POS N
Hg) POS N
and POS N
ALT POS N
(6.04 POS N
mm POS N
Hg) POS N
groups POS N
at POS N
1 POS N
year POS N
or POS N
at POS N
any POS N
other POS N
time POS N
points, POS N
nor POS N
were POS N
there POS N
any POS N
significant POS N
differences POS N
in POS N
the POS N
rate POS N
of POS N
early POS N
or POS N
late POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

SLT POS N
is POS N
equivalent POS N
to POS N
ALT POS N
in POS N
terms POS N
of POS N
IOP POS N
lowering POS N
at POS N
1 POS N
year, POS N
and POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
procedure POS N
for POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

SLT POS N
is POS N
equivalent POS N
to POS N
ALT POS N
in POS N
terms POS N
of POS N
IOP POS N
lowering POS N
at POS N
1 POS N
year, POS N
and POS N
is POS N
a POS N
safe POS N
and POS N
effective POS N
procedure POS N
for POS N
patients POS N
with POS N
open-angle POS N
glaucoma. POS N

No POS N
significant POS N
difference POS N
(p POS N
= POS N
0.846) POS N
was POS N
found POS N
in POS N
mean POS N
decrease POS N
in POS N
IOP POS N
between POS N
the POS N
SLT POS N
(5.86 POS N
mm POS N
Hg) POS N
and POS N
ALT POS N
(6.04 POS N
mm POS N
Hg) POS N
groups POS N
at POS N
1 POS N
year POS N
or POS N
at POS N
any POS N
other POS N
time POS N
points, POS N
nor POS N
were POS N
there POS N
any POS N
significant POS N
differences POS N
in POS N
the POS N
rate POS N
of POS N
early POS N
or POS N
late POS N
complications POS N
between POS N
the POS N
two POS N
groups. POS N

